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Abstract 
Introduction: Hepatitis B virus (HBV) remains endemic in sub-Saharan Africa (SSA). While the 
roll-out of pediatric HBV immunization from six weeks of age has had an impact on horizontal 
transmission of the virus, mother-to-child transmission (MTCT) has been identified as the driver 
of the current HBV epidemic in the region. Given the high likelihood of developing chronic HBV 
infection (CHB) if the infection is acquired during infancy, preventing HBV MTCT in SSA is 
vital. Where MTCT occurs, it is essential to identify the HBV-infected children for appropriate 
management, especially in the context of HIV. Current antiretroviral therapy (ART) for the 
management of HIV infection includes tenofovir for children ≥ 10 years old. Children below the 
age of 10 years are treated with lamivudine. However, many of the HIV/HBV co-infected children 
are left on lamivudine treatment for more than ten years and are at risk of developing HBV drug 
resistance and uncontrolled HBV infection. Uncontrolled HBV infection is a known factor for 
increased risk of severe liver damage. Aim: This research project aimed to (1) assess the molecular 
character of HBV and the liver health of HIV/HBV co-infected children who have been on long-
term lamivudine treatment, (2) to determine the feasibility of a screen-treat-vaccinate intervention 
to prevent HBV MTCT, and (3) to measure the costs and health outcomes of combined 
prophylactic measures against HBV MTCT, in Namibia. Methodology: Three sub-studies were 
conducted as part of this research project, to answer each of its aims. The first sub-study involved 
HIV/HBV co-infected children and adolescents below the age of 18 years old, and who have been 
exposed to lamivudine. Venous blood samples were collected from these children for HBV 
serological testing (HBsAg, HBeAg, anti-HBe and anti-HBc total) using Murex ELISA assays. 
Dried blood spots (DBS) samples were used for HBV DNA levels measurement and genotyping. 
HBV DNA measurements were completed using the automated AmpliPrep/COBAS TaqMan 
HBV test V2.0. Genotyping and mutation analyses were performed using online tools. Liver health 
was assessed through AST platelet ratio index (APRI). An APRI score > 0.5 was considered a sign 
of liver fibrosis. Mothers attending with these children and adolescents were also enrolled in the 
study, to determine the role of HBV MTCT in these pediatric HBV infections. DBS were collected 
from these mothers for HBV molecular characterization as well. The second sub-study focused on 
pregnant women attending antenatal clinics (ANCs) in Windhoek. These women were recruited 
following informed consent and screened for HBV using the Alere DetermineTM HBsAg rapid test. 
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HBsAg positive pregnant women were tested for further HBV serological markers (HBeAg, anti-
HBe, anti-HBc IgM), and HBV viral loads were measured to determine the risk of MTCT. Positive 
mothers at high risk of MTCT were reviewed for antiviral prophylaxis and offered treatment where 
necessary. HBV-exposed babies were immunized as per Namibian guidelines, and followed-up to 
determine the rate of MTCT. The feasibility of offering routine antenatal HBV rapid testing was 
assessed quantitatively and qualitatively. The former involved determining the diagnostic accuracy 
of the rapid test used for HBsAg screening, and the latter focused on the perceptions of this 
antenatal care service by healthcare workers (HCWs). In the third sub-study, the costs and health 
outcomes of four interventions against HBV MTCT were assessed through a cost-effectiveness 
analysis. The interventions included: (1) universal birth dose (BD) vaccination, (2) BD vaccination 
and HBIG, (3) BD vaccination, HBIG, and maternal antiviral prophylaxis informed by sequential 
HBV viral load testing, and (4) BD vaccination, HBIG, and maternal antiviral prophylaxis 
informed by sequential HBeAg testing. All resources including consumables, HCW’s time, 
building space and facilities (and their quantity) were measured and valued to determine the unit 
costs of HBsAg screening at the ANCs, providing antenatal treatment and administering pediatric 
immunoprophylaxis. Health outcomes were measured in terms of the number of pediatric HBV 
infections averted. The incremental cost-effectiveness ratios (ICERs) of these interventions were 
calculated and were used to compare each intervention to the previous less expensive one. Results: 
Fifteen HIV/HBV co-infected children/adolescents and six mothers attending with the children 
were enrolled in the first sub-study. Ten serum samples obtained from Windhoek were further 
tested for HBV serological markers; seven were HBeAg positive/anti-HBe negative (7/10; 70%), 
three were HBeAg negative (3/10; 30%), and all were reactive for anti-HBc (total) (10/10; 100%). 
Among HBeAg negatives, one was anti-HBe negative and two were anti-HBe positive. Eight of 
the fifteen children (8/15; 53.3%) were HBV DNA positive. The viral strains were grouped with 
genotype E (6/8; 75%) and genotype D3 (2/8; 25%) and harbored lamivudine drug-associated 
resistance variants and immune escape mutants. Liver health was assessed in nine children: five 
with detectable levels of HBV DNA and four with undetectable levels of HBV DNA. An abnormal 
APRI score of 0.713, was detected in one HBV DNA positive child (1/9; 11.1%). In the second 
sub-study an HBsAg seroprevalence of 5.4% was observed among 515 (28/515) pregnant women 
enrolled at ANCs in Windhoek. Three pregnant women (3/28; 10.7%) were positive for HBeAg; 
of whom one was HIV/HBV co-infected and the other two were HBV mono-infected. The two 
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(2/28; 7.14%) HBV mono-infected/HBeAg-positive patients presented with viral load > 105 IU/ml, 
the study cut-off for antenatal treatment to prevent HBV MTCT; one received antiviral prophylaxis 
with tenofovir, the other was offered prophylaxis but did not receive it. Postpartum, 25 of the 28 
HBV-exposed babies (25/28; 89.3%) were traced and followed-up to determine their HBV status 
and the rate of HBV MTCT. Fourteen (14/25; 56%) were males, and eleven were females (11/25; 
44%). All babies had been vaccinated against HBV at birth, and 15 (15/25; 60%) had received 
hepatitis B immunoglobulin (HBIG). The 25 babies were tested for HBsAg at a median age of 
seven weeks (Range: 5.57 weeks – 20.29 weeks). All were non-reactive for HBsAg, including 
both babies born to the highly viremic women. With regards to the feasibility of HBV rapid testing 
as part of antenatal care services, the DetermineTM HBsAg rapid test had a 100% diagnostic 
sensitivity and specificity. HCWs found the test simple to use and showed a preference for rapid 
testing over laboratory testing for routine antenatal screening of HBV. They believed that this 
method would improve early diagnosis and treatment of HBV of pregnant women. In the cost-
effectiveness analysis conducted in the third sub-study, a preventive strategy with universal BD 
vaccination alone was the cheapest option but was less effective. Adding HBIG to BD vaccination, 
and providing maternal antiviral prophylaxis was the most effective and the most costly strategy. 
The strategy that includes antiviral prophylaxis with sequential HBeAg testing added to BD 
vaccination and HBIG had an ICER of US$6 262.42 per infection averted, in comparison to the 
strategy including BD vaccination and HBIG only. The BD vaccination and HBIG strategy had an 
ICER of US$4 550.34/ pediatric HBV infection averted, in comparison to BD vaccination alone. 
These ICERs were highly sensitive to the prevalence of highly infectious pregnant women, the 
cost of the HBeAg test, and the effectiveness of each strategy for preventing MTCT in highly 
infectious pregnant women. Conclusion: Results from this research project reemphasized the issue 
of pediatric CHB, especially in HIV/HBV co-infected children. The data described in this study 
also showed that elimination of MTCT of HBV in Namibia is achievable, through routine antenatal 
HBsAg screening, treating pregnant women at high risk of MTCT, and providing HBV vaccination 
from birth. Screening using rapid testing was found cheap, and a feasible alternative for detecting 
HBV infection in pregnant women. The costs and health benefits of implementing antenatal 
antiviral prophylaxis and HBIG presented in the study provide background data for further 
assessment of the value for money of these interventions in SSA, and to explore alternatives 
excluding HBIG for HBV PMTCT.  
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Abstrakt 
Inleiding: Die Hepatitis B virus (HBV) bly endemies in Afrika suid van die Sahara (SSA). Terwyl 
die uitrol van pediatriese HBV-immunisasie vanaf ses weke 'n impak gehad het op die horisontale 
oordrag van die virus, is moeder-tot-kind-oordrag (MTCT) geïdentifiseer as die  belangrikste 
dryfveer van die huidige HBV-epidemie in die streek. Gegewe die hoë waarskynlikheid om 
chroniese HBV-infeksie (CHB) te ontwikkel indien die infeksie gedurende die kinderjare verwerf 
word, is die voorkoming van HBV MTCT in SSA noodsaaklik. Waar MTCT plaasgevind het, is 
dit noodsaaklik om die HBV-geïnfekteerde kinders te identifiseer en voortaan te monitor vir 
gepaste hantering, veral in die konteks van MIV infeksies. Huidige antiretrovirale terapie (ART) 
vir die behandeling van MIV-infeksie sluit tenofovir vir kinders ≥ 10 jaar in. Kinders onder die 
ouderdom van 10 jaar word behandel met lamivudien. Baie van die kinders met MIV/HBV ko-
infeksie is egter al meer as tien jaar aan lamivudienbehandeling blootgestel en loop die risiko om 
HBV-middelweerstand en ongekontroleerde HBV-infeksie te ontwikkel. Ongekontroleerde HBV 
infeksie is 'n bekende faktor vir verhoogde risiko van ernstige lewerskade. Doelwitte: Hierdie 
navorsingsprojek het ten doel om (1) die molekulêre eienskappe van HBV en die lewergesondheid 
van MIV/HBV mede-besmette kinders te beoordeel wat op langtermyn lamivudienbehandeling 
was, (2) om die lewensvatbaarheid van 'n sifting-behandeling-inenting ingreep om HBV MTCT te 
voorkom, te bepaal en (3) om die koste en gesondheidsuitkomste van gekombineerde profilaktiese 
maatreëls teen HBV MTCT in Namibië te meet. Metodiek: Drie substudies is uitgevoer om elkeen 
van die studiedoelwitte aan te spreek. Die eerste substudie het kinders en adolessente met 
MIV/HBV ko-infeksie onder die ouderdom van 18 jaar, en wat aan lamivudien blootgestel is, 
ingesluit. Veneuse bloedmonsters is van hierdie kinders versamel vir HBV serologiese toetsing 
(HBsAg, HBeAg, anti-HBe en totale anti-HBc) deur die Murex ELISA toetse. Gedroogde 
bloedvlek (DBS) monsters is gebruik om HBV DNA vlakke te meet en die virus te genotpieer. 
HBV DNA-metings is voltooi met behulp van die geoutomatiseerde AmpliPrep / COBAS TaqMan 
HBV toets V2.0. Genotipering en mutasie analises is uitgevoer met behulp van aanlyn-metodes. 
Lewer gesondheid is geassesseer deur die AST bloedplaatjie verhouding indeks (APRI) te gebruik. 
'n APRI-telling> 0.5 is beskou as 'n teken van lewerfibrose. Betrokke moeders is ook in die studie 
ingeskryf om die rol van HBV MTCT in die pediatriese HBV-infeksies te bepaal. DBS is 
ingesamel uit hierdie moeders vir HBV molekulêre karakterisering. Die tweede substudie het 
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gefokus op swanger vroue wat voorgeboorteklinieke (ANC’s) in Windhoek bygewoon het. Hierdie 
vroue is gewerf na ingeligte toestemming en gesif vir HBV met behulp van die Alere Determine 
TM HBsAg vinnige toets. HBsAg positiewe swanger vroue is verder getoets vir HBV serologiese 
merkers (HBeAg, anti-HBe, anti-HBc IgM) en HBV virale ladings is gemeet om die risiko van 
MTCT te bepaal. Positiewe moeders met 'n hoë risiko van MTCT is oorweeg vir antivirale 
profilakse en behandeling is aangebied waar nodig. HBV-blootgestelde babas is geïmmuniseer 
volgens Namibiese riglyne, en gevolg om die tempo van MTCT te bepaal. Die uitvoerbaarheid 
van die aanbied van roetine voorgeboortelike HBV vinnige toetsing is kwantitatief en kwalitatief 
geassesseer. Eersgenoemde behels die bepaling van die diagnostiese akkuraatheid van die vinnige 
toets wat gebruik word vir HBsAg-screening, en laasgenoemde het gefokus op die persepsies van 
hierdie voorgeboortesorgdiens deur gesondheidswerkers (HCWs). In die derde substudie is die 
koste en gesondheidsuitkomste van vier intervensies teen HBV MTCT geassesseer deur 'n koste-
effektiwiteitsanalise. Die intervensies sluit in: (1) BD-inenting, (2) BD-inenting en HBIG, (3) BD-
inenting, HBIG en antivirale profylaksis van die moeder wat ingelig word deur sekwensiële HBV 
virale ladingstoetsing en (4) BD-inenting, HBIG, en antivirale profylaxe van die moeder 
geïnformeer deur sekwensiële HBeAg toetsing. Alle hulpbronne, insluitend verbruiksgoedere, 
HCW se tyd, gebouruimte en fasiliteite (en hul hoeveelheid) is gemeet en gewaardeer om die 
eenheidskoste van HBsAg-screening by die ANC te bepaal, wat voorgeboortelike behandeling en 
die administrasie van pediatriese immunoprofielaksis verskaf. Gesondheidsuitkomste is gemeet in 
terme van die aantal pediatriese HBV-infeksies afgewend. Die inkrementele koste-
effektiwiteitsverhoudings (ICER's) van hierdie intervensies is bereken en is gebruik om elke 
intervensie met die vorige goedkoper een te vergelyk. Resultate: Vyftien MIV/HBV mede-
besmette kinders/adolessente en ses moeders was in die eerste substudie ingeskryf. Tien 
serummonsters wat van Windhoek verkry is, is verder getoets vir HBV serologiese merkers; sewe 
was HBeAg positief/anti-HBe negatief (7/10, 70%), drie was HBeAg negatief (3/10; 30%) en 
almal was reaktief vir anti-HBc (totaal) (10/10; 100%). Onder HBeAg negatiewe, was een anti-
HBe negatief en twee was anti-HBe positief. Ag van die vyftien kinders (8/15; 53,3%) was HBV 
DNA positief. Die virusstamme is gegroepeer met genotipe E (6/8; 75%) en genotipe D3 (2/8; 
25%) en bevat lamivudien-middel-verwante weerstandsvariante en immuun-ontwyk-mutante. 
Lewer gesondheid is in nege kinders geassesseer: vyf met waarneembare vlakke van HBV DNA 
en vier met onopspoorbare vlakke van HBV DNA. 'n Abnormale APRI-telling van 0.713 is 
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opgespoor in een HBV DNA positiewe kind (1/9, 11.1%). In die tweede substudie is ' n HBsAg 
seroprevalensie van 5,4% waargeneem onder 515 (28/515) swanger vroue wat by ANC's in 
Windhoek ingeskryf is. Drie swanger vroue (3/28; 10.7%) was positief vir HBeAg; van wie een 
MIV/HBV ko-infeksieen die ander twee slegs HBVinfeksie gehad het.. Die twee (2/28, 7.14%) 
HBV mono-geïnfekteerde/HBeAg-positiewe pasiënte het 'n viruslading> 105 IE / ml, die studie 
afgesny vir voorgeboortelike behandeling om HBV MTCT te voorkom; een het antivirale 
profilakse met tenofovir ontvang, die ander is profilakse aangebied, maar het dit nie ontvang nie. 
Postpartum, 25 van die 28 HBV-blootgestelde babas (25/28, 89.3%) is opgevolg om hul HBV 
status en die tempo van HBV MTCT te bepaal. Veertien (14/25, 56%) was mans, en elf was vroue 
(11/25; 44%). Alle babas is teen geboorte teen HBV ingeënt en 15 (15/25, 60%) het hepatitis B 
immunoglobulien (HBIG) ontvang. Die 25 babas is getoets vir HBsAg op mediane ouderdom van 
sewe weke (Bereik: 5.57 weke – 20.29 weke). Almal was nie-reaktief vir HBsAg, insluitende albei 
babas wat gebore is aan die hoogs viremiese vroue. Met betrekking tot die haalbaarheid van HBV 
vinnige toetsing as deel van voorgeboortesorgdienste, het die Determine TM HBsAg vinnige toets 
'n 100% diagnostiese sensitiwiteit en spesifisiteit gehad. HCWs het die toets maklik gevind om te 
gebruik en het 'n voorkeur getoon vir vinnige toetse oor laboratoriumtoetse vir roetine-
voorgeboortelike screening van HBV. Hulle het geglo dat hierdie metode vroeë diagnose en 
behandeling van HBV van swanger vroue sal verbeter. In die koste-effektiwiteitsanalise wat in die 
derde substudie gedoen is, was 'n voorkomende strategie met universele BD-inenting alleen die 
goedkoopste opsie, maar was minder effektief. Die toevoeging van HBIG tot BD-inenting, en die 
voorsiening van moeder se antivirale profylaksis was die mees effektiewe en die duurste strategie. 
Die strategie wat antivirale profilakse sluit met sekwensiële HbeAg toets bygevoeg BD inenting 
en HBIG het 'n ICER van $6 per infeksie afwyk, in vergelyking met die strategie, insluitende BD-
inenting en slegs HBIG. Die BD-inenting en HBIG-strategie het 'n ICER van US $ 4 
550.34/pediatriese HBV-infeksie afgeneem, in vergelyking met BD-inenting alleen. Hierdie 
ICER's was hoogs sensitief vir die voorkoms van hoogs aansteeklike swanger vroue, die koste van 
die HBeAg-toets en die effektiwiteit van elke strategie om MTCT te voorkom in hoogs 
aansteeklike swanger vroue. Slotsom: Resultate van hierdie navorsingsprojek het die kwessie en 
ernstigheid van pediatriese CHB infeksie herbeklemtoon, veral in MIV/HBV mede-besmette 
kinders. Die data wat in hierdie studie beskryf is, het ook getoon dat die eliminasie van MTCT van 
HBV in Namibië bereik kan word deur roetine-voorgeboortelike HBsAg-sifting, behandeling van 
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swanger vroue met hoë risiko van MTCT en die verskaffing van HBV-inenting vanaf geboorte. 
Sifting-toetsingmet behulp van vinnige toetsing is goedkoop en 'n haalbare alternatief vir die 
opsporing van HBV infeksie in swanger vroue. Die koste en gesondheidsvoordele van die 
implementering van voorgeboortelike antivirale profilakse en HBIG wat in die studie beskryf 
word, verskaf data vir verdere assessering van die waarde vir geld van hierdie intervensies in SSA 
en om alternatiewe te ondersoek wat HBIG vir HBV PMTCT uitgesluit het. 
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CHAPTER 1: Introduction 
Hepatitis B virus (HBV) infection causes inflammation of the liver which may be acute and 
resolve within six weeks or may become chronic. While the former usually manifests as a self-
limiting illness, the latter may result in chronic infection and over the years lead to a number 
of liver related complications. About 15% to 40% of chronic cases lead to liver cirrhosis; of 
which 5% to 30% progress to primary liver cancer, specifically hepatocellular carcinoma 
(HCC), later in life (Tang et al., 2018). HCC may also develop from chronic hepatitis, in the 
absence of cirrhosis (Chayanupatkul et al., 2017). The likelihood of becoming a chronic 
carrier of HBV is inversely related to the age at which the infection is acquired. HBV-infected 
infants and young children are more likely than adults to develop chronic hepatitis B. Those 
with infections from early childhood present with the highest risk of HCC as a result of viral 
persistence (Shimakawa et al., 2013). Thus, preventing pediatric (both early infancy and 
childhood) HBV infection constitutes a key aspect of disease control. Access and scale-up of 
the HBV vaccine have significantly reduced the prevalence of early childhood infections, from 
4.7% to 1.3% in children under the age of five years old in 2015, globally (WHO, 2017a). 
However, infections in newborns are still occurring (Wiseman et al., 2009; Chasela et al., 
2014; Chotun et al., 2015; Keane et al., 2016, Babatunde et al., 2018). Since chronic 
infection is most likely to occur following infection in neonates, prevention of mother-to-child 
transmission (MTCT) should be a priority. 
Rationale of the study 
It has been widely thought that horizontal transmission is the major mode of the spread of HBV 
in sub-Saharan Africa (SSA); based on highest prevalence of the virus found in children older 
than five years of age (Prozesky et al., 1983; Botha et al., 1984), and the lower rate of hepatitis 
B e antigen (HBeAg) seropositivity in pregnant women, when compared to Asian populations. 
However, an increasing amount of data has emerged, reporting on high rates of HBeAg among 
both human immunodeficiency virus (HIV)-uninfected (Andersson et al., 2013; Fomulu et 
al., 2013; Bayo et al., 2014; De Paschale et al., 2014) and HIV-infected pregnant women 
(Andersson et al., 2013; Thumbiran et al., 2014) across the region. The presence of HBeAg 
is usually indicative of high viral replication activity; thus, HBeAg positive pregnant women 
often present with high levels of HBV deoxyribonucleic acid (DNA) and are at elevated risk 
of transmitting HBV to their infants (Okada et al., 1976; Beasley et al., 1977). Based on a 
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large body of data from Asia, the likelihood of an HBsAg/HBeAg positive pregnant woman to 
transmit HBV to her infant has been estimated to about 87.5%, as opposed to 13.2% from 
HBsAg positive/HBeAg negative women, both in the absence of pediatric prophylaxis after 
birth (Edmunds et al., 1996). With timely HBV birth dose (BD) vaccination of infants, this 
risk drops to about 24% and below 0.5% from HBeAg positive women and HBeAg negative 
women, respectively (Lee et al., 2007; Machaira et al., 2015). Recent data from SSA suggest 
a 39% risk of transmission from HBeAg positive women and a 4% risk from HBeAg negative 
women without pediatric immunoprophylaxis, based on a small subset of data (Keane et al., 
2016). Even though HBV MTCT may occur at low prevalence in SSA, as compared to Asia, it 
plays an essential role in the sustained endemicity of the disease across the region. An estimated 
367 250 newborns are infected with HBV at birth, annually, in the region (Keane et al., 2016). 
These statistics highlight the urgent need for controlling HBV MTCT in SSA. In the absence 
of effective preventive measures in place such as BD vaccination, continued transmission of 
HBV to infants would further increase the pool of persons with chronic HBV at risk of 
developing HBV-associated liver diseases and perpetuate transmission of the virus in 
communities.  
Antiretroviral therapy (ART) effective against HBV include the nucleos(t)ide analogs tenofovir 
(TDF) and entecavir as the drugs of choice owing to their low probability of inducing viral 
resistance. In the context of HIV, first-line adult ART includes TDF and lamivudine. In 
children below 10 years of age, lamivudine is the only available drug against HBV. Although 
potent, long-term therapy with lamivudine alone results in the emergence of a group of HBV 
mutations known as the tyrosine-methionine-aspartate-aspartate or YMDD motif mutations in 
the polymerase (pol) gene of the HBV genome. This group of mutations leads to therapy 
failure, characterized by increased viral replication and seroreversion to HBeAg. The incidence 
of these mutations is higher in HIV-infected individuals and is dependent on the duration of 
treatment: 20% at one year of treatment, 50% at two years, 73% at two to four years, and 94% 
after four years of lamivudine monotherapy (Benhamou et al., 1999; Matthews et al., 2010). 
Owing to the overlap of the surface (surf) gene and pol gene reading frames, lamivudine-
induced mutations arising in the pol gene will cause alterations on the surf (HBsAg) gene. This 
may result in the selection of potentially drug-resistant or vaccine escape mutant viruses 
(Torresi et al., 2002), thus exposing HIV-HBV co-infected children to a higher risk of liver 
damage. This is another reason to support the need to prevent pediatric HBV infection.  
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HBV vaccination commencing immediately after birth is the cornerstone of preventing 
infection in newborns. In much of SSA, HBV BD is not part of the national vaccination 
schedule, and most infants only start HBV vaccination as from six weeks of age. The risk of 
transmission can be further reduced by adding passive immunization with hepatitis B 
immunoglobulin (HBIG) to BD vaccination, especially for those who are most at risk (Lee et 
al., 2006, 2007). This practice requires identifying HBV-infected HBeAg positive pregnant 
women. Still, breakthrough HBV infection in infants born to highly viremic HBV-infected 
mothers may still occur despite both active and passive immunoprophylaxis (Ngui et al., 1998; 
Wiseman et al., 2009; Foaud et al., 2015; Sellier et al., 2015). For this reason, reducing 
maternal viral load during pregnancy using antiviral drugs would be of added value (Xu et al., 
2009; Pan et al., 2012; Tan et al., 2016). BD vaccination and access to antiviral medication 
could be a feasible way to prevent MTCT in SSA. In areas where it is available, HBIG may be 
of added value in those infants at highest risk. Implementation of national policies for the 
prevention of HBV MTCT not only relies on robust epidemiological data. It would also require 
an assessment of the costs and health benefits associated with these interventions, alone or 
combined, to increase social benefits and for practical use of the resources available. 
Context of the study – why Namibia? 
While HBV statistics are available from most parts of SSA, data on the epidemiology of HBV 
in Namibia is profoundly lacking. Available HBsAg seroprevalence figures date from studies 
conducted more than two decades ago in Northern Namibia. These include a 1983 study among 
the general population living in the Kavango province, where the authors detected a 13.6% 
HBsAg carrier state (Joubert et al., 1985). Ovambo children and their mothers showed 15% 
and 11% HBsAg carrier rates, respectively, while a higher seroprevalence (17%) was described 
among Ovambo men (Botha et al., 1984). The higher prevalence of HBV in men as opposed 
to women was noted in another study in Eastern Caprivi (Joubert et al., 1991). Joubert et al. 
(1991) reported a 19.0% (90/475) HBs antigenemia rate in males as compared to 10.7% 
(45/419) in females (Joubert et al., 1991). 
Our study is built on an earlier retrospective study conducted in HIV-infected children and 
adolescents in two regions of Namibia, namely Ohangwena and Omusati, both in Northern 
Namibia. HBV prevalences as high as 6.5% and 13.3% were observed among children aged 
less than one and older than ten years, respectively (Brandt et al., 2012). These data suggested 
Stellenbosch University https://scholar.sun.ac.za
4 
 
a high prevalence of HBV pediatric infections, potentially resulting from both vertical and 
horizontal transmission. As a result of being HIV co-infected, the majority of these children 
were exposed to lamivudine monotherapy against HBV for long periods of time and may have 
developed resistant strains. These children may have formed part of a reservoir of HBV 
infections that may be continuously transmitted in communities. Further research is needed to 
identify whether this reservoir may form part of an ongoing reservoir of infection. 
In 2014, Namibia introduced HBV BD vaccination for all infants. Although this is World 
Health Organization policy recommendation (WHO, 2017b), Namibia is one of only nine 
African countries to have implemented this policy (WHO, 2018). It is also one of the few 
countries in SSA with a documented policy of routine antenatal HBV screening; pregnant 
women are tested for HBV infection as part of the routine tests performed at first antenatal care 
visits (MoHSS, 2011). Part of infant care includes the provision of HBIG, in addition to HBV 
BD vaccination, to babies born to HBsAg positive mothers (MoHSS, 2014a). Given the 
availability of these national policies, evaluating the feasibility of adding maternal antiviral 
prophylaxis for pregnant women with high viral loads to avert HBV MTCT would serve as a 
proof of concept on the possibility of controlling HBV MTCT in SSA. The costs and health 
benefits associated with a screen-vaccinate (BD +HBIG) health intervention, and with a screen-
treat-vaccinate intervention, through economic evaluations, would also be valuable for policy-
making nationally and across the SSA region. 
Chapter 2 is a literature review, presenting the epidemiology of HBV, both in the pediatric and 
the antenatal populations of SSA as well as HBV MTCT and preventive measures against HBV 
MTCT. It also discusses the published literature on the economic analyses of these preventive 
interventions, alone or combined. 
Chapter 3 describes the investigation of the molecular epidemiology of HBV in HIV/HBV co-
infected children and adolescents. 
Chapter 4 focuses on the feasibility of implementing a screen, treat, and vaccinate health 
intervention for the prevention of HBV MTCT. The feasibility is assessed in terms of the rate 
of HBV MTCT, defined as the number of perinatal HBV infections detected in mother-child 
pairs in the studied cohort. In an attempt to identify those at risk of HBV, the risk factors 
associated with HBsAg seropositivity in the studied cohort are also reported. 
The costs, as well as the health consequences of this intervention, are reported through a cost-
effectiveness analysis in Chapter 5. This chapter also reports on the costs and health benefits 
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of the current strategy in place in Namibia for the prevention of HBV MTCT and universal BD 
vaccination alone. 
Chapter 6 summarizes the significance of findings presented in chapters 3, 4 and 5 and 
discusses their implications for addressing HBV MTCT in both Namibia and SSA. Concluding 
remarks are also presented. 
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CHAPTER 2: Literature Review 
This chapter describes hepatitis B virus (HBV) and its epidemiology, specifically within the 
obstetrics and pediatric populations in sub-Saharan Africa (SSA). This is followed by a 
breakdown of the natural history of the infection and available HBV diagnostic technologies. 
The dynamics of transmission of the virus within the African population are also elaborated 
on, with a focus on mother-to-child transmission (MTCT). The strategies to prevent 
transmission are reviewed, and finally, economic evaluations of the different prophylactic 
options are discussed. 
2.1 Virology of hepatitis B virus 
2.1.1 Viral taxonomy 
HBV is a prototype of the Hepadnaviridae family of small hepatotropic enveloped DNA 
viruses. Viruses within this family are grouped in two genera: while Avihepadnaviruses infect 
birds, Orthohepadnaviruses mainly infects mammals. Members of the Orthohepadnaviruses 
genus include HBV, the Woodchuck Hepatitis Virus (WHV) and Ground Squirrel Hepatitis 
Virus (GSHV) affecting humans and apes, woodchucks, and ground squirrels, respectively 
(Howard, 1994). 
2.1.2 Viral morphology  
Electron microscopy of the virus reveals the presence of three morphologically distinct forms 
of the virus. Spherical and filamentous particles of 20-22 nm in diameter are distinguished from 
a double-shelled particle of 42 nm in diameter; that is the complete virion known as the Dane 
particle (Dane, Cameron & Briggs, 1970). The virion is surrounded by the Envelope – a lipid 
bilayer in which are embedded viral surface proteins (HBsAg). This bilayer protects an 
icosahedral nucleocapsid core enclosing the DNA genome, the core antigen (HBcAg) and the 
e antigen (HBeAg). The 20 nm particles, referred to as the sub-viral particles (SVPs), do not 
contain the viral genome (Farag & Mansour, 2016) and are not infectious. They represent an 
excess of the HBsAg produced during viral replication, usually exceeding the concentration of 
Dane particles by a factor of 103 to 105 (Howard, 1986; Ganem & Prince, 2004). SVPs are 
thought to play a role in immune evasion (Ganem, 1991; Ortega-Prieto & Dorner, 2017), 
and appear to increase HBV infectivity (Bruns et al., 1998). 
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2.1.3 Organization of the HBV genome 
The HBV genome is a partially double-stranded deoxyribonucleic acid (DNA) molecule 
consisting of a 3200 base pairs (bp) complete (+) strand and an incomplete (-) strand, shorter 
by about 700 nucleotides (nt) (~2500 bp). The DNA molecule is held in a circular conformation 
by a cohesive overlap between the 5’ends of the two DNA strands. The viral proteins are 
encoded by four open reading frames (ORFs) namely polymerase, surface, core, and X, 
overlapping each other (See Figure 2.1) (Howard, 1986; Ganem & Prince, 2004). The 
polymerase (P) ORF is made of three functional domains namely: the terminal protein (TP) –
priming domain involved in the priming of the minus strand synthesis (initiation of reverse 
transcription), the reverse transcriptase (RT) domain coding for the viral Polymerase enzyme 
used during viral replication, and the RNase H domain. The RNase H domain encodes the 
RNase H enzyme that cleaves the template messenger ribonucleic acid (mRNA) used for the 
synthesis of the minus DNA strand during reverse transcription. The surface (S) ORF encodes 
for the large (LHBs), middle (MHBs) and small (SHBs) surface glycoproteins. The translation 
of these proteins is initiated by three distinct start codons situated in the S, pre-S2 and pre-S1 
domains, coding for LHBs, MHBs and SHBs, respectively. All proteins share a common C-
terminus. Pre-core (pre-C) and core are encoded from the core ORF through two in-frame 
initiation start sites (AUG), yielding two small proteins. Synthesis of the Core protein (HBcAg) 
is prompted by the translation of the internal AUG (Glebe & Bremer, 2013). HBcAg is a 
structural protein that is essential for viral assembly and encapsidation of the viral genome and 
polymerase (Birnbaum & Nassal, 1990). The translation of the upstream AUG results in the 
synthesis of a precursor polypeptide. Further processing of this polypeptide in the cells’ 
endoplasmic reticulum leads to the secretion of a non-structural protein named hepatitis B e 
antigen (HBeAg). HBeAg plays no role in the viral life cycle but is a serological marker of 
high viral replication. It is used as a proxy to assess infectivity (Siegert et al., 1979). The 
protein behaves like an immune tolerogen, and as such has been associated with the 
establishment of viral chronicity (Milich et al., 1990; Chen et al., 2004; Walsh & Locarnini, 
2012). The smallest ORF codes for a 154 amino acid (aa) long regulatory protein called the X 
protein. HBx is a multi-functional protein that modulates a number of host and cellular 
processes, such as signal transduction and gene expression (Ganem & Prince, 2004; 
Bouchard & Schneider, 2004). The protein is essential in initiating and maintaining viral 
replication post infection (Lucifora et al., 2011), and has been associated with HBV-induced 
hepatocarcinogenesis (Poussin et al., 1999; Zhang et al., 2005; Park et al., 2007). 
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Figure 2.1: The genome of the hepatitis B virus (HBV). The 3.2kb DNA genome is double-stranded 
with a complete minus (-) strand and the incomplete plus (+) strand. The genome consists of four 
overlapping frames (ORFs): P, S, C and X. Four polyadenylated 3‘co-terminal RNAs of different length 
((0.7kb, 2.1kb, 2.4kb and 3.5 kb; represented as black circles), initiated by four viral promoters (pre-C, 
preS1, preS2/S and HBx; in blue) and two enhancers (Enh1 and Enh2; in red) are used for viral 
transcription of these four ORFs. During the viral replication cycle, the pre-genome transcript of 3.5kb 
(pgRNA) is translated to the core protein (the ORF in black), and the viral polymerase (the ORF in 
green). The other lengthy transcript serves for the expression of the core protein as well as the HBeAg 
protein. The 2.4 kb mRNA transcript is translated to the large HBV surface protein (LHB; the yellow, 
orange and red segments of the S ORF) whilst the middle (MHBs; the red and orange segments of the 
S ORF), and small (SHBs; the red segment of the S ORF) proteins are encoded from the 2.1kb transcript. 
The smallest mRNA (0.7kb) encodes the X protein (the ORF in purple). Ε (epsilon) is the signal located 
in the pgRNA. PRE, posttranscriptional regulatory element, allows the nuclear export of viral mRNAs 
without splicing (Nassal & Schaller, 1993; Harrison, Dusheiko & Zuckerman, 2009; Glebe & 
Bremer, 2013). Reproduced from Glebe & Bremer, 2013 with permission. 
2.1.4 Viral molecular diversity 
To date, HBV has evolved to ten phylogenetically distinct genotypes, defined as divergence 
greater than 8% at the nucleotide level across the complete genomic sequence. These genotypes 
are named A to J (Table 2.1). Genotypes A, B, C, D, and F are further classified in sub-
genotypes, with a 4% intergroup difference in the surface gene (Lin & Kao, 2017). Little is 
known about genotypes I and J that seem to be products of recombination events between other 
HBV genotypes (Tran, Trinh & Abe, 2008; Tatematsu et al., 2009). Figure 2.2 depicts the 
geographical distribution of HBV genotypes. 
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The molecular diversity of the virus has been implicated as one, among other factors, in the 
pathogenesis and pattern of transmission of HBV. Genotypes B and C prevail in Southeast 
Asia, where perinatal transmission of the virus is commonly observed. The predominance of 
this mode of transmission has been attributed to the high HBeAg seropositivity rate (indicative 
of high viral replication) of HBV infection observed in women of child-bearing age in the 
region (Okada et al., 1976; Tran et al., 2015). HBV genotype C infection has been associated 
with an increased risk of HCC compared to HBV genotype B-related infections (Yang et al., 
2008). In Africa, genotypes A (sub-genotypes A1, A3, and A4), D (sub-genotypes D1 and D3) 
and E are found. Genotype A is predominantly found in SSA, followed by genotype D. Whilst 
genotype E is more common in West and Central Africa, forming the “genotype E crescent”. 
Reports of this strain outside of the region follow migration patterns from Africa and is often 
seen among West African immigrants elsewhere (Palumbo et al., 2007; Rivas et al., 2013; 
Thurnheer et al., 2017; Malagnino et al., 2018). Compared to patients infected with genotype 
B and C strains, early seroconversion from HBeAg positive to HBeAg negative is seen in 
individuals infected with genotype A or D viruses (Livingston et al., 2007). Consequently, a 
lower rate of HBeAg positivity is usually found among pregnant women in Africa; thus, 
horizontal transmission prevails over perinatal transmission in the region (Derso et al., 1978; 
Sellier et al., 2015). With regards to pathogenesis in African populations, a greater 
hepatocarcinogenic potential is seen among patients chronically infected with HBV genotype 
A compared to carriers of genotype D (Kew et al., 2005). Earlier HBeAg seroconversion and 
decay of viral replication, and a lower frequency of HCC were observed among patients 
infected with HBV genotype E compared to genotype A infections (Shimakawa et al., 2016a). 
A higher prevalence of genomic mutations in the core gene has also been reported among HBV 
genotype E-infected patients in comparison to genotype A- and D-infected patients 
(Thurnheer et al., 2017). Genotype F, with four sub-genotypes (F1 – F4), has been isolated in 
Central and South America (Kramvis, 2014). Reports of genotype G viruses come from 
France, Germany and the United States (Stuyver et al., 2000; Lin & Kao, 2017). Interestingly, 
HBV genotype G-related infections can only be established in the presence of other HBV 
genotypes, mainly genotype A. Phylogenetically this genotype seems to be closer to genotype 
E, owing to a shared unique 30-basepair segment in the pre-S region (Lindh, 2005; Kramvis, 
2014). Genotype H is also found in Central America and Mexico (Lin & Kao, 2017). The new 
I and J genotypes were isolated in Vietnam and Laos (Tran, Trinh & Abe, 2008; Thuy et al., 
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2010) and Japan (Tatematsu et al., 2009). Very little is known with regards to the pathogenesis 
of these viruses. 
Table 2.1: Virological characteristics of HBV genotypes (Kramvis, 2014). Reproduced with 
permission, S. Karger AG Publishers. 
Genotype Length (kb) Differentiating features Sub-genotypes 
A 3221 6-nucleotide insert at 
carboxyl end of core gene 
A1, A2, quasi-sub-
genotype A3 (A3, A4, 
A5)*, A4 (A6) 
B 3215  B1, B2, quasi-sub-
genotype B3 (B3, B5, 
B7–B9, B6 China)* B4, 
B5 (B6)* 
C 3215  C1, quasi-sub-genotype 
C2 (C2, C14, undefined 
sequences)*, C3, C4, C5, 
C6 – C12, C13 – C15, 
C16 
D 3182 33-nucleotide deletion at the amino 
terminus of the preS1 region 
D1, D2, D3, D4, D5, D6 
E 3212 3-nucleotide deletion at the amino 
terminus of the preS1 region 
 
F 3215  F1, F2, F3, F4 
G 3248 36-nucleotide insert, 3′ of position 
1905; 3-nucleotide deletion at the 
amino terminus of the preS1 region; 
stop codons at positions 2 and 28 of 
the pre-C region 
 
H 3215   
I 3215  I1, I2 
J 3182 33-nucleotide deletion at the amino 
terminus of the preS1 region 
 
*Earlier sub-genotype designation  
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Figure 2.2: Geographic distribution of HBV genotypes. This map presents the global distribution of 
HBV genotypes. Genotypes A, E, and D are predominantly seen in Africa; with genotype E constrained 
in West Africa, genotype D dominating Northern Africa and genotype A found in Southern and Eastern 
Africa. A mixture of these strains is found in Northern and Southern Africa. Central America and 
Southern America are dominated by genotype F. Genotypes B and C are found in Asia. The numbers 
seen next to the pie charts represent the number of isolates genotyped. (Kramvis, Kew & François, 
2005). Reproduced from Kramvis, Kew & François, 2005 with permission. 
2.1.5 Viral genomic mutations 
A unique feature of HBV, as a DNA virus, is its replication strategy. Viral replication includes 
a reverse transcription step, catalyzed through the HBV-encoded RT enzyme. However, the 
lack of proofreading activity of the RT enzyme leads to transcription errors, resulting in 
nucleotide substitutions. The frequency of substitution is currently accepted at about 10-4 to 10-
5 nucleotide substitutions per site per year (s/s/t) (Zhou & Holmes, 2007; Harrison et al., 
2011). However, recent data suggest that substitution may be occurring at a slower rate of 10-
6 to 10-7 s/s/t (Littlejohn, Locarnini & Yuen, 2016). The overlap of the viral ORFs means that 
a substitution may affect two frames and possibly lead to a change in amino acids of either or 
both proteins. These substitutions may have consequences for therapy or prevention, which 
may be beneficial or harmful to the host. 
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Mutations in the polymerase gene 
The most common group of mutations described in the polymerase gene are found in the 
tyrosine-methionine-aspartate-aspartate (YMDD) motif, the catalytic site of the DNA 
polymerase enzyme involved in viral replication (Cai et al., 2016; Mokaya et al., 2018). The 
selection of mutations in this genomic region is induced by prolonged therapy with anti-HBV 
nucleos(t)ide analogs targeting the YMDD motif. Seven oral anti-HBV nucleos(t)ide analogs 
have been approved by the United States of America (USA) Food and Drug Administration 
(FDA). These are adefovir (Gilead Sciences, California, USA), emtricitabine (Gilead 
Sciences), entecavir (Bristol-Myers Squibb, New York City, USA), lamivudine 
(GlaxoSmithKline, Middlesex, United Kingdom (UK)), telbivudine (Novartis, Basel, 
Switzerland), and tenofovir (tenofovir disoproxil fumarate (TDF), and recently available as the 
prodrug tenofovir alafenamide fumarate (TAF) (Gilead Sciences). The pressure induced by 
these drugs may lead to the selection of adaptive mutations that reduce the sensitivity of the 
virus to the hindering effects of the drugs, thereby causing antiviral resistance. Polymerase 
mutations are frequently observed in patients following lamivudine-based antiviral therapy. 
Antiviral resistance to this drug requires the selection of a single mutation: rtM204V/I (Allen 
et al., 1998; Ono-Nita et al., 1999). The selection of this mutant also causes resistance to 
emtricitabine and telbivudine. The presence of the rtM204V/I has been detected in 70% of 
HBV mono-infected (Lok et al., 2003; Lai et al, 2003) and 90% of HIV/HBV co-infected 
patients (Benhamou et al., 1999), after four years of monotherapy with lamivudine (Figure 
2.3). On the other hand, resistance to emtricitabine is noted in 18% of HBV mono-infected 
patients following two years of therapy (Gish et al., 2005). In the same timeframe, 25% of 
HBeAg positive and 11% of HBeAg negative patients would mount resistance against 
telbivudine (Liaw et al., 2009). The selection of rtN236T or rtA181V/T mutants confers viral 
resistance to adefovir and happens following five years of therapy at a rate of 30% 
(Hadziyannis et al., 2005, 2006). Entecavir has a lower resistance rate of 1.2% among 
treatment-naïve patients following five years of monotherapy. Viral resistance to the drug is 
due to the selection of three missense mutations: rtL180M, rtM204V and either rtT184G/S or 
rtS202I/G or rtM250V (Tenney et al., 2009). Unlike the other nucleos(t)ide analogs, the 
primary mutation associated with TDF resistance has not been clearly defined. Conflicting 
results have been reported concerning the rtA194T change as a TDF-resistant substitution 
(Sheldon et al., 2005; Delaney et al., 2006; Amini-Bavil-Olyaee et al., 2009), but require 
further investigations. Still, reduced susceptibility to the drug has been observed in the presence 
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of the aa substitutions rtP177G and rtF249A (Qin et al., 2013), and rtN236T+ rtA181T 
(Murakami et al., 2016) through in vivo and in vitro models. Virological breakthrough has 
also been noted among TDF-treated patients harboring multi-site RT mutations including 
rtL80M, rtL180M, rtM204V/I, rtA200V, rtF221Y, rtS223A, rtT184A/L, rtR153Q, and rtV191I 
(Lee et al., 2014), and more recently the rtS78T aa substitution (Shirvani-Dastgerdi et al., 
2017). To date, no mutation associated with TAF has been reported. A summary of drug 
resistance-associated mutations is outlined in Table 2.2 below.  
 
Figure 2.3: The cumulative incidence rate of resistance following anti-HBV therapy in HBV 
mono-infected patients. The incidence rate portrayed for adefovir concerns HBeAg negative patients 
(De Clercq, 2015). Reproduced with permission. 
Table 2.2: Amino acid substitutions in the RT region of the polymerase gene associated with 
nucleoside analog resistance. (Menéndez-Arias, Alvarez & Pacheco, 2014). Reproduced with 
permission. 
Antiviral drug Major mutations 
Adefovir rtL80I/V, rtA181S, rtA181T, rtA181V, rtE218G, rtN236T 
Emtricitabine rtA181S, rtM204I/V 
Entecavir rtI169T, rtT184A/F/G/L/M/S, rtS202C/G/I, rtM204I/V, rtM250I/V/L 
Lamivudine rtL80I/V, rtV173L, rtL180M, rtA181S, rtA181T, rtT184S, rtM204I/V, 
rtM204Q, rtV207I 
Telbivudine rtM204I/V 
Tenofovir rtS78T, rtP177G, rtA181S, rtA181T, rtN236T, rtF249A 
Underlined bold amino acid substitutions are primary mutations and by themselves confer high-level 
resistance to the drug. Important resistance mutations are indicated in bold. 
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Mutations in the surface gene 
Amino acid changes in the surface gene, precisely the S domain of the gene, may arise as a 
result of nucleos(t)ide analog-resistance mutations in the overlapping RT domain of the 
polymerase gene. These changes are commonly referred to as antiviral drug-associated S gene 
mutations. From a clinical and public health perspective, the selection of these mutants may 
have diagnostic repercussions in the form of false-negative HBsAg serology results, or lead to 
vaccine escape where the RT changes cause alterations in the “a” determinant of the HBsAg 
protein (Pollicino et al., 2014; Zhang et al., 2016; Valaydon & Locarnini, 2017). The pre-S 
domain is also prone to alterations ranging from deletions, insertions, to missense mutations. 
As illustrated in Figure 2.4, several epitopes for T and B cells are found in the pre-S1 and pre-
S2 domains; hence play essential roles in the interaction with the host immune system (Chen, 
2018). In-frame deletions may, therefore, serve as a mechanism of viral immune escape. Pre-S 
mutations have been extensively described among genotypes B and C patients (Liu et al., 
2009; Wang et al., 2015a; Chen, 2016). Still, pre-S2 deletions have also been observed in 
HBV genotype D and genotype A patients co-infected with HIV in South Africa (Makondo et 
al., 2012). Then again, Biswas et al. (2012) observed pre-S1 deletions and pre-S2 start codon 
mutations among genotype D and A infected patients, respectively, in Eastern India (Biswas 
et al., 2012). The oncogenic potential of mutations in these two genomic domains, mostly the 
pre-S2, has been well studied in Asia. Case-control Asian studies have reported a higher 
prevalence of in-frame deletions in HCC patients as compared to non-HCC patients (Qu et al., 
2014a; Zhang et al., 2015), thereby suggesting their potential role in HCC risk prediction. 
Longitudinal studies have demonstrated a cumulative selection of pre-S mutations as the 
chronic disease progresses, leading to the development of HCC (Qu et al., 2014a; Zhang et 
al., 2015, 2017). 
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Figure 2.4: Immune epitopes and functional domains in the pre-S1 and pre-S2 domains. The pre-
S1 domain consists of an N-terminus (amino acids 1-57) and a C-terminus (amino acids 58-119); both 
form a total of 119 amino acids. The pre-S2 domain is made up of 55 amino acids (amino acids 120-
174). Myristylation at the second amino acid is represented by the black triangle. The N-link 
glycosylation at N-4 of the MHB protein is denoted by the white triangle indicates, and the O-link 
glycosylation at T-37 of the MHB protein is shown by the gray triangle. The B-epitopes are pS1-B1, 
pS1-B2, pS2-B1, pS2-B2, and pS2-B3. T-epitopes are pS1-T1 and pS2-T1. B- and T-epitope: pS1-BT 
(Chen, 2018). Reproduced with permission, Baishideng Publishing Group. 
Mutations in the core gene 
Pre-core (pre-C) and basal core promoter (BCP) mutations are the most common and the largest 
group of mutants described in the core gene. Pre-C mutants have been associated with reduced 
or abolished expression of the HBeAg protein. The most common pre-C mutation is G1896A. 
The mutation creates a stop codon TAG at nucleotide (nt) 1896 (or codon 28: TGG). G1896A 
occurs in the encapsidation signal (ε) structure of the pre-C region and stops the production of 
HBeAg at a translational level without affecting viral replication (Jammeh et al., 2008). The 
mutant enables the stabilization of the ε structure by maintaining its stem-loop structure, 
through base pairing between nt 1858 and nt 1896 (Lok et al., 1994). The incidence of the 
mutant would depend on the base at position 1858. T-A pairing is more stable than T-G pairing 
(Lok et al., 1994); thus the mutant is frequently found in genotypes with a T1858 such as 
genotypes B, C, D, and E. C1858 is found in genotypes A and F, hence the rare occurrence of 
the G1896A mutant in these two genotypes (Caligiuri et al., 2016). The G1896 stop mutation 
may or may not occur in conjunction with G1899A. Selection of both mutations was shown to 
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increase the stability of the ε stem-loop structure (Lok et al., 1994). BCP mutants, on the other 
hand, may influence both viral replication and the expression of HBeAg. For instance, the 
C1766T/T1768A double BCP variant has demonstrated enhanced production of both viral 
particles, and of HBeAg as compared to wild-type viruses in transfection studies (Jammeh et 
al., 2008). Other BCP nucleotide substitutions may take place at positions 1653, 1753-1757, 
1762 and 1764. These changes may or may not occur together, and have been associated with 
upregulation of viral DNA replication while having an effect on the production of HBeAg 
(Quarleri, 2014; Caligiuri et al., 2016; Zhang et al., 2016). Interestingly, the combined 
presence of both BCP and pre-C variants have been associated with advanced liver disease, as 
demonstrated by Asian studies, and may be used in algorithms for liver disease prediction 
(Jang et al., 2012; Lyu et al., 2013; Park et al., 2014; Qu et al., 2014b; Lapalus et al., 2015; 
Tseng et al., 2015). Viral changes can also take place in the upstream part of the core promoter, 
known as the upper regulatory region (URR) (Figure 2.5). The URR comprises both positive 
and negative regulatory elements that modulate the transcription of both the pre-C messenger 
RNA (mRNA) and pregenomic RNA (pgRNA) (Kramvis & Kew, 1999). Limited data are 
available on the type and effects of variants in this genomic domain.  
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Figure 2.5: Molecular structure of the HBV core promoter. The core promoter (CP) (nt 1613-1849) 
encloses two domains namely the upper regulatory region (URR) and the basic core promoter (BCP). 
The URR comprises a negative regulatory element (NRE) and a core upstream regulatory sequence 
(CURS). The CURS is further divided in CURS-A and CURS-B domains. The enhancer II and binding 
sites hepatocyte nuclear factor 1, 3 and 4 (HNF1, HNF3, HNF4) are shown. SPI: S promoter; DR: direct 
repeat (Quarleri, 2014). Reproduced with permission, Baishideng Publishing Group. 
Mutations in the X gene 
Figure 2.5 above shows overlapping of the CP with the 3’end of the X gene. Therefore, changes 
in the CP may affect the overlapping sequence in the X gene; as presented in Figure 2.6. As an 
example, the well-described A1762T/G1764A double BCP mutation leads to the amino acid 
changes K130M and V131I in the X gene. As most other viral genomic mutations described so 
far, the presence of HBx mutants has also been related to hepatocarcinogenesis (Kim et al., 
2016). Among these mutants, K130M, V131I, H94Y (BCP mutant C1653T), and I127L,T,N,S 
(BCP mutant T1753V) have been frequently reported (Kim et al., 2016).  
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Figure 2.6: Molecular structure of the X gene. The X gene is 465 bp long (nt 1374 -1838) and 
comprises two domains: the regulatory domain (nt 1374-1523) and the transactivation domain (nt 1524-
1838). The overlaps with the core promoter (nt1362-1383), enhancer II (1636-1744) and the 
microRNA-binding region (nt 1362 to 1383) are shown. The most frequent viral variants are shown too 
(Kim et al., 2016). Reproduced with permission, Baishideng Publishing Group. 
2.2 Epidemiology of HBV infection in sub-Saharan Africa 
According to recent estimates on the global burden of viral hepatitis from the World Health 
Organization (WHO), about 257 million individuals are affected by HBV; translating to a 
global prevalence of 3.5% (WHO, 2017a). The HBV burden is distributed unevenly across the 
world and between different population groups.  
After the West Pacific region, Africa is the second most affected area with chronic hepatitis B 
(CHB) infection. The regional prevalence of the infection is estimated at 6.1% (95% 
uncertainty interval: 4.6% – 8.5%). This translates to 60 million chronic carriers at high risk of 
developing end-stage liver diseases. These cases are not spread evenly across the African 
continent (WHO, 2017a). Prevalence rates up to 15% are reported in West Africa (Schweitzer 
et al., 2015). In a recent population screening in Southern Nigeria, the authors described an 
HBsAg seroprevalence of 8.8% among 1365 adults (Okonkwo et al., 2017). This is lower than 
the 2013 national prevalence reported at 13.6% (95% confidence interval [CI]: 11.5% - 15.7%) 
(Musa et al., 2015). A 9.8% prevalence was observed among 2207 individuals screened in 
Ouagadougou, Burkina Faso (Diarra et al., 2017). An even higher prevalence, 13.7%, was 
observed in Sierra Leone (Ansumana et al., 2018). Studies in Central Africa have reported 
infection rates of 10.6%, 9.3% and 10.6% in Cameroon (Bigna et al., 2017), Angola 
(Guimarães Nebenzahl et al., 2013) and rural Gabon (Komas et al., 2013), respectively. A 
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recent study in South West Chad reported a significantly higher seroprevalence of HBsAg 
among 1309 individuals (22.9%) (Suesstrunk & Djongali, 2017). Southern Africa is not 
spared. Interestingly, HBV epidemiology has been investigated predominantly in the HIV-
infected population, most probably owing to the high burden of both viruses in this region. 
HIV/HBV co-infection rates of 6.6%, 11.3%, and 7.6% have been lately reported in Tanzania 
(Kilonzo et al., 2017), Zambia (Wandeler et al., 2016), and Mozambique (Wandeler et al., 
2016), respectively. While HBV statistics are widely available from other parts of Southern 
Africa, the burden of the infection in Namibia is not well known. Available HBsAg 
seroprevalence figures originate from earlier studies conducted in the northern part of the 
country. These include a 1983 research study among the general population living in the 
Kavango province, where the authors detected a 13.6% HBsAg carrier state (Joubert et al., 
1985). In Eastern Caprivi, Joubert et al. (1991) noticed an 18.95% (90/475) HBs antigenemia 
in males as compared to 10.71% (45/419) found in females (Joubert et al., 1991). However, 
current national data are lacking. 
2.2.1 Epidemiology of HBV infection in pregnant women 
Rates of HBV infection have been studied in pregnant women in SSA. This population has 
been extensively studied in Nigeria; where a national seroprevalence of 14.1% within this 
population was observed (Musa et al., 2015). This is slightly higher than the 13.1% pooled 
seroprevalence described in Ghana (Ofori-Asenso & Agyeman, 2016). Other West African 
countries reported HBsAg seropositivity rate of 8.0%, 10.7% and 15.2% in Mali (MacLean et 
al., 2012), Mauritania (Mansour et al., 2012) and Burkina Faso (Sanou et al., 2018), 
respectively. Rates in Ethiopia range from 3.8% in the northern part of the country (Zenebe et 
al., 2014) to 7.8% in southern Ethiopia (Metaferia, Dessie & Amsalu, 2016). Similar rates 
have been described in Kenya (3.8%, Ngaira et al., 2016), Rwanda (3.7%, Mutagoma et al., 
2017) and in Tanzania (8%, Manyahi et al., 2017). In Cape Town, South Africa, a 4.5% 
HBsAg seroprevalence was described among 134 HIV-uninfected pregnant women (Chotun 
et al., 2017). This rate was similar to the 2.9% described in 2013 among HIV-uninfected 
pregnant women in the Western Cape Province, South Africa (Andersson et al., 2013). On the 
other hand, these rates are significantly higher than the 0.8% (18/2368) reported in the Tshwane 
district, South Africa (Diale et al., 2016); suggesting heterogeneity between provinces in the 
country. A similar provincial heterogeneity of the prevalence of the infection is seen in 
Namibia. While a pooled prevalence of HBsAg of 7.3% was described in 2013 within the 
Stellenbosch University https://scholar.sun.ac.za
20 
 
national obstetrics population, rates as high as 10.1% and as low as 5.6% were described in 
provinces of the country (Mhata et al., 2017). It is important to note that the retrospective 
study conducted by Mhata et al. (2017) is the only one, to date, investigating HBV infection 
among pregnant women in Namibia.  
While appreciating that these statistics are already quite high in the HIV-uninfected antenatal 
population, higher rates are found among HIV-infected pregnant women. Chasela et al. (2014) 
found a 5% HBV infection rate among HIV-infected pregnant women in Malawi (Chasela et 
al., 2014). A comparable HIV/HBV co-infection rate of 4.1% was described in Rwanda 
(Mutagoma et al., 2017). Among 1543 HIV-infected pregnant women screened in the Western 
Cape Province of South Africa, 3.4% (53) tested HBsAg positive (Andersson et al., 2013). In 
the province of KwaZulu-Natal, South Africa, a higher HBsAg prevalence was found in HIV-
infected (7.4%; 16/215) as compared to HIV-uninfected (14/294; 4.8%) (Thumbiran et al., 
2014). Looking at Central Africa, of 650 pregnant women tested in Yaoundé, Cameroon, 
7.85% (51) tested positive for HBsAg; among whom 28/301 (9.3%) were HIV/HBV co-
infected, and 23/349 (6.59%) were HBV mono-infected (Kfutwah, Tejiokem & Njouom, 
2012). Despite this high burden of HBV infection within the antenatal population, routine 
screening of pregnant women for HBV is not offered in most parts of SSA. The high prevalence 
of HBV infection in pregnant women also raises concerns regarding the rates of vertical 
transmission of HBV to infants in SSA. 
2.2.2 Epidemiology of HBV infection in children 
HBV epidemiological data in the pediatric population are limited. A cross-sectional study 
conducted in the Central African Republic, Cameroon and Senegal in 2009-2010 among 
hospitalized children between the ages of three months and six years described HBV 
prevalence rates of 5.1%, 0.7%, and 0.2%, respectively (Rey-Cuille et al., 2013). On the other 
hand, a national survey conducted in Nigeria found HBs antigenemia in 9.8% (4/41) of children 
below the age of 10 years (Olayinka et al., 2016). This figure is quite high in comparison to 
those of South Africa, where rates of HBsAg range between 0.4% (Chotun et al., 2015) and 
0.8% (Jooste et al., 2016); the higher bound represented the prevalence among HIV-infected 
children. HBV seems to be relatively common among HIV-infected children in SSA. A recent 
seroprevalence study in Malawi found a low HBsAg positivity status of 2.2% (2/91) among 
HIV-infected children aged between three months and less than 15 years (Varo et al., 2016). 
Pediatric HIV/HBV co-infection rates described in other Southern African countries such as 
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Tanzania (Muro et al., 2013) and Zambia (Peebles et al., 2015) are higher, with a prevalence 
of 7.0% and 10.4%, respectively. In the Zambian study, the authors distinguished the 
prevalence of HBsAg between children and adolescents born prior and post-implementation of 
HBV immunization starting at six weeks: 11.8% compared to 6.6% (p = 0.24), respectively 
(Peebles et al., 2015). Data from Namibia revealed an 8.7% prevalence of HBV in 1057 HIV-
infected children and adolescents (older than18 years). Children below the age of one year 
showed an approximate 6.5% HBsAg seropositivity rate (Brandt et al., 2012). These statistics 
are indicative of the presence of a reservoir of chronic HBV infections in SSA. 
2.3 Natural history and pathogenesis of HBV infection 
As mentioned earlier, primary infection with HBV may cause an acute transient infection 
leading to acute or in severe cases of fulminant hepatitis. The infection may thereafter persist, 
leading to a chronic state; the risk for this depends on the age at which the infection is acquired.  
2.3.1 Acute hepatitis B infection 
Acute hepatitis B is characterized by self-limited inflammation of the liver cells ending with 
the formation of lasting immunity (Figure 2.7). The infection can be asymptomatic or 
symptomatic; the former occurs more often than the latter. Asymptomatic hepatitis is 
commonly seen in adults, while only about 10% of children between the age of one and five 
years old develop a symptomatic infection (Ganem & Prince, 2004). Following a one to four 
months incubation period, from primary infection with the virus, HBsAg is produced. Soon 
after, HBeAg and HBV DNA can be detected. Antibodies to HBcAg (anti-HBc), of the IgM 
isotype (IgM anti-HBc), follow approximately one to two weeks later and remain detectable 
for up to six months post clearance of circulating HBsAg. As the infection progresses, HBsAg 
and IgM anti-HBc are cleared, leaving antibodies against HBsAg (anti-HBs) and total 
antibodies to anti-HBc (anti-HBc (total)). Anti-HBc (total) persists for life and is often used as 
a serological marker to determine past HBV infection. Anti-HBs, in contrast, tends to wane 
over time. This marker is used to determine immunity against the virus and usually develops 
following active immunization against HBV. Although short-lived in approximately 95% of 
adult cases, acute HBV infection may carry on in about 5% of adult cases, developing to 
persistent infection (Hyams, 1995; Liaw & Chu, 2009). 
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Figure 2.7: Clinical course of acute hepatitis B infection. A: HBV markers changes in acute HBV 
infection. From 3-4 weeks of acquisition of the virus, HBsAg can be detected. The production of HBeAg 
and HBV DNA follows. Within approximately two months of the infection, anti-HBc IgM and anti-
HBc IgG can be detected. As the levels of anti-HBc IgM decline, anti-HBs are produced by the immune 
system and persist for life. Flares of ALT are detected following the appearance of HBc antibodies too. 
B: Transition of acute to chronic HBV infection. It is characterized by the persistence of HBsAg and 
HBV DNA (Trepo, Chan & Lok, 2014). Reproduced with permission from Trepo, Chan & Lok, 2014.  
2.3.2 Chronic hepatitis B infection 
Chronic hepatitis B (CHB) infection is defined as the persistence of HBsAg in serum for more 
than six months, following an acute infection. HBV DNA viremia and HBe antigenemia persist 
too, and anti-HBs do not become detectable. CHB develops in about 90% of neonates born to 
HBsAg/HBeAg positive mothers and 30% of neonates of HBsAg positive/HBeAg negative 
mothers (Beasley et al., 1977). Persistent HBV infection occurs in 30% to 50% of childhood 
infections acquired between the age of one and six years old (Hyams, 1995). The immaturity 
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of the immune system of these infants and children may be responsible for the high rate of 
chronicity of HBV seen among this young age group. The immune tolerance developed by the 
fetus, as a result of the maternal transplacental transfer of HBeAg, also plays a role in the 
development of chronicity in neonates exposed to HBeAg in utero (Milich & Liang, 2003). 
Based on the host immune response towards the hepatic inflammation and HBV replication 
level, the natural course of CHB is broken down to at least five major clinical phases, see Figure 
2.8. 
(1) The initial high replicative, low inflammatory phase 
This phase clinically presents with high viremia (HBV DNA levels above 108 IU/ml), a 
seropositive status for HBeAg, minimal or no necroinflammation of the liver, and normal 
aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels. Failure of the 
host immune system to recognize the virus as foreign has been attributed to the exhaustion of 
the HBV-specific T-cells in the presence of high levels of HBeAg; hence the term “immune 
tolerant” to describe this phase (Hadziyannis, 2011; Yang & Kao, 2016). The duration of the 
immunotolerance phase varies according to the mode of acquisition of the infection. In 
vertically-acquired infections, immune tolerance may last for more than three decades, while 
it is short-lived and difficult to recognize in children infected through horizontal transmission 
(Yim & Lok, 2006). However, in the absence of HBeAg, brought about by the selection of 
viruses harboring mutations in the pre-C or CP regions of the pre-C/C gene, the 
immunotolerance is reduced. Then, the immune system slowly starts to recognize the foreign 
antigens, resulting in a strong immune response against the HBV-infected hepatocytes (Milich 
& Liang, 2003). HBeAg-negative infection may occur as the disease progresses or may result 
from perinatal transmission of an HBeAg negative virus. The former may be used as an 
indicator of entry of the patient in the “immune clearance” phase of CHB. On the other hand, 
materno-fetal transmission of HBeAg negative virus is a known cause of fulminant hepatitis in 
neonates (Chang et al., 1987; Beath et al., 1992; Liaw & Chu, 2009).  
(2) The immune clearance phase 
The mechanisms prompting the transition from the initial immune tolerance phase to this 
reactive phase remain unknown. The phase is marked by seroconversion from HBeAg to anti-
HBe. Fluctuations of ALT levels, ranging from 100 U/mL to more than 1000 U/mL, are 
observed; representing changes during the inflammation. The stronger the immune response, 
the higher the degree of inflammation and ALT levels; high ALT levels are associated with 
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increased liver injury (Liaw & Chu, 2009). A decrease of HBV DNA levels and 
seroconversion of HBeAg to anti-HBe eventually follow (Gish et al., 2015; Yang & Kao, 
2016). The duration of this phase with subsequent loss of HBeAg varies depending on age, the 
HBV genotype, the maternal HBsAg status, the mode of acquisition of the infection, and the 
geographic location (Yim & Lok, 2006). HBeAg clearance is rare in children. Spontaneous 
seroconversion to anti-HBe in perinatally-infected children younger than three years old occurs 
at a rate below 2% (Chang et al., 1989; Chang et al., 1995), and increases to 4% - 5% in 
children older than three years old in South-East Asia; where genotypes B and C predominate 
(Chang et al., 1989). On the other hand, a higher annual rate of 14% to 16% is recorded in the 
Euro-Mediterranean and African region; where genotypes A and D viruses are found, and 
horizontal transmission commonly happens (Iorio et al., 2007; Kramvis, 2016). A small 
proportion of patients would also experience a loss of HBsAg. However, the rate is as low as 
0.1% to 0.8% in children and increases to 0.4% - 2% in adults (Liu et al., 2010; Shimakawa 
et al., 2016a; Kramvis, 2016). 
It is noteworthy that the difference in the duration of the immune clearance phase between 
South-East Asia, Euro-Mediterranean and African countries may contribute to the different 
rates of liver cirrhosis and HCC between these regions. Delayed HBeAg seroconversion, as it 
is seen in south-East Asia, may lengthen liver inflammation, thereby prolonging the liver 
damage (Yim & Lok, 2006). Then again, following HBeAg seroconversion, the prognosis of 
the infection may not always be good but is dependent on the severity of the liver injury caused. 
(3) The HBeAg-negative chronic hepatitis phase 
During this phase, hepatic necroinflammation continues. It is characterized by fluctuating ALT 
levels and high to moderate viral loads, progressively leading to liver disease (Gish et al., 
2015; Kramvis, 2016). Abortion of the production of HBeAg, with no effects on viral 
replication from the selection of pre-C mutants such as the pre-C G1896A stop codon, may be 
attributed to this state of the infection (Hadziyannis, 2011). 
(4) The low replicative phase 
Previously referred to as the “inactive HBsAg carrier state’’. In this phase, patients present with 
normalization of ALT levels, low levels of serum HBV DNA (< 2000 IU/ mL), absence of 
HBeAg and the presence of anti-HBe (Gish et al., 2015; Kramvis, 2016; Yang & Kao, 2016). 
Patients often remain in this inactive state of the infection for a lifetime. Still, about 5% of them 
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could experience seroreversion to HBeAg. About 10% to 20% could revert to the HBeAg-
negative chronic hepatitis phase and may require antiviral treatment (Yang & Kao, 2016).  
(5) The reactivation phase 
Recurrence of viremia, reversion to HBeAg and ALT flares are seen at this stage of the chronic 
infection; resulting in an increased risk of developing liver cirrhosis, fibrosis and HCC 
(Kramvis, 2016). Immunosuppression brought by chemotherapy or any other 
immunosuppressive therapy as well as immunosuppressive infections may account for this 
viral rebound. As the immune system deteriorates, it fails to control the low level viral 
replication (McMahon, 2009). 
The rate of disease progression and the severity of the liver disease vary between individuals, 
depending on both viral and host factors. The former include HBV genotypes and mutations, 
as outlined in sections 2.1.4 and 2.1.5. Host factors such as gender and genetic variants have 
also been implicated in the pathogenesis of the disease. For instance, it is well established that 
men are more likely to develop CHB compared to women (Blumberg et al., 1972). Similarly, 
a higher prevalence of HBV-related end-stage liver diseases has been reported among men 
compared to women (Yuen et al., 2009; Stroffolini et al., 2015; Sun et al., 2017), due to the 
opposing effects of the sex hormones androgen and estrogen on the liver (Liu & Liu, 2014; 
Wang, Chen & Yeh, 2015). Polymorphisms in the human leukocyte antigen (HLA) classes II 
allele (HLA-II), especially HLA-DP, HLA-DQ, and HLA-DR, have also been associated with 
persistent HBV infection (Wong et al., 2013; Chang et al., 2014; Akgöllü et al., 2017), and 
with protection against CHB (Nishida et al., 2012; Trinks et al., 2017). 
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Figure 2.8: Clinical phases of chronic hepatitis infection. This figure depicts the clinical course of 
chronic hepatitis B (CHB) over the lifetime of the infected individual. Four phases are depicted on this 
figure namely (1) the immune tolerance, referred in the test as the initial high replicative, low 
inflammatory phase, (2) the immune clearance phase, (3) the inactive state, and (4) the reactivation 
phase. The selection of viral mutants over time is also displayed. As the infection progresses, viral 
genomic mutations may arise and may worsen liver damage (Yang & Kao, 2016). Reproduced with 
permission.  
2.4 Diagnostic testing for HBV infection 
Testing and diagnosis of HBV infections allow access to preventive measures and treatment 
services available, which are a key component in the control of HBV. Historically, diagnostic 
technology has influenced where testing could be performed. With technological 
improvements, testing can be decentralized from the laboratory setting to the point-of-care 
level.  
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2.4.1 Laboratory-based testing of HBV 
Laboratory assays remain the reference method for diagnostics worldwide, mainly due to their 
diagnostic and analytical accuracy. Current laboratory diagnostic technologies for HBV 
include both immune-based assays and nucleic acid-based assays.  
Immune-based assays 
HBV immune-based assays, also known as serological assays, are used to determine the 
presence or absence of viral antigens, such as HBsAg and HBeAg, and to assess the host 
immune response through measurement of host antibodies produced against the viral proteins 
(anti-HBs, anti-HBeAg, and anti-HBc). These assays are commonly found in the form of 
enzyme immunoassays (EIAs), chemiluminescence immunoassays (CLIAs) and 
electrochemiluminescence immunoassays (ECLIAs). These immunoassays differ by the modes 
of detection of immune complexes. EIAs are based on a calorimetric principle whereby the 
intensity of a color change, produced by a catalytic reaction between an enzyme bound to the 
antigen-antibody complexes present in the reaction and its substrate, is measured (Koivunen 
& Krogsrud, 2006). Results are recorded as optical density (OD) values. CLIAs and ECLIAs, 
on the other hand, measure a light signal emitted on antigen-antibody complexes bound to a 
chemiluminescent or electrochemiluminescent compound. The signal is normalized in relation 
to a signal to cut-off (S/CO) value. The OD and S/CO values obtained for the samples tested 
are compared to a cut-off value. This cut-off value is usually determined by calibration of the 
assay and specifies whether the analyzed specimen is considered reactive or non-reactive for 
the analyte sought.  
Although many of these assays offer excellent accuracy and allow a high-throughput of 
samples, they rely on the use of sophisticated equipment, a continuous supply of electricity, a 
high level of infrastructure (cold-storage, a temperature controlled-environment, precision 
pipettes, centrifuges, and computers), and can only be operated by skilled medical technologists 
(Villar et al., 2015; Peeling et al., 2017).  
Nucleic acid-based assays 
Nucleic acid testing (NAT) includes qualitative and quantitative methodologies for 
confirmation of the presence or absence of viral nucleic acid, and for measurement of the levels 
of viral DNA, respectively. The assay is most frequently performed using the polymerase chain 
reaction (PCR)-based technology. Alternative nucleic acid amplification technologies include 
loop-mediated isothermal amplification (LAMP), nucleic acid sequence-based amplification 
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(NASBA), ligase chain reaction (LCR), rolling circle amplification (RCA), and many more. 
All, but LCR which is similar to PCR, are isothermal amplification assays performed at a single 
temperature without the need of a thermal cycler (Fakruddin et al., 2013; Datta, Chatterjee 
& Veer, 2014). NAT is clinically performed to assess viral replication in HBV chronic patients, 
to guide treatment initiation and to monitor treatment response (Peeling et al., 2017). Antiviral 
drug resistance can also be detected through qualitative NAT, followed by viral genome 
sequencing in case of a positive result and viral genotyping (Villar et al., 2015). NAT assays 
are usually highly sensitive, with a possible limit of detection as low as six international units 
(IU)/ml (Villar et al., 2015). Similarly to laboratory-based immunoassays, considerable 
infrastructure and skilled staff are required, too. Owing to the high costs of these tests, they are 
not readily available in many resource-limited settings (RLS). 
2.4.2 Point-of-care testing of HBV 
Point-of-care (POC) testing (POCT) has traditionally been defined as rapid diagnostic testing 
performed at the level of patient care rather than in centrally localized laboratories (Kost et al., 
1999). While this was not previously feasible, today’s technologic advancements have 
facilitated the integration of traditional laboratory-based diagnostic assays performed on large 
and complex analyzers onto simplified, miniaturized and portable devices known as rapid 
diagnostic tests (RDTs). RDTs represent a potential diagnostic approach to improve the control 
and management of infectious diseases in many RLS, where advanced diagnostic resources are 
lacking. Unlike laboratory-based assays, they present with a simple format allowing for easy 
manipulation by trained lay providers or healthcare workers, low labor, low sample volume 
and rapid turnaround time (Kost et al., 1999; Hanafiah, Garcia & Anderson, 2013; 
Chevaliez & Pawlotsky, 2018). The majority of RDTs can be performed with capillary blood 
collected via finger-prick, thereby eliminating the need for venipuncture at the POC level. 
Many can also make use of venous blood, serum, plasma or oral fluid samples (Chevaliez & 
Pawlotsky, 2018). 
HBV RDTs exist in the form of lateral flow, flow through or agglutination 
immunochromatographic devices (Amini et al., 2017). The results are commonly displayed in 
the form of visible lines, appearing with different intensities that can be gauged by the naked 
eye. Several rapid tests exist for the qualitative assessment of HBsAg. To date, only a few of 
these assays are European Conformity (CE)-marked and WHO-prequalified (WHO, 2017c). 
Currently available and commercialized HBsAg rapid tests have been reported as reliable 
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diagnostic tools for HBV diagnosis in a few SSA countries including The Gambia (Njai et al., 
2015), South Africa (Chotun et al., 2017) and Zambia (Chisenga et al., 2018) using capillary 
blood, and in Tanzania, using EDTA whole blood samples (Franzeck et al., 2013). Results 
regarding the diagnostic sensitivity of these tests in HIV-infected individuals are somewhat 
conflicting. Previous laboratory based-studies reported an unsatisfactory sensitivity of 55.9% 
in Malawi (Nyirenda et al., 2008) and of 69.3% in Ghana (Geretti et al., 2010) of the Alere 
DetermineTM HBsAg test (Alere Inc., Massachusetts, USA). However, a recent Zambian study 
observed an 87.9% sensitivity of the DetermineTM HBsAg test in HIV-infected patients 
(Chisenga et al., 2018). Low HBV DNA viral load and low levels of HBsAg observed in 
patients with false-negative test results have been suggested as possible reasons for the poorer 
performance of RDTs among HIV-infected patients (Geretti et al., 2010). A recent systematic 
review and meta-analysis revealed an excellent pooled specificity of 99.5% (95% CI: 99.4% –
99.5%), and pooled diagnostic sensitivity of 90% (95% CI: 89.1% – 90.8%) of 33 brands of 
HBsAg RDTs compared to HBsAg laboratory-based immunoassays (Amini et al., 2017). It is 
important to note that the diagnostic accuracy of RDTs varied widely among brands. The 
DetermineTM HBsAg test and the Vikia HBsAg assay (BioMerieux, Basingstoke, UK) showed 
the highest diagnostic accuracy (Sensitivity 90.8% and specificity 99.1% compared to 
sensitivity 82.5% and specificity 99.9%, respectively) (Amini et al., 2017).  
Rapid tests for the detection of other HBV serological markers, such as HBeAg and anti-HBs 
have also been developed. An earlier systematic review and meta-analysis of studies performed 
between 1980 and 2010 reported a pooled sensitivity of 95.5% (95% CI: 88.9% - 99.4%), and 
a pooled specificity of 99.8% (95% CI: 99.3% - 100%) of the Binax dual HBsAg/HBeAg test 
(Binax Inc., Portland, Maine), the only HBeAg rapid test reported in the analysis. Anti-HBs 
RDTs presented with a pooled sensitivity of 93.2% (95% CI: 85.1% - 98.5%) and pooled 
specificity of 93.1% (95% CI: 81.9% - 99.9%) (Shivkumar et al., 2012). Updated statistics on 
the performance of current commercially available rapid tests for anti-HBs (Bottero et al., 
2013; Poiteau et al., 2017) and HBeAg (Seck et al., 2018) are limited.  
2.4.3 Algorithm for HBV testing  
The presence of an HBV infection is conventionally assessed by HBsAg screening, as a first-
line assessment, using a quality-assured immune-based assay. The recent WHO guidelines on 
HBV testing recommend the use of a single serological assay, laboratory-based immunoassay 
or RDT, in regions where the prevalence of HBsAg is above 0.4%. In settings with a prevalence 
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of HBsAg below 0.4%, a positive HBsAg result should be confirmed, with a different assay of 
a similar precision or with neutralization test if using a first-line laboratory-based immunoassay 
(WHO, 2017d; Peeling et al., 2017). The choice of immunoassay technology is dependent on 
the type and the capacity of infrastructures and resources available. Where RDT testing is the 
technique of choice, the diagnostic accuracy and the quality of the rapid test should be 
considered.  
The presence of other serological markers of HBV may also be used to differentiate acute from 
chronic infection. Acute hepatitis is characterized by an IgM anti-HBc immune response, 
which disappears approximately six months post-HBsAg seroconversion. Although the marker 
is also seen in case of reactivation of the infection, an IgM anti-HBc negative result would 
indicate the absence of a recent new infection or the reactivation of an established infection 
(Centers for Disease Control, 2011; Krajden, McNabb & Petric, 2005). As chronic hepatitis 
establishes, HBeAg persists along with HBsAg. The persistence of these two antigens would 
indicate the early phase of CHB and the presence of viral replication. Seroconversion from 
HBeAg to anti-HBe is often seen in the late phase of CHB. The presence of anti-HBe and anti-
HBc IgM would be indicative of an acute infection. Where the serological profile of CHB is 
confirmed (HBsAg positive, HBeAg positive and anti-HBc IgM negative), the testing process 
follows to distinguish between the inactive and active stage of the chronic infection using NAT 
to quantify viremia and to guide and monitor treatment (WHO, 2017d; Peeling et al., 2017). 
However, in many RLS, NAT may not always be feasible due to the high costs of HBV viral 
load tests.  
2.4.4 Blood sampling approaches for laboratory testing 
Serum and plasma samples, prepared from whole blood specimens collected by venipuncture, 
have traditionally been used as biological substrates for diagnostic testing. However, they can 
be logistically challenging in rural settings or remote areas in SSA with regards to transport 
and storage (following collection and during transportation). In contrast, dried blood spots 
(DBS) specimens do not require venipuncture, can be kept at room temperature and offer a 
lower biohazard risk. They can easily be transported from remote areas to central laboratories. 
They are prepared by applying capillary blood collected by finger or heel punctures directly 
onto the filter paper card, alternatively using venous blood collected via venipuncture (Mei et 
al., 2001; Snijdewind et al., 2012). This sample type has been increasingly and successively 
used for HIV NAT, as well as early infant HIV diagnosis in many RLS (Erba et al., 2015; 
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Mavedzenge et al., 2015; Dowling et al., 2018). Only a few studies have reported on its 
reliability and precision for molecular testing of HBV. A recent systematic review and meta-
analysis analyzed the pooled diagnostic accuracy and the analytical sensitivities of HBV viral 
load testing using DBS samples, in studies published between 1970 and 2015. The meta-
analysis showed a pooled sensitivity of 96% (95% CI: 90% –98%) and pooled specificity of 
99% (95% CI: 55% – 100%) of HBV DNA viral load testing using DBS. The limit of detection 
(LOD) of the assays incorporated in this analysis ranged from 10 to 100 IU/ml using serum or 
plasma samples (Lange et al., 2017). Among these five studies, two reported on the LOD using 
DBS. These were 914 IU/ml (Mohamed et al., 2013) and 1000 IU/ml (Vinikoor et al., 2015) 
for the COBAS AmpliPrep/COBAS TaqMan HBV test Version 2.0 (Roche Diagnostics, Basel, 
Switzerland), and 500 IU/ml for the rt2000 real-time PCR instrument (Abbott Molecular, 
DesMoines, IL, USA) (Stene-Johansen et al., 2016). Vinikoor et al. (2015) also assessed the 
diagnostic accuracy of diluted samples at different cut-off values. At a cut-off value of 200 
IU/ml, the test could not pick up 13.8% (95% CI: 7.7% – 23.7%) of DBS samples whose paired 
plasma were detected. This probability dropped to 1.8% (95% CI: 0.5% – 6.6%) at a 2,000 
IU/ml cut-off and 0.2% (95% CI: 0.03% – 1.7%) at 20,000 IU/ml (Vinikoor et al., 2015). All 
authors were in agreement for the use of DBS, as an alternative sampling for HBV DNA testing. 
The LODs observed in these reports, ranging from 500 to 1000 IU/ml – below the WHO 
recommended 20 000 IU/ml threshold for treatment initiation (WHO, 2015), suggest DBS 
testing as a potential diagnostic tool to identify HBV chronically infected patients in need of 
antiviral treatment. However, further assessment of the use of DBS for HBV viral load 
measurement in SSA is required. 
2.5 Transmission of HBV in sub-Saharan Africa  
As a blood-borne pathogen, HBV is most commonly transmitted through percutaneous or 
mucosal contact with blood from infected individuals. The virus is also found in other bodily 
fluids including saliva, breast milk, semen, menstrual and vaginal discharge. Contact with any 
of these infected bodily fluids could result in the transmission of HBV. Transmission may take 
place horizontally or vertically. The virus can also remain stable outside of the human body for 
at least seven days (Bond et al., 1981), and is known 100 times more infectious than HIV 
(Alter, 2006). 
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Horizontal transmission 
Horizontal transmission has been regarded as the main driver of the epidemic of HBV in SSA, 
and the main route of transmission of childhood-acquired HBV infections. From early 
epidemiological data in SSA, children older than two years compared to newborns were the 
most afflicted by HBV. In Namibia, Botha et al. (1984) noted a 1% (4/314) prevalence of 
HBsAg in children below the age of six months compared to a 13% (81/604) prevalence in 
those above the age of one year (Botha et al., 1984). HBsAg prevalence in two Gambian 
villages was of 7.26% (9/124) in children one year old and younger compared to a 20.37% 
(33/162) in those between the age of two and four years (Whittle et al., 1983). Pediatric 
infections were associated with contact with other infected children or infected siblings, and 
with infected parents within the same household (Davis, Weber & Lemon, 1989; Whittle et 
al., 1983, 1990; Dumpis et al., 2001). Sharing bath towels, eaten candies or dental cleaning 
equipment, being bitten by a carrier, biting of fingernails, back scratching of a carrier, 
scarification, and injection by traditional healers represented other possible sources of 
transmission of the virus among children (Martinson et al., 1998). Adulthood infections were, 
and remain, associated with a number of behavioral risk factors such as unprotected homo- and 
heterosexual intercourse with multiple sexual partners, and unsafe injections. Nosocomial 
infections through contaminated medical and surgical instrumentation, blood transfusions, and 
organ transplantations also occur (Trepo, Chan & Lok, 2014). Scale-up of blood donation 
screening for HBsAg (Apata et al., 2014; WHO, 2017e) resulted in a substantial reduction of 
nosocomial HBV infections. However, a residual risk is left; depending on the screening 
strategies in place for blood donations (Candotti & Laperche, 2018). 
Vertical transmission 
Commonly known as MTCT or perinatal transmission, vertical transmission remains the 
primary cause of chronic HBV infection in children worldwide; especially in East Asia where 
40% to 50% of new cases of HBV infection is a direct consequence of MTCT (Xu, 2013). 
Perinatal HBV infection is defined as the presence of HBsAg or HBV DNA in the serum of an 
infant born to an HBV-infected mother, within the first year of life (Edmunds et al., 1996). 
Transmission may take place in utero (intrauterine transmission) or during delivery 
(intrapartum transmission). Intrauterine transmission of the virus from the mother’s blood to 
the placenta could result following damage to the placenta (Xu et al., 2001; Chen et al., 
2013a), or through transmission of maternal HBV-infected peripheral blood mononuclear cells 
(PBMCs) to the fetal circulation (Xu et al., 2015). Intrapartum transmission may occur from 
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maternal-fetal microtransfusion, or the swallowing of infective fluids in the genital tract by the 
newborns during delivery (Lee, Ip & Wong, 1978; Mavilia & Wu, 2017). Although HBV is 
detected in breast milk, current evidence does not suggest that breastfeeding contributes to 
HBV MTCT under recommended immunization (Chen et al., 2013b; Zhang et al., 2014; 
Wang et al., 2015b).  
Historically, perinatal transmission of HBV has been of little concern in SSA. The risk of 
MTCT is mainly dependent on the maternal HBeAg serostatus (Okada et al., 1976; Beasley 
et al., 1977) and the maternal HBV viral load (Zhang, Han & Yue, 1998); both are markers 
of HBV infectivity. While HBV DNA positivity is poorly documented among HBV-infected 
pregnant women in SSA, HBeAg seropositivity rates have been increasingly described. HBeAg 
seroprevalence rates range from 16.6% (1/6) (Chotun et al., 2017) to 17.1% (7/41) 
(Andersson et al., 2013) among HBV mono-infected pregnant women in the Western Cape 
Province of South Africa. East African women have shown lower seropositivity rates 14.9% 
(7/47) in Uganda (Bayo et al., 2014) and 3.8% (8/211) in Tanzania (Mirambo et al., 2016). 
Central and West Africa rates are as high as 22.7% (59/259) in Cameroon (Ducancelle et al., 
2013) and 36.4% (4/11) in Nigeria (Adegbesan-Omilabu et al., 2015). These data reflect the 
risk of HBV MTCT in different parts of SSA. In the context of HIV, a higher proportion of 
HBeAg positive pregnant women and increased viral replication are noted (Andersson et al., 
2013; Diale et al., 2016; Thumbiran et al., 2014); thereby increasing the risk of maternal 
transmission of HBV (Chasela et al., 2014; Hoffmann et al., 2014).  
It is extensively quoted that HBeAg positive pregnant women present with a 70% to 90% risk 
of transmitting HBV to their infants globally (Thio et al., 2015; Mavilia & Wu, 2017). Yet, a 
recent systematic review and meta-analysis revealed that the rate of MTCT is 39% in SSA 
(Keane et al., 2016) and thus substantially lower. However, the robustness of this estimate is 
questionable owing to the small number of studies with small sample sizes used in that meta-
analysis. Interestingly, the same meta-analysis also showed a higher risk of MTCT of HBeAg 
positive mothers from West Africa as opposed to East Africa: 66.4% vs. 21.2% (p = 0.3), 
respectively (Keane et al., 2016). Although this difference was not statistically significant and 
inferred from a small sample size, it may suggest a geographical difference in the rate of MTCT 
in SSA and may be related to the different viral strains circulating in different parts of the 
region. Keane et al. (2016) also estimated that about 367 250 newborns acquire HBV at birth 
from their infected mothers every year in SSA (Keane et al., 2016). These children become 
part of the reservoir of chronic HBV infections in SSA: HBV-infected female children may 
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become at risk of transmitting the virus to their infants, and HBV-infected male children may 
transmit to their sexual partners later in life; thereby perpetuating the cycle of continuous 
perinatal and horizontal transmission of HBV within communities. A shift of thinking, with 
regards to the role of MTCT in SSA, is needed to control the regional HBV epidemic.  
2.6 Prevention of HBV MTCT 
The annual number of perinatal HBV infections (n = 367 250) occurring in SSA (Keane et al., 
2016) demonstrates the need for preventing HBV MTCT regionally. The WHO standard 
strategy for the prevention of HBV MTCT includes active HBV immunization, commencing 
at birth (WHO, 2017b). Adding passive immunization, with hepatitis B immunoglobulin 
(HBIG), to active immunization at birth may increase protection to HBV-exposed newborns 
(Wong et al., 1984; WHO, 2017b). This would, however, require identifying HBV-exposed 
pregnancies as HBIG is scarce, expensive and requires substantial infrastructure.  
2.6.1 Pediatric active HBV immunoprophylaxis 
Active immunization with the HBV vaccine is the cornerstone of strategies against HBV 
infection. The vaccine is safe and effective and has been available for nearly four decades. 
Commercially launched in 1982, the first generation of the vaccine was made from plasma-
derived HBsAg proteins, harvested from the plasma of chronically infected individuals. A 
recombinant form of the vaccine was introduced in 1986, prepared from HBsAg synthesized 
in yeast or mammalian cells in which the HBsAg gene (HBsAg/pre-HBsAg genes) has been 
inserted (Stevens et al., 2017).  
Recognizing the global burden of HBV, the WHO Global Strategic Advisory Group of Experts 
on Immunization recommended including the HBV vaccine in the Expanded Programme on 
Immunization (EPI) in 1991 (WHO, 1992). The planned schedule for the implementation and 
delivery of the vaccine was based on the epidemiology of the infection in countries: countries 
with an HBV prevalence of 8% or above were required to integrate the policy by 1995, while 
1997 was the target date for countries with lower prevalence (WHO, 1992). The HBV vaccine 
is available as a monovalent formulation, as well as a fixed combination with other vaccines. 
As a preventive measure against HBV MTCT, vaccination against HBV should commence at 
birth, ideally within 24-hours of birth, given in the form of the monovalent formulation (WHO, 
2004, 2009, 2017b). The BD vaccine should be followed by two additional doses given at six 
and fourteen weeks, to coincide with the first and third diphtheria–tetanus–pertussis (DTP) 
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vaccination. A four-dose schedule may be used too, with three additional doses administered 
at six, ten and fourteen weeks. These subsequent doses may be administered as a monovalent 
vaccine or as part of multivalent vaccine formulations (WHO, 2004, 2009, 2017b). A large 
body of clinical trials has proven the effectiveness of this strategy (Lee et al., 2006, 2007). 
From its recommendation in 1992, the global coverage of the pediatric HBV vaccination 
peaked from 1% to 84% in 2015. The BD vaccine coverage, on the other hand, remains low 
(39%) (WHO, 2017b).  
Universal HBV vaccination has been introduced in all 47 member states of the WHO African 
region. In 2015, about 76% of children in SSA were vaccinated against HBV, but only 10% 
received the BD vaccine (Casey et al., 2016). BD vaccination is only provided in eleven 
countries (23.4%); of which nine have introduced universal BD vaccination, as presented in 
Table 2.3 (Breakwell et al., 2017; Tamandjou et al., 2017). Mauritius and Sao Tome and 
Principe offer birth vaccination only to babies whose mothers are HBsAg positive (Breakwell 
et al., 2017). Implementation of this policy remains under consideration in seven countries 
namely Benin, Cameroon, the Republic of Congo, Côte d’Ivoire, Ethiopia, Ghana, and Sierra 
Leone (Spearman et al., 2017).  
Table 2.3: Hepatitis B vaccine birth dose (BD) coverage in the WHO African Region. Adapted 
from Breakwell et al. (2017) (Breakwell et al., 2017) and WHO UNICEF Joint Reporting, 2017. 
Country 
Year of 
introduction1 
Coverage (%)1 
2013 2014 2015 2016 
Algeria 2004 99 99 99 99 
Angola 2015 - - 19 - 
Botswana Pre 2000 - - - - 
Cabo Verde 2002 94 99 93 96 
The Gambia 1990 - - - - 
Mauritania 2013 - - 51 51 
Mauritius2 NA - - - - 
Namibia 2014 - 1 87 87 
Nigeria 2004 32 32 32 32 
Sao Tome and Principe2 2002 - - - - 
Senegal 2016 - - - 58 
1Coverage estimates are derived from WHO UNICEF Joint Reporting, updated in July 2017. Available 
at: 
http://apps.who.int/immunization_monitoring/globalsummary/timeseries/tswucoveragehepb_bd.html. 
Accessed on July 11, 2018. 2BD vaccination is only provided to HBV-exposed babies.  
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2.6.2 Pediatric passive HBV immunoprophylaxis 
Passive HBV immunization involves providing temporary immunity against HBV, using 
inoculation of immune globulin derived from donors with high titers of anti-HB, referred to as 
HBIG. Early clinical trials of HBIG in newborns born to HBsAg/HBeAg positive mothers, 
conducted in Southeast Asia, described a reduced rate of chronic HBV infection in children 
receiving HBIG compared to the controls: 54% in infants given a single dose of HBIG and 
only 26% with three doses of HBIG (at birth, three months, and six months), compared to 92% 
in controls (Beasley et al., 1981, 1983a). During the same time period, European data 
suggested that a single dose of HBIG, immediately after birth, may provide enough protection 
to babies born to HBsAg/HBeAg positive mothers (Rosendahl et al., 1983). However, passive 
antibodies provided by the doses of HBIG disappear three to four months later, leaving these 
children susceptible to HBV; and some infants became infected after their first year of life 
(Beasley & Hwang, 1983). These results encouraged the theory that combining HBIG with 
the HBV vaccine would further decrease the risk of persistent HBs antigenemia in HBV-
exposed babies while providing a lasting immunity against the infection. Indeed, children 
receiving both HBIG and HBV vaccine were significantly less likely to become carriers 
compared to those to whom neither HBIG nor vaccine had been given: 6% compared to 88%, 
respectively. Moreover, increased effectiveness of HBIG in conjunction with the HBV vaccine 
of 94% compared to 71% with HBIG alone and 75% with the HBV vaccine alone was observed 
(Beasley et al., 1983b). Subsequent clinical trials corroborated findings from Beasley et al. 
(1983b): passive combined with active immunization is more effective than either on its own 
in children born to HBsAg/HBeAg positive mothers, regardless of the type of vaccine 
(recombinant or plasma-derived) (Lee et al., 2006, 2007). HBeAg negative/anti-HBe positive 
mothers present a lower risk of MTCT, on the other hand (Rosendahl et al., 1983; Lee et al., 
2006). A recent Chinese study observed no difference in the occurrence of perinatal 
transmission between HBeAg negative/anti-HBe positive mothers whose babies received 
HBIG + vaccine and those receiving vaccine alone (0.1% (1/752) vs. 0.0% (0/132), p = 1.000) 
(Lu et al., 2017); suggesting that vaccine alone may be enough for preventing perinatal HBV 
infection in infants born to HBeAg negative mothers (Yang et al., 2003; Chen et al., 2012; 
Lu et al., 2017).  
While the use of active immunization starting at birth in combination with HBIG for babies 
born to HBeAg positive mothers is routine practice in many parts of Southeast Asia and in 
high-income countries, this is not the case in SSA. There is no published documentation of 
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SSA countries with a formal policy of passive and active immunization for HBV MTCT. The 
high cost associated with HBIG is an important barrier (Tamandjou et al., 2017), leaving 
neonates of HBeAg positive mothers still at risk of perinatal HBV infection. Still, passive and 
active immunization may also not be enough to eliminate the risk of maternal transmission of 
HBV. 
2.6.3 Maternal antiviral therapy against HBV 
A growing body of evidence has emerged describing the added benefits of maternal antiviral 
therapy against HBV MTCT; such attempts are driven by breakthrough HBV infections despite 
standard passive-active immunoprophylaxis in neonates born to HBeAg positive mothers 
(Ngui et al., 1998; Wiseman et al., 2009; Wen et al., 2013; Foaud et al., 2015; Sellier et al., 
2015). Maternal viral loads above 200 000 IU/ml and maternal HBeAg serostatus were 
established as the main predictors of immunoprophylaxis failure in neonates (Song et al., 2007; 
Zou et al., 2012; Yin et al., 2013; Liu et al., 2015).  
Among the seven oral nucleos(t)ide analogs agents approved by the FDA for the treatment of 
CHB (refer to section 2.1.5), lamivudine (Xu et al., 2009), telbivudine (Tan et al., 2016) and 
TDF (Pan et al., 2012; Celen et al., 2013) have been reasonably well investigated for the 
prevention of perinatal transmission of HBV. A systematic review and meta-analysis of the 
data produced from these clinical research studies showed that the use of any of these three 
drugs in conjunction with passive-active immunization demonstrated a reduction of MTCT in 
HBV infectious women, compared to the use of immunization alone; with no adverse outcomes 
for the women nor the newborns (Brown et al., 2016). The efficacy of this intervention is 
dependent on the type of antiviral drug used and the viral load of the mother. Lamivudine 
showed a 71% risk reduction, and telbivudine offered a 77% risk reduction (Brown et al., 
2016). Unlike TDF, lamivudine and telbivudine possess a low barrier to resistance, raising the 
issue of the emergence of resistance with the use of any of these two drugs. The efficacy of 
TDF for HBV MTCT was demonstrated in five geographic locations of China, through a 
randomized controlled trial. The trial included 200 HBeAg positive pregnant women with HBV 
DNA levels above 200 000 IU/ml (at risk of maternal transmission despite pediatric active-
passive immunoprophylaxis), who were randomly assigned to a treatment group and a no 
treatment group. Women received TDF 300 mg daily from gestational age 30–32 week to four 
weeks postpartum. Passive and active immunoprophylaxis were provided to all neonates at 
birth. At postpartum week 28, significantly fewer perinatal HBV infections were diagnosed in 
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neonates born to TDF-treated mothers than in those born to untreated mothers: 0% vs. 7% (p 
= 0·01) by per-protocol analysis and 5% vs. 18% ( p = 0·007) by intention-to-treat analysis 
(Pan et al., 2016). A meta-analysis of this data along with non-randomized controlled trials 
demonstrated a 77% risk reduction of perinatal transmission of HBV in TDF-treated women 
versus untreated women. No serious adverse effects were observed (Hyun et al., 2017).  
As encouraging as these data are, no formal recommendation for routine maternal antiviral 
therapy for the prevention of HBV MTCT has been made by the WHO so far. In contrast, the 
three most prominent international liver organizations, namely American Association for the 
Study of Liver Diseases (AASLD), European Association for the Study of the Liver (EASL) 
and Asian Pacific Association for the Study of the Liver (APASL), suggest the initiation of 
TDF 300 mg daily at 28–32 weeks of pregnancy in those with an HBV DNA concentration 
equal to or above 200 000 IU/mL (Sarin et al., 2016; EASL, 2017; Terrault et al., 2016, 
2018). Although most clinical trials discontinued maternal antiviral therapy at birth or three 
months postpartum, EASL supports therapy discontinuation at 12 weeks postpartum (EASL, 
2017). These women should be monitored for ALT flares every three months for six months, 
following therapy discontinuation (Terrault et al., 2018).  
While extensive data about the efficiency of combining maternal antiviral prophylaxis with 
TDF and passive-active immunization have been published from Southeast Asia, where 
genotypes B and C are found, very little is known about this strategy in SSA. A relatively small 
prospective study investigated the efficacy of TDF and active immunization at birth in South 
Africa. A total of 134 women were enrolled in the study and were screened for HBV by means 
of a rapid test. Six of these women were found HBsAg positive, among whom two had high 
HBV DNA concentrations of 23 000 IU/ml and 767 000 IU/ml. A 300 mg daily dose of TDF 
was initiated to these two women at a gestational age of 28 – 26 weeks and interrupted one 
month postpartum. At follow up, after birth and seven months postpartum, none of the babies 
born to these two TDF-treated women had contracted HBV infection (Chotun et al., 2017). 
Results from that study suggest that maternal antiviral therapy may be effective against HBV 
MTCT in Africa, too, possibly obviating the need for HBIG.  
2.6.4 Routine HBV antenatal screening  
Passive immunoprophylaxis and providing maternal antiviral therapy would certainly require 
identifying HBV-infected pregnant women, especially the HBeAg positive ones with high 
HBV DNA levels. Consequently, a starting point in reducing perinatal transmission of HBV 
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would involve antenatal HBV screening, as endorsed by many academics (Andersson et al., 
2015; Shimakawa et al., 2016b; Spearman et al., 2017). Antenatal screening for HBsAg has 
been endorsed by WHO, for settings with a ≥ 2% seroprevalence of HBsAg in the general 
population. The aim is to increase CHB case detection and to prevent further transmission of 
the virus within communities (WHO, 2017d). However, many countries in SSA do not offer 
routine HBsAg screening to pregnant women. 
From a public health point of view, screening allows the implementation of adequate safety 
measures to prevent the disease from spreading to the rest of the community. In the context of 
HBV MTCT, this would be to prevent transmission of the virus from the infected mother to 
the infant. Ideally, this should be done during the first trimester of pregnancy; thereby allowing 
adequate documentation of HBV-exposed babies in need of further care at birth, and linkage 
to maternal care and treatment services available. Screening programmes are required to adhere 
to the Wilson-Jungner criteria. Firstly, the disease should be an important public health 
problem, with treatment available for patients infected. The natural history of the disease 
should be adequately understood, and the latent or early symptomatic stage of the disease 
should be recognized. The infrastructures required for diagnosis and treatment of the disease 
should also be available. A suitable test or examination should be available, and acceptable to 
the population. Furthermore, there should be guidelines in place on whom to treat as patients, 
and the cost of case-finding that include diagnosis and treatment of patients should be 
economically balanced in relation to possible expenditure on medical care as a whole. Finally, 
the case-finding should be a continuing process rather than a one-off project (Wilson & 
Jungner, 1968; Andermann et al., 2008). An antenatal screening programme for HBV would 
certainly fulfill most of the Wilson-Jungner criteria (Chotun et al., 2017). The cost of 
screening pregnant women, on the other hand, remains poorly explored in SSA and requires 
attention (Shimakawa et al., 2016b). Cost-effective screening strategies may need to be 
identified and validated for use in the region (Shimakawa et al., 2018).  
2.7 Management of pediatric chronic hepatitis B virus infection 
Failure to prevent maternal or horizontal transmission of HBV to infants and children would 
almost certainly lead to childhood CHB. As described in section 2.3.2, many will remain in the 
immunotolerant phase with minimal or no necroinflammation of the liver. The absence of 
histological disease during this phase of the infection does not warrant treatment for reasons of 
drug safety in children, and the potential risk of antiviral resistance from prolonged exposure 
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to anti-HBV drugs. Where severe and sustained hepatic necroinflammation is detected, 
treatment with antiviral drugs may be required. However, the choice of drug is quite limited 
and age-dependent. As mentioned above, seven oral anti-HBV nucleos(t)ide analogs drugs 
have been FDA approved, along with the interferon-based therapy. While all can be used for 
the treatment of CHB in adults, only five have been evaluated and approved for use in children. 
These are interferon alpha (IFN-α), adefovir, entecavir, lamivudine, and TDF.  
IFN-α is the most studied and the very first drug used for the treatment of CHB in children. 
While treatment with the drug leads to early HBeAg clearance or early HBeAg seroconversion, 
as well as HBsAg seroconversion, similar outcomes were observed in untreated patients at 
long-term (Sokal et al., 1998; Bortolotti et al., 2000; Diem et al., 2005). A significant 
reduction of the risk of developing cirrhosis or HCC was not observed (Jonas et al., 2016a). 
IFN-α based therapy offers the advantage of eliminating the risk of drug-resistance viral 
genomic mutations developing; but it requires multiple subcutaneous injections, leads to 
frequent undesired effects and is costly (Della Corte et al., 2014). Lamivudine and entecavir 
are nucleoside analogs which, upon phosphorylation, act as chain terminators through 
competition with natural nucleotides during viral DNA synthesis, thereby inhibiting viral DNA 
replication (Menéndez-Arias, Alvarez & Pacheco, 2014). While lamivudine only inhibits 
synthesis of the HBV DNA (+) strand, entecavir also hinders the DNA polymerase priming 
reaction (Seifer et al., 1998; Jones et al., 2013) and the reverse transcription of the minus 
strand from the mRNA (Seifer et al., 1998). Both drugs can be prescribed from the age of two 
years in children. Lamivudine-based therapy is associated with a higher rate of selection of 
drug-resistance mutations (Jonas et al., 2002) as compared to entecavir (Jonas et al., 2016b). 
Adefovir and TDF are nucleotide analogs. Both drugs have been approved for use in children 
above 12 years of age with CHB (WHO, 2015; Terrault et al., 2018). This was based on 
results of a large multicenter randomized controlled trial showing significant antiviral efficacy 
in adefovir treated adolescents between the age of 12 to 17 years old, but not in those below 12 
years old (Jonas et al., 2008). TDF has only been studied in children ≥ 12 years old (Murray 
et al., 2012). Thus, treatment options for children below the age of 12 years are quite limited. 
Drug-resistance mutations from therapy with either of these two antiviral agents, adefovir and 
TDF, in children have not been reported to date. It is noteworthy that efficacy and safety data 
of the antiviral agents used for the treatment of CHB in children were based on comparisons 
between treatment and placebo or no treatment, leaving gaps on how these analogs compared 
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with one another in children. Based on the comparison of these drugs performed in adults, 
entecavir and TDF are considered the drugs of choice to treat CHB (WHO, 2015). 
With regards to HIV co-infection, entecavir, lamivudine, and TDF possess anti-HIV activity 
too. However, monotherapy with entecavir in HIV/HBV co-infected patients can result to the 
selection of the HIV drug resistance mutation M184V (Sasadeusz et al., 2008); thus, the drug 
cannot be used as monotherapy in the presence of HIV infection. Lamivudine is currently part 
of the preferred first-line ART regimen for the treatment of HIV/HBV co-infection in children 
below ten years old, as the only drug against HBV (WHO, 2015). However, due to its low 
barrier to HBV resistance, children on a lamivudine-based therapy are at high risk of mounting 
HBV viral resistance. TDF, despite its high potency against HIV and its high barrier to HBV 
resistance, has been associated with decreased bone mineral density in children co-infected 
with HIV and HBV (Purdy et al., 2008); and it is part of alternative first-line ART regimens 
in HIV/HBV co-infected children between the age of three and ten years (WHO, 2015). 
2.8 Health economics and prevention of HBV MTCT in SSA 
Resource availability and costs are important considerations for implementing health 
interventions. Various programmes against HBV MTCT could be assessed using economic 
evaluations to inform decision-making with regards to the allocations of finite resources such 
as facilities, space, personnel and time to maximize health benefits in the society.  
2.8.1 Principles and forms of economic evaluation 
According to Drummond et al. (2015), an economic evaluation may be defined as the 
"comparative analysis of alternative courses of action regarding both their costs and 
consequences" (Drummond et al., 2015). This definition embraces two fundamental concepts 
namely (1) the comparison of alternative options, and (2) their evaluations regarding both their 
costs and their health benefits. From the viewpoint of this definition, an economic evaluation 
in healthcare assists with an informed allocation of resources to one use instead of another to 
maximize social health benefits. As such, all costs and consequences related to the alternatives 
considered in the analysis should be identified, measured, valued and compared (Drummond 
et al., 2015).  
A shared feature of all economic evaluations is the method for measuring and valuing costs, 
referred to as a cost-analysis. Costs represent the value of the resources used for a particular 
health intervention. These resources may derive from: 
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• The health sector: drugs, medical equipment, hospital stays,  
• Other public sectors: public agencies or voluntary agencies,  
• Patient/family: transportation, child care, patient care; or  
• Production losses or gains: loss of time at work, lost productivity while at work 
The range of costs included in a cost-analysis is decided based on the perspective taken by the 
economic evaluation; which could be from a provider, patient or societal point of view. From 
a provider's perspective, health costs would involve direct medical costs: capital costs and 
recurrent costs. The latter include personnel costs, consumables costs, and overhead/operating 
costs. From the perspective of a patient or society, these costs would be predominantly patient 
related such as transportation, productivity losses due to the disease, and other public non-
health care sectors associated with the disease. The costs included in a cost-analysis also reflect 
opportunity costs. These represent the lost opportunity to invest the same resources in another 
health intervention that could have return greater health benefits (Shiell et al., 2002; 
Drummond et al., 2015).  
In contrast to cost-analysis, the approach for measuring health benefits may differ depending 
on the nature of the outputs (health benefits) stemming from the considered alternatives. Three 
types of economic evaluations are commonly performed. These are cost-effectiveness analysis 
(CEA), cost-utility analysis (CUA) and cost-benefit analysis (CBA). The use of one type over 
the other is dependent on the question addressed in the economic evaluation. In a CEA, the 
common outcomes to the considered alternatives are measured in naturally occurring units such 
as life years (LYs) gained, cases detected by a screening programme, or cases averted by a 
treatment programme. The costs associated with this common outcome may differ in 
magnitude and are compared. Results from a CEA may be expressed as cost per unit of effect, 
or as effect per unit of cost. An incremental cost-effectiveness ratio (ICER) is calculated to 
determine the extra cost per unit of outcome obtained from one alternative compared to the 
other (Drummond et al., 2015). A CEA is particularly useful where limited options are 
available for a limited budget (Donaldson & Shackley, 1997). In a CUA, a broader unit of 
measure known as utility is used. Utility focuses on the quality of the health outcome produced 
or forgone by the considered health interventions; therefore is subjective to individuals or 
society’s preferences for any particular set of health outcomes. The use of utilities enables a 
broader comparison of costs and outcomes across different programmes; thus is often seen as 
more useful than a CEA. Utility can be expressed in various quality of life scales such as 
quality-adjusted life years (QALYs), disability-adjusted life years (DALYs) (Tan-Torres 
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Edejer et al. 2003), or healthy years equivalents (HYEs) (Mehrez & Gafni, 1989). 
Consequently, results from a CUA are typically stated in terms of the cost per QALY gained 
or cost per DALY averted (Robinson, 1993; Shiell et al., 2002; Drummond et al., 2015). In 
contrast to CEA and CUA, both the costs and the health outcomes of alternative health 
programmes considered in a CBA are measured in monetary terms (Drummond et al., 2015). 
This form of economic evaluation is typically used to identify whether or not the extra costs of 
obtaining a specific health outcome is worth it. The CBA provides the absolute and relative 
benefits of the healthcare programmes considered. Although assigning a monetary value to a 
health benefit may be challenging, a CBA enables comparison of health interventions across 
public sectors (Shiell et al., 2002). The output of the analysis may be expressed in terms of a 
ratio of costs to benefits, or as a sum representing the net benefit or loss of one alternative over 
another (Drummond et al., 2015).  
Often, the costs and consequences of healthcare interventions may present with different time 
profiles. For instance, although an antenatal screening programme for HBV infection may incur 
immediate costs, the effects of avoiding liver cirrhosis caused by vertically-acquired CHB 
would only take place in the future. The comparison of this alternative to another would require 
adjustment of both costs and consequences to the present values through discounting, using a 
constant rate. This rate may either be predetermined by national health authorities or extracted 
from the literature (Cairns, 2001; Drummond et al., 2015).  
Furthermore, results from an economic evaluation, usually in the form of ICER, is compared 
to a benchmark or threshold to determine whether the assessed health intervention is cost-
effective or not. If the ICER is lower than the threshold, the intervention is said to be cost-
effective, because it yields greater benefits at a low cost. In contrast, if the ICER falls above 
the threshold, the intervention is not considered cost-effective. This benchmark represents what 
society is willing to pay for a healthcare service for health gains, and as such is known as the 
willingness-to-pay (WTP) threshold (Drummond et al., 2015; Thokala et al., 2018). Various 
WTP thresholds have been suggested. According to the World Bank, ICERs ranging from $150 
to $200 per DALYs averted are considered cost-effective in middle-income countries. In lower-
income countries, an ICER below $50 per DALY averted is considered highly cost-effective 
(World Bank, 1993). As per the WHO’s Choosing Interventions that are Cost–Effective 
(WHO-CHOICE) project, health programmes whose ICERs fall between one to three times a 
country’s gross domestic product (GDP) per capita per DALY averted are considered cost-
effective. If the ICER is below the country’s GDP, the intervention is concluded highly cost-
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effective (WHO, 2002; Hutubessy, Chisholm &Edejer, 2003). The WTP threshold of one to 
three times GDP per capita has been highly used in economic evaluations of health 
interventions in low- and middle-income countries (Leech et al., 2018). However, Leech et al. 
(2018) argue that rather than relying on generic economic thresholds, countries should make 
use of country-specific cost-effectiveness thresholds (CET) that reflect local preferences, to 
determine the cost-effectiveness of health interventions (Leech et al., 2018). Countries are 
called to generate WTP thresholds in the context of their resources; to help in determining the 
cost-effectiveness of new health interventions.  
2.8.2 Economic evaluations of interventions against HBV MTCT 
A few economic evaluations have examined and compared various strategies for the prevention 
of MTCT (PMTCT) of HBV. The majority have focused on routine newborn HBV vaccination. 
This strategy remained consistently cost-effective in both SSA and other low- and middle-
income countries (Aggarwal, Ghohal & Naik, 2003; Griffiths, Hutton & Pascoal, 2005; 
Vimolket & Poovorawan, 2005; Chen et al., 2013c; Lu et al., 2013) except in areas of low 
HBV endemicity (Lee & Park, 2016). The provision of universal newborn HBV vaccination 
in The Gambia was shown to produce an extra cost of US$28 per DALY averted from a societal 
perspective, or US$47 per DALY averted from a payer’s perspective. Both ICERS fell below 
the 2002 country’s GDP per capita; thus, the intervention was considered highly cost-effective 
(Kim, Salomon & Goldie, 2007). Subsequent economic evaluations in SSA produced similar 
observations. In Mozambique, an additional BD of the HBV vaccine was compared to 
vaccination starting from six weeks of age of the infants, the status quo of the country. An 
ICER of US$250.95 per DALY averted was obtained from the CEA. Birth vaccination was 
also considered highly cost-effective as the ICER was lower than the WTP threshold of 
US$441, the 2008 GDP per capita of Mozambique (Klingler, Thoumi & Mrithinjayam, 
2012). Recent work in South Africa reported an ICER of US$329 per DALY averted, in 
comparison to vaccination from six weeks. Using a CET of US$3 810, which represents half 
per capita GDP of the country, the strategy was deemed highly cost-effective too (Hecht et al., 
2018). The high cost-effectiveness of this intervention remains, using the number of pediatric 
infections averted as the measure of outcome of the intervention. The recent analytic model 
from Cameroon also revealed that universal HBV vaccination with BD was the most cost-
effective strategy for reducing pediatric HBV infections, as opposed to universal vaccination 
from six weeks, at a WTP threshold of US$150. Maternal HBsAg screening followed by 
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targeted HBV birth vaccination was also analyzed in the model. The intervention appeared to 
be the least costly alternative but did not show a greater decrease in pediatric HBV infections 
in comparison to the universal birth vaccination strategy (Anderson et al., 2018). The costs 
and health benefits of maternal HBsAg screening has been predominantly studied along with 
universal HBV birth vaccination. In high incomes countries, mixed cost-effectiveness results 
have been reported. Compared to a do-nothing strategy, routine screening of pregnant women 
for HBsAg was shown to be cost-effective in the United States of America (USA), at an HBsAg 
prevalence of 0.2%. From the authors' analysis, the policy was found cost-saving (Arevalo & 
Washington, 1988). The same policy, however, was not cost-saving in the Belgian context, 
with an HBsAg prevalence of 0.67% within the antenatal population (Tormans et al., 1993). 
Whether this policy is cost-effective in SSA or not remains unknown. Other interventions, 
including the provision of HBIG to HBsAg-exposed babies in combination with universal birth 
vaccination, or maternal antiviral prophylaxis have also been economically assessed. In fact, 
Chen et al. (2016) demonstrated that universal HBV birth vaccination combined with HBIG 
could produce both direct and societal cost savings (US$11.68 billion and US$ 45.14 billion, 
respectively), while averting more than 12 million new HBV infections, and 576 209 cases of 
HBV related deaths (Chen et al., 2016). Maternal antiviral prophylaxis with lamivudine from 
the third trimester of pregnancy, in addition to HBIG, produced an additional 0.0024 QALYs 
gain and averted 0.23 acute infections per birth in Taiwan, at a WTP threshold of US$20 000 
(Hung & Chen, 2011). The cost-effectiveness of these two interventions is unknown in SSA. 
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CHAPTER 3: A study of hepatitis B virus infection in HIV-infected children in 
Namibia 
This chapter describes the molecular characterization of HBV infection in HIV/HBV co-
infected children in Windhoek, Namibia, exposed to antiretroviral therapy (ART) containing 
lamivudine. The presence of any biochemical evidence of liver disease among these children 
is also reported.  
3.1 Introduction 
As in many countries in SSA, little is known of the burden of HBV infection in Namibian 
children in the era of HIV. To our knowledge, the only prevalence data available on HIV/HBV 
co-infection within this population date from a retrospective study conducted in Northern 
Namibia. An HBsAg seropositivity rate of 8.7% was found. All children were on ART therapy 
for HIV (Brandt et al., 2012).  
According to the 2016 WHO HIV treatment guidelines, the preferred first-line ART therapy 
for the management of HIV infection includes lamivudine alone as an antiviral agent with 
activity against HBV in children less than 10 years old, and a combination of TDF and 
lamivudine (or emtricitabine) in individuals/children of 10 years old and above against HBV 
(WHO, 2016). Despite its potency against both HIV and HBV, prolonged exposure to 
lamivudine only against HBV is well known to be associated with the development of HBV 
resistance in infected individuals. Resistance to the drug is brought by the selection of viral 
mutants in the pol gene of the HBV genome (Sokal et al., 2006), and leads to uncontrolled 
HBV infection. The uncontrolled infection is characterized by persistent high viral replication; 
it is a significant risk factor for advanced liver disease (Beasley et al., 1981; Shimakawa et 
al., 2013). The selection of other genomic mutations with increased viral replication may also 
occur, thereby exacerbating liver damage.  
3.2 Study aims 
Primary aim 
This study primarily aimed to characterize HBV in Namibian children with HIV/HBV co-
infection who had been exposed to a lamivudine-based ART regimen. 
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Secondary aim 
The study also sought to determine the role of HBV MTCT in the HBV infections described in 
these HIV/HBV co-infected children. 
3.3 Study objectives 
The aims of the study were achieved through the following objectives: 
• Determine the rate of active HBV infection among HIV/HBV-infected children. 
• Determine the circulating HBV genotypes and the prevalence of HBV mutants. 
• Determine liver health, by AST platelet ratio index (APRI), in children who are co-
infected with HIV and HBV. 
3.4 Materials and Methods 
3.4.1 Ethical considerations 
The full protocol of this study was submitted to the Health Research Ethics Committee (HREC) 
of the Faculty of Medicine and Health Sciences, Stellenbosch University, and to the Biomedical 
Research Ethics Committee (BREC) and Research Management Committee (RMC) at the 
Namibian Ministry of Health and Social Services (MoHSS) for ethical review. Ethical approval 
was obtained from both bodies with the HREC reference number N13/02/022. Approval letters 
from the HREC are found in Appendix A. 
According to HREC guidelines, children participating in a research study should be given the 
opportunity to agree for participation in a research study through assent. This is an agreement 
given by an individual who is unable to give legal consent for participating in a research 
activity. Assent from the child should be accompanied by consent from the parent or legal 
guardian. As per these guidelines, assent was sought from children attending the study site for 
enrolment in the study, and consent was sought from the legal guardians too. Informed consent 
was also required from mothers attending with these children for their own participation in the 
study. 
3.4.2 Study design  
This was a cross-sectional study conducted at a pediatric HIV ART clinic at the Intermediate 
Katutura hospital, a state hospital in Katutura, a township of Windhoek.  
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3.4.3 Study setting 
The Republic of Namibia is a country in the southwestern part of Africa covering a total area 
of 825 615 km2 inhabited by 2 534 000 people (United Nations, 2017). The country is divided 
into 14 regions: Kunene, Omusati, Oshana, Ohangwena, Oshikoto, Kavango West, Kavango 
East, Zambezi, Erongo, Otjozondjupa, Omaheke, Khomas, Hardap and Karas (Figure 3.1); 
further sub-divided in constituencies, localities, and villages. 
The capital and largest city of Namibia is Windhoek, with 325 858 inhabitants as per the last 
2011 census (Namibia Statistics Agency, 2011). The city is located in the Khomas region, in 
the centre of the country, bordered by the Erongo region to the West, by Otjozondjupa to the 
North and by Omaheke to the East. Healthcare-wise, the regional health directorate comprises 
two hospitals: Windhoek Central hospital and Intermediate Katutura hospital, three health 
centers (Katutura, Okuryangava, and Khomasdal Health Centres) and eight primary healthcare 
clinics (MoHSS, 2018). 
Intermediate Katutura hospital is a teaching hospital with a bed capacity of 830. The pediatric 
HIV clinic opened its doors in 2010 for the care, support, and management of children and 
adolescents living with HIV. The clinic delivers integrated services including ART, voluntary 
counseling and testing (VCT), treatment adherence counseling, prevention and treatment of 
opportunistic infections, HIV disclosure as well as health education to caregivers and 
adolescent health services.  
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Figure 3.1: Geographic location of Namibia. The country is bordered by Zambia and Angola to the 
North, Botswana to the East and South Africa to the South and East. The map was produced using the 
ArcGIS® Online Software by Esri© 2018 (www.esri.com/software/arcgis/arcgisonline). Namibia 
province distribution shapefile was obtained from map library (www.maplibrary.com). 
3.4.4 Study population 
HIV-infected children aged less than 18 years old, exposed to lamivudine as part of their HIV 
infection treatment and thus inadvertently on monotherapy against HBV, attending the 
Katutura pediatric HIV ART clinic in Windhoek, Khomas, were considered for enrolment in 
the study. Current Namibian national guidelines recommend HBsAg screening for all 
individuals at HIV diagnosis (MoHSS, 2014a). A repeat HBsAg test is done six months 
following the initial positive test. If the repeat test is negative, it is concluded that the patient 
is not a chronic carrier of HBV. If the repeat test is positive, the patient has chronic HBV 
infection and is initiated on ART including abacavir/lamivudine, if weighing less than 35 kg 
or TDF/lamivudine/efavirenz if weighing at least 35 kg. Children initiated on 
abacavir/lamivudine should be switched to TDF/3TC as soon as they weigh at least 35 kg. 
Children who already weigh at least 35 kg should initiate ART with TDF/lamivudine/efavirenz 
(MoHSS, 2014a). HBV screening is performed by sending samples collected at the clinic to 
the Namibia Institute of Pathology laboratory for testing. Consequently, HIV/HBV co-infected 
children are known to the clinic. Using convenience sampling, children identified as HBsAg 
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positive were informed and their assent was sought for participation in the study following the 
below-mentioned inclusion criteria. 
• HBV infection diagnosed by an HBsAg test at the laboratory. 
• HIV infection confirmed and diagnosed by: 
o Children 18 months or older at time of diagnosis: a positive rapid HIV antibody 
testing confirmed by a second rapid HIV antibody test,  
o Children younger than 18 months: a positive virologic test (HIV DNA PCR) for 
HIV or its components confirmed by a second virologic or antibody test 
performed on a separately obtained sample. 
• On ART for ≥ 18 months. This criterion was applied based on the incidence of 
mutations associated with lamivudine resistance, which is known to increase with the 
duration of lamivudine monotherapy: 20% after 12 months of treatment, reaching 90% 
after 48 months (Benhamou, 1999). 
Recruitment took place at the 6-monthly routine follow-up appointment. HIV/HBV co-infected 
children referred from other provincial or local clinics to the study clinic were recruited at the 
initial contact. These children were known HIV/HBV co-infected based on laboratory records, 
available in both the patient’s health booklet and in the laboratory system at health facilities in 
Namibia. Mothers attending with these children were invited to take part in the study. 
3.4.5 Sample size  
Given that this was an observational study to determine the molecular character of HBV 
infection in co-infected children in the presence of inadvertent exposure to lamivudine 
monotherapy against HBV, we planned to recruit about 20 HIV/HBV co-infected children 
using convenience sampling. 
3.4.6 Sample collection 
Five dried blood spots (DBS) were collected, through finger prick, on a Whatman perforated 
filter paper card (5 spots/card) (Lasec, Cape Town, South Africa). A total volume of 10 ml of 
blood was drawn in a serum separator tube (SST) and in an ethylenediamine tetraacetic acid 
(EDTA) blood tube from enrolled children ≥ two years old and adolescents. DBS were used 
for HBV characterization, while SST blood samples were of use for liver biochemistry and 
Stellenbosch University https://scholar.sun.ac.za
51 
 
HBV serological testing. EDTA blood samples were used for full blood count analysis. A DBS 
card, only, was collected from the consenting mothers attending with their HBV-infected 
children for HBV molecular characterization. 
3.4.7 Data collection 
Children/adolescents variables recorded include contact details, sex, gestation (preterm/term), 
mode of delivery, birth weight, HBV vaccination history (verbal history from mother and 
confirmation from patient care booklet), past history of liver disease, details of opportunistic 
infections, baseline CD4/ nadir CD4, date of commencing ARVs, type of current and past ART 
regimens. This information was collected from the patient care booklets. The maternal 
variables collected from their care booklets include: age, parity, region of birth, HBV status 
and HBV markers (where available), family history of liver disease, date of commencing 
ARVs, previous ART, current ART, CD4 count, HIV viral load (where available). 
3.4.8 Sample handling 
HBV viral load, HBV genotyping, HBeAg, anti-HBe, and anti-HBc are not routine tests offered 
by the national laboratory in Namibia. These tests were performed at the Division of Medical 
Virology, Stellenbosch University. 
DBS and serum samples were stored at -20°C at the Namibia Institute of Pathology following 
collection. DBS were thawed at room temperature prior to shipment (for a minimum of 30 
minutes), repackaged and sent at ambient temperature to the Division of Medical Virology 
laboratory at Stellenbosch University, South Africa, whilst residual serum samples were sent 
on dry ice. At the Division of Medical Virology, all samples (DBS and serum samples) were 
stored at -20°C and thawed at room temperature in a biosafety cabinet prior to analysis. 
Laboratory analyses performed on these samples are summarized in Figure 3.2. 
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Figure 3.2: A flow diagram of laboratory analysis of samples collected from study participants. This 
diagram illustrates all the laboratory testing performed on blood samples and DBS samples collected from 
children enrolled in the study. DBS only were collected from the mothers attending with these children 
and were used for HBV molecular testing as illustrated in the second branch of the flow diagram. The 
laboratory testing highlighted in red were conducted at our laboratory while the others were conducted at 
the Namibian laboratory. ALT: alanine transaminase; AST: aspartate transaminase; anti-HBc: antibodies 
against hepatitis B core antigen, anti-HBe: antibodies against hepatitis B e antigen; DBS: dried blood spots; 
EDTA: ethylenediamine tetraacetic acid; HBeAg: hepatitis B e antigen, HBsAg: hepatitis B surface 
antigen; HBV: hepatitis B virus; IgM: immunoglobulin M; SST: Serum Separator Tube.  
3.4.9 Hepatitis B virus serology assays 
Residual serum samples received from the Namibia Institute of Pathology were tested for 
HBsAg and anti-HBc using the Murex Version 3 GE 34/36 Surface Antigen and the Murex 
anti-HBc and assays (Diasorin, Saluggia, Italy). HBeAg and anti-HBe were detected by the 
HBeAg/anti-HBe Diasorin assays (Diasorin). 
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3.4.9.1 HBsAg assay 
Principle of the assay: The Murex HBsAg Version 3 GE 34/36 qualitatively measures the 
presence of HBsAg in human serum or plasma using the principle of a sandwich ELISA 
(Diasorin Murex version 3 kit insert).  
Assay procedure: Detection of the HBs antigen was performed using 75 µl of the neat sample, 
following the manufacturer’s instructions, as briefly explained henceforth. A volume of 75 µl 
of each sample and controls (two replicates of negative control and one replicate of positive 
control, provided in the kit) were incubated with 25 µl of sample diluent for a period of 60 
minutes at 37ºC in a thermostatically-controlled incubator, the Auto Flow IR Direct Heat CO2 
Incubator – 37°C, 5% CO2 standard requirements (Nuaire, Plymouth, USA). A 50 µl volume 
of the conjugate was added to the mix and incubated for another 30 minutes at 37ºC. After the 
30-minute incubation period, the plate was washed five times with a maximum volume of 350 
µl of wash buffer for each well using an automatic plate washer, the MW-12A Microplate 
Washer (Mindray, Shenzhen, China). Following the washing step, 100 µl of the substrate 
solution was added to the plate and incubated for 30 minutes at 37ºC; leading to a purple change 
in color where HBsAg was present. Then, 50 µl of stop solution (0.5M H2SO4) was added to 
each well, converting the purple color to a yellow color in reactive wells. The color intensity 
was measured at 450 nanometers (nm) and 630 nm as reference wavelengths using the dual 
wavelength ELx800 Universal Microplate Reader (Bio-Tek Instruments Inc, Winooski, 
Vermont, USA).  
Interpretation of results: As per the manufacturer’s directives, the absorbance values 
obtained from the spectrophotometer were compared to a cut-off value. This cut-off value was 
calculated by adding 0.05 to the mean absorbance of the replicates of the negative control (NC). 
Samples with an OD value above the cut-off value, specific to each run, were considered 
reactive for HBsAg.  
Quality control: Results of the assay were considered valid if: 
(1) The mean absorbance of the NC was less than 0.15. 
(2) The mean absorbance of the positive control (PC) was above 0.8.  
3.4.9.2 HBeAg assay 
Principle of the assay: The qualitative detection of this marker was achieved with the ETI-
EBK PLUS kit, a direct non-competitive ELISA assay whereby mouse monoclonal antibody, 
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pre-coated on the microwells of the polystyrene microtitre plate (provided with the kit), reacts 
directly with the HBeAg present in the tested sample (DiaSorin ETI-EBK PLUS kit insert).  
Assay procedure: Following the manufacturer’s instructions, 50 μl of incubation buffer plus 
100 μl of calibrator (three replicates), negative and positive controls and samples were 
dispensed in the microwells of the ELISA plate and incubated at 37°C in the Auto Flow IR 
Direct Heat CO2 Incubator. The first microwell of the ELISA plate is left empty, referred here 
as the blank well. Following a 2-hour incubation period, a 5-cycle wash was done with a 
maximum volume of 350 µl of wash buffer on the MW-12A Microplate Washer (Mindray, 
Shenzhen, China). Then, 100 µL of enzyme tracer was added in the microwells of the plate, 
with the exception of the blank well. The reaction was left in the Auto Flow IR Direct Heat 
CO2 Incubator for an hour at 37°C. Unbound enzyme was removed through a 5-cycle wash, 
and 100 µl of chromogen/substrate was pipetted in all wells of the reaction plate. Following a 
30-minute incubation time at room temperature, away from direct light, 100 µl of 0.5M H2SO4 
was added in all wells; converting the blue color in reactive wells to a yellow color. Non-
reactive wells remained colorless. The color intensity of each microwell was measured with a 
spectrophotometer, the dual wavelength ELx800 Universal Microplate Reader (Bio-Tek 
Instruments Inc, Winooski, Vermont, USA) at 450 nm.  
Interpretation of results: The HBeAg reactivity of the samples were measured by comparing 
their absorbance values to a cut-off value. This cut-off was calculated by adding 0.060 to the 
mean absorbance of the three calibrators used during the assay. Sample positive for HBeAg 
required to have an OD value above the calculated cut-off value.  
Quality control: Results of this assay were valid if the following criteria were met: 
(1) The blank well OD ranged between 0.000 and 0.150. This well contained the substrate 
only and was used to blank the Microreader Plate. 
(2) The mean absorbance for the calibrator was above -0.020, but less than 0.120. 
(3) The OD of the NC ranged between -0.020 and 0.500 and the OD of the PC was between 
0.120 and 2.500.  
(4) The difference between the absorbance value of the positive control and the negative 
control was higher than 0.450.  
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3.4.9.3 Anti-HBe assay 
Principle of the assay: The ETI-AB-EBK PLUS kit qualitatively determines the presence of 
anti-HBe in human serum or plasma. This is a competitive assay. Anti-HBe present in the 
sample together with monoclonal anti-HBe pre-coated microwells of the ELISA plate 
(provided with the kit) compete for binding to recombinant HBeAg (Diasorin ETI-AB-EBK 
PLUS kit insert).  
Assay procedure: The assay was conducted according to the manufacturer’s guidance. 
Accordingly, 50 μl incubation buffer was pipetted in the microwells of the plate (depending on 
the number of samples being tested); the first one was left empty and is referred to as the blank 
well. Then, 50 μl calibrator (three replicates), negative and positive controls and samples were 
dispensed in their respective microwells. A change in color to green or dark blue was observed. 
A volume of 50 μl of neutralizing solution was added to the microwells, apart from the blank 
well, and incubated for two hours at 37°C. A 5-cycle wash followed and 100 μl working 
enzyme tracer solution was pipetted in the wells in use, with the exception of the blank well. 
The reaction was placed in the Auto Flow IR Direct Heat CO2 Incubator (Nuaire, Plymouth, 
USA) for an hour at 37°C. Another 5-cycle wash followed and 100 μl chromogen/substrate 
solution was dispensed in all wells in use, including the blank well. The plate was placed away 
from direct light at room temperature; allowing the colorimetric reaction to take place. The 
colorimetric reaction was stopped past 30 minutes with the addition of 100 μl of 0.5M H2SO4, 
the stop solution, in each well. Within an hour of adding the stop solution, the plate was read 
on the ELx800 Universal Microplate Reader, to determine the absorbance values of each used 
well.  
Calculation of results: The presence of anti-HBe in the tested samples was determined by 
comparing the absorbance readings to a cut-off value. This cut-off value was determined by 
multiplying 0.500 by the mean absorbance of the three calibrators. As this is a competitive 
assay, samples with an absorbance value above the cut-off value were considered negative for 
anti-HBe. 
Quality control: The following criteria were used to validate the results obtained from the 
assay: 
(1) The absorbance for the blank well ranged between 0.000 and 0.150.  
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(2) The mean absorbance for the calibrator was above 0.500, but less than 2.500; with each 
calibrator within this range too. 
(3) The absorbance for the NC was higher than 0.500 and lesser than 2.500, and the 
absorbance of the PC was between 0.050 and 0.300.  
(4) The difference between the absorbance value of the NC and the PC was higher than 
0.250.  
3.4.9.4 Anti-HBc (total) assay 
Principle of the assay: The Murex anti-HBc (total) qualitatively tests for the presence of total 
antibodies against HBc antigen (HBcAg) in human serum or plasma, following the principle 
of a competitive enzyme immunoassay too (Diasorin Murex anti-HBc (total) kit insert). 
Assay procedure: Briefly, a mix of 50 μl of sample diluent and 50 μl of sample and control 
(two replicates of the positive controls and two replicates of the negative control) was pipetted 
in each well of the ELISA plate and incubated for 30 minutes at 37°C. The wells were washed 
five times, with a maximum volume of 350 µl of wash buffer per well. Then, 50 μl of the 
conjugate was dispensed in each well and once more placed in the incubator for 30 minutes at 
37°C. A second 5-times washing cycle followed, and 100 μl of substrate solution was 
immediately dispensed in the sample’s wells. A final incubation step at 37°C for 30 minutes 
was done, and finally 50 μl of the stop solution (0.5M H2SO4) was added in the wells of the 
plate. The intensity of the color (orange) developed was inversely proportional to the 
concentration of anti-HBc present in the tested samples. Within 15 minutes from adding the 
stop solution, the absorbance in the sample’s wells were measured using the Anthos HT3 
Microtiter Plate Reader (Anthos Labtec Instruments GmbH, Salzburg, Austria) at 450 nm, 
using 630 nm as the reference wavelength. 
Calculation of the results: Results were interpreted based on a cut-off value, resulting from 
an addition of the mean absorbances of the PC and the NC, divided by two. A result was 
considered positive where the absorbance value was lower than the cut-off value, whilst an 
absorbance value lower than the cut-off was concluded reactive for the tested analyte, anti-
HBc.  
Quality control: The interpretation of results was considered if set criteria were met. These 
include: 
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(1) The NC minus the PC was higher than 0.5 but less than 2.2.  
(2) The mean absorbance of the PC was lower than 0.24.  
3.4.9.5 Safety and quality measures for serology tests  
All assays were performed under a class II biological laminar flow cabinet Bioflow-II cabinet 
(Labotec, South Africa), protecting the user from biohazardous substances handled in the 
cabinet and the reaction (kits and samples) from unsterile contaminants. The surface of the 
cabinet was disinfected with 10% bleach and 70% ethanol before and after every procedure. 
Pipettes were also cleaned before and after use with 10% bleach and 70% ethanol. Samples 
were centrifuged for one minute at 6000 x g (G-force), using the Centrifuge 5415D (Eppendorf, 
Hamburg, Germany) before being opened to remove droplets inside the lid of the sample tubes 
that may potentially cause cross-contamination between samples. Filtered tips were used and 
changed for each sample and between pipetting exercises performed during the testing 
procedures. 
3.4.10 Hepatitis B virus molecular assays 
3.4.10.1  Viral DNA quantification 
Levels of HBV DNA present in patient’s samples were quantified using DBS on the automated 
COBAS AmpliPrep/COBAS TaqMan HBV test Version 2.0 (Roche Diagnostics, Risch-
Rotkreuz, Switzerland). The test was completed at the National Health Laboratory Services 
(NHLS), Division of Medical Virology, Tygerberg. According to the manufacturer, the assay 
can detect HBV DNA levels ranging from 20 IU/ml to 170 000 000 IU/ml in serum or plasma 
specimens.  
Principle of the assay: The instrument executes two major processes: HBV DNA isolation 
through the COBAS AmpliPrep, and subsequently simultaneous PCR amplification of the 
target DNA and HBV Quantitation Standard (QS) DNA coupled with detection of the dual-
labeled probe specific to the target through the COBAS TaqMan analyzer. HBV QS DNA is a 
non-infectious DNA construct with similar primer binding sites as the HBV target DNA and a 
unique probe binding region allowing a distinction between the target HBV amplicon in the 
specimen and the HBV QS amplicon during amplification and quantitation.  
Making use of generic silica-based capture technology, the COBAS AmpliPrep processes 500 
µl of the specimen for DNA isolation. The sample is incubated with a known copy number of 
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HBV QS DNA, protease, chaotropic lysis buffer and magnetic glass particles at elevated 
temperatures. This incubation allows the lysis of HBV viral particles and the release of HBV 
nucleic acids. Released DNA and HBV QS DNA bind to the surface of the glass particles, and 
a washing step follows. During the washing step, unbound substances (salts, proteins, and other 
impurities) are removed from the reaction. An aqueous solution is used for nucleic acids elution 
(both target HBV DNA and HBV QS DNA). Eluted nucleic acids are added to the amplification 
mixture and transferred to the COBAS TaqMan analyzer equipped with a thermal cycler. The 
latter heats the reaction mixture allowing denaturation of the double-stranded DNA, followed 
by primers annealing to the target DNA as the mixture cools down. In the presence of 
manganese (Mn2+) and excess deoxynucleotide triphosphates (dNTPs) such as 
deoxyadenosine, deoxyguanosine, deoxycytidine and deoxyuridine (in place of thymidine), the 
annealed primers are elongated along the target template forming a double-stranded DNA 
molecule (the amplicon) through the activity of the thermostable Thermus species Z05 DNA 
Polymerase. This process is repeated through a required number of cycles, each doubling the 
amount of DNA amplicons. These amplicons are detected in real-time, as they accumulate, 
using dual-labeled fluorescent probes. During each amplification process, the probes bind to a 
target sequence and are cleaved by the 5' → 3' nuclease activity of the Z05 DNA polymerase. 
The fluorescent lights emitted during each amplification cycle are measured at different 
wavelengths for target HBV DNA and HBV QS DNA. 
Sample processing: Briefly, one DBS was eluted in a 1000 µl volume of sample pre-extraction 
(SPEX) buffer (30 mM sodium citrate dihydrate, 42.5% guanidine thiocyanate, 4% 
polydocanol and 2% dithiothreitol), provided in the AmpliPrep/COBAS TaqMan HBV test 
Version 2.0 kit. Elution took place overnight on a slow shaker, The Coulter Mixer, (Coulter 
Electronics Limited, Luton Bedfordshire, UK) at room temperature. The eluate was used for 
both viral DNA extraction and amplification by the analyzer.  
Dilution factor between DBS and plasma: Plasma forms 60% of whole blood. In an 
approximate volume of 50 µl of capillary blood applied on a DBS, theoretically, 30 µl of 
plasma was eluted in the 1000 µl of SPEX buffer. Of this, 650 µl is used for the assay 
corresponding to an input sample volume of 20 µl in the assay. Given that HBV DNA viral 
load is reported by the analyzer as the number of international units in a 1000 µl, a dilution 
factor of 50 was used to calculate the viral loads.  
Quality control: Three controls including the HBV High Positive Control (HPC), the HBV 
Low Positive Control (LPC) and the HBV Negative Control (human plasma) are provided in 
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the AmpliPrep/COBAS TaqMan HBV test V2.0 kit. These controls were included during each 
test batch on the AmpliPrep/COBAS TaqMan to validate the results. The HBV DNA IU/ml 
result obtained for each positive control was verified to fall within the ranges provided by the 
manufacturer (LPC range: 102 – 103 IU/ml, HPC range: 3.21 x 105 – 3.20 x 106 IU/ml) and the 
negative control must give a “Target not detected (TND)” result. 
Interpretation of results: An in-house validation for the use of DBS specimen for HBV viral 
load was previously completed at the NHLS laboratory, Tygerberg Hospital, South Africa. The 
assay showed a limit of quantification (LoQ) of 843 IU/ml (2.93 log10 IU/ml) (95% CI: 479 
IU/ml – 2600 IU/ml) (Claassen et al., unpublished) (Appendix B). Where the assay recorded 
a viral load < 20 IU/ml, the result was reported as < 843 IU/ml. A “TND” output was recorded 
as “lower than the detection limit (LDL)”. Where a value within the range of the assay was 
obtained, this was multiplied by 50, the dilution factor, and recorded as the HBV DNA 
concentration of the analyzed sample. Further molecular analysis was performed on samples 
with detectable levels of HBV DNA, described as follow. 
3.4.10.2 Manual viral DNA extraction 
Viral DNA was manually extracted from samples with detectable levels of DNA for genome 
sequencing using the QIAamp® MinElute® Virus Spin kit (QIAGEN, Hilden, Germany). Prior 
to viral nucleic acid extraction, DBS were eluted following a previously published protocol 
(Mössner et al., 2015), with slight modifications. Briefly, one DBS (per patient) was pushed 
out from the perforated card in a clean 1.5 ml microcentrifuge tube (Thermo Fisher Scientific 
Inc, California, USA) using a clean tip. Tips were changed between samples. A 500 µl volume 
of 1xPBS/0.05% Tween 20/0.08% sodium azide (NaN3) elution buffer was pipetted in the 
microcentrifuge tubes. The samples were gently shaken on a microtube foam adapter inserted 
on the Vortex Genie 2 (Scientific Industries Inc, New York, USA) for overnight elution at room 
temperature. Viral DNA was extracted, as per the manufacturer’s instructions using 200 µl of 
eluates (QIAamp® MinElute® Virus Spin Handbook). 
The viral nucleic acid extraction procedure follows four main steps namely: lysis, binding, 
washing, and elution. During the lysis step, 200 µl of each eluate is added to 25 μl of QIAGEN 
protease solution (reconstituted in buffer AVE) in a 2 ml microcentrifuge tube. A 200 µl 
volume of buffer AL mix, containing 5.6 μg of carrier RNA and 3.5 μl of murine 
cytomegalovirus (mCMV) extract, was added to the sample. The reaction was mixed by pulse-
vortexing for 15 seconds and incubated at 56ºC for 15 minutes on a heating block (Omega 
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Scientific Pte, Ltd, Thailand). The mCMV extract, here considered as the internal control, was 
received from the Blood Borne Virus Unit (BBVU), PHE (Colindale, UK). After the 15-
minutes incubation period, the reaction tubes were briefly centrifuged in the Eppendorf 
centrifuge 5415 D (Merck, New Jersey, USA) and 250 μl of 100% ethanol (Merck, USA) was 
added in the reactions. The lysates were thoroughly mixed by pulse-vortexing, and a five-
minute incubation followed at room temperature. Following another brief spin of the 
microcentrifuge tubes, each lysate was pipetted onto the QIAamp Mini spin column and 
centrifuged for a minute at 6000 x g; allowing the viral DNA to bind to the silica membrane of 
the columns. Bound viral DNA was purified through two subsequent washing cycles, 
performed using 500 μl buffer AW1 and 500 μl buffer AW2. Centrifugation at 6000 x g for a 
minute followed each washing cycle. Final DNA purification was completed by adding 500 μl 
of 100% ethanol to the membrane of the QIAamp mini columns. The columns were centrifuged 
at 6000 x g for three minutes. Ethanol carry over that may be present in the columns was 
removed through additional centrifugation at 20 000 x g, and the columns were incubated at 
56ºC for three minutes with caps opened for complete evaporation of remaining ethanol. To 
end, 60 μl of buffer AVE (the elution buffer) was pipetted to the center of the silica membrane 
of the mini columns, and DNA elution was completed at 20 000 x g for a minute, following a 
five minute incubation period.  
Extracted HBV DNA was subjected to Sanger sequencing for HBV genotyping, and to 
determine the presence of drug-associated or vaccine-escape mutants as well as mutants that 
have been previously associated with the development of HCC. 
3.4.10.3 Nucleotide sequencing of the polymerase/surface and X/core genes  
Sequencing of these two genes was performed using protocols developed at the BBVU, PHE 
(http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1194947340684). These protocols 
have been transferred to and are now established in our laboratory.  
Genomic sequences were obtained through DNA amplification by means of nested PCR to 
generate specific DNA for the sequencing reaction, gel electrophoresis, DNA template 
purification, cycle sequencing PCR and capillary electrophoresis. Details of each step are 
provided below. 
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3.4.10.3.1 DNA Amplification of the polymerase/surface (pol/surf) gene 
First round of amplification (Pre-nested PCR) 
Two primers (Table 3.1) were used to amplify the pol/surf region, including domains A to E 
of the RT region, of the viral genome. A master mix was prepared in a 2 ml microcentrifuge 
tube as per Table 3.2 and pipetted in volumes of 20 µl in 0.2 ml PCR tubes while working on 
ice. Five microlitres of DNA was added in their respective PCR tubes, and the reaction was 
carried on in the GeneAmp PCR system 9700 (Applied Biosystems (ABI)) following cycling 
conditions tabulated in Table 3.3.  
Table 3.1: Oligonucleotides used for pre-nested PCR amplification of the pol/surf gene 
Oligonucleotide 
name# 
5’→3’ Sequence 
Position on HBV 
genome*  
HBV Z – Forward  AGC CCT CAG GCT CAG GGC ATA 1179 - 1199  
HBV 3 – Reverse CGT TGC CKD GCA ACS GGG TAA AGG 2478 - 2455  
#http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1194947340684. *Numbered according to 
Pugh et al. (1986) (Pugh et al., 1986). 
Table 3.2: Master Mix for pre-nested PCR amplification of the pol/surf gene 
Reagents Stock concentration 
Volume (μl) per 1 
rxn 
Final concentration 
PCR buffer 10X 2.50 1 x 
MgCl2 50mM 0.75 1.5mM 
dNTPs 10mM 0.50 0.2mM 
Taq Polymerase  0.10  
HBV 3 20pmol/μl 0.50 0.4pmol/μl 
HBV Z 20pmol/μl 0.50 0.4pmol/μl 
NFW  n/a 15.15 n/a 
Total volume µl n/a 20.00 n/a 
Combine 5 µl of DNA with 20 µl of Master Mix 
PCR buffer (Invitrogen, California); deoxynucleoside triphosphate (dNTP) mix (Bioline, London); 
magnesium chloride (MgCl2) (Invitrogen, California); Thermus aquaticus (Taq) Polymerase 
(Invitrogen, California); NFW: Nuclease free water; mM: millimolar; pmol/μl: picomole per microlitres; 
n/a: not applicable; Rxn: reaction. 
Table 3.3: Cycle conditions for pre-nested PCR amplification of the pol/surf gene 
Steps Cycling parameters Cycles Temperature Time 
1 Initial denaturation 1 95ºC 5 minutes 
2 Denaturation 34 94ºC 30 seconds 
3 Annealing 34 55ºc 30 seconds 
4 Extension 34 72ºC 1minute 
5 Final extension 1 72ºC 2 minutes 
Steps 2, 3 and 4 were repeated 34 times. 
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Second round of amplification (Nested PCR) 
The second round of amplification, using the pre-nested PCR products as templates and a 
different set of primers (see Table 3.4), was performed. Each reaction was prepared by 
combining one µl of the pre-nested PCR product with 49 µl of a master mix, prepared as per 
Table 3.5. DNA amplification was performed in the GeneAmp PCR system 9700 (ABI) at 
cycling conditions tabulated in Table 3.6. DNA products acquired from the nested PCR were 
visualized by gel electrophoresis (see below), allowing confirmation of the correct size of the 
amplicons for pol/surf genomic sequencing. 
Table 3.4: Oligonucleotides used for Nested PCR amplification of the pol/surf gene 
Oligonucleotide 
name# 
5’→3’ Sequence 
Position on HBV 
genome* 
HBV P – Forward  TCA TCC TCA GGC CAT GCA GT 1292 – 1311  
HBV M – Reverse GAC ACA CTT TCC AAT CAA TNG G 2306 – 2287  
#http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1194947340684. *Numbered according to 
Pugh et al. (1986) (Pugh et al., 1986). 
Table 3.5: Master Mix for nested PCR amplification of the pol/surf gene 
Reagents Stock concentration 
Volume (μl) per 1 
rxn 
Final concentration 
PCR buffer 10X 5.0 1 x 
MgCl2 50mM 1.5 1.5mM 
dNTPs 10mM 1.0 0.2mM 
Taq Polymerase  0.2  
HBV P 20pmol/μl 1.0 0.4pmol/μl 
HBV M 20pmol/μl 1.0 0.4pmol/μl 
NFW n/a 39.3 n/a 
Total volume µl n/a 49.0 n/a 
Combine 1 µl of pre-nested DNA product with 49 µl of Master Mix 
PCR buffer (Invitrogen, California); deoxynucleoside triphosphate (dNTP) mix (Bioline, London); 
magnesium chloride (MgCl2) (Invitrogen, California); Thermus aquaticus (Taq) Polymerase 
(Invitrogen, California); NFW: Nuclease free water; mM: millimolar; pmol/μl: picomole per microlitres; 
n/a: not applicable; Rxn: reaction. 
Table 3.6: Cycle conditions for nested PCR amplification of the pol/surf gene 
Steps Cycling parameters Cycles Temperature Time 
1 Initial denaturation 1 95ºC 5 minutes 
2 Denaturation 34 94ºC 30 seconds 
3 Annealing 34 50ºc 30 seconds 
4 Extension 34 72ºC 1 minute 
5 Final extension 1 72ºC 7 minutes 
Steps 2, 3 and 4 were repeated 34 times. 
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3.4.10.3.2 DNA Amplification of the X/core gene 
As performed for the amplification of the pol/surf gene in section 3.3.9.3.1, DNA templates of 
the X/core gene were produced through two rounds of amplification too.  
First round of amplification 
The pre-nested PCR reaction was prepared using two primers (Table 3.7) pipetted in a master 
mix, as detailed in Table 3.8, to make a total volume of 20 µl. Five microlitres of the DNA 
template was pipetted in 0.2 ml PCR tubes with the master mix. The PCR was completed in 
the GeneAmp PCR system 9700 (ABI) using cycling conditions presented in Table 3.9. 
Table 3.7: Pre-nested PCR oligonucleotides for HBV X/core gene amplification 
Oligonucleotide 
name#  
5’→3’ Sequence 
Position on HBV 
genome* 
H4072 – Forward  TCT TGC CCA AGG TCT TAC AT 1602 – 1621  
Outer core – Reverse  TCC CAC CTT ATG AGT CCA AG 2468 - 2449  
#(Dervisevic et al., 2007). *Numbered according to Pugh et al. (1986) (Pugh et al., 1986). 
Table 3.8: Master Mix for pre-nested PCR amplification of the X/core gene 
Reagents Stock concentration 
Volume (μl) per 1 
rxn 
Final concentration 
PCR buffer 10X 2.50 1 x 
MgCl2 50mM 0.75 1.5mM 
dNTPs 10mM 0.50 0.2mM 
Taq Polymerase  0.10  
H4072 20pmol/μl 0.50 0.4pmol/μl 
Outer Core  20pmol/μl 0.50 0.4pmol/μl 
NFW n/a 15.15 n/a 
Total volume µl n/a 20.00 n/a 
Combine 5 µl of pre-nested DNA product with 20 µl of Master Mix 
PCR buffer (Invitrogen, California); deoxynucleoside triphosphate (dNTP) mix (Bioline, London); 
magnesium chloride (MgCl2) (Invitrogen, California); Thermus aquaticus (Taq) Polymerase 
(Invitrogen, California); NFW: Nuclease free water; mM: millimolar; pmol/μl: picomole per microlitres; 
n/a: not applicable; Rxn: reaction.  
Table 3.9 Cycling conditions for pre-nested PCR amplification of the X/core gene 
Steps Cycling parameters Cycles Temperature Time 
1 Initial denaturation 1 94ºC 2 minutes 
2 Denaturation 35 94ºC 30 seconds 
3 Annealing 35 55ºc 30 seconds 
4 Extension 35 72ºC 1minute 
5 Final extension 1 72ºC 2 minutes 
Steps 2, 3 and 4 were repeated 34 times. 
Stellenbosch University https://scholar.sun.ac.za
64 
 
Second round of amplification 
This was completed using a 50 µl reaction combining 49 µl of a prepared Master Mix (Table 
3.11) and one µl of pre-nested PCR DNA product. The primers used are listed in Table 3.10. 
DNA amplification took place in the GeneAmp PCR system 9700 (ABI) using cycling 
parameters similar to the first round of amplification; mentioned above (Table 3.9). Next, DNA 
amplicons were analyzed by gel electrophoresis. 
Table 3.10 Nested PCR oligonucleotide for nested PCR amplification of the X/core gene  
Oligonucleotide 
name#  
5’→3’ Sequence 
Position on HBV 
genome* 
H4072 – Forward  TCTTGCCCAAGGTCTTACAT 1602 – 1621  
Inner core – Reverse  CAGCGAGGCGAGGGAGTTCTTCTT 2422 – 2445  
#(Dervisevic et al., 2007).*Numbered according to Pugh et al. (1986) (Pugh et al., 1986). 
Table 3.11 Master Mix for nested PCR amplification of the X/core gene 
Reagents Stock concentration 
Volume (μl) per 1 
rxn 
Final concentration 
PCR buffer 10X 5.0 1x 
MgCl2 50mM 1.5 1.5mM 
dNTPs 10mM 1.0 0.2mM 
Taq Polymerase  0.2  
H4072 20pmol/μl 1.0 0.4pmol/μl 
Inner core  20pmol/μl 1.0 0.4pmol/μl 
NFW n/a 39.3 n/a 
Total volume µl n/a 49.0 n/a 
Combine 1 µl of pre-nested DNA product with 49 µl of Master Mix 
PCR buffer (Invitrogen, California); deoxynucleoside triphosphate (dNTP) mix (Bioline, 
London); magnesium chloride (MgCl2) (Invitrogen, California); Thermus aquaticus (Taq) 
Polymerase (Invitrogen, California); NFW: Nuclease free water; mM: millimolar; pmol/μl: 
picomole per microlitres; n/a: not applicable; Rxn: reaction.  
3.4.10.3.3 Gel electrophoresis 
This method is used for the separation of nucleic acids (DNA or RNA) and proteins molecules 
according to their molecular size. During the gel electrophoresis, the molecules are pulled to 
move through the pores of the gel by an electric field; the smaller molecules move faster and 
migrate farther than the larger ones, forming different size bands on the gel.  
Agarose gel electrophoresis was used. The concentration of agarose used is dependent on the 
size of the DNA fragments to be separated. For DNA fragments of approximately 1kb, a 1.5% 
gel is often used. A 1.5% agarose gel was prepared by heat-dissolving 1.5 g of powder 
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SeaKem® LE agarose (LONZA, Base, Switzerland) in 100 ml of 1× tris-acetate-ethylene 
diamine tetra acetic acid (TAE) buffer for two minutes in a microwave. The 1×TAE buffer was 
prepared from a 50×TAE stock solution, prepared by dissolving 242 g Tris base (Boehringer, 
Mannheim, Germany) in 57.1 ml of glacial acid (Merck Chemicals, Germany), 100 ml of 0.5 
EDTA of pH = 8.0 and distilled water. The melted agarose was allowed to cool down at room 
temperature and poured in a gel cast, whose dimensions were dependent on the number of 
samples analyzed during each experiment. A comb was immediately placed in the geld mold 
to create wells for the loading of samples. Once set, the comb was removed, and the gel was 
submerged in 1×TAE buffer for loading of DNA. Five microlitres of each nested PCR product 
was mixed with one µl of 6X Novel Juice (GeneDireX Inc, Taiwan), the loading dye, and 
loaded in each well of the gel. Novel Juice is a fluorescent dye providing instant visualization 
of DNA bands upon applying blue light or UV light to the agarose gel. The buffer contains 
three tracking dyes namely Bromophenol Blue (dark blue color) migrating with larger DNA 
fragments, Xylene Cyanol FF (light blue color) co-migrating smaller fragments and, Orange G 
(light orange) migrating ahead of Bromophenol Blue; thereby enabling visual tracking of DNA 
fragments migrating through the gel during gel electrophoresis 
(https://www.genedirex.com/novel-juice/). A one kb DNA ladder (GeneRuler™, Fermentas, 
Massachusetts, USA) was used as a molecular marker to confirm the molecular weight of the 
amplified DNA products. The DNA ladder was stained with Novel Juice and pipetted at one 
end of the gel. Electrophoresis was conducted at 80Volts for 30 minutes. The gel slab was 
visualized on the UVItec Prochemi (UVItec, Cambridge, UK) image acquisition system, after 
being exposed to ultraviolet (UV) light at 245 nm wavelength. Images acquired were edited 
using the UVIband-1D gel analysis software (Cambridge, UK) and stored for interpretation.  
An approximate DNA size of 1000 bp and 750 bp was expected for the pol/surf and the X/Core 
genes, respectively. DNA products of the correct size were purified for further molecular 
analysis. 
3.4.10.3.4 Purification of nested PCR products and DNA concentration quantification 
Purification of DNA products seen on the gel slab was done by means of the Isolate II PCR 
and Gel Kit (Bioline, London, UK). The kit allows both purification and concentration of DNA 
through the principle of DNA capture - DNA binding - washing and elution. 
As per the manufacturer’s instructions, one volume (45 µl) of each sample was mixed in two 
volumes (90 µl) of binding buffer CB in labeled Isolate II PCR and gel columns, provided in 
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the kit. The columns were centrifuged for 30 seconds at 11 000 x g, using the Prism™ 
Microcentrifuge (Labnet International Inc, Edison, New Jersey, USA) and the flow through 
was discarded. A 700 µl volume of wash buffer CW was pipetted in the columns. These 
columns were subsequently centrifuged at 11 000 x g for another 30 seconds. The flow-through 
was discarded, and the column placed back in the collection tube. Another centrifugation step 
followed for 60 seconds at 11 000 x g, to remove residual ethanol present in the wash buffer. 
Finally, the columns were placed in clean 1.5 ml microcentrifuge tubes and 15 µl of elution 
buffer C was directly applied onto the silica membrane of the columns and left to incubate for 
60 seconds at room temperature. Centrifugation followed at 11 000 x g for 60 seconds for DNA 
elution. 
The purified DNA products were quantified spectrophotometrically by means of the 
NanoDrop® ND-1000 (Thermo Fisher Scientific, USA). This device makes use of a patented 
retention technology operating with surface tension alone to hold the sample in place. This 
technology eliminates the need for cuvettes and other sample containment devices and allows 
for rapid cleaning between samples during measurements. A blanking cycle was performed at 
first: one µl of the elution buffer C was measured to confirm that the instrument is working as 
expected. One µl of each purified product was pipetted onto the instrument, and the 
concentration and purity of DNA present were automatically determined with the “Nucleic 
Acid” Application module of the NanoDrop Software Version 3.1.0. DNA purity was 
determined as per the absorbance 260/280 ratio (A260/280nm ratio); a ratio of approximately 1.8 
is accepted as “pure”. Absorbance was measured at a 260 nm wavelength, and nucleic acid 
concentration (in ng/µl) was calculated. The pedestal was cleaned up between samples to avoid 
cross-contamination. Results were printed and analyzed. Samples with a DNA concentration 
above 20ng/μl were diluted to the recommended range (5-20ng/μl) for the sequencing PCR 
reaction. 
3.4.10.3.5 Cycle sequencing PCR using purified nested DNA products 
The entire HBsAg gene region, which includes domains A to E of the overlapping HBV pol 
region, was investigated for HBV genotyping. Mutations associated with vaccine escape and 
antiviral drug resistance were of interest in this region, while the BCP and pre-C nucleotide 
sequences were of interest in the core gene. Sequencing of these viral genes was performed 
through Sanger sequencing, also known as the chain-termination method. This methodology is 
based on the selective incorporation of chain-terminating modified dNTPs known as 
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dideoxynucleotide triphosphates (ddNTPs). ddNTPs do not have the 3’-hydroxyl (OH) group 
required for the formation of a phosphodiester bond between two nucleotides (nt), thereby 
causing termination of DNA elongation when incorporated. During this reaction, when a dNTP 
(A, C, G, or T) is added to the 3′ end of the single-stranded DNA template, chain extension 
carries on. And, when a ddNTP (ddA, ddC, ddG, or ddT) is added to the 3´ end of the primer, 
DNA synthesis ends.  
The reaction was prepared through a fluorescent-based cycle sequencing PCR using the 
BigDye® Terminator V3.1 Cycle Sequencing Ready Reaction kit (ABI, California, USA), a 
pre-mixed format to which the template, purified nested DNA products, and primers specific 
to the region of interest (listed in Table 3.12 and Table 3.13) were added in. Fluorescent-labeled 
dNTPs are incorporated by a DNA polymerase for DNA elongation, and whenever a ddNTP is 
added, the DNA polymerase ceases elongation; resulting in the formation of DNA fragments 
of various lengths with ddNTPs at the 3′ -OH end. 
The number of reactions for each sample was dependent on the number of primers required; 
thus four reactions were prepared for each sample, as four primers (two forward primers and 
two reverse primers) were needed for each gene. A 10 µl reaction, per sample, was prepared as 
outlined in Table 3.14 and pipetted in a 96-well plate (ThermoFisher Scientific, Massachusetts, 
USA). The cycle sequencing PCR was executed on the GeneAmp PCR system 9700 (ABI) 
through cycling conditions presented in Table 3.15. Sequencing products acquired were 
purified. 
Table 3.12: Oligonucleotides used for sequencing the HBV pol/surf gene 
Oligonucleotide 
name 
5’→3’ Sequence 
Position on HBV 
genome* 
HBV P – Forward TCA TCC TCA GGC CAT GCA GT 1292 - 1311  
HBV M – Reverse GAC ACA CTT TCC AAT CAA TNG G 2306 - 2287  
HBV H – Forward  TAT CAA GGA ATT CTG CCC GTT TGT CCT 1767 - 1793  
HBV N - Reverse ACT GAG CCA GGA GAA ACG GAC TGA GGC 1991 - 1965  
*Numbered according to Pugh et al. (1986) (Pugh et al., 1986). 
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Table 3.13: Oligonucleotide used for sequencing the HBV X/core gene 
Oligonucleotide 
name 
5’→3’ Sequence  
Position on HBV 
genome*  
H4072 - Forward  TCT TGC CCA AGG TCT TAC AT 1602 – 1621  
Inner Core– Reverse  CAG CGA GGC GAG GGA GTT CTT CTT 2422 – 2445  
CSEQR – Reverse  GGA GGA GTG CGA ATC CAC ACT 2314 – 2334  
RSP – Forward  GTT CAA GCC TCC AAG 1830 – 1844  
*Numbered according to Pugh et al. (1986) (Pugh et al., 1986). 
Table 3.14: Sequencing PCR reaction mix 
Reagents Volume (μl) per 1 rxn 
Terminator ready reaction mix  1 µl 
ABI sequencing buffer  3 µl 
Nuclease-free water  4 µl 
Total Volume  8 µl 
Combine 8 µl of this mater mix with 1 µl of each primer per well and 1 µl of DNA amplicons 
Rxn: reaction 
Table 3.15: Cycling conditions for sequencing pol/surf and X/core genes 
Steps Cycling parameters  Cycles Temperature Time 
1 Denaturation  30 96ºC 20 seconds 
2 Annealing  30 55ºC 20 seconds 
3 Extension  30 60ºC 4 minutes 
These three steps were repeated 30 times 
3.4.10.3.6 Purification of cycle sequencing products 
Purification of the sequencing reaction products entails removal of unincorporated ddNTPs 
used during the sequencing reaction and salts that might interfere with base calling during 
capillary electrophoresis, using the BigDye® Xterminator Purification Kit (ABI, Foster City, 
California, USA). The XTerminator® solution gets rid of unincorporated dye terminators and 
free salts, while the SAMTM solution enhances the XTerminator performance and stabilizes the 
samples after purification.  
A master mix was pre-made, composed of 49.5 μL SAM solution and 11 μL XTerminator 
solution per sample. Fifty-five µl of the mix was pipetted in each well of the 96-well plate 
containing the sequencing products. The plate was closed with a MicroAmp Optical sheet 
(ABI, California, USA) and vortexed on the Multi-microplate Genie microplate shaker 
(Scientific Industries, New York) for 30 minutes at 2000 x g. Centrifugation of the plate for 
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two minutes at 1000 x g followed to collect all the liquids at the bottom of the wells, and the 
sequences were read on the ABI Prism 3130xl genetic analyzer (ABI, California, USA). 
3.4.10.4 Sequence and phylogenetic analysis 
Sequence chromatograms acquired from the DNA sequencing analysis software on the 3130xl 
genetic analyzer were uploaded and analyzed on Geneious Version 10.2.3 (Biomatters, New 
Zealand). The raw sequences were trimmed and edited, where necessary, and contigs were 
assembled for each sample. The consensus sequences were fed in the Basic Local Alignment 
Sequence Tool (BLAST) on the NCBI website to confirm that the sequences acquired were truly the 
targeted regions of HBV. Pol/surf consensus sequences were submitted to the National Library of 
Medicine HBV Genotyping tool (http://www.ncbi.nlm.nih.gov/projects/genotyping/formpage.cgi) for 
genotyping, and to the Max Planck Institute for Informatics HBV genotyping tool (Geno2Pheno) 
(http://hbv.geno2pheno.org/index.php) and the HBV Sequencing tool from Stanford University 
(https://hivdb.stanford.edu/HBV/HBVseq/development/HBVseq.html) for mutation analysis.  
Viral pol/surf gene sequences matching our query sequences on Genbank, based on the 
nucleotide similarities and geographical location similarities, were downloaded and fed in 
Geneious Version 10.2.3. The ClustalW algorithm was used for sequence alignment in 
Geneious. The aligned sequences were imported in Molecular Evolutionary Genetics Analysis 
(MEGA) Version 7 (Kumar et al., 2016). The phylogenetic relationship between sequences in 
our dataset was inferred through a neighbor-joining tree analysis (Saitou & Nei, 1987), 
performed using the p-distance model. A bootstrap test (1000 replicates) (Felsenstein, 1985) 
was included to validate the accuracy of the tree. The p-distance model calculated the 
proportion of nucleotide sites at which a pair of sequences being compared differs. A best-fit 
substitution model analysis was run in the JModelTest Version 2.1.3 software (Posada 2008). 
As the name suggests, the analysis is aimed to determine the most suitable model for use to 
infer the evolutionary relationship between the sequences in our dataset. The programme 
compares different nucleotide substitution models and chooses among them the most 
appropriate one for analysis of the dataset using five strategies namely hierarchical and 
dynamical likelihood ratio tests (hLRT and dLRT), Akaike and Bayesian information criteria 
(AIC and BIC), and a decision theory method (DT). The best-fitted model, chosen using AIC 
and BIC scores, was applied to our dataset to complete a maximum-likelihood analysis 
(Felsenstein, 1981) in MEGA7. 
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The URR (nt 1653 to nt 1741), BCP (nt 1742–1849) and pre-C (nt 1814–1900) regions of the 
HBV core sequences were manually extracted using Geneious Version 10.2.3 and variants 
were manually detected using BioEdit Version 7.2.5. (Hall, 1999), using the wild-type gene 
sequences as references. These gene sequence references were provided by the BBVU at PHE 
(Colindale, UK). 
3.4.10.5 Quality assurance for molecular assays 
All molecular assays were performed in dedicated rooms, under a class II biological laminar 
flow cabinet (Bioflow-II cabinet). Clean gloves were always worn when completing the 
different procedures. The surfaces of the biosafety cabinets and of the laboratory benches were 
disinfected with 10% bleach and 70% ethanol before and after each procedure. Pipettes were 
also cleaned before and after use with 10% bleach and 70% ethanol.  
Sample tubes were briefly centrifuged to eliminate sample-glove contact. An NC, normal 
human plasma (NHP) previously tested negative for all HBV markers was used for each 
extraction procedure and during each PCR procedure to detect cross-contamination during 
sample handling. A PC and a No Template Control (NTC) were added in each PCR procedure. 
The NTC (nuclease-free water) was used to exclude contamination from the reagents used in 
the assays, and the PC served to confirm true positive results. The PC was extracted from a 
dilution (4 log10 IU/ml) of an in-house HBV control, with a known viral load of 8 log
10 IU/ml, 
made in NHP. The in-house HBV control was previously calibrated against the second WHO 
HBV DNA standard for NAT assays obtained from the National Institute for Biological 
Standards and Control (NIBSC) (NIBSC code: 97/750).The NIBSC standard had an HBV 
DNA viral load of 6 log10 IU/ml. 
3.4.11 Liver health evaluation 
All HIV/HBV co-infected children were evaluated for laboratory evidence of liver disease. 
This entailed a laboratory assessment including liver biochemistry, full blood count and the 
AST platelet ratio index (APRI). AST, ALT and platelet count testing were performed at the 
Namibia Institute of Pathology in Windhoek. These measurements were used for the 
calculation of the APRI score following the formula: APRI = (AST level/Upper normal limit) 
X100/platelet count. An AST upper limit of normal (ULN) value of 40 was used to calculate 
the APRI score, and an APRI > 0.5 was considered a sign of liver fibrosis (McGoogan et al., 
2010). 
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3.5 Results 
3.5.1 Patient recruitment 
Between September 2014 and May 2015, 21 participants were enrolled in the study: 15 
children/adolescents and six mothers attending with their children. The mothers of six 
participants were deceased, and the other two mothers did not attend the clinic with their 
children at the time of recruitment. Demographics and baseline clinical characteristics of 
participants are represented in Table 3.16. At enrolment, three children were following a TDF-
containing ART regimen, and 11 were on lamivudine therapy as the only agent against HBV. 
One child (Child 2C) previously on a TDF-based ART had been switched to lamivudine 
therapy. Treatment history was unknown for one child (14C). A summary of pediatric ARV 
therapy regimen is provided below in Table 3.17. All mothers enrolled were following a TDF-
containing ART regimen for the treatment of their HIV-1 infection. 
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Table 3.16: Demographics and clinical characteristics of study participants 
Characteristic Children  Mothers 
Sample number 
15  
n/N; % 
6 
n/N; % 
Age at sample collection   
Median 14 years 41.5 years 
Range (min – max) 8 – 19 32 – 46 
Sex   
Female 7/15 ; 46.7% 6/6; 100% 
Male 8/15; 53.3% NA 
HBV vaccination   
Yes 0/15; 0.0% NA 
No 13/15; 86.7% NA  
Unknown 2/15; 13.3% NA  
Past liver disease   
Yes 1/15; 6.7% NA 
No 12/15; 80.0% NA 
Unknown 2/15; 13.3% NA 
Baseline AST¥ (IU/ml)   
Median 27 Not Available 
Range (min – max) 27 – 27 Not Available  
Baseline ALT$ (IU/ml)   
Median 38 35 
Range (min – max) 13 – 359  20 – 59  
CD4 count$ (most recent at enrollment)   
Median 628 405 
Range (min – max) 447 – 1887  120 – 1312 
¥Baseline AST level was available for patient 9C only. $Baseline ALT levels and the most recent CD4 
count from the date of enrollment were available for 13 patients. ALT: alanine aminotransferase; AST: 
aspartate aminotransferase; HBV: hepatitis B virus; IU/ml: international units per milliliter; Kg: 
kilogram; NA: Not Applicable. 
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Table 3.17: Antiretroviral therapy regimen history of children and adolescents enrolled  
Patient SID HAART regimen at 
enrolment 
Start date Previous 
HAART 
regimen 
Start date 
1C* ABC/3TC/EFV 08/04/2014 D4T/3TC/EFV 02/09/2008 
2C AZT/3TC/NVP 07/03/2014 TDF/3TC/NVP 26/01/2011 
3C AZT/3TC/NVP 08/12/2005 AZT/3TC/NVP 08/12/2005 
4C AZT/3TC/EFV 22/07/2011 AZT/3TC/EFV 22/07/2011 
5C TDF/3TC/NVP 15/09/2010 AZT/3TC/NVP 03/10/2008 
6C AZT/3TC/NVP 20/02/2014 D4T/3TC/NVP 15/09/2005 
7C AZT/3TC/LPV/r 23/01/2014 D4T/3TC/Lpv/r 11/05/2007 
8C 
AZT/3TC/ABC/LPV/
r 
02/04/2014 AZT/3TC/NVP 
09/09/2004 
9C AZT/3TC/TDF 22/08/2011 AZT/3TC/NVP 29/04/2004 
10C AZT/3TC/NVP 28/07/2005 AZT/3TC/NVP 28/07/2005 
12C AZT/3TC/LPV/r 06/07/2006 AZT/3TC/Lpv/r 06/07/2006 
13C AZT/3TC/EFV 30/03/2005 AZT/3TC/EFV 30/03/2005 
14C Unknown Unknown Unknown Unknown  
16C TDF/3TC/EFV 16/04/2014 AZT/3TC/NVP 28/07/2005 
17C AZT/3TC/EFV 30/01/2014 D4T/3TC/EFV 07/01/2011 
*Child 1C had followed two other HAART regimen prior 2008-09-02. These were: AZT/3TC/NVP 
in 04/11/2008 and AZT/3TC/EFV in 29/04/2008. 3TC: Lamivudine; ABC: Abacavir; AZT: 
Stavudine; C: Child; EFV: Efavirenz; HAART: Highly Active Antiretroviral Therapy; LPV/r: 
Ritonavir-boosted Lopinavir; NVP: Nevirapine; SID: Study Identificant; TDF: Tenofovir. In red are 
marked children receiving a TDF-based ART for the treatment of their HIV infection. 
3.5.2 Sample collection 
DBS and blood samples were successfully collected from all recruited patients. These were 21 
DBS samples (15 pediatric and six maternal samples) and 15 blood samples from the children 
and adolescents. All 21 DBS samples (15 pediatric and six maternal samples) and 10 residual 
pediatric serum samples were shipped to and received at the Division of Medical Virology for 
further HBV laboratory testing. The other five pediatric serum samples could not be traced for 
retrieval at the Namibian laboratory and were not forwarded to the Division of Medical 
Virology at Stellenbosch University, South Africa. Serological testing was performed using 
serum samples, while DBS were used for molecular testing.  
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3.5.3 Hepatitis B virus serological profiles 
3.5.3.1 HBsAg assay results 
All 10 samples received from the Namibian laboratory were re-tested for HBsAg. HBsAg 
reactivity was confirmed in all 10 samples.  
3.5.3.2 HBeAg assay results  
HBeAg seropositivity was noted in seven samples (7/10; 70%). The other three samples (3/10; 
30%) were found non-reactive for HBeAg.  
3.5.3.3 Anti-HBe assay results 
Eight samples tested non-reactive for anti-HBe (8/10; 80%); of which one (sample 5C) had an 
OD value falling within the ±10% of the cut-off value thus was re-tested. A repeat testing of 
the sample confirmed non-reactivity for anti-HBe. Two samples tested positive for anti-HBe; 
these samples were HBeAg negative. 
3.5.3.4 Anti-HBc (total) assay results 
All samples reacted positive for anti-HBc (total).  
All quality control criteria were met, thereby validating the results obtained in these assays. 
These results are summarized in Table 3.18. 
Table 3.18: HBV markers profiles of HIV/HBV co-infected children  
Patient ID 
HBsAg HBeAg Anti-HBe Anti-HBc (total) 
1C 
+ - + + 
2C 
+ + - + 
3C 
+ + - + 
4C 
+ - + + 
5C 
+ - - + 
6C 
+ + - + 
7C 
+ + - + 
8C 
+ + - + 
10C 
+ + - + 
13C 
+ + - + 
Anti-HBc: antibodies against hepatitis B core antigen; anti-HBe: antibodies against 
hepatitis B e antigen; HBsAg: hepatitis B surface antigen; ID: identificant.  
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3.5.4 Hepatitis B virus molecular profiles 
3.5.4.1 HBV DNA viral load 
HBV DNA viral level measurements were performed for all 21 participants, 15 children, and 
six mothers. Eight of the children tested positive for HBV DNA (8/15; 53.3%), while none of 
the mothers had detectable levels of HBV DNA. HBV DNA levels of positive patients ranged 
from 6.23 log10 IU/ml to 7.64 log10 IU/ml (median: 7.20 log10 IU/ml); tabulated in Table 3.18. 
Of these eight HBV DNA positive children, seven were HBsAg and HBeAg positive, anti-HBe 
negative. The eight child was not tested for these serological markers, as we did not receive a 
serum sample to do so. Of the other seven children with undetectable levels of DNA, three 
were tested for further HBV serological markers. Of these three children, two were HBeAg 
negative/anti-HBe positive, and one was HBeAg negative/anti-HBe negative. Viral nucleic 
acid was successfully extracted from the eight HBV DNA positive samples for sequencing of 
the pol/surf and X/core genes. 
Table 3.19: HBV DNA viral load of HBV DNA positive children. 
Patient ID HBV viral 
load* (IU/ml) 
HBV viral load log10 
(IU/ml) 
HBsAg HBeAg Anti-HBe 
2C 12 850 000 7.11 + + - 
3C 30 400 000 7.48 + + - 
6C 7 200 000 6.86 + + - 
7C 1 695 000 6.23 + + - 
8C 19 850 000 7.30 + + - 
10C 44 000 000 7.64 + + - 
13C 19 700 000 7.29 + + - 
17C 4 755 000 6.68 ND ND ND 
Median HBV viral load: 7.20 log10 IU/ml 
*These values were obtained from multiplying the results obtained by the COBAS AmpliPrep/COBAS 
TaqMan HBV test Version 2.0 by the dilution factor between DBS and plasma (50). Anti-HBe: 
antibodies against hepatitis B e antigen; HBeAg: hepatitis B e antigen; HBsAg: hepatitis B surface 
antigen; HBV: hepatitis B virus; ID: identificant; IU/ml: international units per millilitre; ND: Not 
done.  
3.5.4.2 Nucleotide sequencing of the pol/surf gene 
DNA template specific for the pol/surf gene was successfully obtained for sequencing of the 
gene from all eight HBV DNA positive pediatric samples. Visualization of the nested PCR 
products is shown in Figure 3.3.  
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Figure 3.3: Nested pol/surf PCR DNA products. This gel slab shows results from the nested PCR 
DNA amplification for seven HBV DNA positive children. The bands indicate the presence of DNA 
products of 1000 bp size; the expected size of the target pol/surf region containing the RT region of the 
gene. No band is observed on the NTC and NC lanes suggesting that cross-contamination did not occur 
during the handling of reagents and samples. The PC lane shows a band of 1000bp too; validating the 
DNA size obtained for our query samples. C: Child; M: Marker of 1kb molecular weight; NTC: No 
Template Control; NC: Negative Control; PC: Positive Control.  
DNA products visualized on this gel slab were purified and spectrophotometrically analyzed 
to assess the purity and to determine the concentration of DNA present in our samples. Results 
from the spectrophotometric analysis, presented in Table 3.20, show that DNA present in our 
samples was “pure” with concentration above the recommended range for sequencing (5-
20ng/μl). 
Table 3.20: DNA concentration and purity of nested PCR products for pol/surf gene sequencing 
Sample ID DNA concentration 
(ng/uL) 
Absorbance (A260) DNA purity 
(A260/280) 
2C 58.48 1.17 1.8 
3C 61.34 1.227 1.79 
6C 55.59 1.112 1.74 
7C 70.94 1.419 1.72 
8C 48.96 0.979 1.78 
10C 75.93 1.519 1.75 
13C 56.23 1.125 1.84 
17C 66.09 1.322 1.80 
A: Absorbance; ID: Identificant, ng/μL: nanogram per microlitres  
Samples were diluted to a 20ng/µl DNA concentration using nuclease-free water for 
sequencing, and the PC used during the HBV DNA amplification reactions was included in the 
sequencing reaction. Products from the sequencing reaction were purified and analyzed on the 
ABI Prism 3130xl genetic analyzer. Resulting chromatograms were edited and trimmed, where 
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necessary, forming contiguous sequences of approximately 980bp long. No sequence was 
acquired from the NC, suggesting that cross-contamination did not take place.  
HBV genotyping 
NCBI HBV Genotyping tool revealed that query strains belonged to genotype E (6/8; 75%) 
and genotype D (2/8; 25%). The Geno2pheno analysis further described the genotype D 
sequences as sub-genotype D3.  
Mutation analysis 
Mutation analysis of these sequences through Geno2Pheno revealed the presence of amino acid 
(aa) substitutions including leucine (L) to isoleucine (I) at position 80 (rtL80I), valine (V) to 
leucine (L) at position 173 (rtV173L), valine (V) to isoleucine (I) at position 191 (rtV191I) and 
methionine (M) to valine (V) or isoleucine (I) at position 204 (rtM204V/I) in the RT region of 
the pol gene; all known as mutations associated with lamivudine drug resistance. Owing to the 
overlap between the pol and surf genes, changes in the RT region led to nucleotide substitutions 
in the overlapping SHB region. These included sE164D, sW182*, sI195M and sW196LS 
representing a change of glutamic acid (E) to aspartate (D) at position 164, tryptophan (W) to 
a stop codon at position 182, isoleucine (I) to methionine (M) at position 195, and tryptophan 
(W) to leucine/serine (L/S) at position 196 of the surface gene, respectively. SHB changes 
related to RT variations are tabulated in Table 3.21.  
These aa changes, associated with lamivudine resistance were observed in patterns including 
rtV173L+rtL180M+rtM204V+sE164D+sI195M (4/8; 50%), rtL80I+rtV173L+rtL180M+rtM204I+ 
sE164D+ sW196LS (1/8; 12.5%), rtL180M+rtM204V+ sI195M (2/8; 25%) and 
rtL80I+rtM204I+sW196L (1/8; 12.5%). 
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Table 3.21: HBsAg changes associated with reverse transcriptase mutations  
HBV RT variants Corresponding changes in HBsAg 
V173L E164D 
L180M None 
V191I W182* 
M204V I195M 
M204I W196*/S/L 
HBsAg: hepatitis B surface antigen; HBV: hepatitis B virus; RT: reverse transcriptase. 
Phylogenetic analysis 
The neighbor-joining analysis, presented in Figure 3.4, indicates that sequences obtained from 
children 2C, 3C, 6C, 7C, 10C, and 13C clustered together. These sequences formed a cluster 
with other genotype E sequences originating from Namibia (Botha et al., 1984; Kramvis et 
al., 2005). 8C and 17C formed a cluster with genotype D sequences and were closely related 
to genotype D3 sequences from South Africa and Botswana. This analysis confirmed the 
genotyping analysis performed with the NCBI HBV online genotyping tool 
(https://www.ncbi.nlm.nih.gov/projects/genotyping/formpage.cgi).  
The maximum likelihood model phylogenetic analysis was completed using the General Time 
Reversible substitution model with gamma distributed rate heterogeneity and a proportion of 
invariant sites (GTR+I+G) (Tavaré, 1986) in MEGA7, based on the AIC and BIC criteria; as 
calculated by the best-fit substitution model analysis ran through the JModelTest 2.1.3 
software. A similar cluster pattern of our query sequences is observed in this analysis; see 
Figure 3.5.  
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Figure 3.4: Phylogenetic analysis of HBV strains identified in the study based on the pol/surf 
region of the HBV genome using the Neighbor-Joining method. The 980bp pol/surf genomic 
fragment was used to infer the evolutionary relationship between our query sequences, using the 
Neighbor-Joining method. The percentage of replicate trees in which the associated taxa clustered 
together in the bootstrap test (1000 replicates) are shown next to the branches. Distance values at the 
branch nodes lower than 70% were excluded from the tree. The evolutionary distances were computed 
using the p-distance method. Sequences obtained in this study are highlighted in bold. The red branches 
represent the close cluster between our sequences and those previously obtained in Namibia. The blue 
branches represent the cluster formed by the study query sequences and other closest sub-genotype D3 
sequences. 
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Figure 3.5: Phylogenetic analysis of HBV sequences identified in the study using the Maximum 
Likelihood method. This analysis was based on the General Time Reversible model with 1000 bootstrap 
replicates. The percentage of trees in which the associated taxa clustered together is shown next to the 
branches. Distance values at the branch nodes lower than 70% were excluded from the tree. A discrete 
Gamma distribution was used to model evolutionary rate differences among sites. There was a total of 
860 positions in the final dataset. Positions containing gaps and missing data were eliminated. Study 
sequences are highlighted in bold with colored bullets: red for Genotype E sequences and pink for 
Genotype D sequences.  
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3.5.4.3 Nucleotide sequencing of the X/core gene 
DNA amplification of the X/core gene was successful; as depicted on the agarose gel below, 
Figure 3.6. Nested PCR products were purified, and the DNA concentration present in each 
sample was measured spectrophotometrically. Results are represented below in Table 3.22. All 
samples had a DNA concentration above the required 20ng/µl for DNA sequencing and were 
diluted to a final concentration of 20ng/µl using nuclease-free water.  
 
Figure 3.6: Nested X/core PCR DNA products. On this gel, results from the nested X/core PCR 
reaction are appreciated for eight HBV DNA positive samples. The bands represented indicate the 
presence of target DNA of 750 bp size; the expected size of the HBV core gene containing the pre-core 
and basal core promoter regions. The NC shows no bands hence we could conclude that cross-
contamination did not occur. The PC lane shows a band at the same level as our samples; validating our 
results. C: child; M: Marker of 1kb DNA ladder; NTC: No Template Control; NC: Negative control. 
Table 3.22: DNA concentration and purity of nested PCR products for X/core gene sequencing 
Sample ID DNA concentration 
(ng/µL) 
Absorbance (A260) DNA purity (A260/280) 
2C 104.07 2.081 1.9 
3C 91.61 1.832 1.91 
6C 95.8 1.916 1.88 
7C 99.43 1.989 1.75 
8C 98.47 1.969 1.92 
10C 102.76 2.055 1.9 
13C 110.05 2.201 1.92 
17C 63.39 1.268 1.87 
A: absorbance; ID: Identificant; ng/μL: nanogram per microlitres  
The diluted products were used to perform the sequencing reaction, and sequencing products 
were analyzed on the ABI Prism 3130xl genetic analyzer. Resulting sequences from each 
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primer and each sample were edited and trimmed (where necessary) and assembled; forming 
contiguous sequences of approximately 730bp. The pre-C and BCP regions of the core 
sequences were extracted and manually analyzed for the presence of viral genomic mutations.  
A portion of the X gene covering nt 1653 to nt 1835 (aa 94 to 154) was analyzed for the 
presence of viral genomic mutations. This region overlapped with the CP from nt 1653 to nt 
1835 (aa 94 to 154). The complete pre-C region (nt 1814 to nt 1900; aa 1 to 29) was also 
analyzed.  
Pre-C mutation analysis 
Substitution of valine (V) to phenylalanine (F) at position 17 (V17F) corresponding to the 
G1862T Pre-C mutant was found in patient 2C. A mixed population of the wild-type virus and 
the Pre-C stop codon W28*/W (G1896A/G) was observed in children 3C and 6C; represented 
in Figure 3.7. 
 
Figure 3.7: Snapshot of the multiple alignment of query sequences and the HBV Pre-Core 
reference sequence represented on Geneious V10.2.3. 2C, 3C, 6C, 7C, 8C, 10C, 13C, and 17C 
represent the pre-Core sequences obtained from the HBV DNA positive children being analyzed. 
Dissimilarity is observed at position V17F (2C); highlighted in beige. The mixed population W28*/W 
is shown too; highlighted in grey for 3C and 6C sequences. * represents a stop codon. C: child. 
Core promoter (CP) mutation analysis 
This genomic region includes the URR (nt 1653 to nt 1741; aa 94 to 122) and the BCP (nt 1742 
to nt 1835; aa 123 to 154). Substitutions were observed in three children: aspartate (D) to 
asparagine (N) at position 119 (D119N) and valine (V) to methionine (M) at position 131 
(V131M) in child 2C, phenylalanine to isoleucine at position 132 (F132I) in child 6C and, 
alanine to valine at position 102 (A102V) in child 7C, as represented on the aa alignment in 
Figure 3.8. These variants are represented as C1678T (A102V) on the overlapping CP region 
(aa 94 to 122), G1728A (D119N), G1764T/C1766G (V131M) and T1768A (F132I) on the 
overlapping BCP region. 
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Figure 3.8: Multiple alignment of the query sequences and the HBV X gene reference. The amino 
acid sequence of this region of the X gene is numbered from 94 to 154. The dots show where amino 
acids are similar to that of the reference gene (X NA ref). 2C, 3C, 6C, 7C, 8C, 10C, 13C, and 17C 
represent the X gene sequences obtained from the HBV DNA positive children being analyzed. 
Dissimilarities are observed at position D119N, V131M (Child 2C), F132I (Child 6C) and A102V 
(Child 7C). C: child. 
 
3.5.5 Liver health 
Liver enzymes measurements were completed for nine children: five with high levels of HBV 
DNA and four with undetectable levels of HBV DNA, see Table 3.23. The median levels of 
AST and ALT were higher in HBV DNA positive children as compared to HBV DNA negative 
children. These were: median ALT = 50.0 IU/L (Interquartile range: 41 - 57) compared to 23.0 
IU/L (Interquartile range: 14.5 – 34.5) (p=0.063), and median AST = 45.0 IU/L (Interquartile 
range: 36.0 – 46.0) compared to 30.0 IU/L (Interquartile range: 26.5 – 38.0) (p=0.190), 
respectively. Median platelet counts among these children were 280 x 109/L. Eight children 
(8/9; 88.9%) showed a normal APRI score (< 0.5); of whom four were HBV DNA positive and 
four were HBV DNA negative. An elevated APRI score of 0.713, suggesting liver fibrosis (> 
0.5), was detected in one HBV DNA positive child (1/9; 11.1%).  
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Table 3.23: Liver biomarkers of HBV positive children 
Patient ID HBV viral load 
log10 (IU/ml) 
Platelets 
(109/L) 
ALT (IU/L) AST (IU/L) APRI 
1C LDL 289 31 43 0,372 
2C 7.11 263 105 75 0.713 
3C 7.48 234 50 45 0.481 
4C LDL 213 14 26 0,305 
5C LDL 287 38 33 0,287 
6C 6.86 349 57 46 0,33 
7C 6.23 280 41 36 0,321 
9C LDL 333 15 27 0,203 
10C 7.64 261 16 26 0.249 
Median ALT: 38 IU/l; Median AST: 36 IU/l; Median platelets: 280 x 109/L 
ALT: Alanine transaminase; APRI: AST platelet Ratio index; AST: Aspartate transaminase; HBV: 
hepatitis B; ID: Identificant; IU/L: International units per liter, LDL: lower than the detection limit. In 
red is marked the child with an APRI score > 0.5. Upper limits of normal were 40 IU/L for both AST 
and ALT, and 400 x 109/L for platelets. 
3.6 Summary of findings 
Active HBV infection was found in more than half of the children included in this study (8/15; 
53.3%); all of them were HBeAg positive. HBV strains were classified as genotype E (6/8; 
75%) and sub-genotype D3 (2/8; 25%). Following sequencing of the RT region of the pol gene, 
eight children harbored genomic mutations associated with resistance to lamivudine. These RT 
changes led to changes in the SHB of the surf gene, overlapping with the RT region. Genomic 
mutations in the X/core gene were also detected in some of these children. Liver biochemistry 
assessments revealed that HBV DNA positive children had higher transaminases as compared 
to those with undetectable viral load; one child presented with an APRI score above 0.5. The 
epidemiological and clinical characteristics acquired from HBV DNA positive children are 
summarized in Table 3.24, below. 
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Table 3. 24: Serology and molecular analysis data of HBV DNA positive children 
Patient ID 2C 3C 6C 7C 8C 10C 13C 17C 
Age at recruitment 
(years) 
17 14 10 8 14 11 19 17 
Gender Male Male Female Female Female Male Female Male 
ART regimen at 
recruitment 
AZT/3TC/NVP AZT/3TC/NVP AZT/3TC/NVP AZT/3TC/LPV/r AZT/3TC/ABC/L
PV/r 
AZT/3TC/NVP AZT/3TC/EFV AZT/3TC/EFV 
Duration of 
lamivudine-only 
therapy (years) 
3 9 9 7 10 9 9 4 
ALT (IU/l) 105 50 57 41 Not Available 16 Not Available Not Available 
AST (IU/l) 75 45 46 36 Not Available 26 Not Available Not Available 
Platelets (109/l) 263 234 349 280 Not Available 261 Not Available Not Available 
APRI 0.713 0.481 0.388 0.378 Not Available 0.249 Not available Not Available 
HBsAg Positive Positive Positive Positive Positive Positive Positive Not Tested 
HBeAg Positive Positive Positive Positive Positive Positive Positive Not Tested 
Anti-HBe Negative Negative Negative Negative Negative Negative Negative Not Tested 
Anti-HBc (total) Positive Positive Positive Positive Positive Positive Positive Not Tested 
HBV DNA (log10 
IU/ml) 
7.11 7.48 6.86 6.23 7.10 7.64 7.29 6.68 
HBV genotype E E E E D3 E E D3 
RT mutations L180M, V191I, 
M204V  
V173L, L180M, 
M204V 
V173L, L180M, 
M204V  
L180M, M204V L80I, V173L, 
L180M, M204I  
V173L, L180M, 
M204V  
V173LV, 
L180M, M204V  
L80I, M204I 
SHB mutations W182*, I195M E164D, I195M E164D, I195M I195M E164D E164D, I195M  E164D, I195M W196L 
Pre-core mutations V17F (G1862T)  W28*W 
(G1896A/G)  
None None None None None None 
BCP and URR 
mutations 
D119N (G1728A), 
V131M 
(G1764T/C1766G) 
None  F132I (T1768A) A102V (C1678T)  None None None None 
3TC: Lamivudine; ABC: Abacavir; ALT: aspartate liver transaminase (reference 10 – 40 IU/l), Anti-HBc (total): Total Antibody to hepatitis B core antigen; Anti-HBe: Antibody to hepatitis B e 
antigen; APRI: AST to Platelet Ratio Index; ART: Antiretroviral therapy; AST: aspartate liver transaminase (reference 15 – 41 IU/l). AZT: Zidovudine; BCP: basal core promoter; EFV: Efavirenz; 
HBeAg: Hepatitis B e antigen; HBsAg: Hepatitis B surface antigen; ID: Identificant; IU: international units; LPVr: Ritonavir-boosted Lopinavir; ml: millilitres; NVP: Nevirapine; RT: reverse 
transcriptase, SHB: small hepatitis B surface antigen, URR: upper regulatory region. 
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3.7 Interpretation of findings 
3.7.1 Active HBV infection in HIV-infected children: clinical implications  
Eight of the sixteen (8/15, 53.3%) HIV/HBV co-infected children enrolled in this study had 
active HBV infection; characterized by high levels of HBV DNA, above 20 000 IU/ml, and 
HBeAg seropositivity. Many of the studies reporting on HBV among HIV-infected children in 
Africa have focused on assessing the presence of the virus through serological testing, but few 
describe HBV viral DNA levels. Published in 2016, Jooste et al. (2016) observed active HBV 
infection in five out of 625 (0.8%) HIV-infected children in Bloemfontein, South Africa. Four 
of those five children were on a lamivudine-containing ART regimen; two presented with DNA 
levels above 5 log10 IU/ml and tested HBeAg positive (Jooste et al., 2016). High viral 
replication and HBeAg seropositivity are known indicators of the high replicative phase of 
CHB. In HBV mono-infected children, this phase can last for three decades if the infection was 
acquired vertically but is short-lived if acquired horizontally (Hoffmann et al., 2007; 
Kramvis, 2016). Although the present data suggest that the risk of developing severe liver 
diseases is low in mono-infected individuals during this phase (Chu et al., 2004), the opposite 
may be seen in the presence of co-infection with HIV. Through immune-suppression, HIV is 
known to cause a delay in seroconversion to anti-HBe and increased replication of HBV among 
HIV/HBV co-infected adults (Thio, 2009). However, very little is known in HIV/HBV co-
infected children; who require further investigations. Extrapolating from studies in adults, 
immune-suppression caused by HIV may lengthen the high replicative phase, characterized by 
high DNA levels and HBeAg seropositivity, in which children in this study presented. Elevated 
HBV DNA levels and persistent HBeAg positivity are known as independent risk factors for 
the development of liver cirrhosis and HCC (Chen et al., 2006a; Iloeje et al., 2006). Viral 
replication may also be maintained through the selection of viral genomic mutations that have 
been associated with an increased risk of liver cirrhosis and HCC. The presence and possible 
clinical implications of these mutants within this cohort are thoroughly discussed in sections 
3.7.4.2 and 3.7.4.3, below.  
These data highlight the need for adequately controlling HBV infection in the HIV-infected 
pediatric population. The presence of active HBV infection observed among eight children 
demonstrates failure of lamivudine treatment, a potent antiretroviral drug with activity against 
both HIV and HBV. As children are initiated on lamivudine against HIV infection, if infection 
occurs during infancy, they are not systematically screened for HBV. Many co-infected with 
HBV go undetected and may grow up to develop liver damage that could have been controlled 
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at an earlier stage. There is thus a need for screening HIV-infected children for HBV, prior to 
initiating lamivudine therapy. Identifying cases of HBV infection in HIV-infected children 
allows for optimization of their antiviral treatment, where necessary. Control of these HBV 
pediatric infections would also prevent horizontal transmission of the virus to other susceptible 
children or adolescents within communities. 
3.7.2 Liver health in HIV-infected children with HBV infection 
Non-invasive evaluation of liver health was completed for 9 out of the 15 patients enrolled in 
this study; based on the APRI score, as the preferred non-invasive test to assess liver disease 
in resource-limited settings (WHO, 2015). This was done in nine children, of whom four had 
undetectable levels of HBV DNA, and five had a high HBV load. One of these nine children 
had an APRI score above 0.5 (0.713). This abnormal APRI score indicated the possible 
presence of liver fibrosis. Elevated APRI scores amongst HIV-infected children have been 
previously documented elsewhere. An investigation of liver disease in Polish HIV-infected 
children and adolescents revealed four of seventy-nine (4/79; 5%) HIV-infected children with 
an APRI score > 0.5. All of these children were co-infected with HBV or HCV. Through a 
multiple regression analysis, the authors showed a positive correlation between an elevated 
APRI score and HBV or HCV co-infection (p-value = 0.0001), as a predictor of liver disease 
in HBV-infected children (Pokorska-Śpiewak et al., 2017). Although liver biopsy remains the 
gold standard for evaluating liver damage, the use of APRI has been previously validated 
against liver biopsy results as a measure of liver fibrosis in children with chronic viral hepatitis 
(McGoogan et al., 2010). The study by McGoogan et al. (2010) showed a reasonable 
performance of the APRI score for predicting fibrosis in children with HCV or HBV, but a 
relatively poor performance for predicting cirrhosis (McGoogan et al., 2010). Although a high 
APRI score does not ascertain the presence of liver fibrosis, it may warrant close monitoring 
of children showing elevated scores, especially where high viremia is noted. Still, further 
research is needed to identify reliable non-invasive markers for the evaluation of liver disease 
in children.  
3.7.3 Transmission of HBV infection in children 
Similarly to the rest of SSA, horizontal transmission has played a key role in the HBV epidemic 
in Namibia. This observation was made by three main studies, conducted more than two 
decades ago in the country (Botha et al., 1984; Joubert et al., 1991; Aspinall et al., 1994).  
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Of these three studies, the one by Botha et al. (1984) alone investigated HBV infection in 
mother-child pairs. The authors noted that children born to HBsAg positive mothers were more 
likely to be HBsAg positive too, but hypothesized that the infection might have occurred at a 
stage beyond the perinatal period (Botha et al., 1984).  
This study investigated the role of MTCT as a possible source of HBV infection in HIV/HBV 
co-infected children, using HBV DNA testing of mothers of HIV/HBV co-infected children 
enrolled in the study. Six mothers of the 15 children participating in the study were successfully 
recruited. Seven mothers were deceased, and the other two did not attend the clinic with their 
children at the time of recruitment. All mothers were HIV-infected and were following TDF- 
containing ART regimens when enrolled. They consequently had undetectable viral loads upon 
HBV DNA testing. Regarding HBsAg serological status, one mother (6M) was reported 
HBsAg positive, three had an unknown HBsAg status, one had an indeterminate HBsAg result, 
and one other mother was noted HBsAg negative (17M). Owing to the unavailability of venous 
blood samples from these mothers, these HBsAg statuses could not be confirmed. Previous 
exposure to the virus could also not be confirmed by anti-HBc testing. For these reasons, HBV 
MTCT as a possible source of HBV infection among these children could not be confirmed. 
Given the reported HBsAg seronegative status of mother 17M, the role of HBV MTCT from 
this mother to her child was debatable. Although rare, HBsAg loss has been recorded among 
HIV/HBV co-infected patients during treatment with TDF (Zoutendijk et al., 2012; Boyd et 
al., 2015). This may be accountable to the HBsAg negative status of mother 17M. On the other 
hand, the HBsAg seropositive status of both mother 6M and her child (6C) suggested possible 
HBV MTCT. This child was born in 2004, prior to the implementation of HBV vaccination at 
six weeks after birth in 2009 and at birth in 2014. Thus, pediatric exposure to HBV could have 
occurred either during the perinatal period, from the mother, or postpartum possibly from the 
mother still. 
All children enrolled in this study were born before universal HBV vaccination from six weeks 
of age, and at birth, were implemented in Namibia. Therefore, the possibility that these children 
could have acquired HBV infection during early childhood (Joubert et al., 1991) could not be 
eliminated. The role of MTCT in this pediatric population could also not be entirely eliminated. 
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3.7.4 Molecular characterization of HBV 
3.7.4.1 HBV genotyping and liver disease progression 
HBV genotyping revealed a predominance of genotype E in 75% (6/8) of viral strains isolated 
in this pediatric cohort. Phylogenetic analysis showed close clustering of genotype E strains 
identified with other genotype E sequences described in Namibia (Kramvis et al., 2005), 
thereby confirming the predominance of this genotype in the country.  
Sub-genotype D3 was uncovered among two isolates (2/8, 27%). From the phylogenetic 
analysis, these sequences grouped with strains from South Africa and Botswana. Namibia is a 
neighbor to Botswana from the East and to South Africa to the South and East. The presence 
of this sub-genotype in Namibia may reflect the effect of human movements across borders in 
Southern Africa.  
In terms of clinical pathogenesis, the natural history and severity of the HBV infection may be 
influenced by the viral genetic differences. For instance, studies in India have shown a more 
severe course of chronic liver disease with genotype D (sub-genotype D1) as compared to 
genotype A (Thakur et al., 2002). In South Africa, where sub-genotype D3 is found, genotype 
A is associated with more severe liver damage as compared to genotype D (Kew et al., 2005). 
The contradicting observation between these two geographic locations, with regards to the 
association between genetic variations in the virus and the progression of liver disease, is 
mainly due to the pathogenic differences between D1 and D3 viruses. The increased risk of 
hepatocarcinogenesis of sub-genotype D1 compared to sub-genotype D3 was demonstrated in 
a recent functional study. Sub-genotype D3 was mostly associated with apoptosis, leading to 
fibrosis. Sub-genotype D1 showed a higher oncogenic potential, characterized by its increased 
ability to induce cell proliferation and higher expression of epithelial-mesenchymal transition 
markers associated with tumor progression in relation to D3 viruses (Khatun et al., 2018). 
Results from Kathun et al. (2018) suggest that children infected with the D3 strains may be at 
higher risk of developing liver fibrosis. With regards to genotype E, a large longitudinal study 
in The Gambia conducted among 405 chronic carriers of HBV revealed an HCC incidence of 
55.5/100 000 carrier-years; 95% of these carriers were infected with genotype E virus and 5% 
with genotype A (Shimakawa et al., 2016a). Children infected with genotype E may thus be 
at a higher risk of developing HCC later in life. Longitudinal follow-up of these children would 
be required to confirm these hypotheses. 
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In agreement with a study performed in Sudanese liver disease patients and HBV asymptomatic 
carriers (Yousif et al., 2013), our results also showed that patients infected with genotype D 
presented with lower viral load and a higher rate of HBeAg seroconversion compared to 
patients infected with genotype E. The distinct virological manifestation between these two 
genotypes may be explained by the prevalence of pre-C and BCP mutations associated with 
the production of HBeAg and viral replication, respectively. The effects of these mutations on 
the virological characteristics of patients are further discussed in section 3.7.4.3, below. 
3.7.4.2 Pol/surf gene mutations 
RT variants 
The primary M204V/I change, characteristic of lamivudine drug resistance (Allen et al., 1998; 
Ono-Nita et al., 1999), was observed in all children with active HBV infection. Selection of 
this mutant has been associated with decreased viral fitness (Allen et al., 1998), subsequently 
leading to the emergence of compensatory changes such as L180M, V173L, L80I/V to partially 
restore viral fitness (Allen et al., 1998; Delaney et al., 2003; Warner et al., 2007). Four 
children harbored the triple mutant V173L+L180M+M204V, one had the quadruple mutant 
L80I+V173L+L180M+M204I, another displayed the L80I+M204I, and two presented with 
L180M+M204V mutations. As observed in this study, the rtL80I mutant often occurs in the 
presence of rtM204I than rtM204V (Warner et al., 2007; Lei et al., 2013), and is most 
commonly described among genotype D strains (Warner et al., 2007). Furthermore, a 
decreased susceptibility to entecavir was observed in the presence of the M204V variant and 
L180M mutant (Mukaide et al., 2010) Drawing from studies in adults, a higher dose of 
entecavir (1mg daily dose) has been proven effective in the HBV DNA suppression in 
lamivudine-exposed patient harboring the M204V and L180M mutants (Pessôa et al., 2008).  
It is well known that the longer the exposure to lamivudine, the higher the incidence of resistant 
HBV (Benhamou et al., 1999; Sokal et al., 2006). Although TDF is recommended from 10 
years of age for the management of HIV infection in children (WHO, 2016), many remain on 
lamivudine therapy for their HIV infection for more than 10 years; owing to the lack of 
pediatric systematic screening for HBV. Seven of these eight children were older than 10 years 
old, and as such qualified for ART regimen including TDF. Yet, they were still on lamivudine 
therapy when enrolled in the study. Unlike lamivudine, TDF carries a very low risk of drug 
resistance, with significant activity against lamivudine-induced resistant strains (Patterson et 
al., 2011). TDF could be used as rescue therapy in lamivudine drug-resistant patients. 
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However, resistance to this drug in the presence of multi-site lamivudine mutants including 
rtL180M and rtM204V/I has been previously reported (Lee et al., 2014). This report raised 
concerns regarding the efficacy of TDF in HIV/HBV co-infected children previously exposed 
to lamivudine. Given that the current dose of TDF is associated with bone mineral density in 
children and nephrotoxicity in HIV-infected children below the age of 10 years old, the need 
for a lower dose of TDF as first-line therapy for the control of HBV-infection in these children 
is emphasized. The use of TAF as an alternative for TDF, for the treatment of pediatric HBV 
infection in HIV/HBV co-infected chldren, is attractive. Recent data from clinical trials have 
demonstrated the effectiveness, tolerability and safety of TAF co-formulated with elvitegravir, 
cobicistat, and emtricitabine (E/C/F/TAF) in HIV-infected children (Giacomet et al., 2018). 
The drug is FDA approved for the use in children from six years of age.  
Three children at the time of enrolment were following a TDF-containing regimen subsequent 
to previous exposure to lamivudine and showed no signs of HBV drug resistance during this 
analysis. Samples prior to TDF initiation were not available to assess the prior existence of 
resistance to lamivudine.  
Other than lamivudine drug-resistant mutants, the rtV191I substitution was also observed. This 
gene variant has been previously described among both nucleotide reverse-transcriptase 
inhibitor (NRTIs) experienced and non-NRTIs experienced patients (Margeridon-Thermet et 
al., 2009); suggesting that its selection may not be involved in drug resistance but may be a 
naturally occurring mutation (Colledge et al., 2017). 
Small surface (SHB) variants 
Amino acid substitutions downstream of the “a” determinant of the SHB were also observed 
amongst the drug-resistant HIV/HBV co-infected children. The most commonly found variants 
were sE164D and sI195M, which corresponded to the rtV173L and rtM204V mutants in the 
RT region, respectively. The presence of these two variants has been associated with minimal 
antigen-antibody binding, a characteristic of viral immune evasion (Torresi et al., 2002). Sloan 
et al. (2008) revealed that immune evasion is brought on by these changes through disruption 
of the “a” determinant (Sloan et al., 2008). The sW196L point mutation was also observed in 
this study. This mutation was selected by the lamivudine-resistant rtM204I mutant. Looking at 
the structure of the SHB protein, the two alpha helices of the carboxyl-terminal end of the 
protein are held together by a loop spanning aa 192 to aa 200. Subsequent changes in this region 
such as sI195M and sW196L may impact on the integrity of the protein, without necessarily 
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affecting viral assembly and secretion (Prange et al., 1995), while leading to reduced antigen-
antibody binding (Torresi et al., 2002). Other than point mutations associated with immune 
escape, a stop codon was also detected. The sW182*, observed in a genotype E sequence, was 
produced by the overlapping rtV191I nucleotide substitution in the RT region. The presence 
of this variant causes termination in the SHB protein. Termination in this viral protein 
subsequently leads to reduced extracellular secretion of HBV viral particles, which accumulate 
intracellularly (Colledge et al., 2017). Prolonged intracellular accumulation of HBsAg protein 
has been previously associated with the development of HCC by causing cellular stress 
(Ringelhan & Protzer, 2015). Colledge et al. (2017) also showed increased apoptosis of 
hepatocytes in the presence of sW182* in comparison to those infected with the wild-type 
virus; this may play an indirect role in hepatocarcinogenesis (Colledge et al., 2017). This 
observation further emphasizes the plausible increased risk of HCC among genotype E infected 
children.  
In view of the current data, children harboring the sW182* may be at an increased risk of liver 
damage if active viral replication is not controlled. Where rescue therapy is initiated, and viral 
replication is suppressed, other viral factors such as BCP and core mutations may play a role 
in carcinogenesis. There may also be potential transmission of immune-escape viruses from 
these HIV/HBV co-infected children to vaccinated individuals, a potential problem that 
requires more exploration. 
3.7.4.3 X and core gene mutations 
Pre-C mutations 
Expression of the HBeAg protein is prompted by the translation of the upstream initiation 
codon in the pre-C domain of the core gene; thus, changes in this region may affect the 
production of the protein (Locarnini, 2004). The well documented G1896A nucleic acid 
mutation, corresponding to the W28* stop codon, was detected in two HIV/HBV co-infected 
children. Located in the encapsidation signal (ε) structure of the pre-C, the selection of this stop 
codon abolishes the synthesis of the HBeAg, hence its association with an HBeAg-seronegative 
status (Locarnini, 2004; Jammeh et al., 2008). However, serum samples of these children 
were positive for HBeAg. HBeAg seropositivity in these children was explained by the 
detection of a mixed viral population of the variant and the wild-type viruses (W28*/W). The 
seropositive status of these two children is suggestive of the dominance of the wild-type species 
over the mutant species. The pre-C sequence of another HIV/HBV co-infected sample (Child 
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2C) carried the G1862T pre-C mutant. This mutant mostly occurs amongst HBV genotype A-
infected patients, especially sub-genotype A1, as opposed to genotype D patients (Tanaka et 
al., 2004; Chandra et al., 2007; Saha et al., 2014). In vitro translational experiments have 
previously demonstrated a reduced production of HBeAg, at the post-translational level, in the 
presence of the G1862T pre-C mutant (Hou et al., 2002). Still, child 2C tested positive for 
HBeAg. Nevertheless, the occurrence of this mutant has been described in both HBeAg 
positive and anti-HBe positive patients (Chandra et al., 2007; Saha et al., 2014). The authors 
indicated that the G1862 pre-C mutant might be a naturally occurring variant change (Chandra 
et al., 2007; Saha et al., 2014). 
Core promoter (CP) mutations 
The CP is composed of two important functional domains namely the URR and the BCP. Both 
domains play an important role in the transcription of the pre-C mRNA, and the pgRNA for 
the synthesis of HBeAg, HBcAg and the polymerase respectively and are thus of critical 
importance for viral replication (Kramvis & Kew, 1999). Viral mutations in the BCP have 
been extensively described and studied amongst genotype B and genotype C infected patients 
(Hu et al., 2015; Wei et al., 2017). On the other hand, there is minimal data on the prevalence 
of mutations in the URR region and their role in the progression of liver damage.  
Analysis of these two domains revealed the presence of four aa substitutions among three drug-
resistant HIV/HBV co-infected children. Two of these mutants, namely C1678T and G1728A, 
occurred in the core upstream regulatory sequence (CURS) of the URR. The CURS is involved 
in the positive regulation of the BCP activity (Yuh et al., 1992). The other two changes 
included the G1764T/C1766G BCP double mutation and the T1768A variant. The former was 
induced by substitution of the aa V131M of the X gene and has been predominantly described 
among cirrhotic patients as compared to chronic patients (Poustchi et al., 2008; Salarneia et 
al., 2016). The G1764T/C1766G BCP double mutation has also been associated with a 
decreased viral replication and HBeAg negativity in patients infected with genotype D (Elkady 
et al., 2008). T1768A has been associated with increased HBV replication, but reduced HBeAg 
expression in genotype C strains (Jammeh et al., 2008). The two children presenting with 
these two mutations were HBeAg positive, had a high viral load and were infected with 
genotype E viruses. Whilst our observation did not match the one made by Elkady et al. (2008) 
(Elkady et al., 2008), the high viral load noted in child 6C (carrier of the T1768A mutant) was 
in agreement with the observations made by Jammeh et al. (2008) (Jammeh et al., 2008). The 
discrepancy between results from Elkady et al. (2008) (Elkady et al., 2008) and ours may be 
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due to the difference in the genotype of the virus. Functional characterization of the 
G1764T/C1766G BCP variant in genotype E viruses would assist in clarifying this observation.  
It is worth mentioning that the viral CP mutants observed in this cohort occurred among 
genotype E viral strains only. Unlike genotypes A – D, genotype E has not been well studied. 
The pathogenesis and clinical impact of viral mutants occurring in HBV E viruses are not well 
understood, but call for thorough investigations for a better understanding of HBV-related liver 
diseases among carriers of this viral strain. 
3.8 Strengths and limitations of the study  
Through this study, children who required optimization of their antiviral treatment, from the 
lamivudine monotherapy to a TDF-based regimen, for the control of their HBV infection were 
identified.  
Limitations of the study included the unavailability of serum samples to confirm the HBV 
status of the mothers. Also, given that all of the enrolled mothers were HIV-infected and 
following a TDF-based treatment against HIV, all had undetectable levels of HBV DNA. For 
that reason, HBV could not be sequenced to determine if MTCT could be the route of 
transmission of HBV in these children and adolescents. Furthermore, the natural history of 
HIV/HBV co-infection in these children could not be established due to the cross-sectional 
design of the study.  
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CHAPTER 4: A study for the prevention of mother-to-child transmission of hepatitis 
B virus in Windhoek, Namibia 
In this chapter, the feasibility of a screen-treat-vaccinate health intervention for the prevention 
of HBV MTCT in Namibia is described. The prevalence of the infection among pregnant 
women attending ANC in Windhoek and the possible risk factors associated with HBV 
infection within this population are also documented.  
4.1 Introduction 
MTCT of HBV is currently regarded as a primary cause of the ongoing transmission of hepatitis 
B in many parts of SSA (Keane et al., 2016). The WHO supports HBV vaccination 
commencing at birth for the prevention of HBV MTCT, especially in high endemic regions. 
The recommendation also makes a note of providing temporary immunity with HBIG for 
babies born to HBeAg positive mothers (WHO, 2017b). Yet, vaccination is provided from six 
weeks of age in all but nine countries in SSA (WHO, 2017a); and HBIG is of limited access 
to SSA owing to its high costs. Although vaccination starting at six weeks has been effective 
in preventing infections occurring during infancy (Amponsah-Dacosta et al., 2014), HBV 
infections in babies vaccinated according to this regimen are not uncommon (Chasela et al., 
2014; Hoffman et al., 2014; Chotun et al., 2015). Combined immunoprophylaxis reduces the 
risk of perinatal transmission; but it may not prevent MTCT where the pregnant woman is 
highly infectious, defined as being seropositive for HBeAg with HBV DNA levels above 200 
000 IU/ml (Wen et al., 2013; Foad et al., 2015; Sellier et al., 2015). Identifying these highly 
infectious women provides further opportunities to establish additional prophylactic measures 
such as antiviral prophylaxis to the mother starting from the third trimester of pregnancy, 
preferably with TDF for its high barrier to resistance (Hyun et al., 2017). The optimal 
preventive measure against HBV MTCT in SSA would include routine antenatal HBV 
screening combined with maternal antiviral prophylaxis and pediatric immune prophylaxis. 
The published literature on the rate of HBsAg seropositivity within the antenatal population is 
relatively extensive in many parts of SSA, but Namibia. Recent Namibian published data, 
dating from 2013, reported national prevalence of 7.3% in pregnant women (Mhata et al., 
2017); which indicated a large proportion of women with a potential risk of transmitting HBV 
to their newborns. Preventive measures against HBV MTCT in Namibia consist of routine 
antenatal HBsAg screening, followed by the provision of HBIG to HBV-exposed babies 
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(MoHSS, 2014a). The national EPI schedule includes HBV vaccination starting from birth, 
followed with three additional doses of the vaccine at six, ten and fourteen weeks (WHO, 
2018). Still, averting immunoprophylaxis failure with maternal antiviral prophylaxis may be 
required for mothers with HBV DNA levels above 200 000 IU/ml.  
4.2 Primary and secondary aims 
4.2.1 Primary aim 
This study sought to determine the feasibility of rapid-test based maternal screening and HBV 
treatment (where necessary) combined with pediatric immunoprophylaxis to prevent HBV 
MTCT, defined here as the number of perinatal HBV infections detected in mother-child pairs. 
4.2.2 Secondary aims 
The secondary aims of the study included: 
• Measuring the prevalence of HBV infection among pregnant women in Windhoek, 
Namibia. 
• Identifying risk factors associated with HBsAg positivity among pregnant women in 
Windhoek, Namibia. 
4.3 Objectives 
Six objectives were set to achieve the study aims. These were: 
• Perform voluntary screening of pregnant women by means of rapid testing.  
• Determine the diagnostic accuracy of the Determine HBsAg rapid test (Alere Inc., 
Massachusetts, USA) 
• Assess the acceptance of the HBsAg rapid test from the perspective of healthcare 
workers 
• Determine the association between possible risk factors and HBsAg seropositivity in 
the studied antenatal population.  
• Establish pathways for continuum of care, including clinical work-up, laboratory tests, 
treatment (where applicable), and referral for women identified as HBV-infected.  
• Determine the rate of MTCT of HBV in mother-child pairs.  
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4.4 Materials and Methodology 
4.4.1 Ethical considerations 
Ethical clearance was obtained from the HREC at Stellenbosch University, South Africa 
(Reference number: S17/01/001), the BREC and RMC at MoHSS (Reference number: 17/3/3), 
and from the Research Ethics committee of the Namibia Institute of Pathology in Namibia (no 
reference number was provided). These approval letters are attached on Appendices C, D and 
E; respectively. 
Written authorization was also obtained from the medical superintendents at the Intermediate 
Katutura hospital and Windhoek Central hospital for conducting the study at the antenatal 
clinics (ANCs) of the hospitals. Verbal approval was also provided by the senior registered 
nurses in charge of the ANCs.  
Written informed consent (Appendix F) was provided by all study participants for inclusion in 
the study. Participation in the study entailed HBV rapid testing, sociodemographic data 
collection, clinical data collection, HBV risk factors data collection, blood sample collection 
and HBV screening for their babies’ post-delivery, where necessary. Participants were also 
given the option to decide on storage of their blood samples after completion of the study for 
further use in viral hepatitis and related fields of scientific research. The storage and use of 
patient’s biological samples are made in the strictest confidentiality and in respect of personal 
rights. Study participants were only identified by a Study Identification Number (SID) to 
ensure the confidentiality of the participants’ information.  
4.4.2 Study design 
This was a longitudinal prospective study conducted at ANCs at the Intermediate Katutura 
hospital and Windhoek Central hospital, two state hospitals located in Katutura, Windhoek. A 
brief overview of the study methodology is outlined below in Figure 4.1. 
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Figure 4.1: Flow diagram of the study methodology at both study sites. Informed consent was 
sought from the pregnant women prior to enrolment. Once given, the women were tested for HBsAg 
using a rapid test, and epidemiological and clinical data were recorded. Where the rapid test was 
positive, a DBS and a blood sample (EDTA and SST blood tubes) were drawn for further molecular 
and serological testing, respectively. The laboratory tests highlighted in red were conducted at the 
Division of Medical Virology, while the others were conducted at the Namibia Institute of Pathology. 
An SST blood sample was collected from a subset of HBsAg negative patients, referred to as “some 
patients” on the diagram, as part of quality assurance. ALT: alanine transaminase; AST: aspartate 
transaminase; anti-HBc: antibodies against hepatitis B core antigen, anti-HBe: antibodies against 
hepatitis B e antigen; DBS: dried blood spots; EDTA: ethylenediamine tetraacetic acid; HBeAg: 
hepatitis B e antigen, HBsAg: hepatitis B surface antigen; HBV: hepatitis B virus; IgM: 
immunoglobulin M; SST: Serum Separator Tube. 
4.4.3 Study setting 
The Windhoek Central hospital, situated 3.7 km away from Intermediate Katutura hospital, is 
an 855 bed capacity referral and teaching hospital in Windhoek. The hospital ANC operates 
Monday to Friday; the first ANC visits take place on Wednesdays and Thursdays, follow-up 
ANC visits on Mondays and Tuesdays, and postnatal care is given on Fridays. Here, first ANC 
is provided to pregnant women referred from other healthcare facilities in Windhoek due to 
pregnancy complications such as hypertension, diabetes and previous miscarriages or previous 
multiple C-sections. The Windhoek Central hospital ANC is visited by 15 to 20 pregnant 
women every Wednesday and Thursday for first ANC. The Intermediate Katutura hospital 
clinic caters for first ANC visits on Tuesdays and Wednesdays for more than 20 pregnant 
women per day. Antenatal follow-up visits happen on Mondays and Thursdays, and postnatal 
care is delivered on Fridays.  
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Both hospital ANCs provide routine antenatal screening services at the first ANC visit, such as 
HIV rapid testing, HBsAg laboratory screening, full blood count, Rhesus factor testing, syphilis 
testing, hemoglobin determination and urinalysis for glucose. In the morning of the first ANC 
visit day, a health education session is offered to the patients, covering topics of HIV and AIDS 
(HIV test, significance of the rapid test results, ART), family planning (injectable, pills, intra-
uterine devices, condoms, tubal ligation, vasectomy and arm implants), breastfeeding for both 
HIV-infected and HIV-uninfected women, danger signs in pregnancy, travel and dress code 
during pregnancy, sexually transmitted infections (STIs), antenatal screening tests 
(significance of the blood tubes and importance of the tests) and the purpose of physical 
examination (MoHSS, 2011). 
4.4.4 Sample size estimation 
The sample size calculation was done to estimate the prevalence of HBV among pregnant 
women in Windhoek, Namibia. Owing to the lack of national and regional epidemiological 
studies among pregnant women by the time of the design of the study, the estimation was made 
using the prevalence of HBV in the Namibian general population. An HBsAg seroprevalence 
of 8%, inferred from studies conducted in the 1970s and 1980s in Namibia (Schweitzer et al., 
2015), was used for the calculation of the study sample size. The minimum number of pregnant 
women required for the study was calculated at 453, with a 95% CI width of 0.05 (5%) and a 
precision of 0.025 (5%), using the Stata 14 software (StataCorp, 2015). Consecutive 
recruitment of pregnant women in the study was set at a target of 500 pregnant women, from 
both study sites. 
4.4.5 Study population and enrollment 
All pregnant women attending for first ANC at the Intermediate Katutura hospital and 
Windhoek Central hospital were considered and approached for inclusion in the study, as they 
presented at the clinics. These pregnant women were informed on the study during the morning 
health education session. A careful explanation of the concept of the study was provided to 
them using a study guide. A nurse also explained the study in the local languages, when it was 
needed. The women were enrolled in the study according to the following inclusion criteria: 
• Pregnant women ≥ 18 years old,  
• Written informed consent given by the pregnant woman for her and her baby’s 
participation in the study. 
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Participation in the study was finalized once written consent was provided by the pregnant 
woman. Informed assent for their babies’ participation in the study was given when signing the 
informed consent form. The form was designed to be relevant for the participation of both the 
pregnant woman and her unborn baby. Women below 18 years of age and patients who did not 
give consent for participation were not enrolled in the study.  
4.4.6 Data collection 
Once informed written consent was obtained from each participant, sociodemographic, clinical 
data were collected using a case record form. Information regarding potential risk factors 
associated with HBV in pregnancy was collected using a structured questionnaire. The 
collection of the data was completed by the PMTCT counselor/testers or myself through face 
to face interviews. Sociodemographic information included age, place and area of birth, level 
of education, marital status, employment status, parity (the number of live births) and gravidity 
(the number of pregnancies). These were also assessed as risk factors for HBV infection 
(HBsAg positive serostatus). Other potential risk factors considered included: syphilis 
exposure, HIV infection, invasive mode of delivery during previous pregnancy(ies), previous 
blood transfusion, previous surgical procedures, family member with HBV infection or liver 
disease, past history of liver disease, previous abortion, tattooing, body piercing, and 
unprotected sexual intercourse.  
Gestational age was estimated using three methods: (1) direct calculation using the date of last 
menstruation period (where the woman could remember), (2) measuring height of fundus, 
and/or (3) obstetric ultrasound. Ultrasonography was performed on the same day as the first 
ANC visit at the Intermediate Katutura hospital ANC, while deferred to the following week 
(Wednesday and Thursday) at the Windhoek Central hospital ANC.  
4.4.7 HIV rapid testing 
Pregnant women attending the ANCs and enrolled in the study were eligible for HIV testing 
using the SURE CHECK® HIV 1/2 test (Chembio Diagnostic Systems Inc, Medford, New 
York, USA). The SURE CHECK® HIV 1/2 test is an immunochromatographic test for the 
detection of antibodies to HIV-1 and HIV-2 in whole blood collected through finger-prick, 
venous whole blood, serum, or plasma specimens. As per the manufacturer’s instructions, 
whole blood was collected from finger-prick in the capillary tip of the sampler of the test device 
until the tip was full. The device was firmly pressed in the buffer cap of the test, and the results 
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were visually read after a 15-minute incubation period. In the presence of the control line only, 
the patient was considered negative for both HIV-1 and HIV-2. Where both the control and the 
patient lines were noted, the result was interpreted as positive for either virus.  
A second rapid test was performed for patients who tested HIV positive by the SURE CHECK® 
HIV 1/2, using the Alere DetermineTM HIV-1/2 kit (Alere Inc., Massachusetts, USA) following 
the manufacturer’s directives. A volume of 50 μL finger-prick whole blood was collected from 
the patient and transferred onto the sample pad of the test strip. One drop of chase buffer was 
immediately dropped onto the sample pad. Following an incubation period of 15 minutes, the 
results were visually read. The interpretation of these results was similar to the SURE CHECK® 
HIV 1/2 test results interpretation. A patient positive by both the SURE CHECK® HIV 1/2 test 
and the DetermineTM HIV-1/2 test was concluded and reported positive for HIV. In case of a 
positive SURE CHECK® HIV 1/2 test result and a negative DetermineTM HIV-1/2 test result, 
whole blood was collected from the patient for confirmation at the laboratory. Patients whose 
HIV status were known, or who were tested within the last three months prior to their visits at 
the ANCs were not re-tested.  
4.4.8 HBsAg rapid testing and quality management 
4.4.8.1 The Alere DetermineTM HBsAg test  
The Alere DetermineTM HBsAg test (Alere Inc., Massachusetts, USA) is a qualitative, visually 
read immunochromatographic assay for the detection of HBsAg in human serum, plasma or 
whole blood. A positive HBsAg result indicates an HBV infection. The manufacturer reported 
a 98.36% sensitivity and a 100% specificity using whole blood, and a 94.64% sensitivity and 
99.85% specificity using serum. 
4.4.8.2 Rapid testing procedure 
Enrolled pregnant women were tested for HBsAg by means of the Alere DetermineTM HBsAg 
assay, following the procedure outlined in Figure 4.2. Similarly to the DetermineTM HIV-1/2 
rapid testing procedure, 50 μL of whole blood was collected from the patient through finger-
prick and pipetted out onto the sample pad of the strip. One drop of chase buffer was 
immediately added to the sample pad, and the results were visually read after 15 minutes. The 
results were interpreted by the nurse(s)/counsellor(s) performing the test or by myself. In the 
presence of two red bands at the control and patient window, the test was considered and 
recorded as a positive test result (Figure 4.3). Only one band on the control line indicated a 
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negative test result (Figure 4.4). Where an indeterminate result was observed, defined as the 
absence of a band on the control line, the test was repeated.  
 
Figure 4.2: Hepatitis B rapid testing procedure using the Alere DetermineTM HBsAg test (Alere 
Inc., Massachusetts, USA). Consented participants were tested for HBsAg at the antenatal clinics by 
trained PMTCT nurses and health assistants.  
 
Figure 4.3: A representation of a negative Determine HBsAg rapid test using finger-prick blood. 
Only the control line is observed, and no band is seen on the patient window, indicating a negative 
HBsAg rapid test result. 
 
Figure 4.4: A representation of a positive Determine HBsAg rapid test using finger-prick blood. 
Both the control and the patient lines are observed, indicating a positive HBsAg rapid test result.  
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4.4.8.3  Rapid testing counseling 
Pre-test and post-test counseling were provided to study participants for both HIV and HBV at 
the same time. Pre-test counseling was done in groups through health education. During health 
education, the topics of HBV and its modes of transmission, MTCT, preventive measures 
(vaccination), antenatal HBV testing, and the interpretation of a negative and a positive HBsAg 
result were discussed. 
Post-test counseling was adapted as per the rapid test results. For those who tested negative for 
HBsAg, the counselor reiterated the meaning of the result, advised HBV vaccination and 
educated the patient on preventive measures for their families and sexual partners (HBV testing 
and HBV vaccination if testing negative for the virus). Where the patient tested HBsAg 
positive, the counsellor clarified the significance of the result and emphasized the need for 
further laboratory testing (liver function tests, repeat of HBsAg testing at the laboratory and 
HBV DNA viral load) to distinguish between active and inactive infection, and to assess the 
need for ART to prevent MTCT of the virus. The counselor also provided information on 
preventing transmission such as vaccinating non-immune family members and sexual partners 
against HBV, in case they test negative for the virus, and more importantly HBV birth 
vaccination of the baby and administration of HBIG if available at birth. Furthermore, the 
women were reminded to bring back their babies for a follow-up at six weeks and 36 weeks of 
age, when they come for the baby’s immunization at the clinic. The aim of the follow-ups was 
to evaluate the HBV status of these babies and is discussed in section 4.4.17. 
4.4.8.4 Quality assurance of HBV rapid testing  
A study-specific quality assurance (QA) scheme for HBV rapid testing at the participating 
ANCs was established. This QA was adapted from the QA programme already established in 
Namibia for HIV RDT. This scheme consisted of two components namely internal QA and 
external QA. 
Internal quality assurance (QA) 
This involved weekly testing of HBsAg positive and HBsAg negative sera controls at the 
clinics, prior to patient testing. Quality control samples are not provided in the Alere Determine 
HBsAg rapid kit. A negative control and positive control were prepared at the Division of 
Medical Virology, Stellenbosch University.  
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The negative control refers to serum, plasma or a whole blood sample negative for the tested 
analyte; in this case, it is HBsAg. This control was produced using normal human plasma 
(NHP) provided by the Western Cape Province Blood Transfusion Service (WPBTS). This 
plasma was negative for HIV-1, HIV-2, HBV, and HCV on serological and molecular 
diagnostic assays. The NHP was tested in duplicate on the Determine HBsAg rapid test to 
confirm its HBsAg seronegative status on the rapid test. Sixty aliquots were prepared in 2 ml 
cryovials; each contained a 300 µl volume of the NHP. 
A positive control is a plasma, serum or whole blood sample with a low concentration of the 
tested analyte. This control sample was prepared using an in-house HBsAg positive control, 
with a known HBsAg concentration. 
A series of 1 in 20 dilutions of the in-house HBsAg serum control was performed, using NHP 
as a diluent, to prepare an HBsAg positive serum sample with a final HBsAg concentration of 
20 IU/ml. The limit of detection of the rapid test lies around 3.4 IU/ml (Geretti et al., 2010). 
The prepared sample was tested in duplicates on the rapid test to confirm its HBsAg 
seropositive status on the rapid test. Once confirmed, 300 µl volume aliquots were prepared in 
60 2 ml cryovials.  
Our study-specific sera controls were shipped on dry ice to the Namibia Institute of Pathology 
Quality assurance department situated at their reference laboratory at Windhoek Central 
Hospital, for local distribution to the participating ANCs. The controls were stored at -20°C in 
the laboratory. 
Packaged by the Namibia Institute of Pathology, 30 negative controls and 30 positive controls 
were dispatched to Windhoek Central hospital ANC and Intermediate Katutura hospital ANC 
for weekly HBV rapid testing using the Determine HBsAg rapid test. The controls were kept 
in temperature-monitored freezers placed at the ANCs.  
A comprehensive test result log, adapted from the HIV rapid test result logging sheet currently 
available at the participating clinics, was designed and provided to the testers to login HBV 
rapid test results every week for the duration of the recruitment. The sheets were checked every 
week, before testing, by myself to ensure that the QA was done and to verify the results.  
The presence of a colored band at the control window was also used to further validate the 
results obtained by the rapid test. As mentioned in section 4.4.8.2, the absence of a control line 
was considered an invalid result and the test had to be repeated until a valid result (presence of 
the control line) was obtained.  
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External quality assurance 
The external QA included a repeat of every fifth sample with an HBsAg negative result 
obtained by the rapid test, during the recruitment, period using the ARCHITECT HBsAg test 
on the automated analyzer ARCHITECT i2000SR (Abbott Laboratories, Abbott Park, Illinois, 
USA). This methodology was based on results from a previous field-based HBsAg screening 
intervention performed in the Gambia. An 11.5% chance of false negatives was reported in the 
study (Njai et al., 2015). This false negativity rate equated to approximately 58 false negative 
results that may have been observed in this study. Here a 20% margin of error (i.e. 80% 
sensitivity) was used, taking into account human errors by the HCWs at the ANCs. This would 
ensure that more than 58 negative results are retested thereby reducing the chance of missing 
infected patients. Every patient testing HBsAg positive by the rapid test was also re-tested at 
the Namibia Institute of Pathology using the ARCHITECT HBsAg test for confirmation, and 
to exclude false positives. 
 PMTCT nurses and HIV counselors were trained to use the rapid test with the help of the 
technical team/representative at Alere Healthcare before the study commenced. Protocols and 
Standard Operating Procedures (SOPs), such as flowcharts for HBV testing, were designed and 
provided at the testing sites to ensure consistent, reliable, good quality testing. 
4.4.8.5 Other quality assurance of HBV rapid testing  
As it is performed for any diagnostic procedure, quality control measures were also put in place 
to maintain the accuracy and reliability of the results.  
Rapid test storage 
The manufacturers recommend storage of the kits at 2-30°C. Owing to the high temperatures 
in Namibia, the rapid test strips and the chase buffers were kept in refrigerators, while the 
capillary tubes remained at room temperature. The temperature in the testing rooms and the 
refrigerators, where the kits were stored, were monitored daily and logged onto temperature 
charts. These charts were checked daily to ensure that all storage conditions were optimum for 
the rapid tests.  
Good testing practices 
Rapid testing was performed in dedicated rooms at each hospital. The surface where the testing 
was completed was covered with linen savers. These were regularly changed in-between 
patient testing. Protective equipment, such as gloves and aprons, were worn at all times 
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throughout the procedure. A new pair of gloves were worn between patient testing to prevent 
cross-contamination.  
4.4.9 Blood sample collection, handling, and shipping 
Blood sample collection 
Approximately 10 ml of venous blood (5 ml of EDTA blood sample and 5 ml of SST blood 
sample) were drawn from each pregnant woman testing HBsAg positive at the ANC for further 
laboratory tests. The EDTA sample was collected for platelet count testing, and the SST tube 
was required for HBsAg laboratory confirmation, for testing other HBV serological markers 
(HBeAg, anti-HBe, and anti-HBc IgM), and for liver function tests (AST and ALT). One dried 
blood spot (DBS) card, five spots per card, was also collected from these patients for HBV 
DNA viral load quantification and other molecular testing.  
As per the external QA established, 5 ml of SST blood sample was collected from a subset of 
pregnant women testing HBsAg negative to confirm the negative result obtained by the rapid 
test at the laboratory. 
Sample handling 
Blood samples collected from the patients were packaged and sent to the Namibia Institute of 
Pathology, as per the protocol established at the ANCs. In brief, the samples were packaged in 
individual Namibia Institute of Pathology sample bags, each containing a requisition form 
filled with the patient details, the doctor’s name and the requested tests to be performed on the 
samples. DBS collected were left on a drying rack overnight to dry and were packaged the next 
morning, according to guidelines established at the ANCs. Porters positioned at Central 
Hospital would make two to four rounds per day at the ANC to collect samples, and would 
drop them by the Namibia Institute of Pathology main laboratory situated at the hospital. The 
samples collected at Intermediate Katutura hospital ANC were transported on ice by Katutura 
Namibia Institute of Pathology to the main laboratory at Central Hospital to ensure central 
testing of our patients.  
DBS samples were batched and sent to the Division of Medical Virology for HBV DNA viral 
load measurements, while recruitment was taking place in Windhoek. The results were used to 
inform on the need for ART against HBV to prevent transmission of HBV from the infected 
mother to her baby. 
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Serum was separated from SST blood samples at the Namibia Institute of Pathology for HBsAg 
and liver biochemistry markers (ALT and AST) testing. Whole EDTA blood samples were 
used for platelet count testing, while DBS were stored at -20°C. Residual serum samples were 
transferred in cryovials labeled with the sample requisition number or Patient Study ID and 
stored at -20°C in a sample box labeled “Stellenbosch University – HBV PMTCT Study”. 
Import permits were obtained from the South African Department of Health for shipping 
samples collected from the study participants to the Division of Medical Virology at 
Stellenbosch University, South Africa. 
Sample shipping 
DBS were batched, packaged as per Namibia Institute of Pathology DBS packaging guidelines, 
and shipped at ambient temperature to the Division of Medical Virology, Stellenbosch 
University. Prior to shipment, the DBS were equilibrated to room temperature (minimum of 30 
minutes) and re-packaged for shipping at ambient temperature. Three batches were made 
during the recruitment period and sent to the Division of Medical Virology. Stored serum 
samples were shipped on dry ice to the Division of Medical Virology at the end of the 
recruitment period for serological tests (HBeAg, anti-HBe and anti-HBc IgM) unavailable at 
the Namibia Institute of Pathology. 
4.4.10 Hepatitis B virus laboratory serological investigations 
All serology laboratory testing was performed using the automated analyzer ARCHITECT 
i2000SR (Abbott Laboratories, Abbott Park, Illinois, USA). This analyzer is positioned at both 
the Namibia Institute of Pathology and the NHLS Virology laboratory, Tygerberg Hospital. 
4.4.10.1 HBsAg testing 
Principle: The ARCHITECT HBsAg Qualitative assay is a chemiluminescent microparticle 
immunoassay (CMIA) used to determine the presence of HBsAg in human serum and plasma. 
Anti-HBs coated paramagnetic microparticles, and anti-HBs acridinium-labeled conjugate are 
incubated with the sample, for the binding of HBsAg present in the specimen to the anti-HBs. 
Unbound particles are washed off. The addition of two substrates, namely the pre-trigger 
(Hydrogen peroxide) and trigger (Sodium hydroxide) solutions, to the reaction triggers a 
chemiluminescent signal measured as relative light units (RLUs). The chemiluminescent signal 
is compared to an S/CO value determined from an active ARCHITECT HBsAg calibration. A 
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signal lower than the cut-off value represents a negative HBsAg result while a signal equal to 
or higher than the cut-off value is interpreted as a positive HBsAg result.  
Assay calibration and quality control: Prior to patient’s sample testing, HBsAg Qualitative 
calibrators (Calibrator 1 and Calibrator 2) were run in triplicates to calibrate the assay every 
time a new kit was used. The mean S/CO values from the calibrators replicates is calculated by 
the system of the machine and is used to calculate the S/CO values of the samples. HBsAg 
Qualitative controls (Negative Control and Positive Control) were tested in single replicate, 
each testing day, as per the manufacturer’s directions and the quality control procedures 
established at the Namibia Institute of Pathology. The assay was deemed calibrated in the case 
when each control result was within the range specified in the package insert of the controls.  
Testing procedure: Serum samples collected from the SST blood samples, registered with a 
requisition number generated by the Namibia Institute of Pathology laboratory sample logging 
system, were inserted in the ARCHITECT i2000SR machine for testing. The machine was 
operated by a trained laboratory technician.  
Interpretation of results: An S/CO value ≥ 1 was considered positive while an S/CO < 1 was 
considered negative. Results obtained were signed off by clinical consultants at the Namibia 
Institute of Pathology and were updated onto their system for access at the healthcare facilities. 
These results were also printed and kept for the study records.  
4.4.10.2 HBeAg testing 
Principle: The ARCHITECT HBeAg assay is a CMIA for the qualitative detection of HBeAg 
in human serum and plasma. The assay is completed in two steps. At first, sample, assay 
diluent, and anti-HBe (mouse, monoclonal) coated paramagnetic microparticles are mixed; 
allowing the HBeAg present in the sample to bind to the anti-HBe coated microparticles. A 
wash step, removing unbound microparticles, follows and the acridinium-labeled anti-HBe 
conjugate is added. This is followed by another washing step and the addition of the pre-trigger 
and trigger solutions to the reaction. The resulting chemiluminescent signal is directly 
proportional to the amount of HBeAg in the sample. The emitted chemiluminescent signal is 
compared to the S/CO determined from an ARCHITECT HBeAg calibration. The tested 
sample is considered reactive for HBeAg if the chemiluminescent signal of the reaction is equal 
to or above the cut-off signal. 
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4.4.10.3 Anti-HBe testing 
Principle: The ARCHITECT Anti-HBe assay is a competitive two-step CMIA. The anti-HBe 
present in the patient’s sample competes with anti-HBe (mouse, monoclonal) coated 
paramagnetic microparticles for binding with recombinant HBeAg present in a neutralizing 
reagent added in the reaction. The resulting chemiluminescent signal detected is inversely 
proportional to the amount of anti-HBe present in the sample. The sample is considered non-
reactive for anti-HBe if the S/CO obtained is greater than the cutoff signal. 
4.4.10.4 Anti-HBc IgM testing 
Anti-HBc IgM serves as a measure of an acute HBV infection; that is an infection of less than 
six months, in the presence of an HBsAg positive result. This testing served to differentiate 
between acute and chronic HBV infection. 
Principle: This is a two-step CMIA for the qualitative detection of anti-HBc IgM in human 
serum and plasma using the ARCHITECT i2000SR. During the assay, the sample is incubated 
with anti-human IgM (mouse monoclonal) coated paramagnetic microparticles; allowing 
human IgM present in the specimen to bind to mouse monoclonal anti-human IgM coated 
microparticles. A washing step is completed to remove unbound microparticles, and the 
acridinium-labeled rHBcAg conjugate is added in the reaction. The resulting chemiluminescent 
signal, following the addition of the Pre-Trigger and Trigger solutions, is proportional to the 
amount of anti-HBc IgM in the sample. A positive anti-HBc IgM result is obtained should the 
chemiluminescent signal of the reaction be greater than or equal to the cutoff signal. 
HBeAg, anti-HBe, and anti-HBc IgM assay Calibration and quality control: Following 
the manufacturer’s directives, HBeAg Assay calibrators (Calibrators 1 and 2), anti-HBe 
calibrator 1 only, anti-HBc IgM Calibrator 1 and Calibrator 2 were run in replicates of three 
whenever a new kit was opened. A single replicate of the controls (Negative Control and 
Positive Control) were run prior to patient’s sample testing to validate the assays calibration. 
The calibration was considered valid providing that each control result was within the ranges 
specified by the manufacturer. These ranges may vary between lot numbers of the kit. 
The control range values for each test, as per the lots used for these assays, are as follow: 
• HBeAg negative control range (0.0 PEI U/mL): 0.000 – 0.800 S/CO 
• HBeAg positive control range (0.7 PEI U/mL): 2.026 – 6.077 S/CO  
• Anti-HBe negative control (0.0 PEI U/mL): 1.30 – 2.70 S/CO 
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• Anti-HBe positive control range (0.38 PEI U/mL): 0.21 – 0.80 S/CO 
• Anti-HBc IgM negative control range (0.0 PEI U/mL): 0 – 0.25 S/CO 
• Anti-HBc IgM positive control range (150 PEI U/mL): 1.608 – 4.825 S.CO 
HBeAg, anti-HBe, and anti-HBc IgM testing procedure: Following successful calibration 
of the assays, residual HBsAg positive serum samples received from the Namibia Institute of 
Pathology were loaded onto the ARCHITECT i2000SR machine at the NHLS Virology 
laboratory at Tygerberg. The HBeAg, anti-HBe and anti-HBc IgM statuses of these samples 
were assessed.  
Interpretation of results: S/CO ≥ 1 results were considered positive for HBeAg or anti-HBc 
IgM and negative for anti-HBe. S/CO < 1 results were deemed positive for anti-HBe, and 
negative for HBeAg or anti-HBc IgM. 
4.4.11 Hepatitis B virus laboratory molecular investigations 
4.4.11.1 HBV DNA viral load quantification 
HBV DNA viral load was determined using both DBS and serum samples, tested on the 
automated COBAS AmpliPrep/COBAS TaqMan HBV test Version 2.0. DBS testing was 
adapted following a previously published methodology (Vinikoor et al., 2015) and the DBS 
viral load assay described in Chapter 3 (section 3.4.9.1). Briefly, two DBS were eluted in a 
1000 µl volume of SPEX buffer. Following the same principle of dilution explained in section 
3.4.9.1 of Chapter 3, 60 µl of plasma (30 µl per spot) is diluted in a 1000 µl of SPEX buffer, 
corresponding to an approximate 39 µl of input sample in the total volume of 650 µl used for 
the assay. The dilution factor between DBS and plasma here was 25.64. Elution took place 
overnight on The Coulter Mixer (Coulter Electronics Limited, Luton Bedfordshire, UK) at 
room temperature. The eluates were used for both viral DNA extraction and amplification, 
completed on the automated COBAS AmpliPrep / COBAS TaqMan system. The rationale 
behind the use of two spots instead of one spot was to increase the volume of plasma sample 
from 30 µl in one spot of whole blood to 60 µl with two spots, to potentially improve the LoQ 
of the assay. Elution was completed at room temperature to mimic conditions in laboratories 
with limited access to specialized equipment. The agreement between serum and DBS 
measurements was assessed by the Bland-Altman analysis, using log10 transformed data 
(Bland & Altman, 1986). DBS measurements (log10-transformed data) were plotted against 
serum samples measurements to determine the linearity and correlation (R2 value) between the 
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two sample types (linear regression analysis). For the purpose of these two analyses, viral load 
measurements with < 20 IU/ml (< 1.30 log10 IU/ml) results were recorded as 10 IU/ml (1 log10 
IU/ml); serum samples viral load with >170 000 000 IU/ml (> 8.3 log10 IU/ml) were recorded 
as 8.3 log10 IU/ml. Samples with an undetectable viral load in serum were removed from the 
analyses.  
The LoQ of this DBS assay was assessed using dilutions of the third WHO HBV international 
standard for NAT assays (NIBSC code 10/264). The standard was reconstituted in 500 µl of 
nuclease-free water to obtain an HBV viral load of 850 000 IU/ml (5.93 log10 IU/mL), as per 
the manufacturer’s instructions, prior to use. The reconstituted material was further diluted 
using whole blood that was negative for HBV serological markers and HBV DNA. DBS cards 
(50 µl per spot) of the dilutions were prepared with Whatman filter paper card (five perforated 
spots/card) (Lasec, Cape Town, South Africa) and left to dry overnight under a biosafety 
cabinet. Eluates were run in triplicates for each concentration during two different days, on the 
automated COBAS AmpliPrep / COBAS TaqMan system. Due to the limited volume of the 
WHO standard, matched DBS and NHP dilutions could not be tested in parallel. The Probit 
regression analysis was completed to infer the LoQ of the assay, as performed elsewhere 
(Weiss et al., 2004; Dowling et al., 2018), with the Statistical Package for Social Sciences 
(SPSS) software Version 25 (IBM Corp., Armonk, New York, USA).  
4.4.11.2 Manual viral DNA extraction 
HBV DNA was manually extracted from samples with detectable levels of DNA using the 
QIAamp® MinElute® Virus Spin kit (QIAGEN, Hilden, Germany). This methodology was 
previously described in Chapter 3, section 3.4.9.2. 
4.4.11.3 Nucleotide sequencing of the pol/surf and X/core genes  
HBV pol/surf and X/core genes sequencing were performed using viral DNA extracted from 
HBV DNA positive samples. These assays were performed as described in Chapter 3, section 
3.4.9.3 with slight modifications, described as follow. Gel electrophoresis was completed using 
the EnduroTM Gel XL Electrophoresis System (Labnet International Inc, Woodbridge, New 
Jersey, USA) at a voltage of 100V for 45 minutes. Cycle sequencing products were sent to the 
DNA sequencing Unit of Central Analytical Facilities, situated at Stellenbosch University, for 
capillary electrophoresis.  
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4.4.11.4 Nucleotide sequence analysis and phylogenetic analysis  
Pol/surf and X/core DNA chromatograms obtained from the DNA sequencing Unit of Central 
Analytical Facilities at Stellenbosch University were analyzed as described in Chapter 3, 
section 3.4.9.4. As per the described protocol, viral pol/surf consensus sequences generated 
were aligned with similar sequences acquired on Genbank using the ClustalW algorithm on 
Geneious Version 10.2.3. The alignment was imported in MEGA 7 for a neighbor-joining tree 
analysis, assessing the distances between the sequences in the dataset. A best-fit substitution 
model analysis followed and was completed using JModelTest 2.1.3 to identify the best fitted 
model for maximum likelihood phylogenetic analysis. The suggested nucleotide substitution 
model was subsequently used for executing maximum likelihood phylogenetic analysis. Core 
gene sequences were analyzed using the BioEdit software.  
4.4.11.5 Quality assurance for molecular assays 
This has been described in detail in Chapter 3, section 3.4.10.5. Briefly, assays were performed 
in dedicated rooms under a class II biological laminar flow cabinet. An NC, NTC, and PC were 
included in each PCR reaction for each gene amplification and sequencing. A dedicated set of 
pipettes and filtered tips were available for use in each room where the assays were completed. 
Lastly, the surfaces of the biosafety cabinets, the laboratory benches and the pipettes used were 
disinfected before and after use with 10% bleach and 70% ethanol.  
4.4.12 Syphilis laboratory testing 
Antenatal syphilis screening was performed at the Namibia Institute of Pathology through a 
two-step process. The first line screening test is done for the detection of non-specific 
antibodies against lipoidal and lipoprotein-like materials released by the host cells damaged by 
the bacterium Treponema pallidum, the causative agent of syphilis. The assay is performed 
using the rapid plasma reagin (RPR) Carbon Antigen Kit (Biorex Diagnostics, Antrim, UK) 
for the detection of reagin antibodies, as per the manufacturer’s instructions. Briefly, a drop of 
the antigen, provided in the kit, is mixed with 50 µl of neat patient’s sample. The antigen, made 
of particulate carbon suspension coated with lipid complexes, binds to reagin antibodies present 
in the sample tested forming clumps. These clumps, viewed macroscopically, indicated the 
presence of reagin antibodies in the sample tested. The absence of clumps indicated the absence 
of reagin antibodies in the sample tested, and the patient was reported negative for syphilis. A 
positive RPR sample was further tested to determine the presence of specific antibodies against 
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the bacterium using the Treponema pallidum haemagglutination (TPHA) kit (Biorex 
Diagnostics, Antrim, UK). The assay was completed following the manufacturer’s directives. 
Briefly, a 1 in 20 diluted sample is incubated with Trepanoma pallidum sensitized avian 
erythrocytes cells for a minimum period of 45 minutes, away from direct sunlight and heat. In 
the presence of antibodies against the bacterium in the sample tested, an agglutination reaction 
takes place between antibodies and antigen, forming a characteristic pattern of cells. The 
sample is thus recorded positive for syphilis.  
4.4.13 Liver health assessment 
All pregnant women testing HBsAg positive by the rapid test were evaluated for biochemical 
evidence of liver disease using the APRI. ALT, AST, and platelet count testing were performed 
at the Namibia Institute of Pathology. Results from these measurements were used to calculate 
the APRI score using the formula outlined in Chapter 3, section 3.4.10. An APRI score >1.5 
was considered abnormal. 
4.4.14 Evaluation of antiviral therapy 
Eligibility for maternal antiviral prophylaxis against HBV MTCT was determined as per the 
2016 American Association for the Study of Liver Diseases (AALSD) guidelines (Terrault et 
al., 2016). That is: HBsAg positive pregnant women with HBV DNA levels above 200 000 
IU/ml were eligible for treatment with TDF, 300 mg oral daily dose. On the basis that access 
to HBIG was uncertain for most women, pregnant women with an HBsAg seropositive status 
with HBV DNA levels above 100 000 IU/ml were reviewed for TDF treatment by a clinician 
collaborating on the study. The risks and benefits of ART were discussed with each woman. 
Where applicable, the HBV-infected pregnant woman was initiated on TDF from 28 weeks of 
pregnancy until one month postpartum for HBV DNA viral load suppression.  
4.4.15 Analysis of risk factors associated with HBsAg seropositivity  
Risk factors associated with an HBsAg positive serostatus were grouped into the categories of 
sociodemographic, social behaviors and nosocomial exposure. The sociodemographic 
variables considered were age, marital status, the area of birth, employment status and 
educational level. Factors related to social behaviors included HIV-infection, syphilis status, 
body tattooing, body piercing, and unprotected sexual activity. Parity, gravidity, route of 
delivery (history of C-section), history of blood transfusions, surgical procedures and abortions 
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represented factors related to nosocomial exposure. The previous history of liver disease, as 
well as the presence of family members with previous/current HBV infection or liver disease, 
were also included in the analysis. The association between these factors and an HBsAg 
seropositive status was investigated through univariate logistic regression. For the purpose of 
this analysis, some variables were categorized in groups: parity (nulliparous, primiparous, 
multiparous), marital status (unmarried, married), unprotected sexual activity (yes or no, the 
“sometimes” responses were counted in as “No” for the purpose of the analysis). With regards 
to the educational level, women with a secondary level of education or less were classified as 
“low”, and “high” for those with a tertiary level of education or enrolled in a tertiary level 
programme. The logistic regression was completed using the SPSS software Version 25 (IBM 
Corp., Armonk, New York, USA). Odds ratio and their 95% CI were recorded and served to 
establish the association between the considered factors and HBsAg seropositivity. 
Multivariate logistic regression analysis was performed including the risk factors with p ≤ 0.25 
in the univariate regression analysis. The significance level was set at p < 0.05 in the 
multivariate logistic regression analysis, to demonstrate the true association between the risk 
factors and HBsAg seropositivity.  
4.4.16 Feasibility of rapid testing analysis 
The feasibility of integrating rapid testing for HBV in existing HIV PMTCT services was 
assessed at both study sites. The concept of feasibility was broken down to the diagnostic 
performance, and the acceptance and usability of the rapid test by the HCWs at the ANCs. The 
perspectives of these HCWs concerning HBV rapid testing was measured using a user-
appraisal questionnaire presented in Appendix G. Copies of this questionnaire were distributed 
to the PMTCT nurses and HIV counselors performing both the HBV and HIV rapid testing 
during the study period. The questionnaire was designed to evaluate the minimal training needs, 
ease of use and user acceptability of the HBV rapid test. It included both closed questions, and 
open-ended questions prompting qualitative responses. The data were collected and entered in 
an Excel sheet for analysis. HBsAg results obtained with the rapid test using finger-prick blood 
were compared to ARCHITECT HBsAg results obtained from venipuncture serum samples at 
the laboratory. This served as determining the diagnostic accuracy (diagnostic sensitivity and 
diagnostic specificity) of the rapid test for field use. A 2x2 contingency table, below, compares 
the diagnostic accuracy criteria between the candidate assay (Determine HBsAg test) against 
the reference diagnostic assay (ARCHITECT i2000SR HBsAg assay). The diagnostic 
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sensitivity measures the ability of the rapid test to correctly identify HBV-infected patients, 
whilst the diagnostic specificity measures the ability of the test to identify those who aren’t 
infected with the virus. The formulas outlined below were used to compute the diagnostic 
sensitivity and specificity of the rapid test used for antenatal HBsAg screening at the ANCs.  
 
Architect i2000SR “Gold standard” 
Total 
Positive Negative 
Determine 
HBsAg rapid 
test 
Positive # true positive (TP)  # false positive (FP) TP+FP  
Negative # false negative (FN) # true negative (TN) 
FN+TN  
 
Total TP+FN  FP+TN   
HBsAg: hepatitis B surface antigen 
• The estimated diagnostic sensitivity (true positive rate) = 100 x [TP/(TP+FN)]  
• The estimated diagnostic specificity (true negative rate) = 100 x [TN/(FP+TN)]  
4.4.17 HBV-exposed babies testing  
Based on the estimated gestational age of the HBsAg positive women identified during the 
recruitment period, the estimated due date of delivery of each woman was calculated. These 
women were traced and telephonically contacted for the six-week follow-up of their babies. At 
this follow-up, an SST pediatric blood sample was collected for HBsAg testing at the Namibia 
Institute of Pathology laboratory, and a case record form was completed. The case record form 
served to document the personal details, HBV vaccination history, and the HIV clinical history, 
where applicable, of the HBV-exposed babies.  
4.5 Results 
4.5.1 Patient recruitment and sociodemographic characteristics 
Between September 29 and November 16 2017, a total of 515 pregnant women were recruited 
in the study: 273 (53%) from Intermediate Katutura hospital ANC and 242 (47%) from 
Windhoek Central hospital ANC. Study participants were of a median age of 28 years old 
(Range: 18 – 45 years old), with a median number of live births of one (Range: 0 – 9 children) 
and a median number of pregnancies of two (Range: 1 – 10 pregnancies). The median 
pregnancy age was 24 weeks (Range: 9 – 39 weeks). 
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The majority of these women were unmarried (433/515; 84.1%) and had a secondary level of 
education (389/515; 75.5%) while only 19.4% (100/515) reported either having some tertiary 
level degree or being enrolled at a tertiary institution. In terms of employment status, 50.7% 
(261/515) women reported having informal or formal employment while 38.6% (199/515) 
were unemployed, and 10.7% (55/515) were students (Table 4.1). Two hundred and ninety-
five (295/515; 57.3%) women were born in urban areas while the remainder were born in rural 
areas (220/515; 42.7%). Geographically, the majority were born in the Khomas province 
(133/515; 25.8%), followed by Omusati (77/515; 15%), and Ohangwena (64/515; 12.4%) 
provinces (Figure 4.5). Some pregnant women were from other African countries including: 
Angola (14/515; 2.7%), Botswana (2/515; 0.4%), Kenya (1/515; 0.2%), South Africa (1/515; 
0.2%), Tanzania (2/515; 0.4%), Zambia (1/515; 0.2%) and Zimbabwe (4/515; 0.8%). 
A significant difference was noted with regards to the level of education (p < 0.001) and 
employment status (p = 0.006) between pregnant women attending these two ANCs. Pregnant 
women attending Windhoek Central hospital ANC had a higher level of education and more 
likely to be employed as compared to those attending Intermediate Katutura hospital ANC.  
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Figure 4.5: Geographic distribution of the study population enrolled in the study in Namibia. 
Study participants originating from neighboring countries of Namibia are not represented on this graph. 
The map was produced using the ArcGIS® Online Software by Esri© 2018 
(www.esri.com/software/arcgis/arcgisonline). Namibia province distribution shapefile was obtained 
from map library (www.maplibrary.com).  
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Table 4.1: Sociodemographic characteristics of enrolled pregnant women 
Variable 
Total 
N (%) 
IKH  
N (%) 
WCH  
N (%) 
p-value 
Patient Count N = 515 273  242  
Age     
≤241  142 (27.6%) 75 (27.5%) 67 (27.7%) 0.94 
25-34 261 (50.7%) 137 (50.2%) 124 (51.2%)  
≥35 112 (21.7%) 61 (22.3%) 51 (21.1%)  
Area of birth    0.518 
Urban 295 (57.3%) 160 (58.6%) 135 (55.8%)  
Rural 220 (42.7%) 113 (41.4%) 107 (44.2%)  
Marital status    0.221 
Unmarried 433 (84.1%) 236 (86.4%) 197 (81.4%)  
Married 80 (15.3%) 36 (13.2%) 44 (18.2%)  
Divorced 2 (0.4%) 1 (0.4%) 1 (0.4%)  
Level of education    < 0.001* 
None 8 (1.6%) 8 (2.9%) 0 (0.0%)  
Primary  18 (3.5%) 18 (6.6%) 0 (0.0%)  
Secondary 389 (75.5%) 213 (78.0%) 176 (72.7%)  
Tertiary 100 (19.4%) 34 (12.5%) 66 (27.3%)  
Employment status    0.004* 
Employed# 261 (50.68%) 123 (45.05%) 138 (57.02%)  
Unemployed 199 (38.6%) 124 (45.4%) 75 (31.0%)  
Student 55 (10.7%) 26 (9.5%) 29 (12.0%)  
Gravidity    0.057 
Primigravida 117 (22.7%) 53 (19.4%) 64 (26.4%)  
Multigravida 398 (77.3%) 220 (80.6%) 178 (73.6%)  
Parity    0.054 
0 130 (25.2%) 59 (21.6%) 71 (29.3%)  
1-3 347 (67.4%) 189 (69.3%) 158 (65.3%)  
> 3 38 (7.4%) 25 (9.2%) 13 (5.4%)  
1include patients from the age of 18 years old. #Include formal and informal employment. *p-value < 0.05 
showing statistically significant differences between variables. Primigravida = first pregnancy; multigravida = 
have had more than one pregnancy. ANC: antenatal clinic; IKH: Intermediate Katutura hospital; WCH: 
Windhoek Central hospital. Statistical significance was computed using the Pearson chi-square test, except for 
the variables Marital status and Level of education which were analyzed using the Fisher’s exact test. 
4.5.2 Seroprevalence of HIV infection  
The HIV infection was detected in 66 women with a median age of 33 years (Range: 18 – 45 
years), a median number of live births of two (Range: 0 – 6 children), and a median number of 
pregnancies of three (Range: 1 – 9 pregnancies). This gave an overall HIV infection 
seroprevalence of 12.8% (66/515). Of these 66 HIV-infected women, 20 (30.3%; 20/66) were 
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newly diagnosed patients during the study period, and 46 (69.7%; 46/66) were known cases of 
HIV infection. The median age within these two groups was 26.5 years (Range: 20 – 39 years) 
for newly HIV-infected women and 34 years (Range: 18 – 45 years) for known HIV-infected 
patients. 
Looking at the distribution of these HIV infections between the two study sites, a 7% (17/242) 
and 17.9% (49/273) prevalence was found at Windhoek Central hospital ANC and Intermediate 
Katutura hospital ANC, respectively. This difference was found to be statistically significant 
(p < 0.001); as seen in Table 4.2. Among these new HIV infections, 65% (13/20) were found 
at the Intermediate Katutura hospital ANC, while only 35% (7/20) were detected at the 
Windhoek Central hospital ANC. Thirty-six (36/46; 78.3%) of the known HIV infections were 
identified at Intermediate Katutura hospital ANC, while ten (21.8%) were from Windhoek 
Central hospital ANC. 
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Table 4.2: Sociodemographic characteristics of enrolled HIV-infected pregnant women 
Variable Total 
HIV status of pregnant women 
Negative n (%) Positive n (%) P-value 
 515 449  66   
Age     
≤241  142 132 (29.4%) 10 (15.2%) 0.001* 
25-34 261 230 (51.2%) 31 (47.0%)  
≥35 112 87 (19.4%) 25 (37.9%)  
Clinic    < 0.001* 
IKH ANC 273 224 (49.9%) 49 (74.2%)  
WCH ANC 242 225 (50.1%) 17 (25.8%)  
Area of Birth    0.630 
Urban 220 190 (42.3%) 30 (45.5%)  
Rural 295 259 (57.7%) 36 (54.5%)  
Marital status    1.000 
Divorced 2 2 (0.4 %) 0 (0%)  
Married 80 70 (15.6%) 10 (15.2%)  
Unmarried 433 377 (84.0%) 56 (84.8%)  
Level of education     
None 8 7 (1.6%) 1 (1.5%) <0.001* 
Primary 18 12 (2.7%) 6 (9.1%)  
Secondary 389 333 (74.2%) 56 (84.8%)  
Tertiary  100 97 (21.6%) 3 (4.5%)  
Employment status    < 0.001* 
Employed# 261 238 (53.0%) 23 (34.8%)  
Student 55 53 (11.8% 2 (3.0%)  
Unemployed 199 158 (35.2%) 41 (62.1%)  
Parity    <0.001* 
0 130 126 (28.1%) 4 (6.1%)  
1 – 3 347 292 (65.0%) 55 (83.3%)  
> 3 38 31 (6.9%) 7 (10.6%)  
Gravidity    < 0.001* 
Primigravida 117 114 (25.4%) 3 (4.5%)  
Multigravida 398 335 (74.6%) 63 (95.5%)  
Primigravida = first pregnancy; multigravida = have had more than one pregnancy. #Include formal and 
informal employment. *p-value < 0.05 showing statistically significant differences between variables. 
ANC: antenatal clinic; IKH: Intermediate Katutura hospital; WCH: Windhoek Central hospital. 
Statistical significance was computed using the Pearson chi-square test. The Fisher’s exact test was 
performed for the variables: Age, Marital status, Level of education, Employment status, Parity and 
Gravidity. 
4.5.3 Seroprevalence of syphilis  
Seven women reacted positive to the RPR test (7/515; 1.4%); of whom five (5/7; 71.4%) tested 
TPHA positive. The proportion of TPHA positive women translated to a 1% (5/515) 
Stellenbosch University https://scholar.sun.ac.za
121 
 
seroprevalence of syphilis in our study population. The median age of these infected women 
was 32 years (Range: 30 – 41 years). The median number of live births was two (Range: 1 – 3 
children), and the median number of pregnancies was four (Range: 2 – 5 pregnancies). Four of 
these five TPHA positive women were HIV positive (p < 0.001), and none were co-infected 
with HBV. 
Table 4.3: Sociodemographic characteristics of enrolled syphilis-infected pregnant women 
Patient 
ID 
Age* 
HIV 
status 
Gravidity Parity 
Area of 
birth 
Marital 
status 
Level of 
education 
Employment 
status 
PG133 33 + 4 3 Urban Unmarried Secondary Employed 
PG137 30 + 3 2 Urban Unmarried Secondary Unemployed 
PG211 41 + 5 3 Urban Unmarried Secondary Unemployed 
M234 32 - 4 2 Urban Married Secondary Unemployed 
M251 30 + 2 1 Urban Unmarried Secondary Unemployed 
*age in years. PG ID patients were enrolled at Intermediate Katutura hospital ANC. M ID patients were 
from Windhoek Central hospital ANC. ANC: antenatal clinic, ID: Identificant, PG: Pregnant Woman, 
M: Mother. 
4.5.4 HBsAg rapid testing results 
4.5.4.1 HBsAg seroprevalence 
Twenty-eight pregnant women were found positive for HBsAg. This is an HBsAg of 5.4% 
(28/515) (95% CI: 3.71% - 7.86%). The median age was 30.5 years [Range: 19 – 41 years], a 
median gestational age of 26 weeks [Range: 15 – 39 weeks], a median gravidity of three 
[Range: 1 – 6 pregnancies] and a median parity of 2 [Range: 0 – 5 children]. Many were from 
rural areas (18/28; 64.3%), and the majority was unmarried (24/28; 85.8%) and possessed a 
secondary level of education (18/28; 64.3%). Seven (7/28; 25%) stated holding a tertiary level 
qualification or pursuing a tertiary level study programme; of whom three were students, three 
were employed, and one was unemployed. Geographically, the majority of these positive 
women originated from the northern part of the country: Ohangwena and Omusati provinces 
(Figure 4.6). The seroprevalence of HBsAg was similar at both ANCs: 5.5% (15/273) at 
Intermediate Katutura hospital ANC and 5.4% (13/242) at Windhoek Central hospital ANC.  
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Figure 4.6: Geographic distribution of HBV positive across Namibia. The majority of HBV-infected 
pregnant women identified in the study were originally from Omusati and Ohangwena, close to the 
border with Angola. The map was produced using the ArcGIS® Online Software by Esri© 2018 
(www.esri.com/software/arcgis/arcgisonline). Namibia province distribution shapefile was obtained 
from map library (www.maplibrary.com).  
Furthermore, 25 of these HBsAg positive women (89.3%) were HBV mono-infected, while 
three were co-infected with HIV, giving a 0.6% (3/515) overall HIV/HBV co-infection 
seroprevalence. None tested reactive for syphilis. Table 4.4 illustrates the sociodemographic 
and clinical characteristics of these HBsAg positive patients. 
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Table 4.4: Sociodemographic and clinical characteristics of HBsAg positive pregnant women 
Patient 
ID 
Age 
(years) 
Gestational 
age (weeks) 
HIV 
status 
Syphilis 
status 
Gravidity 
Area of 
birth 
Marital 
status 
Level of 
education 
Employment 
status 
PG16 38 27 + - 5 Urban Married Primary Unemployed 
PG22 30 18 - - 3 Urban Unmarried Tertiary Student 
PG39 21 38 - - 2 Rural Unmarried Secondary Employed 
PG62 32 39 - - 4 Urban Unmarried Primary Unemployed 
PG74 26 19 - - 3 Urban Unmarried Secondary Employed 
PG87 27 29 - - 1 Rural Unmarried Secondary Employed 
PG108 30 25 - - 3 Rural Unmarried Secondary Unemployed 
PG119 19 31 - - 1 Rural Unmarried Secondary Unemployed 
PG127 23 28 - - 2 Rural Unmarried Tertiary Employed 
PG162 31 19 - - 1 Rural Married Secondary Employed 
PG194 37 25 - - 5 Urban Unmarried Secondary Unemployed 
PG196 33 23 - - 3 Urban Married Primary Unemployed 
PG225 33 29 - - 6 Rural Unmarried Secondary Employed 
PG246 24 22 - - 2 Rural Unmarried Secondary Employed 
PG272 25 29 - - 4 Rural Unmarried Secondary Unemployed 
M26 36 15 - - 3 Urban Married Tertiary Student 
M66 28 24 - - 2 Rural Unmarried Tertiary Student 
M81 24 28 - - 1 Rural Unmarried Secondary Student 
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M99 22 27 - - 1 Urban Unmarried Secondary Unemployed 
M148 41 21 - - 4 Rural Unmarried Secondary Employed 
M151 34 26 - - 3 Rural Unmarried Tertiary Employed 
M170 23 26 + - 3 Rural Unmarried Secondary Unemployed 
M174 28 22 - - 3 Urban Unmarried Secondary Employed 
M179 34 27 - - 2 Rural Unmarried Secondary Unemployed 
M180 31 21 - - 3 Rural Unmarried Tertiary Employed 
M190 32 23 - - 1 Rural Unmarried Tertiary Unemployed 
M244 33 32 + - 5 Rural Unmarried Secondary Unemployed 
M245 34 36 - - 2 Urban Unmarried Secondary Unemployed 
PG ID patients were enrolled at Intermediate Katutura hospital ANC. M ID patients were from Windhoek Central hospital ANC. ID: Identificant, PG: 
Pregnant Woman, M: Mother. 
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4.5.4.2 Quality assurance results  
Internal quality assurance 
The HBV positive controls and negative controls, prepared at the Division of Medical Virology 
as previously explained (section 4.4.8.4), were successfully tested at the ANCs every week, 
prior to the patient’s testing. All positive controls remained positive on the rapid test, and all 
negative controls remained negative on the rapid test, throughout the testing period. The results 
from this exercise are attached in Appendix H and Appendix I for Intermediate Katutura 
hospital ANC and Windhoek Central hospital ANC, respectively.  
External quality assurance 
Every fifth HBsAg negative rapid test result attained at the ANCs was planned to be repeated 
at the laboratory. This corresponded to every fifth of 487 HBsAg negative results and equated 
to 97 samples to repeat at the laboratory. However, 268 HBsAg negative results obtained at the 
ANCs were repeated at the laboratory. A seventh of HBsAg negative patients identified by the 
rapid test at Intermediate Katutura hospital ANC (n = 39/258), and all patients testing HBsAg 
negative by the rapid test at Windhoek Central hospital ANC (n = 229) were re-tested for 
HBsAg using the ARCHITECT HBsAg CLIA assay at the Namibia Institute of Pathology. The 
28 HBsAg positive patients detected using the Determine HBsAg rapid test were successfully 
re-tested at the laboratory for HBsAg too. 
4.5.5 Sample collection and shipping  
A total of 28 DBS and blood samples were collected from HBsAg positive patients on the day 
of their testing and sent to the Namibia Institute of Pathology laboratory. All 28 DBS were 
successfully shipped to and received at the Division of Medical Virology for HBV molecular 
testing. However, six of the serum samples collected could not be traced for retrieval at the 
laboratory, and 22 out of the 28 serum samples were shipped to and received at the Division of 
Medical Virology for further HBV serological markers testing. The other six samples were re-
collected post-partum but were still included in our analysis. 
4.5.6 Hepatitis B virus laboratory serological results 
4.5.6.1 HBsAg testing 
All HBsAg positive patients (28) detected by the rapid test at the ANCs, repeated at the 
Namibian laboratory, and remained HBsAg positive on the Architect i2000SR. All HBsAg 
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negative samples (39 from Intermediate Katutura hospital ANC and 229 from Windhoek 
Central hospital ANC) re-tested, as part of EQA, remained HBsAg negative too. These results 
are schematically presented in Figure 4.7. 
 
Figure 4.7: A flowchart representation of HBsAg testing using the Determine HBsAg rapid test 
and the Architect HBsAg laboratory test. ANC: antenatal clinic; HBsAg: hepatitis B surface antigen; 
IKH: intermediate Katutura hospital; WCH: Windhoek Central hospital. 
4.5.6.2 Seroprevalence of HBeAg among HBsAg positive  
All 28 serum samples were available for HBeAg testing. Three specimens were HBeAg 
reactive (3/28; 10.7%), whilst the rest were non-reactive (25/28; 89.3%).  
4.5.6.3 Seroprevalence of anti-HBe among HBsAg positive 
Of the 28 HBsAg positive samples, 24 were anti-HBe reactive (24/28; 85.7%); all were HBeAg 
negative. Four samples were anti-HBe non-reactive (4/28; 14.3%): three were HBeAg positive, 
and the other was HBeAg negative. 
4.5.6.4 Seroprevalence of anti-HBc IgM among HBsAg positive 
All 28 samples were also tested for anti-HBc IgM. They tested nonreactive for this marker.  
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4.5.7 Hepatitis B virus laboratory molecular results 
4.5.7.1 Viral DNA quantification 
Limit of quantification of the two DBS assay 
Results of the repeat testing of DBS from dilutions of the third HBV WHO international 
standard for NAT assays (NIBSC 10/264) are shown in Table 4.5. As tabulated in Table 4.6, 
the level at which 50% of the reactions were quantified was 3.70 log10 IU/ml (5000 IU/ml). At 
a minimum 95% quantification rate, determined by the Probit analysis, the lower limit of 
quantification of the COBAS AmpliPrep/COBAS TaqMan HBV test Version 2.0 was 
approximately 7110 IU/ml (3.85 log10 IU/ml) using two DBS (Appendix J).  
Table 4. 5: HBV DNA measurements in two DBS using dilutions of the NIBSC 10/264 
NIBSC HBV DNA 
levels (IU/ml) 
NIBSC HBV DNA 
levels (log10 IU/ml) 
2 DBS HBV DNA 
levels* (log10) 
Difference* 
2000  3.30 < 20 Not computed 
5000 3.70 2.85# 0.85 
10 000 4.00 3.26 0.74 
15 000 4.18 3.47 0.70 
20 000 4.30 3.62 0.68 
30 000 4.48 3.69 0.79 
35 000 4.54 3.70 0.85 
200 000 5.30 4.43 0.87 
*Computed from six replicates of each dilution. #Three out of six replicates were successfully 
quantified. DBS: dried blood spot; HBV: hepatitis B virus; NIBSC: National Institute for Biological 
Standards and Control. 
Table 4. 6: Limit of quantification in two DBS of the COBAS AmpliPrep/COBAS TaqMan 
HBV Test version 2.0 assay 
NIBSC HBV DNA 
levels (IU/ml) 
NIBSC HBV DNA 
levels (log10 IU/ml) 
Number of 
replicates 
Number 
quantified 
Rate of 
quantification 
2000  3.30 6 0 0% 
5000 3.70 6 3 50% 
10 000 4.00 6 6 100% 
15 000 4.18 6 6 100% 
20 000 4.30 6 6 100% 
30 000 4.48 6 6 100% 
35 000 4.54 6 6 100% 
200 000 5.30 6 6 100% 
PROBIT 95% hit rate: 7110 IU/ml (3.85 log10 IU/ml)   
DBS: dried blood spot; HBV: hepatitis B virus; NIBSC: National Institute for Biological Standards 
and Control. 
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Viral load measurements in patient’s samples 
HBV DNA was quantifiable in six DBS samples (6/28; 21.43%), with a median HBV viral 
load of 3.52 log10 IU/ml (Range: 3.12 – 7.43 log10 IU/ml). Of these six samples, HBV DNA 
levels above 100 000 IU/ml (5 log10 IU/ml), the threshold for maternal TDF treatment initiation 
in the study, were noted in two samples: 6.91 log10 IU/ml and 7.43 log10 IU/ml. These two 
patients were HBeAg positive and anti-HBe negative. HBV DNA levels in their corresponding 
plasma samples were above > 8.23 log10 IU/ml, the upper limit of quantification of the assay 
using serum or plasma samples. The median viral load in the corresponding plasma samples of 
the other four patients with quantifiable DNA in DBS was 2.99 log10 IU/ml (Range: 2.82 – 
3.95 log10 IU/ml).  
HBV DNA was detected, but not quantifiable, in seven DBS samples (7/28; 25%). The 
matching serum samples had a median viral load of 3.17 log10 IU/ml (Range: 2.73 – 3.42 log10 
IU/ml). HBV DNA was undetectable in 15 DBS samples (15/28; 53.57%); of which three 
belonged to HIV co-infected patients on a TDF-based ART (TDF/FTC/EFV fixed-dose 
combination). Similar results were noted in the corresponding serum samples of five of these 
15 DBS samples; two of the five samples were HIV/HBV co-infected. Of the remaining 10 
corresponding serum samples, two had a viral load < 20 IU/ml (one was co-infected with HIV), 
and the other eight had a median viral load of 1.66 log10 IU/ml (Range: 1.36 log10 – 2.62 log10 
IU/ml), below the level of quantification of the DBS assay. These results are summarized in 
Table 4.7.  
Correlation, linearity, and agreement between DBS and serum sample measurements 
Twenty-two matched DBS and serum samples collected during the antepartum period of these 
patients were available to assess the agreement between viral measurements of these two 
sample types. Four samples with undetectable viral loads in both serum and DBS were 
excluded, and the remainder 18 were further analyzed. DBS viral loads were on average 1.05 
log10 IU/ml (95% CI: 0.68 - 1.42 log10 IU/ml) lower than their matching serum samples (p < 
0.001). The Bland-Altman plot, illustrating the agreement between the two measurements, 
showed that the differences in viral load between these two sample types fell within the 95% 
limits of agreement (-0.40 to 2.50 log10 IU/ml) of the average difference (Figure 4.8).  
Correlation and linearity between viral load measurements obtained with these two sample 
types were assessed using 10 matched samples, with detectable viral loads in both 2 DBS and 
Stellenbosch University https://scholar.sun.ac.za
129 
 
serum samples. As per Figure 4.9, the R2 = 0.89 suggested strong correlation between HBV 
DNA levels attained with the two paired sample types (Figure 4.9). 
Table 4.7: HBV viral copies and HBV serological status of HBsAg positive patients 
Patient 
ID 
HIV 
status 
Serum HBV 
DNA log10 
(IU/ml) 
DBS HBV 
DNA log10 
(IU/ml) 
HBsAg HBeAg Anti-
HBe 
Anti-
HBc IgM 
PG16¥ + LDL LDL + - + - 
PG22 - 2.87 LQL + - + - 
PG39 - LDL LDL + - + - 
PG62 - 3.42 LQL + - + - 
PG74 - LQL LDL + - + - 
PG87 - 1.63 LDL + - + - 
M26 - 2.62 LDL + - + - 
PG108# - LDL LDL + - + - 
M66 - 3.35 LQL + - + - 
M81 - 1.36 LDL + - + - 
PG119 - 3.45 LQL + - + - 
PG127 - > 8.23 6.90 + + - - 
PG162 - LDL LDL + - + - 
M99 - 2.82 3.53 + - + - 
M148* - 1.49 LDL + - + - 
M151* - 1.69 LDL + - + - 
M170 + LQL LDL + - + - 
M174* - 2.98 3.11 + - + - 
PG194* - > 8.23 7.41 + + - - 
PG196* - 3.00 3.48 + - + - 
PG225 - 1.98 LDL + - + - 
M179 - 2.73 LQL + - + - 
M180 - 1.49 LDL + - + - 
M190 - 3.95 3.33 + - + - 
M244* + LDL LDL + + - - 
M245 - 1.71 LDL + - - - 
PG246 - 2.76 LQL + - + - 
PG272 - 3.17 LQL + - + - 
¥Result from a ½ dilution, due to insufficient sample volume for the assay. #Result from a 1/10 dilution, 
due to insufficient sample volume for the assay. *Blood samples collected from these patients at 
enrollment were lost at the Namibian laboratory and were re-collected postpartum. Anti-HBc IgM: 
antibodies Immunoglobulin M against hepatitis B core antigen; anti-HBe: antibodies against hepatitis 
B e antigen; HBeAg: hepatitis B e antigen; HBsAg: hepatitis B surface antigen; IU/ml: International 
Units per millilitres; LDL: lower than the detection limit; LQL: lower than the quantification limit (< 
20 IU/ml with serum and 3.85 IU/ml with DBS); M: Mother; NT: Not Tested; PG: Pregnant woman; 
TND: Target Not Detected. In red are HIV/HBV co-infected patients.  
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Figure 4.8: Bland-Altman plot of agreement between HBV DNA viral loads of 18 paired serum 
samples and DBS samples. The solid line represents the mean difference between the serum and DBS 
viral load measurements. The dashed lines represent the upper and lower limit of agreements (±1.96 
standard deviations) of the differences between the measurements of both samples’ types. DBS: Dried 
blood spots; LoA: lower limit of agreement; UoA: upper limit of agreement. 
 
 
Figure 4.9: Linear regression analysis HBV DNA levels of 10 paired DBS and serum samples. 
The graph shows a good correlation (R2 = 0.89) between measurements attained in two DBS and 
serum samples. HBV: hepatitis B virus. 
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4.5.7.2  Nucleotide sequencing of the pol/surf gene  
Viral DNA extraction was completed on all HBsAg positive patients with detectable levels of 
DNA and pol/surf gene amplification was completed. HBV DNA was successfully amplified 
for 11 out of the 13 samples (11/13; 84.6%) with detectable DNA. 
Nested PCR products were purified and used for cycle sequencing. Purified sequencing 
products went through capillary electrophoresis. Chromatograms were obtained from the 11 
samples with detectable HBV DNA, and consensus sequences of approximately 900 bp long 
were formed. These were further analyzed for genotyping and the presence of genomic 
mutations. 
HBV genotyping 
Viral sequences were fed in the NCBI HBV Genotyping tool. Genotype E was identified in 
eight samples (8/11; 73%). The other three viral strains belonged to Genotype D and were 
further described as sub-genotype D1 through Geno2Pheno analysis.  
HBV Reverse transcriptase mutation analysis 
The RT region of the pol gene was explored for the presence of drug-associated mutations. 
Twenty-seven polymorphisms were found in the analyzed sequences; of which one was found 
(V27I) in both genotypes while the others were genotype-specific. However, none were 
associated with resistance to any nucleos(t)ide analogs drugs used for the treatment of HBV. 
A list of these genetic variants is shown in Table 4.8. 
Table 4.8: Distribution of mutations in the RT region of the polymerase gene 
Sample ID Genotype RT amino acid substitutions 
PG22 E V27I, R110S, K154EK 
PG119 E V27I 
PG127 E M267L, R274IR 
M99 E M267L 
M174 E K11R, N76D, M267L, D271E, N279H 
PG194 E K11R, I122T, Y126H, W257F, M267L 
PG196 E M267L, D271E 
PG272 E M267L 
PG62 D1 
V27IV, Y54HY, N118T, N123D, Y135S, L164M, I233V, 
N248H, I266R, Q267H 
M179 D1 
A38E, Y54H, N123D, Y135S, L164M, I233V, N238HN, 
K241R, Y245H, N248H, I266R, Q267H 
M190 D1 
N53KN, L115M, N123D, Y135S, L164M, I233V, N248H, 
C256S, I266R, Q267H 
Substitutions, highlighted in green, were found in both genotype E and sub-genotype D1. The other 
substitutions appeared genotype-specific. ID: identificant; RT: reverse transcriptase. 
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HBV surf gene mutation analysis 
Due to the overlap between the pol and the surf reading frames, the small surface antigen (SHB) 
overlapping with the RT region was also examined for possible genetic variations. Twenty-one 
amino acid polymorphisms were observed in ten samples; each had more than one variant. 
None were associated with vaccine escape when analyzed with the geno2pheno web-based 
genotyping tool. One strain harbored a premature stop codon at aa L216*. Moreover, mixed 
viral populations were observed in two sub-genotype D1 samples. These samples showed a 
mixture of wild-type and mutant viruses. Table 4.9 shows the list of variants observed in the 
SHB region of our dataset and their genotypes. 
Interestingly, the genotype E strain harboring the stop codon L216* also presented with a 15 
bp deletion in the pre-S2 region, spanning from nt 51 to nt 65. This nucleotide deletion 
corresponds to the deletion of aa 137 to aa 141.  
 
Table 4.9: Distribution of mutations in the surface antigen region. 
Sample ID Genotype  surface antigen amino acid substitutions 
PG22 E N3S, L13R, F20S, Q51L, T57I, G102A, S136L, A184V 
PG119 E N3S, T57I, P67L, L215R, L216*, aa 137-141 deletion 
PG127 E N3S, T57I, L127P 
M99 E N3S, T57I 
M174 E N3G, T57I 
PG194 E N3G, T57I, S114P 
PG196 E N3S, T57I 
PG272 E N3S, T57I, T189I 
PG62 D1 F8S, I110L, P203R, Y206CY, S207N, P214LP 
M179 D1 Q30K, S174N 
M190 D1 T45NT  
Substitutions, highlighted in green, represent mixed viral populations observed. ID: identificant.  
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Phylogenetic analysis 
A neighbor-joining analysis was completed to assess the distances between the query 
sequences and those obtained in Genbank through BLAST. The phylogenetic tree constructed 
(Figure 4.10) showed close clustering of HBV genotype E sequences from Namibia with 
Genotype E strains identified in the study: PG196, M99, M174, PG194, and PG127. These 
sequences also appeared to be closely related to other HBV Genotype E sequences identified 
in Chapter 3 (section 3.5.4.2). HBV sequences from Chapter 3 are represented in the tree as 
2C, 3C, 6C, 7C, 10C, and 13C. On the other hand, genotype D sequences identified in these 
two studies showed no relationship. As reported in Chapter 3 (section 3.7.4.2), HBV sequences 
from 8C and 17C clustered with sub-genotype D3 sequences from Botswana and South Africa; 
while sequences from PG62, M179, and M190 clustered with sub-genotype D1 and D2 
sequences. 
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Figure 4.10: Molecular phylogenetic analysis of HBV strains identified in the study based on the 
pol/surf region of the HBV genome using Neighbor-joining model. The evolutionary relationships 
between the study query sequences were inferred using the pol/surf genomic fragment. The evolutionary 
distances were computed using the p-distance method (Nei & Kumar, 2000), and the consensus tree 
was inferred from 1000 bootstrap replicates. Distances values at the branch nodes lower than 70% are 
not shown. The antenatal sequences are represented with purple pentagons, and the pediatric sequences 
(Chapter 3) are represented with bright green pentagons.  
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Maximum likelihood phylogenetic analysis was completed using the GTR+I+G model, as per 
the JModelTest 2.13 test results. A similar cluster of sequences was observed on this 
phylogenetic tree, Figure 4.11.  
Pairwise comparison of sub-genotype D1 sequences showed a close similarity between the 
query sequences (PG62, M179, and M190) and sub-genotype D1 sequences from Sudan 
(KM108605.1), India (KP322599.1) and New Zealand (HQ700511.1). All genotype E 
sequences were closely similar.  
The close clustering of HBV genotype E sequences identified in the dataset (pediatric and 
antenatal HBV DNA positive samples) prompted further phylogenetic molecular analysis. 
Genotype E sequences from other parts of South West Africa and from West and Central Africa 
were retrieved from Genbank. These sequences were aligned with the HBV DNA positive 
pediatric and antenatal sequences, and the multiple alignment was fed in MEGA 7 for 
maximum likelihood phylogenetic analysis using the GTR+I+G model (Figure 4.12). PG22 
and PG119, only, appeared closely related to other Genotype E sequences from Namibia, while 
the other study Genotype E sequences grouped with sequences from Angola. While these 
strains are part of one clade (Genotype E), they appear as two lineages on the phylogenetic 
tree: isolates from West and Central Africa (Cameroon, Central African Republic (CAR), Cote 
d’Ivoire, Ghana, Guinea, Niger, and Nigeria) grouped together, while strains from the Southern 
part of Africa (Namibia, Angola and the Democratic Republic of Congo (DRC)) formed 
another group. 
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Figure 4.11: Molecular phylogenetic analysis of HBV strains identified in the study based on the 
pol/surf region of the HBV genome using maximum-likelihood model. This evolutionary history 
was inferred based on the General Time Reversible model. Bootstrap statistical analysis was performed 
using 1000 replicates. Distance values at the branch nodes lower than 70% were excluded from the tree. 
Antenatal and pediatric query sequences are represented with purple and bright green pentagons, 
respectively. The red lines show the relationship between Genotype E sequences and lines highlighted 
in teal represent D1 sequences. 
 DQ060824.1 Genotype E Namibia
 DQ060825.1 Genotype E Namibia
 PG194
 KF849719.1 Genotype E Angola
 M174
 AY935700.1 Genotype E Belgium
 PG196
 DQ060823.1 Genotype E Angola
 JN604166.1 Genotype E USA
 PG127
 7C
 10C
 6C
 2C
 13C
 3C
 M99
 DQ060822.1 Genotype E Angola
 KF922439.1 Genotype E South Africa
 PG119
 PG22
 PG272
 JQ023664.1 Genotype E Columbia
 AB201290.1 Genotype E Benin
 DQ060826.1 Genotype E Namibia
 DQ060828.1 Genotype E Namibia
 DQ060827.1 Genotype E Namibia
Genotype E 
 AB274969.1 Genotype E
 DQ060830.1 Genotype E Madagascar
 GQ161830.1 Genotype E Guinea
 DQ060829.1 Genotype E Namibia
 HE974382.1 Genotype D4 Martinique
 8C
 17C
 KR139747.1 Genotype D3 Botswana
 KF476028.1 Genotype A2/D3 South Africa
 KP091719.1 Genotype D3 Italy
 JF815610.1 Genotype D3 Brazil
 EF514293.1 Genotype D3 Italy
 HM101127.1 Genotype D3 Brazil
 EU908804.1 Genotype D3 Italy
 HE974379.1 Genotype D3 Martinique
 KF170746.1 Genotype D3 Sudan
 AY233293.1 Genotype D3 South Africa
 JX090661.1 Genotype D3 Russia
 JN370949.1 Genotype D3 USA
 KF170749.1 Genotype D1 Sudan
 KF170748.1 Genotype D1 Sudan
 M179
 M190
 PG62
 KM108605.1 Genotype D1 Sudan
 AB267090.1 Genotype D2 Japan
 AB263410.1 Genotype D1 Mongolia
 HQ700511.1 Genotype D1 New Zealand
 KX276999.1 Genotype D1 China
 EU908822.1 Genotype D1 Italy
 KP322599.1 Genotype D1 India
 JN604278.1 Genotype D1 USA
 KF170747.1 Genotype D1 Sudan
 KM108606.1 Genotype D1 Sudan
 KM108607.1 Genotype D1 Sudan
Sub-genotype D1
 KC836877.1 Genotype A Japan
 KT364751.1 Genotype C China
 AB644285.1 Genotype C/G Indonesia
 AB644282.1 Genotype B/C Indonesia
 HE974369.1 Genotype F2 Martinique
 HE974368.1 Genotype F4 Martinique99
99
70
99
97
92
90
96
98
71
99
Stellenbosch University https://scholar.sun.ac.za
137 
 
 
 
Figure 4.12: Molecular phylogenetic analysis of Study HBV Genotype E strains with other African 
HBV genotype E strains. Evolutionary distances were inferred using the maximum likelihood method, 
based on the General Time Reversible model, using 1000 bootstrap replicates. Distance values at the branch 
nodes lower than 70% were excluded from the tree. The query sequences are annotated with colored 
pentagons: in purple are strains from HBV-infected pregnant women (Chapter 4) and in bright green are 
strains from HIV/HBV-infected children (Chapter 3). The lines in blue show the cluster formed by query 
sequences and those from Angola. The pink lines denote the relationship between the query sequences and 
those from Namibia. The uncolored part of the tree shows Genotype E sequences from Cameroon, Central 
African Republic (CAR), Cote d’Ivoire, Ghana, Guinea, Niger, and Nigeria. The tree was rooted with 
Genotype D sequences annotated in dark green at the root of the tree. 
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4.5.7.3 Nucleotide sequencing of the X/core gene 
Thirteen samples with detectable HBV DNA levels went through cycle sequencing for the X/core 
gene.  
These PCR products were purified and analyzed via spectrophotometry to assess the purity and 
measure the concentration of DNA present. All DNA products, but M99, were diluted to a final 
DNA concentration of 20 ng/µl using nuclease-free water and were sequenced. The sequencing 
products were sent to the DNA sequencing Unit of Central Analytical Facilities at Stellenbosch 
University for capillary electrophoresis, and the resulting chromatograms were analyzed. 
Consensus sequences were successfully obtained for all 13 samples with detectable HBV DNA.  
Pre-C mutation analysis 
Pre-C genomic mutations were observed in all, but three patients (PG127, PG194, and PG196) 
Figure 4.13. Eight HBV viral strains (8/13; 61.5%) harbored the pre-C stop codon W28*, 
corresponding to the G1896A nucleic acid mutation. In two of these strains, PG272 - Genotype E) 
and M179 - sub-Genotype D1), W28* were accompanied by the G29D mutant corresponding to a 
G to A exchange at nt1899 (G1899A). The point mutation G to T at position 1816 (G1816T), the 
pre-C start codon, was also observed in patient M190. The mutation led to the M1I amino acid 
substitution. Lastly, patient M174 – genotype E, showed an insertion of an adenine between nt1839 
and nt1840. This insertion was confirmed by additional independent experiments and is depicted 
in Figure 4.14. 
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Figure 4.13: Graphic representation of pre-C mutations on BioEdit V7.2.5 and their frequency in the 
study dataset. The amino acid sequence of this region is numbered from 1 to 29. PG119, PG272, PG246, 
PG196, PG127, PG62, PG22, M190, M179, and M66 represent our query pre-C sequences. The W28* 
mutant is shown for patients PG22, PG62, PG119, PG246, PG272, M66, M99, and M179; * representing a 
stop codon. G29D mutant is seen in patients PG272 and M179 too. The Pre-C initiation codon point 
mutation M1I is observed in M190 pre-C sequences. X represent ambiguities in the nucleic acid sequence. 
The dots show where amino acid similarities are observed between query sequences and the pre-C reference 
sequence. Unknown genotypes are samples whose pol/surf sequencing could not be completed due to low 
HBV viral load. M: mother; PG: pregnant woman. 
 
Figure 4.14: A snapshot of the multiple alignment of M174 and the pre-C reference nucleotide 
sequences. The nucleotide sequence of this region is numbered from 1814 to 1900. Cycle sequencing of 
the X/core gene for sample M174 was repeated to obtain more than one consensus sequence confirming the 
insertion of an adenine between nt 1839 and nt 1840. The dots represent similarities between the sequences. 
M: mother; nt: nucleotide. 
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Core promoter (CP) mutation analysis 
Amino acid substitutions in the X gene, overlapping with the BCP region, were observed in eight 
sequences. The most prevalent aa substitution was at position 127; found in four samples namely: 
PG62, PG196, M99, and M179. These were a change of isoleucine to thymine (I127T), 
corresponding to a T to C nucleotide change at position 1753 in samples PG62, PG196, and M179. 
On the other hand, M99 had a substitution of isoleucine to serine (I127S), corresponding to the 
double A1752T/T1753C nucleic acid mutation. The double A1762T/G1764A (K130M/V131I) 
BCP mutant was detected in the viral sequences of three samples: M66, M99, and PG196. M99 
and PG196 were also harboring the I127T and I127S changes in their viral sequences, respectively. 
The V131I (G1764A) amino acid change was found alone in the viral sequence of patient PG246, 
who also had the W28* stop codon and G29D (G1899A) pre-C mutations. The pre-C start codon 
mutation (M1I) noted in patient M190 was observed in the BCP region as C148F (G1816T), where 
the overlap between the BCP and the pre-C regions starts. This viral strain belonged to sub-
genotype D1. Lastly, one genotype E showed an adenine (A) insertion between nucleotides 1765 
and 1766. These genomic changes are graphically represented in Figure 4.15.  
Changes in the URR were observed in seven samples. Sequences from these samples harbored 
pre-C mutants too, Figure 4.15. The most prevalent URR mutant observed was the adenine to 
valine at position 102 (A102V), translating to the C1678T amino acid substitution. The mutation 
was found in six samples. Three were genotype E, two sub-genotype D1, and one was of unknown 
genotype. A one bp deletion at position 1686 was found in the URR sequence from sample M190. 
This deletion is represented in Figure 4.16 along with the BCP nucleotide insertion. The 
distribution of these amino acid substitutions is listed in Table 4.10 
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Table 4.10: Distribution of CP mutations among HBV positive women 
Sample ID Genotype  Nucleotide (amino acid) substitutions 
PG22 E C1678T (A102V) 
PG62 D1 C1678T (A102V), T1753C (I127T) 
M66 Unknown A1762T/G1764A (K130M/V131I) 
M99 E A1752T/T1753C(I127S), A1762T/G1764A (K130M/V131I) 
PG196 E A1762T/G1764A (K130M/V131I), T1753C (I127T) 
PG119 E C1678T (A102V) 
M174 E C1678T (A102V) 
M179 D1 C1678T (A102V), T1753C (I127T) 
M190 D1 G1816T (C148F), 1 bp deletion at position 1686 
PG246 Unknown C1678T (A102V), G1764A (V131I) 
PG194 E 1 bp insertion between nucleotides 1765 and 1766 
Bp: base pair; M: mother; ID: identificant; PG: pregnant woman.  
 
 
Figure 4.15: Multiple alignment of the query sequences and the HBV X gene reference represented 
on BioEdit V7.2.5. The amino acid sequence of this region is numbered from 94 to 154 (nt 1653 to nt 
1835). PG119, PG272, PG246, PG196, PG127, PG62, PG22, M190, M179, and M66 represent our query 
BCP sequences. The A102V amino acid change is found in PG22, PG62, PG119, PG246, M174, and M179. 
Amino acid substitution at position 127 is seen for PG62, PG196, M179 (I127T), and M99 (I127S). PG196, 
M66, and M99 harbor the double K130M/V131I mutation.V131I only is found in PG246. M190 shows a 
C148F amino acid substitution. X represent ambiguities in the nucleic acid sequence. The dots show amino 
acid similarities between query sequences and the pre-C reference sequence. BCP: basal core promoter; M: 
mother; nt: nucleotide; PG: Pregnant woman. 
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Figure 4.16: Multiple alignment of M190 and PG194 with the X gene reference nucleic acid 
sequences, from nt1653 to 1778. A gap/deletion is observed at position 1686 in the X gene sequence of 
patient M190 (in the red rectangle) while an adenine (A) is added between nucleotides 1765 and 1766 and 
in the X gene sequence of patient PG194 (in the blue rectangle). M: mother; PG: pregnant woman.  
Core gene mutation analysis 
Scrutiny of the rest of the core gene (nt 1901 to nt 2452) sequences revealed an 89 bp deletion in 
a genotype E viral strain. This deletion spanned from nt 2168 to nt 2257, corresponding to the 
deletion of 30 aa (aa 89 to aa 119) Figure 4.17.  
 
Figure 4.17: A snapshot of the multiple alignment of PG194 and other HBV genotype E whole genome 
sequences from Namibia downloaded from Genbank. These whole genome sequences are numbered from 1 to 
3215; the core region is spanning from nucleotide 1901 to 2452. The two repeats core gene sequences of PG194 
show 89 bp deletions from nucleotide 2168 to nucleotide 2257. NC003977.21 represents the NCBI HBV reference 
sequence. Sequences starting with DQ are other HBV genotype E whole genome sequences downloaded in 
Genbank. Bp: base pairs; PG: pregnant woman. 
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Six samples harbored genetic variations in more than one region of the X/core gene. These samples 
are summarized in Table 4.11. 
Table 4.11: Summary of samples with combined pre-C and BCP mutations 
Patient 
ID 
Genotype HBeAg 
Anti-
HBe 
pre-C mutants BCP mutants 
PG62 D1 - + G1896A (W28*) T1753C (I127T) 
M66 Unknown - + G1896A (W28*) 
A1762T/G1764A 
(K130M/V131I) 
M99 E - + G1896A (W28*) 
A1752T/T1753C(I127S), 
A1762T/G1764A 
(K130M/V131I) 
M179 D1 - + 
G1896A (W28*), 
G1899A (G29D) 
T1753C (I127T) 
M190 D1 - + G1816T (M1I) G1816T (C148F) 
PG246 Unknown - + G1896A (W28*) G1764A (V131I) 
Unknown are samples whose pol/surface sequencing failed owing to low HBV DNA. Anti-HBe: antibodies 
against HBeAg; BCP: basal core promoter; HBeAg: hepatitis B e antigen; ID: identificant; M: mother; PG: 
Pregnant woman; pre-C: pre-core. 
4.5.8 Liver health assessment results 
AST, ALT, and platelet count measurements were successfully completed for all HBsAg positive 
pregnant women identified during the testing period (Table 4.12). Median liver transaminases were 
slightly higher in patients with HBV DNA viral load > 5 log10 IU/ml in comparison to those with 
a viral load < 3.6 log10 IU/ml in DBS. The median ALT in both groups was 16.5 IU/l compared to 
13 IU/l, respectively. Median AST was 21.5 IU/l compared to 19 IU/l, respectively. On the other 
hand, these levels were comparable between patients with HBV DNA levels > 5 log10 IU/ml and 
those with undetectable or unquantifiable HBV DNA levels: median ALT between the two groups 
was 16.5 IU/l vs. 16 IU/l, respectively; and median AST was 21.5 IU/l vs. 20 IU/l, respectively. 
An AST range of 15 to 41 IU/l is used as the AST reference range at the Namibia Institute of 
Pathology. The ULN AST value of 41 was used in the APRI score calculation. The APRI scores 
of this cohort did not suggest any evidence of liver cirrhosis. 
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Table 4.12: Liver transaminases, platelets and APRI results of HBsAg positive women 
Patient ID DBS HBV DNA 
log10 (IU/ml)* 
Platelets 
(x109/L) 
ALT (IU/l) AST (IU/l) APRI 
PG16 LDL 181 59 71 0.957 
PG22 LQL 192 11 16 0.203 
PG39 LDL 276 9 17 0.15 
PG62 LQL 249 14 20 0.196 
PG74 LDL 353 20 19 0.131 
PG87 LDL 177 28 48 0.661 
M26 LDL 275 10 14 0.124 
PG108 LDL 287 16 15 0.127 
M66 LQL 218 13 19 0.213 
M81 LDL 205 19 23 0.274 
PG119 LQL 231 10 18 0.19 
PG127 6.90 271 18 24 0.216 
PG162 LDL 222 18 20 0.22 
M99 3.53 240 13 23 0.234 
M148 LDL 225 17 20 0.217 
M151 LDL 243 16 19 0.191 
M170 LDL 229 18 22 0.234 
M174 3.11 116 13 14 0.294 
PG194 7.41 209 15 19 0.222 
PG196 3.48 212 16 23 0.265 
PG225 LDL 308 13 21 0.166 
M179 LQL 257 16 19 0.18 
M180 LDL 220 14 20 0.222 
M190 3.33 226 11 14 0.151 
M244 LDL 275 16 21 0.186 
M245 LDL 193 16 21 0.265 
PG246 LQL 204 17 16 0.191 
PG272 LQL 218 17 20 0.224 
*DBS measurements. ALT: Alanine transaminase; APRI: AST platelet Ratio index; AST: Aspartate 
transaminase; ID: Identificant; IU/l: International units per liter; LDL: lower than the detection limit; LQL: 
lower than quantitation limit (3.92 log10 IU/ml – 8422 IU/ml); M: Mother; PG: pregnant woman. 
4.5.9 Antiviral therapy evaluation results 
Two HBsAg positive pregnant women (PG127 and PG194) presented with HBV DNA levels in 
DBS of 6.90 log10 IU/ml and 7.41 log10 IU/ml, respectively. They were reviewed for ART against 
HBV with TDF. PG127 was started on a 300 mg daily dose of TDF on October 27 2017, for three 
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months; she was 29 weeks and 03 days pregnant. Although patient PG194 was offered TDF, this 
was not provided to her. This woman was enrolled in the study on October 25, 2017; she was 29 
weeks and 01 day pregnant. Following her HBV viral load result, she was reviewed on November 
15 2017, to assess kidney functions, prior TDF initiation. Her gestational age was 32 weeks and 
01 day and her estimated date of delivery was on January 01 2018.  
4.5.10 Analysis of risk factors associated with HBsAg seropositivity  
Results from the univariate logistic regression analyses are depicted in Table 4.13. Area of birth 
was statistically associated with HBsAg seropositivity. Pregnant women born in rural areas had 
2.54 times greater odds of being HBsAg positive than those born in urban areas (COR: 2.541, 95% 
CI: 1.148 - 5.617, p = 0.021). None of the other sociodemographic variables included in this 
analysis showed a statistically significant association with an HBsAg positive serostatus. HIV 
infection (COR: 0.808, 95% CI: 0.237 - 2.753, p = 0.733) and syphilis infection (p = 0.99) were 
also not identified as statistically significant risk factors with an HBsAg seropositive status.  
A total of 109 (21.2%) pregnant women had undergone surgical procedures, 75 women (75/515; 
14.6%) had previously undergone caesarian sections, and 26 (5.0%) had a history of abortion. 
Twenty-eight women reported a history of blood transfusion (5.4%). About 29.5% (152/515) of 
these pregnant women reported being involved in unprotected sexual activities. Body tattoos and 
piercing were found in 71 (71/515; 13.8%) and 486 (486/515; 94.4%) pregnant women, 
respectively. None of these risk factors were associated with an HBsAg seropositive status.  
Women with a history of liver disease (2/515; 0.4%) had 19 times greater odds of being HBsAg 
positive than those without a history of liver disease (COR: 19.783, 95% CI: 1.199 - 326.387, p = 
0.037). The majority of the patients had no knowledge of any family member who had or is still 
suffering from HBV infection (343/515; 66.6%) or liver disease (235/515; 45.6%). Among the 
remainder, 26 (26/280; 9.3%) and eight (8/172; 4.7%) had a family history of liver disease or HBV 
infection, respectively. Pregnant women with a family history of liver disease were 3.67 times 
more likely (COR: 3.667, 95% CI: 1.090 - 12.331, p = 0.036) to be HBsAg positive as compared 
to those without, while no statistically significant association was found between HBsAg 
seropositivity and a family history of HBV infection (COR: 2.200, 95% CI: 0.246 - 19.672, p = 
0.481).  
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Variables with a p-value ≤ 0.25 including the area of birth, abortion history, body tattooing, body 
piercing, patient’s history of liver disease and a family member with a previous liver disease were 
selected for multivariate regression analysis. The analysis was performed, using the backward 
stepwise (likelihood ratio) model, to determine which of these variables were independently 
associated with HBsAg seropositivity. As represented in Table 4.13, the multivariate regression 
model showed that none of the variables, included in the model, was an independent risk factor for 
an HBsAg seropositive status. 
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Table 4.13: Association between studied risk factors and HBsAg positivity among pregnant women attending Intermediate Katutura 
hospital and Windhoek Central hospital ANCs 
Variable Total 
HBsAg 
negative 
n (%) 
HBsAg 
positive 
n (%) 
COR (95% CI) p value AOR (95%CI) p value 
 515 487 28     
Age        
≤24 142 135 (27.7%) 7 (25.0%) 1 (reference)    
25-34 261 244 (50.1%) 17 (60.7%) 1.344 (0.544 - 3.321) 0.522   
≥35 112 108 (22.2%) 4 (14.3%) 0.714 (0.204 - 2.504) 0.599   
Gravidity        
Primigravida 117 111 (22.8%) 6 (21.4%) 1 (reference)    
Multigravida 398 376 (77.2%) 22 (78.6%) 1.082 (0.428 - 2.736) 0.867   
Parity        
Nulliparous 131 125 (25.7%) 6 (21.4%) 0.72 (0.27 - 1.93) 0.52   
Primiparous 159 151 (31.0%) 8 (28.6%) 0.80 (0.33 -1.95) 0.62   
Multiparous 225 211 (43.3%) 14 (50.0%) 1 (reference)    
Marital status        
Unmarried1 435 411 (84.4%) 24 (85.7%) 1.109 (0.374 - 3.288) 0.851   
Married 80 76 (15.6%) 4 (14.3%) 1 (reference)    
Area of birth        
Rural 220 202 (41.5%) 18 (64.3%) 2.540 (1.148 - 5.617) 0.021* 2.130 (0.941 - 4.819) 0.070 
Urban 295 285 (58.5%) 10 (35.7%) 1 (reference)  1 (reference)  
Educational level        
Low2 415 394 (80.9%) 21 (75.0%) 0.708 (0.292 - 1.715) 0.445   
High3 100 93 (19.1%) 7 (25.0%) 1 (reference)    
Employment status4        
Employed 261 250 (51.3%) 11 (39.3%) 1 (reference)    
Student 55 51 (10.5%) 4 (14.3%) 1.783 (0.546-5.820) 0.338   
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Unemployed 199 186 (38.2%) 13 (46.4%) 1.588 (0.696-3.625) 0.272   
HIV status        
Negative 449 424 (87.1%) 25 (89.3%) 1 (reference)    
Positive 66 63 (12.9%) 3 (10.7%) 0.808 (0.237 - 2.753) 0.733   
Syphilis status        
Negative 510 482 (99.0%) 28 (100.0%) 1 (reference)    
Positive 5 5 (1.0%) 0 (0%) 0.000 0.999   
Previous C-section        
No5 440 415 (85.2%) 25 (89.3%) 1 (reference)    
Yes 75 72 (14.8%) 3 (10.7%) 0.692 (0.204 - 2.351) 0.555   
Abortion history        
No 489 464 (95.3%) 25 (89.3%) 1 (reference)  1 (reference)  
Yes 26 23 (4.7%) 3 (10.7%) 2.421 (0.681- 8.609) 0.172 1.715 (0.427 - 7.892) 0.447 
Blood transfusion 
history 
 
      
No 485 458 (94.1%) 27 (96.4%) 1 (reference)    
Yes 28 27 (5.5%) 1 (3.6%) 0.628 (0.082 - 4.800) 0.654   
Don’t know  2 2 (0.4%) 0 (0%) 0.000 0.999   
Surgical history6        
No 405 382 (78.4%) 23 (82.1%) 1 (reference)    
Yes 109 104 (21.4%) 5 (17.9%) 0.798 (0.296 - 2.151) 0.656   
Unprotected sexual 
activity 
 
      
No 363 341 (70.0%) 22 (78.6%) 1 (reference)    
Yes 152 146 (30.0%) 6 (21.4%) 0.637 (0.253 - 1.604) 0.338   
Body tattooing        
No 444 417 (85.6%) 27 (96.4%) 1 (reference)  1 (reference)  
Yes 71 70 (14.4%) 1 (3.6%) 0.221 (0.030 - 1.650) 0.141 0.289 (0.038 - 2.215) 0.232 
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Body piercing        
No 29 26 (5.3%) 3 (10.7%) 1 (reference)  1 (reference)  
Yes 486 461 (94.7%) 25 (89.3%) 0.470 (0.133 - 1.659) 0.241 0.480 (0.132 - 1.741) 0.264 
History of liver 
disease 
 
      
No 478 455 (93.4%) 23 (82.1%) 1 (reference)  1 (reference)  
Yes 2 1 (0.2%) 1 (3.6%) 19.783 (1.199 - 326.387) 0.037* 4.430 (0.198 - 98.932) 0.348 
Don’t know 35  31 (6.4%) 4 (14.3%) 2.553 (0.831 - 7.842) 0.102 2.632 (0.803 - 8.634) 0.110 
Family member 
with previous HBV 
infection9 
 
      
No 164 154 (31.6%) 10 (35.7%) 1 (reference)    
Yes 8 7 (1.4%) 1 (3.6%) 2.200 (0.246 - 19.672) 0.481   
Don’t know 343 326 (67.0%) 17 (60.7%) 0.803 (0.359 - 1.795) 0.593   
Family member 
with previous liver 
disease 
 
      
No 254 242 (49.7%) 12 (42.9%) 1 (reference)  1 (reference)  
Yes 26 22 (4.5%) 4 (14.3%) 3.667 (1.090 - 12.331) 0.036* 2.419 (0.610 - 9.592) 0.209 
Don’t know 235 223 (45.8%) 12 (42.9%) 1.085 (0.478 - 2.465) 0.845 0.905 (0.382 - 2.146) 0.821 
1two divorced patients were counted as unmarried in the analysis and were HBsAg negative. 2include eight patients with no formal education, 18 
with primary and 389 with secondary level of education. 3include all patients with a tertiary level of education, of whom 37 are enrolled in a tertiary 
level programme. 4 Include formal and non-formal employment. 5include 126 Primigravida pregnant women. 6Include patients with previous cesarean 
sections. AOR: adjusted odds ratio; CI: Confidence interval; COR: crude odds ratio. *p-value < 0.05 showing statistically significant association 
with HBsAg seropositivity.  
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4.5.11 Feasibility analysis of HBsAg rapid testing  
Qualitative assessment 
Six HCWs directly involved in the study, including four health assistants and two registered 
PMTCT nurses, completed a structured questionnaire that assessed their perceptions of the ease of 
use and user acceptability of the rapid test. Table 4.14 shows the HCWs responses to the 
questionnaire questions.  
All HCWs (100%) had previously performed rapid testing, found the instructions of use of the kit 
very easy to understand, and none (0%) found any steps of the testing difficult to perform. Many 
HCWs commented about the “easy” and “simple” nature of the testing steps. One PMTCT nurse 
mentioned, “Because it’s the same steps that I am using when I perform the HIV rapid test” as a 
reason for the ease of use of the rapid test. The majority (83.3%) found the rapid test very 
convenient to perform and were very confident that they had well performed the test. All (100%) 
trusted the results obtained from the rapid tests, suggesting that this is because the kits are 
unexpired, quality controls and confirmation procedures are in place for the rapid testing: 
“Because all the test kits was not expired and we ran the controls every week and for positive 
results we collect venous blood for confirmation” - Counsellor. A PMTCT nurse stated “The test 
is instantly done and results are available after 15 minutes, hence there is no contamination of 
blood on devices”, as another reason for the trust in the results of the rapid test. The HCWs (100%) 
also thought that it is useful for the patients to know their HBV result within 15 minutes and would 
support the use of the test at the ANCs for antenatal care. Reported reasons for these responses 
included that this method of testing is cheaper, quicker and more accessible, can facilitate early 
detection and treatment, and that the immediate nature of the results may reduce patient anxiety. 
A PMTCT nurse commented “It is cheaper and reliable. In ± 15 minutes the client will know her 
result”. A counselor stated, “It is very much helpful to the mommies, for knowing their HB status 
for early detection”.  
These HCWs (100%) deemed that the test was acceptable to the patient, justified by the fact that 
the majority of patients approached at the ANCs consented to be tested and were happy and eager 
to receive their results after 15 minutes: “Clients were happy to know their results in 15 minutes 
time” – PMTCT counselor. However, the HCWs also indicated concerns about patients’ reactions 
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to the test, with 33.3% and 66.7% of HCWs reporting that patients were very anxious or a little 
anxious, respectively, with regards to the rapid test.  
Quantitative assessment – Diagnostic performance of the Determine HBsAg rapid test 
The diagnostic accuracy of the Determine HBsAg rapid test was measured using HBsAg results 
obtained from the subset of patients (296) who were tested using both the Determine HBsAg rapid 
test and the ARCHITECT HBsAg CLIA test. As described in section 4.5.4.2, all HBsAg positive 
and negative samples re-tested with the laboratory-based CLIA HBsAg test matched HBsAg 
results attained with the rapid test. These results translated to a sensitivity of 100% and a specificity 
of 100%.  
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Table 4.14: Assessment of training needs, ease of use and user acceptability of the Determine 
HBsAg rapid test among HCWs at Intermediate Katutura hospital and Windhoek Central 
hospital ANCs. 
Response N (%) Justification 
1. Have you 
previously perform 
rapid test? 
  
Yes 6 (100) - 
No 0 (0) 
2. Did you find the 
instructions of use of 
the kit easy to 
understand? 
  
Very easy 6 (100) - 
Easy 0 (0) 
Little difficult 0 (0) 
Very difficult 0 (0) 
3. How convenient 
was it to perform the 
rapid test? 
  
Very convenient 5 (83.3) - 
Convenient 1 (16.7) 
Little inconvenient 0 (0) 
Inconvenient 0 (0) 
4. Which steps of the 
kit did you find 
difficult? 
  
Preparing the kit 0 (0) “Because I found no difficulties in doing the test and 
preparations of the kit.” 
“All the way to use the kit it was easy.” 
“To me everything is simple and easy to perform.” 
“All the methods used in the kit were easy to perform.” 
“Because it’s the same steps that I am using when I perform 
the HIV rapid test.” 
Taking the sample 0 (0) 
Adding the buffer 0 (0) 
Reading the results 0 (0) 
None 6 (100) 
6. How confident are 
you that you have 
done the HBV rapid 
test correctly? 
  
Very confident 5 (83.3) - 
Confident 1 (16.7) 
Little unconfident 0 (0) 
Very unconfident 0 (0) 
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7. Do you trust the 
result of the HBV 
rapid test? 
  
Yes 6 (100) “Because all the test kits was not expired and we ran the 
controls every week and for positive results we collect venous 
blood for confirmation.” 
“Yes, I do because the HBV is done by drawing the Elisa. So 
far the results were the same” 
“Because after 15 minutes, the results are clear and visible 
very well.” 
“The test is instantly done and results are available after 15 
minutes, hence there is no contamination of blood on devices.” 
“Because it is according to the algorithm and also confirm by 
DBS, venous blood, (sALT, AST, HBsAg)” 
No 0 (0) 
 
9. How did the 
patient react to the 
HBV rapid test? 
  
Little anxious 4 (66.7) - 
Very anxious 2 (33.3) 
Not anxious 0 (0) 
10. Do you think that 
knowing the results 
in 15 minutes is 
useful for the 
patient? 
  
Yes 6 (100) “Very much useful because it is for early detection and for 
early treatment.” 
“The sooner the better for treatment and prevention.” 
“Because all the patient who tested for HBV just waiting for 
their result after they were tested.” 
“Because in 15 minutes result is clear and you can see them 
well.” 
“Yes, because it is cheaper and fast, even accessible.” 
“Because the results can be confirmed within 15minutes, and 
to reduce anxiety of the client.” 
No 0 (0) 
 
12. Would you 
recommend the use 
of this test at the 
clinic for antenatal 
care? 
  
Yes 6 (100) “It is very much helpful to the mommies, for knowing their HB 
status for early detection.” No 0 (0) 
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“I wouldn’t say much since the HBV tube is included in the 
process of ANC.” 
“Because to know your result on the same day is very 
understandable than waiting for few days.” 
“Because it is fast and the patient is just getting her result in 
the same day.” 
“It is cheaper and reliable. In ± 15 minutes the client will know 
her result.” 
“Because there were many patients who were tested positive.” 
14. Was the test 
acceptable by the 
patient? 
  
Yes  6 (100) “They had no problem of testing and as well as receiving their 
results.” 
“Majority, although some didn’t much agree.” 
“Because most of the patients sign the consent forms.” 
“Yes, because the kit is clearly showing the result just after 15 
minutes.” 
“Clients were happy to know their results in 15 minutes time.” 
“Because most of the patients were eager to know their HBV 
results.” 
No  0 (0) 
 
16. Any additional comments 
“Thank you so much for this study. It was really helpful to our nation and community.” 
 “HBV must be introduced in all facilities for the people to do it as a rapid test.” 
“It must be introduced in all ante-natal care, so that the client can be evaluated.” 
AST: Aspartate aminotransferase; DBS: Dried blood spots; HB: hepatitis B; HBsAg: hepatitis B surface antigen; 
HBV: hepatitis B virus; sALT: Serum alanine aminotransferase 
 
 
4.5.12 HBV-exposed babies testing 
A total of 25 of 28 (89.3%) HBV-exposed babies were successfully traced and called back to the 
ANCs for HBsAg testing: 13 from Intermediate Katutura hospital ANC and 12 from Windhoek 
Central hospital ANC. Three babies, born to mothers M170, PG225 and PG108, were lost to 
follow-up. These mothers had traveled outside of Windhoek. The 25 babies were tested within the 
neonatal period 5 – 20 weeks after birth. Fourteen (14/25; 56%) were males, and eleven were 
females (44%); all were non-reactive for HBsAg. The characteristics of the tested babies are given 
in Table 4.15, below. 
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Table 4.15: Characteristics of HBV-exposed babies tested for HBsAg 
Characteristics Number, n/N (%) 
Sample number 25/28 (89.3%) 
Age at sample collection (weeks)  
Median 7 
Range (min – max)  5.57 – 20.29 
Sex  
Male 14/25 (56%) 
Female 11/25 (44%) 
HBV BD vaccine  
Yes* 25/25 (100%) 
HBIG at birth  
Yes 15/25 (60%) 
No#  4/25 (16%) 
No record 6/25 (24%) 
HBV vaccination at 06 weeks   
Yes 25/25 (100%) 
No  0/25 (0%) 
HIV status  
No 2/25 (8%) 
Not Applicable 23/25 (92%) 
*21 babies were vaccinated within 24 hours of birth, three babies were vaccinated two days postpartum, 
and one baby was vaccinated four days postpartum. #two babies did not receive HBIG due to a shortage of 
stock, and two babies were not considered HBV-exposed as the mothers were not recorded HBsAg positive 
at the labor wards. ANC: antenatal clinic; BD: birth dose; HBV: hepatitis B virus; HIBG: hepatitis B 
immunoglobulin; HIV: human immunodeficiency virus. 
4.6 Summary of findings 
A 5.4% HBsAg seroprevalence (28/515) was observed amongst 515 pregnant women tested at 
ANCs in Windhoek, Namibia. None of the predisposing risk factors considered in the study was 
independently associated with HBsAg seropositivity. Among these HBsAg positive women, two 
had DNA levels above 100 000 IU/ml (2/28; 7.1%) and were eligible for ART with TDF, as per 
the study cut-off for initiation of antiviral prophylaxis against HBV MTCT. These two women 
were also HBeAg positive, thus, were at high risk of infecting their newborns. HBV viral strains 
within the infected population predominantly grouped with genotype E virus (8/11; 72.7%), 
followed by sub-genotype D1 viruses (3/11; 27.3%). Postpartum, 25 babies born to these 28 HBV-
infected pregnant women (25/28; 89.3%) were followed-up. All infants received a BD of the HBV 
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vaccine, and 15 (60%) were administered HBIG. None of these babies presented with acute HBV 
infection, including the babies born to the two pregnant women (PG127 and PG194) with HBV 
DNA levels above 100 000 IU/ml. 
4.7 Interpretation of findings 
4.7.1 HBsAg seroprevalence 
In the present study, a cohort of 515 pregnant women was enrolled in Windhoek, Namibia. Among 
these women, an HBsAg seroprevalence of 5.4% (28/515) was found. This seroprevalence was 
lower than the national 7.3% seroprevalence that was previously reported amongst 11 390 
pregnant women screened nationwide for HBV in Namibia during the year 2013 (Mhata et al., 
2017). According to the WHO classification of HBV endemicity (Previsani & Lavanchy, 2002), 
the seroprevalence reported by Mhata et al. (2017) suggested an intermediate to high 
seroprevalence of HBV in the Namibian antenatal population. 
The study by Mhata et al. (2017) also investigated the seroprevalence of the virus across provinces 
in Namibia. Among 6235 pregnant women tested for HBV in the Khomas province, in which 
Windhoek is situated, 350 (5.6%) had tested HBsAg reactive (Mhata et al., 2017); a 
seroprevalence comparable to the 5.4% described within our cohort. The similarity in the rate of 
HBsAg seroprevalence observed in 2013 (Mhata et al., 2017) and in this study, 5.6% vs. 5.4%, 
respectively may indicate the existence of an HBV reservoir in the country. This similarity could 
be attributed to both (1) the historical trend of horizontal transmission of the virus during 
childhood, as is the case in most SSA countries, and to (2) residual MTCT. Differentiating between 
acute and chronic HBV infection within the adult population may be informative in terms of 
understanding the current dynamics of transmission of the virus within this population, as well as 
the general population. A higher rate of chronic infection, as compared to acute infection, may 
further strengthen the hypothesis of the presence of an HBV reservoir, while a higher prevalence 
of acute infections may reflect on current behaviors associated with continuous horizontal 
transmission of the virus within communities; bearing in mind that 5% to 10% of adulthood 
acquired infections progress to chronic infection in the presence of immune-suppression 
(McMahon et al., 1985; Hyams, 1995). These HBsAg positive women were negative for anti-
HBc IgM, a marker of recent infection or re-infection; which indicated that it is unlikely that these 
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women were newly infected by the virus. Noting that universal HBV vaccination (from six weeks 
of age) was introduced in Namibia in 2009, the majority of these women (median age of 30.5 
years) were not vaccinated; suggesting that these infections may have been acquired during early 
childhood or infancy.  
Furthermore, the seroprevalence of HBsAg among women enrolled appeared heterogeneous, 
depending on the province of birth. The majority of HBsAg seropositive pregnant women were 
born in the Omusati (7/28) and Ohangwena (7/28) provinces. In relation to the number of patients 
enrolled from these two regions, this translated to a 9.1% (7/77) and 10.9% (7/64) HBsAg 
seroprevalence, respectively. The seroprevalence observed in Ohangwena (10.9%) is comparable 
to the 10.1% described among 4096 pregnant women tested for HBV in that province, before 
(Mhata et al., 2017). On the other hand, the rate seen among women from the Omusati region 
(9.1%) suggested an increasing trend of the prevalence of the infection, in comparison to the earlier 
report of 6.8% (48/705) in the same province in 2013 (Mhata et al., 2017). These statistics are 
indicative of high endemicity of HBV in these two Namibian provinces. Omusati and Ohangwena 
provinces are situated in the northern part of the country, neighboring Angola; where HBV 
infections were previously recorded at a rate of 9.3% (Guimarães Nebenzahl et al., 2013) and 
12.4% (Schweitzer et al., 2015). The proximity between Angola and Northern Namibia facilitates 
easy migration between the two regions. The constant movements between the two countries may 
lead to a shared burden of HBV infections. Interestingly, the high seroprevalence of HBsAg noted 
among women born in Northern Namibia (9.1% in Omusati and 10.9% in Ohangwena) in the 
present study is in accordance with reports from earlier studies conducted in this part of the 
country. Botha et al. (1984) observed an HBsAg carrier state of 11% among mothers in 
Ovamboland (Botha et al., 1984). Ovamboland regroups four provinces namely Omusati, 
Ohangwena, Oshana, and Oshikoto in Northern Namibia. In another province of Northern 
Namibia, Eastern Caprivi (now called Zambezi), Joubert et al. (1991) described a 10.7% 
prevalence among women within the general population (Joubert et al., 1991). There is little 
known about the endemicity of the virus in other parts, and provinces of Namibia. Still, migrations 
between provinces in the country could have possibly led to a spill-over of HBV infection from 
the northern part of the country to the provinces situated inland. This is illustrated by the 
heterogeneity of patients enrolled in this study. The majority of enrolled women were born in the 
Khomas province (133/515; 25.8%) followed by the Omusati (77/515; 15%) and Ohangwena 
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(64/515; 12.4%) provinces. Yet, only one out of 133 patients (1/133; 0.75%) of Khomas origin 
was HBsAg positive compared to the 9.1% (7/77) and 10.9% (7/64) seroprevalence observed in 
women born in Omusati and Ohangwena, respectively. The heterogeneity of HBsAg prevalence 
seen between provinces is not unique to Namibia. Similar trends are seen elsewhere in SSA. A 4.5 
% HBsAg seroprevalence was recently noted among 134 pregnant women in the Western Cape 
Province of South Africa (Chotun et al., 2017), while a 0.8% (18/2368) seropositivity rate had 
been reported in the Tshwane district of Gauteng province, in South Africa still (Diale et al., 2016).  
To date, the literature counts only one study reporting on the prevalence of HBV infection among 
pregnant women in Namibia (Mhata et al., 2017). The study was a retrospective analysis of a 
nationwide laboratory dataset of antenatal HBV results and only reported on the seroprevalence of 
HBsAg. Earlier studies had investigated women within the general population in Northern 
Namibia (Botha et al., 1984; Joubert et al., 1991). The present study thereby provides updated 
statistics on the burden of HBV infection within the Namibian antenatal population. These data 
may be used for the planning of strategies against MTCT of HBV, and for the elimination of HBV 
in the country. 
4.7.2 Seroprevalence of HIV infection  
As per national policies, all pregnant women enrolled in our study were tested for HIV. A 12.8% 
(66/515) seroprevalence was found within the present cohort. This prevalence was slightly less 
than the pooled 16.6% (54/236) prevalence observed during the last 2016 biennial National HIV 
Sentinel Survey (NHSS) conducted in Windhoek (MoHSS, 2016), based on sampling performed 
at Windhoek Central hospital and Intermediate Katutura hospital ANCs. Patients enrolled in the 
NHSS were tested for HIV using the Abbott ARCHITECT HIV Ag/Ab combo assay (Abbott 
Diagnostics, USA) to detect HIV-1/2 antibodies. Positive results acquired with the ARCHITECT 
HIV-1/2 assay were confirmed using the DXI 800 (Beckman-Coulter, USA), testing for the p24 
antigen and HIV antibodies. Positive samples recorded by both assays were documented as 
positive for HIV. During the 2016 NHSS, 80 women were enrolled at Windhoek Central hospital 
ANC; five of whom were HIV positive (6.2%). At Intermediate Katutura hospital ANC, 246 
women were enrolled, and 49 were found HIV positive (19.9%) (MoHSS, 2016). The lower 
seropositive rate of HIV observed in our study as compared to the 2016 NHSS data (16.6% in 2016 
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compared to 12.8% in 2017) may represent a cohort effect; with fewer HIV-infected pregnant 
women attending ANC visits rather than a decrease in the HIV prevalence.  
Considering the rate at each ANC, a 19.9% rate of infection was noted at Intermediate Katutura 
hospital during this 2016 NHSS compared to 17.9% in 2017, described in this study. At Windhoek 
Central hospital, a 6.2% prevalence rate was reported in 2016, while a 7% was noted in this study. 
The statistical difference (7% vs. 17.9%, p < 0.001) of the HIV positivity rate between the two 
ANCs observed in our study was statistically significant. This substantial difference appeared 
historical (MoHSS, 2016), and may be an artifact of the sociodemographic of the patients 
attending these two health facilities. Patients attending Intermediate Katutura hospital ANC were 
found less educated and showed a lower employment status compared to those attending 
Windhoek Central hospital ANC. These two variables were statistically significant between the 
HIV-infected group and the HIV-uninfected group (level of education: p = 0.001 and employment 
status: p < 0.001), which puts forward the role of socioeconomic inequality and education in this 
disparity. The literature shows conflicting results with regards to the association between education 
and HIV in SSA. A higher prevalence of HIV amongst higher educated individuals has been 
previously noted in Ethiopia and Malawi; whilst lower educated individuals were the most afflicted 
by the epidemic in Lesotho, Kenya, and Zimbabwe (Hargreaves et al., 2015). However, earlier 
data suggested a positive correlation between the low level of education and HIV infection 
(Hargreaves et al., 2008). Similarly, while poverty is mostly assumed to be a driver of 
promiscuity, thereby predisposing individuals to HIV, a growing body of evidence has been 
challenging that connection. Higher HIV seropositivity rates have been described among wealthier 
countries in SSA, and wealthier individuals in SSA countries (Fox, 2010; Hajizadeh et al., 2014). 
In the context of Namibia, earlier data showed a decreasing prevalence of the infection as 
educational attainment increased (Gustafsson-Wright et al., 2011). The same data portrayed a 
higher rate of the infection amongst employed individuals compared to the unemployed ones: 
11.1% (117/1053) vs. 7.8% (65/838), respectively (Gustafsson-Wright et al., 2011). The last 
national demographic health survey, dating from 2014, also revealed that wealthier individuals 
were less likely to be HIV-infected (MoHSS, 2014b). The positive correlation between HIV 
infection and a low level of education captured in our study is in agreement with data from 
Gustafsson-Wright et al. (2011) (Gustafsson-Wright et al., 2011). However, unlike Gustafsson-
Wright et al. (2011), a higher rate of HIV infection was noted among unemployed pregnant women 
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compared to employed pregnant women: 41/66 (62.1%) vs. 23/66 (34.8%) (p<0.001). This 
discrepancy may be due to the difference in the groups of population studied between the two 
studies. Anthropological investigations may be required for a better understanding of the societal 
determinants of HIV within the Namibian antenatal population. 
4.7.3 Risk factors associated with HBV infection 
The HBsAg seropositivity rate presented in this study was lower than the rates recorded in parts 
of West Africa, such as in Nigeria (14%) (Musa et al., 2015), but higher than reports in Southern 
Africa (4.5% in South Africa (Chotun et al., 2017). These epidemiological differences may be 
attributable to sociodemographic or social behaviors associated with the risk of acquiring the 
infection. A few known predisposing factors to HBV infection, in the categories of 
sociodemographic, nosocomial exposure and social behaviors, were analyzed as potential risk 
factors of HBV infection within this cohort of women. 
4.7.3.1 Sociodemographic variables 
HBsAg positive women and HBsAg negative women were compared with regards to 
sociodemographic characteristics such as age, marital status, area of birth (urban or rural), 
employment status, gravidity, parity and educational level using univariate logistic regression. 
Among these variables, area of birth only appeared to be statistically associated with being HBV 
infected (HBsAg positive). Pregnant women born in rural areas were more likely than those born 
in urban areas to be HBV infected (COR: 2.541, 95% CI: 1.148 - 5.617, p = 0.021). As mentioned 
in section 4.7.1, the majority of patients participating in this study were born in Northern Namibia 
and had the highest HBsAg seropositivity rates (10.9% in Ohangwena and 9.1% in Omusati); the 
region is predominantly rural. Earlier investigations of HBV in this region of the country had also 
noted a high prevalence of HBV among both males and females of the general population. Various 
factors including cultural practices, such as ritual scarification (Joubert et al., 1991) and tick 
vectors such as the hut tampan tick (Ornithodoros moubata) (Joubert et al., 1985) were 
hypothesized as possible routes of horizontal transmission of the virus within communities. 
Extrapolating from these studies, being born in a rural area could be a confounder variable rather 
than a risk factor of HBV infection within this population. This interpretation was confirmed in 
the multivariate logistic regression model, which showed that being born in a rural area was not 
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independently associated with a HBsAg seropositive status (Adjusted OR [AOR]: 2.103, 95% CI: 
0.932 - 4.745, p =0.074). These observations prompt for further anthropological studies in 
Northern Namibia. These studies may be important to understand the reason why the prevalence 
of HBV remains high in this region in comparison to other parts of the country. 
A high proportion of pregnant women within the age groups of 25 to 34 years old (17/28; 60.7%) 
were HBV-infected. However, a statistically significant difference in the distribution of HBV in 
different age groups (p > 0.05) was not observed. This finding is similar to recent data from a case-
control study conducted in Namibia (Mwaningange, 2018). The study investigated the risk factors 
associated with HBV infection among pregnant women in the Kunene province of the country. 
The author noted a statistically significant difference in the distribution of HBV in different age 
groups (p = 0.02) in the univariate logistic regression; but the observation was not confirmed with 
a multivariate logistic regression model (Mwaningange, 2018). These results concur with findings 
from other African countries such as Tanzania (Rashid, Kilewo & Aboud, 2014), Ethiopia 
(Yohanes, Zerdo & Chufamo, 2016), and Cameroon (Noubiap et al., 2015). In contrast, a study 
in Uganda noted a significant association between HBV infection and the age group below 20 
years old. The authors hypothesized that this significant association might have been related to the 
high vulnerability of these young women to STIs (Bayo et al., 2014). Similarly to our findings, 
the prevalence of HBV infection in the case-control study in Kunene was higher within the age 
group of 20 to 35 years old (Mwaningange, 2018). The author attributed this observation to the 
fact that the majority of study participants were within that age group, as it was the case in our 
study group too. The population of pregnant women within this age group may also represent a 
subset of the reservoir of chronic HBV in Namibia. However, this hypothesis requires confirmation 
through further research.  
With regards to marital status, no association was found between HBV infection (HBsAg positive) 
and not being married. Yet, a high proportion of unmarried pregnant women carried the virus. 
These results are also in accordance with findings from Uganda (Bayo et al., 2014), Tanzania 
(Rashid, Kilewo & Aboud, 2014) and Cameroon (Noubiap et al., 2015). In contrast, polygamous 
marriages appeared as a significant risk factor for HBV acquisition in the Kunene region 
(Mwaningange, 2018); this significant association suggested that sexual transmission of the virus 
may be occurring among pregnant women in Kunene. 
Stellenbosch University https://scholar.sun.ac.za
162 
 
HBV infection was mostly detected among multigravida (22/28; 78.6%) and multiparous (14/28; 
50%) women. Yet, there was no significant association between multiple pregnancies and HBsAg 
seropositivity. This observation was in agreement with a report from the Eastern region of Ghana 
(Cho et al., 2012), and data from the Kunene region of Namibia too (Mwaningange, 2018). 
Multiple pregnancies often indicate engagement in multiple unprotected sexual activities. 
Although these sexual activities may not necessarily take place with multiple sexual partners, the 
susceptibility to STIs including HBV infection would be increased. The apparent lack of 
significant association between these two variables may suggest the limited role of sexual 
transmission in the spread of HBV within this population. This hypothesis does not infer the 
complete absence of sexually transmitted HBV infections within this community.  
The majority of HBsAg positive pregnant women were unemployed (13/28, 46.4%). Among them, 
many (11/13; 84.6%) were unmarried and had a primary (3/13; 23.1%) or secondary (9/13; 69.2%) 
level of education. These observations indicated a low socio-economic status within our cohort. 
Poverty has been previously associated with risky socio-behaviors such as having multiple sexual 
partners as a means for accessing basic needs (Buot et al., 2014), and unprotected sexual activity 
is often seen among individuals with a low level of education (Lagarde et al., 2001). The lack of 
a significant association between both unemployment and a low level of education observed in 
this cohort could mean that a low socio-economic status in Windhoek may not be a predisposing 
risk factor for acquiring HBV infection; as it has been observed in other parts of SSA (Rabiu et 
al., 2010; Rashid, Kilewo & Aboud, 2014; Noubiap et al., 2015; Yohanes, Zerdo & Chufamo, 
2016).  
4.7.3.2 Risk of nosocomial HBV infection 
Possible sources of HBV infection also include the nosocomial route through the instrumentation 
used during abortion and other surgical procedures such as caesarian section, or blood products 
obtained through blood transfusions. In this study, history of abortion, blood transfusion, caesarian 
section, and surgery were investigated as potential risk factors for HBsAg seropositivity. 
Surprisingly, these variables showed no significant association with HBsAg seropositivity. 
Although these findings are in agreement with studies conducted elsewhere (Rabiu et al., 2010; 
Alegbeleye et al., 2013; Rashid, Kilewo & Aboud, 2014; Metaferia, Dessie & Amsalu, 2016), 
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other African studies have found opposing results with regards to abortion (Ngaira et al., 2016; 
Yohanes, Zerdo & Chufamo, 2016), blood transfusions and surgery (Zenebe et al., 2014).  
The lack of association between HBsAg positive serostatus and blood transfusion noted in this 
study was also found in the Kunene region (Mwaningange, 2018). These findings reflect the 
strength of national policy on the universal screening of all blood donations for transfusion-
transmitted infections, including HBV infection, in Namibia (Mavenyengwa et al., 2014). In 
contrast, abortion appeared to be a significant risk factor (AOR: 2.91; 95% CI: 1.38-6.16; p-value: 
0.00) of HBV infection within the Kunene cohort (Mwaningange, 2018). The absent correlation 
between a history of caesarian section or any other surgery and HBsAg positivity may indicate 
compliances with safe practices and the use of sterile equipment for patient’s care at healthcare 
facilities in Namibia. Yet, dental procedures were significantly associated with HBV infection 
within the antenatal population studied in Kunene (Mwaningange, 2018). The difference seen 
with regards to these three variables (history of abortion, caesarian section, and surgical 
procedures) between these two Namibian cohorts may be a reflection of different risk factors of 
the infection in different regions of the country. 
4.7.3.3 Social behaviors and patient’s clinical characteristics  
The role of sexual transmission as a source of HBV amongst these pregnant women was further 
explored through data associated with risky social behaviors such as unprotected sexual activity, 
HIV infection, and syphilis. Unprotected sexual activity did not show any significant association 
with an HBsAg positive serostatus. Similarly, HIV and syphilis infections also showed no 
significant association with HBV infection (HBsAg positive). In contrast, a positive correlation 
has been previously observed between syphilis infection and HBsAg seropositivity (Rabiu et al., 
2010) or HIV infection and HBsAg seropositivity (Noubiap et al., 2015) in Nigeria and 
Cameroon, respectively. The difference seen with regards to these two infections (HIV and 
syphilis) may be explained by the absence of HBV-syphilis co-infection, and the proportionate 
distribution of HIV infection among HBV-infected (10.71%; 3/28) and HBV-uninfected pregnant 
women (12.9% 63/424) recorded in this cohort. This observation further emphasizes the 
hypothesis regarding the minor role of sexual transmission as the source of HBV among these 
pregnant women (section 4.7.3.1).  
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The risk of acquiring blood transmissible infections such as HBV using unsterile needles for body 
tattooing or body piercing is also not negligible. In fact, both body tattooing and body 
piercing/scarification were found to be significant risk factors for HBV infection among pregnant 
women in Kunene (Mwaningange, 2018). A similar observation was made in pregnant women 
studied in Bahir Dar city, Northwest Ethiopia (Zenebe et al., 2014). Using multivariate logistic 
regression analysis, Zenebe et al. (2014) revealed that pregnant women with body tattoos were 5.7 
times more likely to be HBsAg positive (Adjusted odds ratio = 5.7, 95% CI, 1.24-26.50) (Zenebe 
et al., 2014). However, this observation was not confirmed in this study, suggesting once more a 
difference in the risk factors between regions of Namibia and outside of Namibia.  
Given that horizontal transmission during childhood has been identified as the major mode of 
transmission of HBV in Namibia (Botha et al., 1984), contact with family members infected with 
HBV was expected to statistically correlate with HBsAg seropositivity. On the contrary, it did not. 
Still, pregnant women in contact with a family member with HBV infection remained 2.2 times 
more likely to test HBsAg positive (COR: 2.200, 95% CI: 0.246 - 19.672, p = 0.481). HBV is well 
known as a silent killer. Patients present at a late stage of the disease with either cirrhosis or HCC 
and are diagnosed then with HBV-related liver disease. Thus, it is not unexpected that many of 
both HBsAg negative and HBsAg positive patients were unaware of their family history of HBV 
infection, or believed that the infection was not present within their family (10/28; 35.7%). 
Furthermore, having a family member with previous liver disease was significantly associated with 
HBV infection (COR: 3.667, 95% CI: 1.090 - 12.331, p = 0.036), as was a medical history of liver 
disease of the patient (COR: 19.783, 95% CI: 1.199 - 326.387, p = 0.037); when they were 
analyzed separately. However, in the multivariate analysis, there was no significant association 
between HBsAg seropositivity and these two variables. Where a history of liver disease within the 
family was reported, alcohol was pointed out as the cause of the disease. Two women (0.4%) 
reported previously suffering from liver disease; one of whom was HBsAg positive. Both women 
remembered being told of having a liver problem when they were younger but had no further 
details with regards to the cause of the health problem. The association found between these two 
factors (family member with previous liver disease and history of liver disease of the patient) and 
HBV infection in the univariate analysis may, therefore, be due to confounding. Although alcohol 
was predominantly cited as the cause of liver disease of family members, HBV infection is a 
known risk factor for liver disease. Drawing from the historical trend of horizontal transmission 
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of HBV in Namibia, contact with a family member with HBV-related liver disease would be a 
predisposing risk factor for HBV acquisition, which in turn would lead to live disease in the patient. 
Given that these two variables are important predisposing risk factors for HBV infection, further 
exploration is required to ascertain their roles in the risk of HBV infection within this population. 
It is also important to mention that the large 95% CI of the ORs attached to the likelihood of 
pregnant women with history of liver disease to be HBsAg positive was indicative of an imprecise 
measure of the association between this variable and HBV infection. The imprecision of this 
measure was due to the low number of HBsAg positive patients with a history of liver disease and 
re-emphasized the need for further research for a precise measure of the association between this 
variable and HBV infection. 
The absence of a significant association between HBsAg seropositivity and the behavioral risk 
factors studied here further supports the possibility that these women may have acquired HBV 
infection in early childhood. It is noteworthy that 75% of these infected women reported the 
occasional use of physical contraceptive; thus, represented a risk of transmission of the virus to 
their partners. Although 90% of HBV infections acquired during adulthood resolve, a 10% risk of 
developing CHB remains if the patient is immunocompromised; as it is the case with HIV-
infection. In fact, the high prevalence of HIV (11.5%) documented among the general population 
aged 15 to 49 years old, during the 2017 Namibia Population-Based HIV Impact Assessment 
(NAMPHIA) survey (MoHSS, 2018), warrants HBV control within the Namibian adult population 
for the prevention of new cases of HBV infections within the HIV-infected population. 
Interventions such as education and catch-up vaccination programmes would be required for 
disease control within the adult population. 
Overall, none of the risk factors considered in this study were independently associated with HBV 
infection within this population. However, they may well be significant risk factors in other parts 
of the country as was seen in the Province of Kunene (Mwaningange, 2018). The differences 
observed between this cohort and the one from Kunene may also be an artifact of the study types. 
The present study was of cross-sectional nature. Studies of this nature are often applied to measure 
prevalence. Case-control studies, on the other hand, are predominantly conducted for the 
investigation of a possible relation between previous exposures and an outcome (Stephenson & 
Babiker, 2000); this study type was applied in Kunene. Still, results from this cross-sectional study 
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may serve to direct case-control studies in Windhoek or the wider Khomas province, for future 
investigations of risk factors associated with HBV infection in this region. It is also important to 
bear in mind that association is not causation. From a sociological perspective, there is no certainty 
that individuals testing positive or negative for HBsAg are so because they are or aren’t part of a 
larger pool of individuals exposed to certain factors (Buot et al., 2014). 
4.7.4 Risk of mother-to-child transmission of HBV  
The risk of HBV MTCT can be assessed through two viral markers namely: HBeAg and levels of 
HBV DNA. The former suggests viral replication and the latter hints at the number of viral 
particles present in the HBV-infected patient. In the presence of HBeAg and high levels of HBV 
DNA, transmission of HBV from the mother to her newborn is high.  
The presence of both HBV infectivity markers was investigated within the HBV-infected 
obstetrics population described in this study. Three women (3/28; 10.7%) tested HBeAg reactive. 
Thirteen women (13/28; 46.4%) had detectable levels of HBV DNA, based on DBS testing. 
Among these 13 HBV DNA positive patients, two (2/13; 15.4%) had a viral load of 6.90 log10 
IU/ml (PG127) and 7.41 log10 IU/ml (PG194). PG127 and PG194 were HBeAg positive too and 
had an 87.5% risk of transmitting HBV to their newborns (Edmunds et al., 1996). The other 11 
patients with detectable levels of DNA were HBeAg negative, thus at a reduced risk of 13.2% 
(Edmunds et al., 1996).  
Vertical transmission in Namibia was explored more than three decades ago by Botha et al. (1984); 
the authors investigated HBV among mothers and their children in Ovamboland, northern 
Namibia. HBsAg was found in 11% (137/1272) of the tested mothers, and 15% (20/136) of these 
HBV-infected mothers were HBeAg positive. Among the HBeAg positive women, 12 (12/19; 
63%) had HBsAg positive children, while 16/92 (17%) HBsAg positive/anti-HBe positive and 
6/16 (38%) HBsAg positive/ anti-HBeAg negative women had HBsAg positive children (Botha 
et al., 1984). Botha et al. (1984) reported horizontal transmission as the main mode of transmission 
of HBV during early childhood within the Namibian HBV epidemic. The authors also recognized 
the role of vertical transmission among HBV-infected children, and supported administering HBIG 
and HBV vaccination shortly after birth for children born to HBV-infected pregnant women, 
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provided that antenatal screening of HBsAg is in place to identify these infected mothers (Botha 
et al., 1984).  
4.7.4.1 Infant active and passive immunoprophylaxis 
Unlike many SSA countries, WHO recommendations regarding HBV BD vaccination and routine 
antenatal HBV screening (WHO, 2017b, d) are currently part of Namibian policies (MoHSS, 
2011; MoHSS, 2014a). As per these policies, every pregnant woman presenting for her first ANC 
should be tested for HIV together with HBV. Where the woman tests positive for HBsAg, HBIG 
should be administered to her baby at birth. HBV BD vaccination at birth is given, as per the 
national EPI, irrespective of the maternal HBV status.  
Immunization data were successfully retrieved from 25 out of the 28 babies (25/28; 89.3%) born 
to HBV-infected pregnant women identified in this study. The 25 babies received a BD of the 
HBV vaccine. Six babies (6/25; 24%) received it within 24 hours of birth, while the rest (19/25; 
76%) were vaccinated within a day to four days postpartum. Babies vaccinated at one day old may 
have been born at night and immunized the next morning or afternoon. With regards to HBIG, 
15/25 (60%) of these babies were passively immunized, while 4/25 (16%) were not: HBIG was 
out of stock in two cases, and two babies were not identified as HBV-exposed because the mothers 
were not recorded as HBV-infected. No record of HBIG administration in the baby’s health 
booklet was noted in six other cases (6/25; 24%).  
The discrepancy between the nationally recommended immunization timing and the immunization 
timing noted in this study portrayed the real-world situation observed in many resource-limited 
settings. Gaps between national recommendations and routine practices with regards to 
immunoprophylaxis in infants born to HBV positive mothers have been revealed elsewhere. A 
provincial population-based study in China reported that out of 298 HBV-exposed babies, only 
37.6% (112) received HBIG, and 84.9% (253/298) received a timely BD vaccine (Hu et al., 2012). 
Hu et al. (2012) raised the issue of insufficient knowledge concerning standard prophylaxis among 
HCWs (Hu et al., 2012). Personal communication with the HCWs in our study revealed that many 
did not know the importance of administering HBV active and passive immunoprophylaxis within 
24-hours of birth; which may also explain the late administration of the HBV BD vaccine in this 
study. Poor knowledge and awareness of HBV among HCWs has been raised before in Namibia 
(Mhata, Small & Hunter, 2017). However, they are not unique to Namibia. A recent Ghanaian 
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study also revealed that 87.3% (110/126) of midwives and physicians were unaware of the 
availability of a vaccine that when combined with HBIG and administered to HBV-exposed babies 
could prevent HBV MTCT (Adjei et al., 2016). The experienced unavailability of HBIG observed 
during the study period was not surprising, as HBIG is costly. Moreover, the two HBV-exposed 
babies missed for the administration of HBIG was apparently due to the oversight of the HCWs at 
the ANCs, and probably reflect the limited human resources seen in many resource-limited settings 
too.  
4.7.4.2 Maternal antiviral prophylaxis  
Two HBV-infected pregnant women (PG127 and PG194) were at high risk of transmitting HBV 
to their newborns, as per their positive HBeAg serostatus and high viral loads. Babies born to these 
two women received the BD of the HBV vaccine within 24 hours of birth. Delivery of HBIG was 
documented in one (PG194) of these two babies. Assuming that both babies received passive 
immunization, a 3% to 10% risk of MTCT remained due to maternal HBV viral load above 5.3 
log10 IU/ml (200 000 IU/ml) (Wiseman et al., 2009; Sellier et al., 2015). As per the AASLD 
recommendations (Terrault et al., 2016, 2018), these two patients were reviewed for antiviral 
prophylaxis with a 300 mg oral daily dose of TDF, starting from the third trimester of pregnancy. 
While PG127 was successfully put on TDF treatment from 29 weeks of gestation, antiviral 
prophylaxis was offered but not provided to PG194. Again, this scenario reflected a real-world 
situation.  
Failure to provide treatment to patient PG194 may be given many reasons. First is the lack of 
transport money from the patient to the clinic or hospital to collect the prescription or for the 
follow-up visit. As highlighted in section 4.7.3.1, many of these infected women were 
unemployed. Thus, money for taxi fares may be difficult to attain for some of them. Second, the 
issue of HCWs’ knowledge and awareness is re-emphasized. Considering that the evidence around 
maternal antiviral prophylaxis to prevent HBV MTCT is relatively new, the knowledge of this 
prophylactic measure may also be low among HCWs; as recently raised in a Canadian study (Van 
Ommen et al., 2017). Thus, if the nurses had knowledge of the high risk of HBV MTCT associated 
with a high HBV viral load for an HBsAg positive pregnant woman and had recognized the need 
for a referral to the doctor for treatment against HBV, treatment may had been provided to this 
patient (PG194). Third, the reference system in place may not be optimal for the care of HBsAg 
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pregnant women. Nurses are the first point of contact of all pregnant women in Windhoek, and 
refer patients to specialized care where the need is recognized. However, the need may not always 
be recognized or may be missed. Taking the case of Burkina Faso as an example, HBsAg positive 
women go through a number of primary caregivers, such as auxiliary midwives and midwives to 
get to a gastroenterologist for care. However, Guingané et al. (2014) observed that only 38% 
(45/119) of Burkinabe HCWs had referred HBV-infected pregnant women for care to the 
hepatologists (Guingané et al., 2014). Fourth is the issue of behavior or attitude of HCWs towards 
patients. A number of negative attitudes and behaviors of maternal health care providers such as 
poor communication and verbal abuse has been documented (Mannava et al., 2015). Although 
these behaviors may have not been common among HCWs at the study sites, patients may have 
been victims of these negative behaviors/attitudes at other health facilities. Exposure to these 
negative attitudes may have created the fear of speaking up to seek care.  
The reasons outlined above should be addressed in future studies in resource-limited settings to 
ensure adequate care of HBV-infected pregnant women and for policy implementation. These 
observations also prove the need for empowering pregnant women to demand care where 
necessary, through education. Similarly, education of HCWs is critical to ensure adequate 
provision of interventions against HBV MTCT in SSA.  
4.7.4.3 The rate of HBV MTCT  
Although HBV MTCT is defined as the presence of HBsAg in infants born to HBV-infected 
mothers from six months of age, HBV infection was assessed in 25 out of the 28 (89.3%) HBV-
exposed babies six weeks postpartum through HBsAg testing. All infants tested non-reactive, 
indicating the absence of acute perinatal HBV infection. These findings are in agreement with 
recent data from South Africa (Chotun et al., 2017). The South African study described the rate 
of HBV MTCT among 134 pregnant women in the Western Cape Province, South Africa. HBsAg 
seropositivity was found in six women (6/134, 4.5%; 95% CI 0.99%–8.01%); of whom two had 
high HBV viral loads of 23 000 IU/ml (4.36 log10 IU/ml) and 767 000 IU/ml (5.88 log10 IU/ml) 
and were offered TDF at 36 and 28 weeks of pregnancy, respectively, till one month postpartum. 
Babies born to the six HBV-infected mothers were vaccinated at birth but did not receive HBIG. 
Four of these six babies were followed-up at a mean age of 97 days (range: 34–151 days) and at 
seven months of age. At both time points, the babies were negative for HBV, including the babies 
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born to the mothers with high HBV viral loads. These two follow-ups demonstrated the absence 
of both acute and persisting HBV infections in babies who were at relatively high risk of infection 
(Chotun et al., 2017). Nine-month follow-ups of the HBV-exposed identified in this study are 
currently on-going and will determine the rate of chronic HBV infections amongst these babies.  
4.7.5 Feasibility of implementing HBsAg rapid screening 
The current national protocol for routine screening of HBV in pregnant women in Namibia 
includes testing for HBsAg at the laboratory (MoHSS, 2011). However, recent data suggest low 
coverage of this policy in many parts of the country (Mhata et al., 2017). This study described the 
feasibility of HBsAg screening at the POC level in Windhoek using RDT as an alternative for 
routine antenatal screening of HBsAg in Namibia.  
4.7.5.1 Diagnostic performance of the HBsAg rapid testing 
Results from this analysis showed that all 28 positive results attained by the Determine HBsAg 
rapid test at the ANCs were confirmed true positives at the laboratory. More than half of the 
negative results (55%; 268/487) recorded by the rapid test were re-tested and confirmed true 
negatives at the laboratory. Based on the number of samples (296 samples) tested at both the POC 
level and at the laboratory level, this data translates to a 100% sensitivity and a 100% specificity. 
This is the very first study in Namibia and the fourth in Africa reporting on the use of this rapid 
test at the POC level, operated by HCWs rather than laboratory technologists. In The Gambia, the 
test showed a diagnostic sensitivity and specificity of 88.5% and 100%, respectively during 
community-screening (Njai et al., 2015). In South Africa, the rapid test was used for the screening 
of HIV-uninfected pregnant women and showed 100% sensitivity. Negative patients were not 
confirmed at the laboratory; this did not allow for measuring the diagnostic specificity of the test 
(Chotun et al., 2017). A sensitivity of 87.9% and a specificity of 99.7% were observed among 
HIV-infected individuals tested in Zambia (Chisenga et al., 2018).  
The possibility that false negative results may have occurred during this study cannot be excluded. 
These were reported in The Gambia (Njai et al., 2015) and in Zambia (Chisenga et al., 2018). 
Low levels of HBsAg (median: 1.2 IU/ml; range: 0.8-25.5 IU/ml) (Njai et al., 2015), and low to 
undetectable viral load (Chisenga et al., 2018) were associated with the false negatives results 
described in these two studies. False negative results may also derive from poor compliance to the 
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recommended testing protocol. Inconsistencies in the use of capillary tube for finger-prick blood 
collection, the immediate application of the chase buffer to the sample pad of the test, and the 
recommended incubation period of the test were described as potential reasons for the low 
sensitivity of HIV rapid tests at the POC level in a previous South African study (Wolpaw et al., 
2010). A recent Zambian study also noted low accuracy levels among non-laboratory personnel 
such as lay counselors and nurses, during two HIV proficiency testing (PT) exercises using HIV 
rapid test as a possible cause of false RDT results (Mwangala et al., 2016). Occurrences of false 
negative, false positive and indeterminate results were higher amongst the non-laboratory 
personnel during both PT exercises. The authors noted an improvement in the accuracy level 
between the two PT exercises among the non-laboratory testers; the improvement was positively 
associated with HIV rapid testing training and adherence to the nationally recommended testing 
algorithm (Mwangala et al., 2016). The risk of obtaining false negative results from procedure 
errors was eliminated during this study by training the counselors prior to the commencement of 
the study and repeating a subset of the HBsAg negative rapid test results. Furthermore, HBV rapid 
testing at the ANCs was performed by HCWs and counselors who are experienced with HIV rapid 
testing using the Determine™ HIV-1/2 rapid test, and continuously go for HIV rapid test training 
as part of the PT exercises in place in Namibia. These data showed that where rapid testing is 
commonly used, training of the testers is vital for good accuracy level and reliability of the results 
communicated to the patients. Rapid testing training should be a continuous process rather than a 
once-off event. 
4.7.5.2 Qualitative assessment of HBsAg rapid screening 
Understanding the perspective and perception of HCWs towards the use of a new RDT, and the 
potential implementation of a new screening programme is also important to consider in the 
planning for an effective strategy for HBV screening. Using a structured questionnaire, this study 
also examined the opinion, ease of use and acceptability of the Determine™ HBsAg rapid test 
amongst the community counselors and nurses involved in the HIV PMTCT programme at the 
ANCs. Overall, these HCWs showed a positive response to the use of the rapid test. All felt 
confident in their use of the test and found similarities with the rapid test they use for HIV 
screening. The trust in regard to the results from the rapid tests was justified by the quality control 
programme and confirmation procedures that were established for the rapid testing during the 
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study. More importantly, they recognized the advantage of rapid testing for HBV over laboratory 
testing for they believed this method would be of low cost and would facilitate early detection and 
treatment of HBV for these pregnant women. These findings are similar to data from Zambia by 
Ansbro et al. (2015) (Ansbro et al., 2015). The authors looked at the feasibility of antenatal 
syphilis rapid testing by comparing the experiences from HCWs during a pilot study and following 
roll-out of the programme in four national districts. Across the two phases, implementing RDT for 
syphilis was accepted and encouraged by the HCWs. Good usability of the rapid test was also 
noted (Ansbro et al., 2015).  
Although the positive response of HCWs towards HBV rapid testing noted in this study is 
encouraging, it may not be generalized to all PMTCT nurses or community counselors in 
Windhoek, or across the country, owing to the small number of HCWs and ANCs examined. The 
integration of this programme in the existing antenatal services also need attention. Looking at the 
distribution of tasks at the ANCs participating to this study, the counselor and PMTCT nurses were 
only involved in the HIV PMTCT programme. This programme entails health education/group 
pre-test counseling, rapid testing and post-test counseling, ART therapy prescription and follow-
ups for HIV. Amongst other ANC services offered, the other ANC nurses were in charge of the 
collection of blood samples for the laboratory HBV test. Offering HBV RDT at the ANCs would 
lead to task shifting among the HCWs at the POC level. HBV PMTCT would be added to the HIV 
PMTCT programme that is currently being carried out by the PMTCT nurses and counselors at 
the ANCs. Adding HBV rapid testing may subsequently have an impact on the number of patients 
seen at the ANCs and lead to difficulties in integrating this service in the clinic’s workflow. 
Integration of HBV RDT in the provided ANC services would, thus, require political buy-in, the 
employment of more HCWs, and constant training to ensure effective scale-up and provision of 
this antenatal service for the benefits of HBV PMTCT.  
With regards to the end-user acceptability, four HCWs (4/6; 66.7%) reported a little anxiety, and 
two (2/6; 33.3%) noted high anxiety amongst patients towards receiving HBV rapid testing. Still, 
many patients were eager to receive their results and were happy to receive them after 15 minutes; 
as reported by the HCWs. For these reasons, added to the high rate of acceptance for participation 
in the study from the patients, the HCWs deemed this practice acceptable to the patient. Although 
the acceptance rate for HBV rapid testing was not quantified in this study, previous studies have 
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noted a high acceptability rate for this service at the POC level. A 93% rate of acceptance was 
reported in a recent antenatal South African study (Chotun et al., 2017), and a 68.9% acceptability 
rate was recorded in The Gambia among the general population (Lemoine et al., 2016). Buy-in 
from the patients is essential in the success of a screening programme. Additional investigations 
of the attitudes and perceptions of pregnant women towards HBV RDT would be useful to drive 
implementation of routine HBV antenatal screening in Namibia. Education may also serve as a 
powerful tool to empower these women and to drive policy-change with regards to rapid test-based 
antenatal screening nationally. RDTs are required to fulfill a set of criteria, known as ASSURED, 
for the implementation of an effective screening programme. The acronym stands for Affordable, 
Sensitive, Specific, User-friendly, Rapid and robust, Equipment free and Deliverable to end-users 
(Peeling et al., 2006). The Determine HBsAg rapid test showed a diagnostic sensitivity and 
specificity of 100%. Its ability to differentiate HBV-infected pregnant women from those who 
aren’t provided the opportunity to deliver adequate care to these pregnant women. The data 
collected from the HCWs informed on the ease of use of the rapid test and its delivery to the end-
user, in this case, the pregnant women. No extra equipment was needed to perform the rapid test 
during the study, and the 15-minute incubation period recommended by the manufacturers 
coincided with the incubation of the HIV rapid test in use at the ANCs. These results are suggestive 
of the compliance of the Determine HBsAg rapid test with the ASSURED criteria; which indicates 
its candidacy as an RDT for HBsAg screening at the POC level in Namibia and across SSA. 
4.7.6 Molecular characterization of HBV 
4.7.6.1 HBV DNA quantification using DBS samples 
The use of DBS as an alternative sampling approach offers the advantages of minimal 
infrastructure for storage and transport and stability at room temperature over blood sampling. This 
specimen type is particularly beneficial for pediatric testing, as it is currently done for neonatal 
HIV screening, and for scale-up of HBV diagnostic testing in remote areas with difficult access to 
centralized laboratories (Peeling et al., 2017; Chevaliez & Pawlotsky, 2018).  
DBS viral load testing was also assessed in this study, as a tool to determine the need for maternal 
ART for HBV PMTCT. Viral load quantification was performed using both DBS samples and 
serum samples of HBsAg positive pregnant women. Viral load measurements from antepartum 
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paired DBS and serum samples were compared. Of the 22 pairs available for analysis, six with 
undetectable HBV DNA in both serum and DBS were excluded. The mean viral load in the 18 
DBS samples analyzed was approximately 1.05 log10 IU/ml (95% CI: 0.68 - 1.42 log10 IU/ml) 
lower compared to viral loads in their matching serum samples. Although this difference was 
statistically significant, the difference in measurements between the two samples types remained 
within the limit of agreements of the mean average (-0.40 to 2.50 log10 IU/ml). The R2 = 0.89 
inferred from the linear regression analysis suggested a strong correlation between HBV DNA 
levels attained with the two paired sample types. The trendline was inferred using five out of the 
10 data points included in the analysis, which suggested a linear relationship between 
measurements attained with 2 DBS and serum, with HBV DNA levels in serum above 103 IU/ml. 
However, a larger dataset is needed to draw firm conclusions. 
The difference in HBV DNA levels observed between serum and DBS was not unexpected, 
considering the smaller input volumes of plasma in DBS (60 µl) in comparison to 650 µl used in 
plasma or serum testing. This phenomenon has been observed in other studies too, with the use of 
one spot (Mohammed et al., 2013; Stene-Johansen et al., 2016) or two spots (Vinikoor et al., 
2015). Aside from the low volume of plasma present in DBS samples, efficient elution of nucleic 
acid from the spots may also explain this difference in viral load and impacts the LoQ of the assay. 
Existing protocols suggest elution of DBS overnight at room temperature (Grüner, Stambouli & 
Ross, 2015; Mössner et al., 2015; Claassen et al., unpublished) or at high temperatures ranging 
from 56°C to 95°C for a duration of 10 minutes to 45 minutes (Mohammed et al., 2013; Vinikoor 
et al., 2015; Stene-Johansen et al., 2016) with continuous agitation. Through elution of one DBS 
with or without using high temperatures, the LoQ of the one DBS assay on the COBAS 
AmpliPrep/COBAS TaqMan HBV test Version 2.0 has been estimated at around 914 IU/ml (2.96 
log10 IU/ml) (Mohamed et al., 2013) and 843 IU/ml (2.93 log10 IU/ml) (Claassen et al., 
unpublished), respectively. Yet, while Vinikoor et al. (2015) described an LoQ of about 3 log10 
IU/ml (1000 IU/ml) using two DBS eluted at a high temperature, an increased LoQ of 3.85 log10 
IU/ml (7110 IU/ml) was observed in this study, as determined by the Probit analysis (95% hit rate). 
The increased LoQ of the assay using two DBS observed in this study was not expected 
considering that heating and incubation at room temperature with one spot has produced a 
comparable LoQ (Mohamed et al., 2013; Claassen et al., unpublished). Although the reduced 
analytical sensitivity (LoQ) of the assay did not impede on the ability to determine treatment 
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eligibility to avert HBV MTCT, the reasons behind this reduced sensitivity are worth further 
investigations. It should be noted that a low volume (500 µl) of the NIBSC 10/264 WHO standard 
was available, hence why the validation only included six replicates per concentration of the 
standard assessed. Given this relatively low number of replicates per concentration assessed, a 
95% CI of the LoQ of the assay could not be calculated in the Probit analysis. 
Translating to the clinical setting, these results showed that the two DBS assay could potentially 
assist in evaluating the need for antepartum antiviral prophylaxis against HBV MTCT at a viral 
load cut-off of 5.3 log10 IU/ml (200 000 IU/ml). With regards to non-pregnant women CHB 
patients, the assay also has the ability to assist in decision-making for treatment initiation using 
the WHO recommended threshold of 4.30 log10 IU/ml (20 000 IU/ml) (WHO, 2015). This level 
of viremia was consistently detected and quantified with dilutions of the NIBSC 10/261 HBV 
DNA standard, as represented in Table 4.5 above. It is worth mentioning that the WHO viral load 
threshold (4.30 log10 IU/ml - 20 000 IU/ml) was also used in the South African study by Chotun 
et al. (2017) (Chotun et al., 2017) to initiate maternal antiviral treatment against HBV MTCT, 
given that babies born to highly viremic mothers had no access to HBIG. Should this HBV DNA 
threshold be potentially used in future studies or in real-world settings, this DBS assay may also 
be useful in assessing the need for antenatal antiviral prophylaxis against HBV MTCT in SSA. 
Given that levels of HBV DNA of 3.30 log10 IU/ml (2000 IU/ml) could not be accurately quantified 
using two DBS, this assay would not be suitable if using viral load of 3.30 log10 IU/ml - 2000 
IU/ml as the threshold to determine HBV treatment eligibility in HBeAg-negative CHB patients, 
as per EASL guidelines (EASL, 2017).  
In view of these findings, it appears that HBV DNA quantification with one DBS is potentially a 
suitable alternative for serum or plasma HBV viral load testing. However, possibilities to increase 
the LoQ of DBS assays may be worth investigating. The utility of the COBAS plasma separation 
cards (Roche Diagnostics, Risch-Rotkreuz, Switzerland), recently launched for HIV diagnostic 
testing, may be explored as a substitute for HBV DBS testing to achieve lower LoQs.  
4.7.6.2 HBV genotyping and phylogenetic analysis: effects on HBV MTCT 
The HBV E viral strain was largely described in this study; representing 73% (8/11) of the strains 
identified in this HBV-infected antenatal cohort. Phylogenetic analysis showed close clustering of 
genotype E strains detected within this cohort with those isolated within the pediatric cohort 
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(Chapter 3), and other genotype E sequences described in Namibia and Angola. Further analysis 
of the evolutionary relationship between these E strains with those from West and Central Africa 
revealed the close proximity of the majority (12/14; 85.7%) of the study-specific sequences (six 
from the pediatric cohort and eight from this antenatal cohort) with isolates from Angola. While 
only two (2/14; 14.3%) appeared closely related to previous sequences from Namibia. The close 
grouping of E Namibian strains with Angolan strains may be interpreted as cross-contamination 
of the virus between Namibia and Angola. The virus may have been introduced within the 
Namibian population by Angolans moving in the country or by Namibians traveling between 
Angola and Namibia. Further work is needed to confirm this hypothesis.  
Interestingly, genotype E sequences from Namibia, Angola and the DRC clustered separately from 
genotype E strains isolated in seven other African countries namely Cameroon, CAR, Cote 
d’Ivoire, Ghana, Guinea, Niger, and Nigeria; situated in West/Central Africa. These two clusters 
are subsequently referred to as the “South-West African lineage” and the “West African lineage”; 
respectively. A similar observation has been previously noted, when comparing partial and full-
length genomic sequences of HBV genotype E viruses originating from the “genotype E crescent” 
(Hübschen, Andernach & Muller, 2008; Lago et al., 2014). Hübschen et al. (2008) detected a 
higher genetic diversity among E sequences from the “West African lineage” than compared to 
those from the “South-West African lineage”; suggesting that this genotype may have emerged in 
West Africa and spread towards the Southern part of the genotype crescent (Hübschen, 
Andernach & Muller, 2008).  
As opposed to the pediatric cohort studied in Chapter 3, where sub-genotype D3 viral strains were 
found, sub-genotype D1 viruses instead were isolated in the present antenatal cohort. These 
sequences fell within a cluster of D1 sequences isolated from different parts of the world but were 
more closely related to those from Sudan and India. Despite the wide global distribution of 
genotype D, D1 viruses are predominantly found in the Middle East and in Central Asia (Kramvis, 
2014), as well as in the northern part of Africa (Pourkarim et al., 2014). The D1 viruses found in 
this study demonstrated yet again the introduction of new genotypes in the region, possibly as a 
result of human migration. To our knowledge, this is the first description of these viral strains in 
Namibia. Increased migration in Africa may lead to the introduction of new genotypes from other 
parts of the region, creating a shift of the regional viral diversity. A clear example of this 
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phenomenon is the uncovering of genotype E in some European countries, introduced by 
immigrants originating from West Africa (Palumbo et al., 2007; Rivas et al., 2013).  
Similarly to the HBV-infected children described in chapter 3, pregnant women infected with 
genotype D presented with lower viral load and many were anti-HBe positive compared to women 
infected with genotype E. Bringing these observations to MTCT, a higher HBeAg seropositivity 
rate and viral load among pregnant women infected with genotype E may imply a higher risk of 
transmitting HBV to their infants compared to women infected with genotype D. This is further 
demonstrated by the recent systematic and meta-analysis by Keane et al. (2016). In their 
heterogeneity analysis, the authors observed a higher risk of HBV MTCT in West Africa, where 
genotype E predominates, as opposed to East Africa (66.4% vs. 21.2%; respectively) where 
genotypes A and D are found (Keane et al., 2016). However, this hypothesis needs further 
investigation.  
4.7.6.3 Surface gene mutations 
The small surface L216* stop codon was detected in a genotype E infected pregnant woman. This 
protein change has been observed in the past amongst NRTIs treated and NRTIs naïve patients 
(Margeridon-Thermet et al., 2009), caused by silent mutations in the overlapping RT region. Its 
clinical significance is unknown and requires further exploration. In addition to the L216* stop 
codon, a 15 bp deletion in the pre-S2 region spanning from aa 137 to aa 141 was detected in this 
genotype E virus. A similar deletion pattern has been observed among HCC patients infected with 
genotype E viral strain in Sudan (Yousif et al., 2013). A positive correlation between the presence 
of pre-S deletions with HCC has been demonstrated amongst CHB patients infected with either 
genotype B or C in numerous Asian studies (Chen et al., 2006b; Fang et al., 2008; Qu et al., 
2014a; Zhang, 2017). The deletion found in this E viral strain infected patient spans part of the B 
cell epitope situated in the pre-S2 region (aa 120-145). Selection of this deletion may form part of 
the viral mechanism for immune evasion, thereby causing accumulation of pre-S2 defective 
viruses in the endoplasmic reticulum of type II ground glass hepatocytes (Wang et al., 2003). 
Accumulation of these defective proteins in the endoplasmic reticulum is known to induce 
oxidative stress that subsequently activates a number of signaling pathways associated with the 
development of HCC (Pollicino et al., 2014). The deletion also spans part of the transactivator 
domain in the pre-S2 region (aa 120 to aa 172) (Chen et al., 2006b); which may also play a role 
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in hepatocarcinogenesis. While there is limited data on the clinical impact of pre-S deletions and 
mutations in HBV chronically infected patients in SSA, findings from Asian studies suggest that 
patients with viral polymorphisms in that genomic region may be at a higher risk of developing 
HCC. Additional studies are required in SSA to establish the prevalence, pathogenesis and clinical 
impact of these mutants among African chronic carriers of HBV. 
4.7.6.4 X and core gene mutations 
Pre-C mutations 
The G1896A (W28*) stop codon was detected in 61.5% (8/13) of the antenatal HBV cases. All 
the pregnant women with pre-C sequences carrying this mutant were HBeAg negative; and its 
presence in conjunction with other core mutants may be a risk factor for hepatocarcinogenesis 
(Jang et al., 2012; Lyu et al., 2013; Park et al., 2014). This hypothesis was further explored by 
Malik et al. (2016) among a spectrum of liver diseases including acute HBV infection, fulminant 
hepatitis, CHB, liver cirrhosis, and HCC. The authors noted a higher rate of the G1896A mutant 
among HCC patients (17/18; 94.4%) and those with fulminant hepatitis (18/21; 85.7%); 
demonstrating that this mutant may be a risk factor for the development of severe liver disease 
(Malik et al., 2016). Furthermore, two isolates harboring the G1896A mutant were accompanied 
by the G1899A nucleic acid mutation, corresponding to the G29D aa change. The combined 
presence of these two variants did not appear genotype-specific. One sub-genotype D1 virus 
(M190) harbored the start codon mutation G1816T that induced the translation of the isoleucine 
instead of the methionine start codon (M1I). Pre-C start codon mutations have been predominantly 
described amongst HBV A1 infected patients (Li et al., 1993; Makondo et al., 2012; Mayaphi 
et al., 2013), but rarely in those infected with non-A genotypes (Sendi et al., 2005; Flichman et 
al., 2009); suggesting that its presence may be the main contributing factor to the HBeAg negative 
infection in patients infected with A1 viruses (Mayaphi et al., 2013). In agreement with these 
studies, the presence of this mutant may explain the negative HBeAg serostatus of this pregnant 
patient (M190). Other than point mutations, a single nucleotide insertion was also detected in a 
genotype E HBeAg negative strain (M174). An adenine (A) was inserted between nucleotide 1839 
and nucleotide 1840. This insert has been previously described in liver tissue samples of HBeAg 
negative chronic carriers of HBV (Dienes et al., 1995) and among HBeAg negative HCC patients 
as well (Kramvis, Kew & Bukofzer, 1998). However, these two studies did not mention the 
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genotypes in which the insert was identified, nor discussed the potential clinical impact of this 
insert. The lack of information regarding this nucleotide insert may warrant additional 
investigations.  
Core promoter (CP) mutations  
The point URR mutation C1678T occurred in 46% (6/13) of the antenatal HBV cases described in 
this study. Another sample presented with one bp deletion in the CURS. The deletion abrogated 
translation of the aa threonine (T) at position 105. Given the scarcity of data on the pathogenesis 
of viral changes in the URR, the impact of this deletion on viral replication is unknown.  
In the BCP region, the most known double A1762T/G1764A BCP mutation happened in 14% 
(3/13) of the HBV antenatal patients. Functional characterization of these viral mutants has 
demonstrated its association with enhanced viral replication (Hussain et al., 2009; Khatun et al., 
2018). In a number of instances, A1762T/G1764A has been observed at higher rates among HCC 
patients compared to chronic HBV carriers (Baptista, Kramvis & Kew, 1999; Tong et al., 2007; 
Yang et al., 2016); suggesting that persistence of the mutant may play a role in liver damage. 
Interestingly, the T1753C mutant occurred as a single mutation amongst D1 viruses. In sequences 
from genotype E strains, the mutant was found in combination with other BCP mutation such as 
the double A1762T/G1764A BCP mutant in patient PG196, and both A1752T (A1752T/T1753C) 
and A1762T/G1764A BCP mutants in patient M99. BCP mutations were recently investigated 
across four clinical phases of HBV infection namely: inactive HBV carriers, active HBV carriers, 
liver, cirrhosis and HCC patients by a Saudi Arabian study. Seventy-nine percent (79%) of the 
patients included in the study were infected with genotype D. The authors found an increased 
frequency of the triple T1753C/A1762T/G1764A as the clinical phase of the infection progresses. 
The mutant appeared in 46.4% (13/28) of the HCC cases compared to 11.5% (3/26) in liver 
cirrhosis patients, 9.4% (23/245) of inactive HBV carriers and 8.8% (11/125) in active HBV 
carriers (Al-Qahtani et al., 2017). Findings from Al-Qahtani et al. (2017) are suggestive of an 
increasing selection of BCP mutants as CHB progresses to HCC, and are similar to results from 
genotypes B and C Asian studies. Extrapolating from those studies, a similar trend may happen 
amongst genotype E infected patients. In addition to point mutations, insertion of an adenine (A) 
at nt 1766 happened in another E strain. Point mutations at this site are well described, and 
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deletions of a nucleotide at this position were recently reported (Salarnia et al., 2017). 
Interestingly, this sequence also harbored an internal core deletion, as described below.  
Core gene mutations 
A single in-frame deletion of the HBV core protein was observed in one pregnant woman, infected 
with a genotype E viral strain. The deletion truncated the gene by 30 aas, spanning from aa 89 to 
aa 119. The HBV core gene contains a number of epitopes involved in the human immune response 
against HBV such as the CD4+ T cell, cytotoxic T lymphocyte (CTL) and B cell recognition 
epitopes, situated within the first 155 aa of the gene (Vanlandschoot, Cao & Leroux-Roels, 
2003). As described elsewhere (Zhu et al., 2012; Xia, Zou & Liu, 2016), the truncated fragment 
of the core gene observed in this patient affected both the B cell epitope (aa 107 to aa 118), and 
the CTL epitope (aa 88 to aa 96) found in the sequence of the core gene. Previous data have shown 
that hepatocytolysis could be triggered through recognition of the CTL epitope by HLA-A11-
restricted CD8+ T-cells (Tsai et al., 1996). Where these epitopes are not expressed, viral immune 
evasion may occur, and lead to immune tolerance. Moreover, truncation of the B-cell epitope 
region may result in ineffective recognition of HBcAg by the B-cells, resulting in on-going 
infection. These findings suggested that deletions in the core gene may play a role in viral immune 
escape, and be a contributing factor to on-going chronic infection. Functional characterization of 
this deletion pattern is required to confirm these hypotheses.  
4.8 Strengths and limitations of the study 
This is the first study in Namibia looking at the effectiveness of preventing HBV MTCT. The large 
sample size of pregnant women available for HBV screening enabled generating updated statistics 
on the prevalence of HBV infection in the Namibian antenatal population and provided feasibility 
data for the implementation of rapid-test based screening for HBV in Namibia and possibly across 
the rest of SSA. This large research study was conducted at primary healthcare facilities and 
involved local HCWs rather than a dedicated research workforce. Involving the local HCWs 
enabled us to assess the feasibility of implementing rapid-test based HBsAg screening in the 
current health system, and to identify gaps related to HBV antenatal care in this health system. The 
study combined medical virology and epidemiology to answer the important public health problem 
that HBV MTCT is in SSA. And, through this project, interdisciplinary knowledge was generated.  
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The study also presents with a few limitations that could have influenced the interpretations of its 
findings. The use of HBsAg seropositivity, instead of anti-HBc (total) seropositivity, as case 
definition for HBV infection may have not been ideal for the accurate measure of risk factors 
associated with HBV infection in pregnant women. Using anti-HBc (total) seropositivity as case 
definition for HBV infection would have enabled us to take into consideration both current and 
resolved HBV infections in this analysis. However, given that resolved HBV infections do not 
impact on HBV MTCT, anti-HBc (total) testing was not performed for HBsAg negative pregnant 
women. Moreover, the small sample size of HCWs questioned for the qualitative assessment of 
rapid-test based HBsAg screening may not allow for the generalizability of these findings to other 
primary healthcare facilities across Namibia. The challenges associated with logistics are also 
highlighted. For instance, given that HBV viral load and HBeAg testing were not available in 
Namibia, samples needed to be sent to the Division of Medical Virology for testing. Due to the 
high costs associated with the shipping of biological samples, these samples were sent in batches 
and brought a delay in the turnaround time for the assessment of maternal antiviral treatment 
eligibility.  
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CHAPTER 5: A cost-effectiveness analysis of strategies for the prevention of mother-to-
child transmission of HBV in Namibia  
This chapter reports on the economic evaluation of preventive strategies against HBV MTCT in 
the context of Namibia. These strategies include combinations of different preventive measures 
such as screening, immunization, and maternal antiviral prophylaxis.  
5.1.  Introduction 
Prevention of HBV MTCT in SSA may require a combination of various health interventions. The 
feasibility of these interventions would depend on the local endemicity of the infection, and more 
importantly on the availability of resources (costs) and the health outcomes associated with these 
interventions. Costs and health outcomes are examined through economic evaluations. These 
evaluations provide a framework for the allocation of scarce resources to health programmes. As 
explained in Chapter 2, economic evaluations compare the costs and health benefits of two or more 
health interventions, usually in terms of an incremental cost-effectiveness ratio (ICER). The ICER 
is considered as the price of health benefits gained through an intervention, and as such is 
compared to a threshold (the WTP threshold) to determine whether or not the intervention is cost-
effective. A number of thresholds have been suggested and include the WHO-CHOICE-
recommended one to three times country’s GDP per capita (WHO, 2002; Hutubessy, Chisholm 
&Edejer, 2003), and the World bank-recommended threshold of $150 to $200 per DALYs averted 
(World Bank, 1993). ICERs below the WTP threshold are considered cost-effective, while those 
above the threshold are not (Drummond et al., 2015). 
There is limited knowledge on economic evaluations of interventions against HBV MTCT in SSA. 
Previous economic evaluations have mainly focused on the implementation of universal infant 
vaccination starting at birth in comparison to infant vaccination starting at six weeks after birth 
(Griffiths, Hutton & Pascoal, 2005; Kim, Salomon & Goldie, 2007; Klingler, Thoumi & 
Mrithinjayam, 2012; Anderson et al., 2018; Hecht et al., 2018). These economic analyses are 
all in agreement regarding the low costs and substantial benefits of universal BD vaccination for 
preventing HBV perinatal transmission in SSA, as opposed to the current practice of vaccination 
from six weeks. Drawing from the Asian experience and results from a number of clinical trials in 
that region, BD vaccination alone may not be enough given the increase in effectiveness when it 
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is combined with HBIG (Beasley et al., 1983b, Lee et al., 2006, 2007). The combination of these 
two immunoprophylactic measures, alongside routine antenatal screening, is the current standard 
of care in many high-income countries. This strategy has been shown to be cost-effective in those 
settings (Chen et al., 2013c; Barbosa et al., 2014; Chen et al., 2016; Fan et al., 2014). In low-
income countries, the issue of costs and cold chain storage limit access to both the BD vaccine and 
HBIG. As a high HBV endemic region with an HBsAg prevalence ≥ 6% (WHO, 2017a), routine 
serological testing of HBsAg of pregnant women has been supported by the WHO (WHO, 2017d). 
Yet, this practice is mainly offered in high-income countries, where the HBV endemicity is lower 
than in SSA. Screening of HBsAg of the general population was found cost-effective in The 
Gambia (Nayagam et al., 2016a). However, the cost-effectiveness of this practice within the 
antenatal population in SSA is unknown. The costs and health outcomes associated with the 
implementation of BD vaccination combined with HBIG in SSA are also unknown. Babies born 
to mothers with high levels of HBV DNA are still at risk of acquiring HBV perinatal infection, 
despite timely administration of the HBV BD vaccine and HBIG (Wiseman et al., 2009; Sellier 
et al., 2015). The addition of maternal antiviral prophylaxis to active and passive immunization to 
eliminate this residual risk of transmission has been studied, and has been considered cost-effective 
(Hung & Chen, 2011; Fan et al., 2016; Lee, Shin & Park, 2018). The value of this strategy (both 
costs and health benefits) has also not been explored in SSA. 
5.2.  Study aims 
5.2.1. Primary aim 
The primary aim of this study was to assess the costs and effectiveness of rapid test-based HBsAg 
antenatal screening combined with maternal ART for HBV-infected pregnant women presenting 
with high HBV viral load, and pediatric active-passive immunization for the prevention of HBV 
MTCT in Namibia. 
5.2.2. Secondary aim 
The secondary aim of the study was to evaluate the costs and health benefits of universal BD 
vaccination, and the combination of BD vaccination and HBIG in the Namibian antenatal 
population.  
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5.2.3. Objectives 
These study aims were attained through completion of the following objectives: 
• Estimating the costs and outcomes of each strategy considered in this analysis, 
• Estimating the ICER of these strategies, 
• Interpreting the calculated ICERs for decision-making. 
5.3. Materials and methodology 
5.3.1. Target population and study setting 
This economic evaluation was conducted alongside the antenatal study described in Chapter 4. 
Briefly, pregnant women attending for their first ANC visit were enrolled in the study at two public 
primary healthcare ANCs in Windhoek, Namibia. Antenatal care provided to pregnant women at 
their first ANC visit includes testing for HBV. Venipuncture is applied for sample collection. The 
HBV test is performed at the national laboratory with a diagnostic assay. HBV-exposed babies 
receive active immunization in the form of a vaccine, and passive immunization using HBIG at 
birth (MoHSS, 2014a). Babies born to HBV negative mothers receive a BD of the HBV vaccine, 
only, as per the current childhood EPI schedule (WHO, 2018). All medical expenses throughout 
this process are covered by the Namibian Ministry of Health and Social Services (MoHSS). 
5.3.2. Comparator strategies  
Based on the current health strategy against MTCT of HBV documented as a policy in Namibia, 
four health strategies were considered in this analysis. All interventions included timely BD 
vaccination. These strategies are summarized in Figure 5.1 and are detailed as follow: 
Strategy 1: Universal HBV BD vaccination 
All infants are vaccinated at birth against HBV. Vaccination is completed, regardless of maternal 
HBsAg status. 
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Strategy 2: Universal BD vaccination and targeted HBIG 
Pregnant women attending their first ANC visit are screened for HBsAg, using the DetermineTM 
HBsAg rapid test. Infants born to HBsAg positive mothers receive HBIG and the HBV vaccine at 
birth. Infants born to HBV-uninfected pregnant women receive the HBV BD vaccine alone.  
Strategy 3: Universal BD vaccination, HBV viral load testing, maternal antiviral prophylaxis 
and targeted HBIG 
In this strategy, pregnant women receive antenatal screening for HBsAg via rapid testing at the 
ANC, and a blood sample is collected from the HBsAg positive patients for HBV viral load testing 
at the laboratory. The viral load test serves to assess both the risk of perinatal transmission and the 
need for maternal ART against HBV to prevent HBV MTCT. According to the 2016 AASLD 
guidelines on the management of chronic HBV infection (Terrault et al., 2016), pregnant women 
with a viral load from 200 000 IU/ml are eligible for ART with a 300 mg daily dose of TDF, 
starting from the third trimester of pregnancy. Antiviral prophylaxis is, thus, initiated from the 
third trimester (26 – 28 weeks) of pregnancy to women presenting with HBV DNA levels ≥ 
200 000 IU/ml at the ANCs. Treatment is stopped at one month postpartum; as previously 
described (Celen et al., 2013; Chen et al., 2015; Pan et al., 2016). Pediatric post-exposure 
prophylaxis includes HBIG and BD vaccination. Babies born to HBV-uninfected pregnant women 
receive birth vaccination against HBV alone.  
Strategy 4: Universal BD vaccination, HBeAg testing, maternal antiviral prophylaxis, and 
targeted HBIG 
Following HBsAg screening with the Determine HBsAg rapid test at the clinic, a serum sample is 
collected from HBsAg positive pregnant women for HBeAg testing at the laboratory. HBeAg is 
used here as a surrogate marker to assess viral replication in the infected pregnant women. Those 
testing positive for HBeAg are offered ART with a 300 mg daily dose of TDF for four months; as 
per the schedule described in strategy 3. HBIG and HBV BD vaccination are administered to HBV-
exposed babies, whilst BD vaccination alone is provided to HBV-unexposed babies. 
The rapid test-based screening methodology, instead of laboratory testing for HBsAg, was used in 
the testing strategies because it was assumed that parts of Namibia and many settings in SSA would 
not be able to provide and sustain routine laboratory testing for HBsAg. These settings would be 
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able to implement HBsAg rapid testing through the infrastructures that are already in place for 
HIV rapid testing. Furthermore, the use of plasma samples, as the standard biological specimen 
for HBV viral load testing at the laboratory was included in this analysis. 
  
Figure 5.1: Study strategies for the prevention of mother-to-child transmission of HBV. BD: birth 
dose; HBIG: hepatitis B immunoglobulin; HBeAg: hepatitis B e antigen; HBsAg: hepatitis B surface 
antigen; HBV: hepatitis B virus; TDF: tenofovir disoproxil fumarate. 
5.3.3. Perspective and time horizon 
This CEA was performed from the perspective of the Namibian MoHSS, the healthcare service 
provider. Thus, only the direct medical costs involved in the study strategies were taken into 
consideration. The time horizon for the analysis was one year, during which all activities were 
performed and health outcomes measured.  
Strategy 1 - Universal BD vaccination
•Prenatal HBV screen: No
•Maternal antiviral prophylaxis: No
•Universal birth dose vaccination
Strategy 2 – Universal BD vaccination + targeted HBIG
•Prenatal HBV screen: HBsAg rapid test
•Maternal antiviral prophylaxis: No
•Paediatric immunization
•HBV-exposed babies: HBIG + BD vaccine
•HBV-unexposed babies: birth vaccine only
Strategy 3 - Universal BD vaccination + HBV viral load testing + maternal antiviral prophylaxis
+ targeted HBIG
•Prenatal HBV screen: HBsAg rapid test + HBV viral load testing of HBsAg positive women
•Maternal antiviral therapy: Yes, indicated for high HBV viral load
•Paediatric imunization
•HBV-exposed babies: HBIG + BD vaccine
•HBV-unexposed babies: birth vaccine only
Strategy 4 - Universal BD vaccination + HBeAg testing + maternal antiviral prophylaxis + 
targeted HBIG
•Prenatal HBV screen: HBsAg rapid test + HBeAg testing of HBsAg positive women
•Maternal antiviral therapy: Yes, indicated for HBeAg positive
•Paediatric imunization
•HBV-exposed babies: HBIG + BD vaccine
•HBV-unexposed babies: birth vaccine only
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5.3.4. Costing methodology  
Costs were estimated based on information collected at both Windhoek Central hospital ANC and 
Intermediate Katutura hospital ANC for the financial year April 2016 to March 2017. The cost-
analysis was completed using a mixed methodology consisting of micro-costing and gross-costing; 
as performed in previous economic evaluations (Hendricks et al., 2014; Cunnama et al., 2016). 
Micro-costing, also referred to as ingredient costing, was applied to identify, measure and value 
all inputs (and their usage) used for providing HBsAg rapid testing at the POC level and maternal 
antiviral prophylaxis with TDF. Conversely, building space, furniture, and clinic overheads were 
computed using gross costing; whereby total expenditures were taken and allocated to a unit cost 
based on allocation factors (Conteh & Walker, 2004). Resource usage was collected 
prospectively through observation and timing of processes during the recruitment period of the 
antenatal study (Chapter 4).  
The costs of assessing infant HBV status postpartum were not taken into consideration, as this 
practice is unlikely to be incorporated as part of pediatric care for infants born to HBV-infected 
mothers. Intervention start-up costs related to rapid test training, the shipping of materials from 
Cape Town to Windhoek, and the design of materials for the rapid testing QA were excluded from 
this analysis. These start-up activities were performed during the antenatal study described in 
Chapter 4 and may vary according to national standards. The future costs of managing or treating 
the sequelae of CHB were also not taken into consideration. 
Costs incurred in each study alternative were classified, depending on the duration of usage of the 
resources used in service delivery. Resources used up in less than a year are referred to as recurrent 
items, while those that last for more than a year are known as capital items. Capital and recurrent 
items involved in the activities and included in the considered strategies were identified, measured 
and valued. The various types of costs considered in this analysis are presented in Table 5.1. 
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Table 5.1: Classification of costs by activities performed in health interventions  
Rapid-test based HBsAg screening  
A. Capital costs B. Recurrent costs 
Clinic 
- Space 
- Furniture 
Consumables 
- HBV rapid test kit 
- Capillary tubes 
- Chase buffer 
- Finger prick consumables 
Clinic human resources 
- HBV pre-test and post-test counseling time (donated)* 
- Community counselor or PMTCT registered nurse 
time for the RDT (donated)* 
Overheads (utilities) 
Laboratory HBV diagnostic 
assessment 
 
A. Capital costs B. Recurrent costs 
Clinic 
- Space 
- Furniture 
Blood collection consumables 
HBV laboratory diagnostic tests: HBeAg, and HBV 
viral load 
Clinic human resources 
-Registered PMTCT nurse time – blood sample 
collection (donated)* 
Overheads (utilities) 
Maternal antiviral prophylaxis  
A. Capital costs B. Recurrent costs 
Clinic  
- Space 
- Furniture 
Laboratory tests: Creatinine, full blood count, ALT, and 
AST 
HBV treatment: TDF  
Clinic human resource  
- Consultation with the Medical Officer (donated)* 
Overheads (utilities) 
Pediatric immunoprophylaxis  
A. Capital costs B. Recurrent costs 
NA HBIG 
BD HBV vaccine 
*The time donated by these HCWs was costed for the purpose of this economic evaluation. ALT: alanine 
transaminase; AST: aspartate transaminase; BD: birth dose; HBIG: hepatitis B immunoglobulin; HBeAg: 
hepatitis B e antigen; HBsAg: hepatitis B surface antigen; HBV: hepatitis B virus; NA: not applicable; 
PMTCT: prevention of mother-to-child transmission; RDT: rapid diagnostic testing; TDF: Tenofovir. 
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5.3.4.1. Measurement and valuation of capital costs  
The capital resources used to perform screening of HBsAg using rapid testing, to collect blood for 
HBV laboratory confirmation (HBeAg and HBV viral load), and to provide maternal antiviral 
prophylaxis were identified at the healthcare facility level. These included the furniture and the 
space used in each of these activities at the ANCs.  
Rapid testing was broken down in three sub-activities: pre-test counseling (also known as health 
education), rapid testing, and post-test counseling. Each of these sub-activities was performed in 
three different rooms. At both ANCs, the testing room was also used to collect blood samples for 
HBV laboratory testing. A consultation with a medical officer was required for the prescription of 
maternal antiviral prophylaxis. At Intermediate Katutura hospital ANC, the consultation with a 
medical officer took place in a separate room, while the post-test counseling room was also used 
for this additional activity at Windhoek Central hospital ANC. The length and width of these four 
rooms (pre-test counseling room, rapid testing room, post-test counseling room, and consultation 
room) were measured. The cost of each room was inferred by multiplying the area (m2) of each 
space by the cost per m2. The cost/m2 was obtained from a construction company (WV 
Construction (Pty) Ltd, Windhoek, Namibia). The furniture in each room was noted down, and 
replacement prices were obtained from furniture companies, such as Waltons and Officeconomix, 
in Windhoek, Namibia. These capital costs were annuitized using a 7% discount rate per year, 
allowing the depreciation aspect and the opportunity cost aspects of these items to be incorporated 
into their costs. The annuitization discount rate (7%) represented the average interest rate between 
April 2016 and March 2017 in Namibia. Buildings were expected to have a life expectancy of 30 
years and equipment 2 to 15 years. The life expectancy and the discount rate (7%) were used to 
determine the annuitization factor of each item, using the discount table by Drummond et al. (2015) 
(Drummond et al., 2015). The formula of this calculation is presented in Box 5.1 below.  
The unit cost of each activity, in terms of space and furniture, was estimated based on allocation 
factors. All first ANC patients were assumed to receive pre-test counseling. The annual number of 
first ANC visits was obtained from each ANC and was used for the allocation of pre-test 
counseling capital costs (both space and furniture). As an example, cost/pre-test counselling = 
(total costs of furniture + total costs of space) / total number of first ANC visits. Post-test 
counseling capital costs were also allocated based on the annual number of first ANCs at 
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Intermediate Katutura hospital ANC. The space and furniture in the post-test counseling room at 
Windhoek Central hospital ANC were shared between post-test counseling and for consultations 
with HBsAg pregnant women who required ART against HBV. Time was used as an allocation 
factor for these two activities at Windhoek Central hospital ANC. The total costs of furniture of 
this shared space were divided by the combined time spent on both activities, annually, to estimate 
a cost per minute of usage of the room. This cost was multiplied by the average time usage per 
each activity to calculate a cost per consultation and a cost per post-test counseling session. The 
same methodology was applied to allocate space costs of this room to these two activities. The two 
unit costs, in terms of furniture and space, were summed to obtain the capital cost per minute for 
the post-test counseling activity at the Windhoek Central ANC (See Box 5.1). Similarly, because 
the testing room was also shared for both HIV and HBV rapid testing and phlebotomy at both 
clinics, time was also used as an allocation factor. The allocation was performed following the 
methodology used to allocate the costs of the post-test counseling room at Windhoek Central 
hospital ANC, following the equations represented in Box 5.1. It is noteworthy that the annual 
time spent in the shared testing room at both clinics and the shared post-test counseling room at 
Windhoek Central hospital ANC would be different for the different strategies included in this 
economic evaluation. In strategies 1 and 2, the annual time usage of the testing room would be an 
addition of the total time to perform HIV and HBV rapid testing, annually. In strategies 3 and 4, 
this would be an addition of the total annual time spent on HIV and HBV rapid testing plus the 
time usage for collecting blood samples for HBV viral load or HBeAg laboratory tests. Similarly, 
the yearly time usage of the post-test counseling room at Windhoek Central hospital ANC in 
strategies 1 and 2 would only represent the annual time spent on post-test counseling for both HBV 
and HIV. In strategies 3 and 4, the time usage would be an addition of the annual time spent on 
post-test counseling for HBV and HIV with the annual time spent for consultation for maternal 
antiviral prophylaxis. These consultations took place in a dedicated room at the Intermediate 
Katutura hospital ANC. The consultation room at the Intermediate Katutura hospital ANC was 
also used for many other activities. Given that the details regarding the types and schedule of these 
other activities were unknown, the total number of minutes during which this room is used in a 
year was estimated. It equated to the annual number of minutes during which the clinic is open. 
The room was assumed to be used for six hours (360 minutes) of a day for 247.25 days, which 
represented the annual total number of working days (number of days in the year – number of 
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weekends – annual number of public holidays) – equating to 89 010 minutes in a year. The total 
costs of space and furniture of this area were divided by the annual time usage to infer a cost per 
minute for the usage of this area. This cost was multiplied by the average time of consultation for 
HBV ART to estimate the unit cost of this activity at the Intermediate Katutura hospital ANC 
(Refer to Box 5.1). 
Box 5.1: Formulae for capital annuitization and capital costs allocations 
 
A. Formulae for capital annuitization 
Annuitization factor = 
1−(1+𝑟)−𝑛
𝑟
. Where n is the useful life of the capital item, r is the interest rate (7%) 
EAC = R / annuitization factor. Where, EAC is equivalent annual cost of each capital item; R is the 
replacement price of the capital item.  
B. Formulae for allocating shared costs 
(1) Post-test counselling room at Windhoek Central Hospital ANC 
- Cost/minuteroom = 
Total EACs of furniture + Total EACs of space
Annual time post−test counselling + Annual time consultations
 
- Cost/medical consultation = Cost/minuteroom X average time per consultation  
- Cost/post-test counselling = Cost/minuteroom X average time per post-test counselling 
(2) Rapid testing room at both ANCs 
- Cost/minuteroom = 
Total EACs of furniture + Total EACs of space
Annual time HBV rapid test + Annual time HIV rapid test+Annual time phlebotomy
 
- Cost/HBV rapid test = Cost/minuteroom X average time per rapid test 
- Cost/Phlebotomy = Cost/minuteroom X average time per phlebotomy 
(3) Consultation room at Intermediate Katutura ANC  
Cost/minuteconsultation room = (total costs of space + total costs of furniture) / 89010. Where 89010 
represents the total number of minutes during which the room was used in a year. 
- Cost/medical consultation = Cost/minuteconsultation room X average time of consultation 
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5.3.4.2. Measurement and valuation of recurrent costs  
Recurrent items included consumables and human resources involved in the activities of all 
strategies. The quantification of resource usage was documented through timing and observation 
of processes, in the context of the antenatal study. 
HBsAg screening 
Recurrent resource use related to HBsAg screening included the rapid test kits, the chase buffer, 
the capillary tubes, other miscellaneous disposable materials used for finger-prick, and the 
healthcare workers (HCWs) time.  
The prices of the rapid test kits, the chase buffer, and the capillary tubes were obtained from 
Analytical Technology & Chemical Supply Pty (Ltd) (Windhoek, Namibia), the supplier of the 
DetermineTM HBsAg rapid test in Namibia. The prices of miscellaneous disposable items such as 
latex gloves, alcohol swabs, absorbent workspace covers, and biohazard waste-disposal bags were 
obtained from quotes supplied by biomedical and medical companies in Windhoek. With regards 
to personnel costs, the level of qualification and the type of HCWs performing counseling (pre- 
and post-test) for HBV rapid testing and the testing itself were noted. The type of HCWs involved 
in this activity included community counselors and the registered HIV PMTCT nurses at the 
ANCs. Hands-on time for each component of the HBV screening (pre-test counseling, testing, 
post-test counseling for HBV negative and HBV positive patients) was observed and recorded 
during the recruitment period of the antenatal study at the ANCs. Personnel costs were calculated 
based on (1) the average time estimates of each sub-activity of the rapid testing procedure, and (2) 
the average public sector annual wage in Namibia, per personnel type. The average time spent on 
HBV rapid testing was presumed the same at both clinics due to the lack of substantial time and 
motion data from Windhoek Central hospital ANC. The HCWs average annual wages were 
obtained from the health facilities where the antenatal study took place. The annual wages of each 
personnel type were divided by the yearly average patient-contact time (in minutes) to estimate 
the average hourly pay (or pay per minute) of each personnel type. These were multiplied by the 
average time spent on each component of the rapid testing procedure (pre-test counseling, testing, 
and post-test counseling). The costs of each component were added to estimate the cost of 
performing HBsAg rapid testing, for each personnel type involved in this activity. 
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Laboratory HBV confirmatory diagnostic testing  
These costs were measured at both the ANC and laboratory levels. Recurrent items used at the 
ANC level included blood collection consumables such as phlebotomy equipment (needles, blood 
tubes), and the personnel time (the registered nurse collecting blood) for blood sample collection.  
The time to collect blood from HBsAg positive patients at the clinic for HBV viral load or HBeAg 
test was assumed to take approximately 10 minutes. The duration of this activity also took into 
consideration the filling of forms and sample packaging. This time estimate was assumed owing 
to the lack of time and motion data. Time costs were calculated as described above for the HBsAg 
screening activity.  
At the laboratory level, the prices charged by the Namibia Institute of Pathology for the HBeAg 
test and the HBV viral load test were used.  
Maternal antiviral prophylaxis 
Resources incurred here included (1) the HCW time for assessing eligibility for treatment with 
TDF, (2) the laboratory tests completed while initiating the eligible patient on TDF, and (3) the 
four-month course of the ART drug (TDF).  
The laboratory tests performed during initiation of TDF were creatinine, full blood count, ALT, 
and AST. The creatinine test served to assess the kidney function, while full blood count, ALT, 
and AST tests were used as non-invasive markers to assess liver fibrosis. These prices were 
obtained from the Namibia Institute of Pathology. 
The consultation with the medical officer, the HCW involved in this activity, was presumed to 
take an average time of 20 minutes. This average time was multiplied by the average public sector 
salary of a medical officer in Namibia.  
The price of the four-month course of TDF (30 tablets for a month, each tablet is a 300 mg dose) 
was obtained by multiplying the unit cost of a month’s prescription (public sector charges) by the 
total number of months (four) of the pregnant woman’s treatment.  
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Pediatric immunoprophylaxis 
The prices of a dose of HBIG and of the HBV BD vaccine were used for costing, based on the 
Namibian public sector charges. An ingredient costing of the HCW's time was not completed due 
to the lack of time and motion data. These data were not recorded given the absence of a researcher 
on site during deliveries of HBV-exposed babies. The HBV vaccination series is completed with 
three subsequent doses of the HBV vaccine at six, 10 and 14 weeks of the infants, given as a 
combined vaccine. These costs, common to all strategies, were not included in the analysis. 
5.3.4.3. Measurement and valuation of overhead costs 
Overheads included items such as electricity, water usage, cleaning, security, telephone usage, 
transport, waste disposal, repairs, and maintenance. These annual expenses were collected from 
each hospital. This costing was completed through a top-down approach whereby overall 
expenditures at a central level were allocated to each ANC patient. The total number of patient day 
equivalent outpatient (PDE-outpatient) visits at each hospital was used as the allocation factor. 
PDE-outpatient visits were calculated using the total number of outpatient visits and total inpatient 
days during the 2016/2017 financial year, following the formula presented in Box 5.2. The 
overhead items included in the analysis differed from each hospital but were based on actual 
spending incurred at each health facility. For each hospital, the costs of each overhead item were 
summed and divided by the total number of PDE-outpatients to obtain a cost per ANC visit (Refer 
to Box 5.2).  
As mentioned above, all costs were inferred using the financial year 2016/2017 as the base year. 
Costs obtained during the year 2018 were deflated to 2017 using the 2016/2017 average consumer 
price index (CPI); by dividing the 2018 prices by the decimal value of the CPI. The 2016/2017 
average CPI was calculated by adding CPIs of April 2016 through March 2017, and the sum was 
divided by 12. The decimal value of the CPI was inferred by dividing the nominal value by 100. 
These calculations are summarized in Box 5.2.  
Costs were collected in Namibian Dollars (NAD) but are presented in US dollars (US$) using an 
average exchange rate of US$1= NAD14.05 (NAD1 = US$0.07), the mean exchange rate of April 
2016 to March 2017 (http://fxtop.com/en/historical-exchange-rates.php, accessed on June 13, 
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2018). Total costs were discounted at a 0% rate as they were incurred in a one year period 
(Drummond et al., 2015).  
Box 5. 2: Formulae for the allocation of overhead costs and deflation of costs 
 
5.3.5. Heath outcome measures 
The effectiveness measure used in this analysis was the number of perinatal HBV infections 
averted. This was defined as a negative HBsAg serostatus at 9 – 12 months of age in a baby born 
to an HBV-infected mother. Since the presence of anti-HBc from passive transfer of maternal 
antibodies usually persists in the infant for 12 months or more and the long-term complications of 
anti-HBc positivity in these children are negligible, this marker was not used as a criterion for 
perinatal HBV infection in the model. The long-term outcomes of perinatal HBV infections were 
not included. These outcomes were not discounted, given that they are measured in a one year 
period.  
5.3.6. Model parameters 
The literature available in the English language was searched in the Scopus and Medline databases 
to obtain HBV epidemiological parameters (Table 5.2) required to assess the effectiveness of each 
study strategy. The search combined the medical subject headings (Mesh) terms “Hepatitis B 
virus” AND “pregnant women”, “Namibia”, OR “Africa” in combination (AND) with each of the 
following words: “prevalence”, “vertical transmission”, “mother-to-child transmission”, “maternal 
A. Formulae for allocating overhead costs 
- PDEoutpatients = (annual inpatient days × 3) + (annual outpatient visits) 
- Cost/ANC visit = 
∑ 𝐶𝑜𝑠𝑡𝑠 𝑜𝑓 𝑜𝑣𝑒𝑟ℎ𝑒𝑎𝑑 𝑖𝑡𝑒𝑚𝑠
PDEoutpatients
 
B. Formulae for deflating costs 
Decimal CPI2016/2017 = 
∑ 𝐶𝑃𝐼𝐴𝑃𝑅𝐼𝐿2016,   𝑀𝐴𝑅𝐶𝐻 2017 
12
/100 
EC = 
𝑅
CPI2016/2017
 
. Where EC is the deflated equivalent cost of the recurrent item; R is the 
replacement price of the recurrent item, and CPI2016/2017 represents the decimal value of the CPI. 
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viral load”, and “tenofovir”. The bibliographies of the identified sources were also searched for 
additional articles.  
5.3.6.1. HBV epidemiological parameters 
The risk of perinatal infection is associated with HBeAg serostatus and high HBV viremia. 
Consequently, the prevalence of HBV infection among pregnant women was differentiated in three 
parts according to (1) the seroprevalence of HBsAg, (2) the prevalence of HBeAg, and (3) the 
prevalence of high viral load (≥ 200 000 IU/ml) among HBsAg positive women. The 200 000 
IU/ml cut-off value for high HBV DNA levels was based on previous studies that have reported 
pediatric breakthrough infections in babies born to HBV-infected mothers presenting with viral 
load from this level of viremia (Ngui et al., 1998; Wiseman et al., 2009; Zou et al., 2012; Wen 
et al., 2013; Foad et al., 2015; Sellier et al., 2015). This level of viremia is the cut-off value for 
maternal antiviral prophylaxis initiation in the AASLD guidelines (Terrault et al., 2016).  
A 7.3% prevalence of HBsAg among pregnant women was used as a base case value; it represented 
the seroprevalence of HBsAg observed in a previous retrospective Namibian study (Mhata et al., 
2017). The lower and upper values of the range of this variable were set at 5.44% (data from our 
antenatal study) and 10.10%, respectively. The upper value of this range represented the maximum 
prevalence of HBsAg reported in one of the 14 Namibian provinces (Mhata et al., 2017). 
Prevalence data for HBeAg were estimated from an earlier study by Botha et al. (1984) and the 
antenatal study (Chapter 4). In the antenatal study, three HBsAg pregnant women, among 28, were 
HBeAg positive. One of these three women was co-infected with HIV. Given that this analysis 
focused on the HBV mono-infected antenatal population, an HBeAg seroprevalence of 7.14% 
(2/28) was considered. Botha et al. (1984) observed an HBeAg prevalence of 14.71% (20/136) 
among HBsAg positive women whose children were HBV-infected, in Ovamboland (Botha et al., 
1984). A pooled estimate of 13.73% from the two studies was calculated using a DerSimonian-
Laird random-effects meta-analysis (DerSimonian & Laird, 1986). The meta-analysis was 
completed with the MedCalc Statistical Software Version 18.9 (MedCalc Software, Ostend, 
Belgium). The software uses a Freeman-Tukey transformation (Freeman & Tukey, 1950) to 
calculate weighted summary proportions. The lower rate of 7.14% and upper rate of 14.71% 
constituted the lower and upper bound of the range of this parameter. 
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Namibia-specific data for HBV viral load among HBV-infected pregnant were not available. 
Looking at other parts of SSA, HBV viral load above 200 000 IU/ml among HBV-infected 
pregnant women has been reported in Cameroon (Ducancelle et al., 2013), Ghana (Candotti, 
Danso & Allain, 2007), Senegal (Seck et al., 2018) and in South Africa (Andersson et al., 2013; 
Chotun et al., 2017). Ducancelle et al. (2013) did not quantify HBV DNA levels in all HBsAg 
positive pregnant women. Viral load levels in the Andersson et al. (2013) study were reported in 
ranges and median. All pregnant women’s samples used in the study by Seck et al. (2018) had a 
high viremia (≥ 200 000 IU/ml). A pooled proportion of HBV viral load among HBsAg positive 
pregnant women could not be estimated from these studies. In the Ghanaian (Candotti, Danso & 
Allain, 2007) and South African (Chotun et al., 2017) studies, all HBsAg positive women with 
an HBeAg seropositive status harbored HBV DNA levels above 200 000 IU/ml. Similarly, all 
HBV mono-infected HBeAg positive pregnant women within the antenatal study (Chapter 4) had 
HBV viral loads above 200 000 IU/ml. Therefore, HBeAg positive women in our analysis were 
assumed to carry HBV DNA levels ≥ 200 000 IU/ml. Consequently, the prevalence rates for these 
two variables, among HBsAg positive women were considered the same in the analysis.  
5.3.6.2. Perinatal transmission rates 
The rate of perinatal transmission of HBV varied according to the type of prophylaxis provided in 
the studied strategies: (1) timely BD vaccine, (2) timely BD vaccine + targeted HBIG, and (3) 
antiviral prophylaxis during pregnancy + timely BD vaccine + targeted HBIG. This rate was 
defined as the proportions of infants positive for HBsAg divided by the total number of 
babies/mothers adhering to the use of each prophylactic measure. Due to the limited availability 
of data on MTCT rates in SSA, these estimates were derived from studies performed elsewhere 
and were pooled if reported by more than one study.  
BD vaccination 
The rate of MTCT of HBV from HBeAg positive pregnant women was extracted from the 
following literature. Among sixteen babies immunized at birth, one month, and six months old 
with a plasma-derived vaccine, Halliday et al. (1992) observed breakthrough infections in eight 
(8/16; 50%) children (Halliday et al., 1992). Similarly, Xu et al. (1995) observed persistence of 
HBsAg among 12 children (21.82%; 12/55) born to HBeAg positive mothers, despite birth 
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vaccination with a plasma-derived vaccine (Xu et al., 1995). In Thailand, Lolekha et al. (2002) 
reported a 12.4% (12/97) rate of HBsAg chronic carriage in children vaccinated with a 
recombinant vaccine (Lolekha et al., 2002). The pooled value of these proportions was estimated 
at 24.68% (95% CI: 10.17% - 43.00%) and was used as the base rate of transmission of HBV with 
BD vaccination from HBeAg positive mothers in the model. 
With regards to HBeAg negative pregnant women, Xu et al. (1995) did not observe any HBV 
infections among vaccinated babies born to these mothers (0/56; 0%), using a plasma-derived 
vaccine (Xu et al., 1995). Similar observations were made by Esteban et al. (0/30; 0%), Lee et al. 
(2016) (0/21; 0%), and Lu et al. (2017) (0/132; 0%) using a recombinant vaccine (Esteban et al., 
1986; Lee et al., 2016; Lu et al., 2017). On the other hand, Halliday et al. (1992) noted four 
infections among 33 children (12.12%; 4/33) (Halliday et al., 1992). Chen et al. (2012) reported 
three HBV-infected children out of 1050 vaccinated children (0.29%; 3/1050) (Chen et al., 2012). 
Results from the meta-analysis produced a pooled value of 1.02% (95% CI: 0.08% - 3.02%). 
BD vaccination plus HBIG 
Rates of MTCT ranging from 1.90% to 18% have been described in previous randomized 
controlled trials (RCTs) from HBeAg positive mothers, with the addition of HBIG to BD 
vaccination. The lowest rate (1.98%) was described by Hieu et al. (2002) among 101 immunized 
children (Hieu et al., 2002). An earlier RCT by Xu et al. (1995) demonstrated a 6.25% (1/16) 
transmission rate in the study group who received 1 mL of HBIG (250 IU/mL) at birth plus plasma-
derived vaccine at birth and at one month and six months of age (Xu et al., 1995). Recent RCTs 
by Pan et al. (2016) and Jourdain et al. (2018) reported 6.82% (6/88) and 2.04% (3/147) MTCT 
rates, respectively (Pan et al., 2016; Jourdain et al., 2018). Looking at other study types, two 
cases of perinatal transmission were described among 24 babies (2/24; 8.33%) born to HBeAg 
positive pregnant women with HBV DNA levels ≥ 200 000 IU/ml in Turkey (Celen et al., 2013). 
Greenup et al. (2014) reported two cases of breakthrough pediatric infections in 10 (20%; 2/10) 
immunized babies born to HBeAg positive mothers with HBV DNA levels above 107 IU/ml 
(Greenup et al., 2014). A 10.71% (6/56) MTCT rate was described from mothers with HBV viral 
load > 107.5 IU/ml in Taiwan (Chen et al., 2015). Results from these studies generated a pooled 
rate of transmission of 6.90% (95% CI: 3.86% - 10.73%). 
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HBeAg negative mothers presented with a lower risk of transmitting the virus to their babies with 
BD and HBIG. Xu et al. (1995), as well as Esteban et al. (1986), did not record any HBV infection 
events in babies born to HBeAg negative mothers (Esteban et al., 1986; Xu et al., 1995). Chen et 
al. (2012) noted an HBsAg positivity rate of 0.14% (1/723) in children born to HBeAg negative 
mothers, despite receiving BD and HBIG at birth in Taiwan (Chen et al., 2012). A similar rate 
(1/752; 0.13%) was observed in China (Lu et al., 2017). In Singapore, perinatal transmission 
occurred in two out of 117 (1.71%) children born to HBeAg negative mothers despite receiving 
HBIG (Lee et al., 2016). Pooling of these studies suggested a transmission rate of 0.34% (95% 
CI: 0.07% - 0.82%) from HBeAg negative mothers, following pediatric active and passive 
immunization. 
BD vaccination, plus HBIG and maternal antiviral prophylaxis with TDF 
The rate of transmission of HBV using this preventive strategy was extracted from five clinical 
trials performed on HBeAg positive pregnant women with HBV DNA levels ≥ 200 000 IU/ml. 
The non-randomized controlled trial (NRCT) by Celen et al. (2013) showed absence of HBV 
infection in children (0/21; 0%) born to HBeAg positive mothers who were treated with TDF 
during pregnancy, added to pediatric BD vaccination and HBIG (Celen et al., 2013). Findings 
from two RCTs corroborated those findings (Pan et al., 2016; Jourdain et al., 2018). Two other 
NRCTs described a 2.27% (1/44) and 1.54% (1/65) residual rate of transmission (Greenup et al., 
2014; Chen et al., 2015). Pooling these data together, a residual rate of transmission of 0.73% 
(95% CI: 0.10% - 1.93%) was estimated. 
5.3.6.3. Diagnostic accuracy of the HBsAg screening tool 
The diagnostic sensitivity and specificity of the Alere Determine HBsAg rapid test were extracted 
from the latest systematic review and meta-analysis of the diagnostic accuracy of HBsAg RDTs 
(Amini et al., 2017). Based on 10 studies, the pooled sensitivity and specificity of the Determine 
HBsAg rapid test was estimated at 90.80% (95% CI: 88.90% - 92.40%), and 99.10% (95% CI: 
98.90% - 99.40%), respectively. A summary of these estimates is found in Table 5.2. 
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Table 5.2: Estimates of HBV prevalence in pregnant women and rates of maternal transmission 
Variables 
Base 
value 
Range values Further description Data sources  
Epidemiological assumptions     
Prevalence of HBsAg  7.30% 5.44% - 10.10% The lower bound is the prevalence described in Chapter 4, and the 
higher bound represents the highest prevalence described in ref [1].  
[1] 
Prevalence of HBeAg/high VL$ 13.73% 7.14% - 14.71% The lowest value of the range is the prevalence described in Chapter 4, 
and the highest value was extracted from ref [2]. 
[2] 
Rate of MTCT with TBD      
HBeAg negative women$ 1.02% 0.08% - 3.02% Range represents the 95% CI [3 – 8] 
HBeAg positive women$  24.68% 10.17% - 43.00% Range represents the 95% CI [4, 5, 9] 
Rate of MTCT with TBD and 
HBIG 
    
HBeAg negative women$  0.34%  0.07% - 0.82% Range represents the 95% CI [3, 5 – 8] 
HBeAg positive women$ 6.90% 3.86% - 10.73% Range represents the 95% CI [5, 6, 10 – 15] 
Rate of MTCT with maternal 
TDF treatment, TBD and HBIG 
    
HBeAg positive women$ 0.73% 0.10% - 1.93%  Range represents the 95% CI  [11 - 15] 
HBsAg rapid test performance     
Diagnostic sensitivity  90.80% 88.90% - 92.40% A full diagnostic assessment including HBV viral load or HBeAg 
would be performed for patients with false positive patients. Range 
values represent 95% CI.  
[16] 
Diagnostic specificity  99.10% 98.90% - 99.40% Patients with a false HBsAg negative results would not be detected at 
the screening stage. Range values represent 95% CI.  
[16] 
$The analysis considered that HBeAg negative women would have a viral load < 200 000 IU/ml and HBeAg positive women would present with a viral load ≥ 
200 000 IU/ml; *Maternal ART with TDF is given from 3rd trimester of pregnancy to 4 weeks postpartum. [1] Mhata et al., 2017; [2] Botha et al., 1984; [3] 
Esteban et al., 1986; [4] Halliday et al., 1992; [5] Xu et al., 1995; [6] Chen et al., 2012; [7] Lee et al., 2016; [8] Lu et al., 2017; [9] Lolekha et al., 2002; 
[10] Hieu et al., 2002; [11] Celen et al., 2013; [12] Greenup et al., 2014; [13] Chen et al., 2015; [14] Pan et al., 2016; [15] Jourdain et al., 2018; [16] 
Amini et al., 2017. CI: confidence interval; HBIG: hepatitis B immunoglobulin; HBeAg: hepatitis B e antigen; HBsAg: hepatitis B surface antigen; MTCT: 
mother-to-child transmission; TBD: timely birth dose; TDF: Tenofovir disoproxil fumarate. 
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5.3.7. Decision analytic model 
A decision tree model was built using Microsoft Excel 2013 (Microsoft, Redmond, 
Washington, USA) to evaluate the costs and health outcomes of each study strategy, using a 
hypothetical cohort of 10 000 women. Identified as the appropriate modeling approach for this 
evaluation, decision trees are the simplest forms of analytical modeling in economic 
evaluations (Karnon & Brown, 1998; Petrou & Gray, 2011). Figures 5.2, 5.3 and 5.4 show 
the branches of the decision tree for all strategies. Each node of the tree represents an 
epidemiological circumstance of HBV, including the prevalence of HBsAg among pregnant 
women, the prevalence of HBeAg positive mothers with a viral load above 200 000 IU/ml 
among HBsAg positive pregnant women, and the rates of transmission with each prophylaxis 
measure. The alternatives branching out from each node are mutually exclusive, and their 
probabilities add up to one. The endpoints of each branch represent an event that reflects the 
outcome measure of the evaluation; in this instance a pediatric HBV infection. The costs 
incurred through each pathway are summed. 
Briefly, women enter the decision tree model with a probability of being HBV-infected given 
by the HBsAg prevalence of 7.3%. In strategy 1, 13.73% of the HBsAg positive women are 
positive for HBeAg, and the remaining women are HBeAg negative. All babies receive the BD 
vaccine and are at a 24.68% or 1.02 % risk of acquiring HBV perinatal infection if born to an 
HBeAg positive or HBeAg negative mother, respectively. In strategies 2, 3 and 4, women are 
tested for HBsAg using a rapid test, and the results are either positive or negative for HBsAg. 
Due to the diagnostic sensitivity (90.80%) and specificity (99.10%) of the rapid test used for 
HBsAg screening, some disease-free women test reactive for HBsAg (false positives), and 
some infected women test negative for HBsAg (false negatives).  
Given that false HBsAg negative results produced by the Determine HBsAg rapid test have 
been attributed to low HBsAg levels and low viral DNA levels (Njai et al., 2015; Chisenga et 
al., 2018), the model takes in consideration that the full proportion of HBeAg positive pregnant 
women is found among true HBsAg positive patients (N x prevalence x RDT diagnostic 
sensitivity). As such, a new proportion of HBeAg positive women/women with a viral load 
above 200 000 IU/ml is recalculated at 15.12% in the model, based on a 90.80% sensitivity of 
the rapid test. This re-calculation is applied to strategies 2, 3, and 4. Consequently, as the 
sensitivity of the rapid test changes, this proportion is automatically re-calculated in the model. 
In the base analysis, 15.12% of the true HBsAg positive patients are HBeAg positive, and the 
remainder are HBeAg negative. Following active and passive immunization in strategy 2, the 
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residual rate of transmission remains at 6.90% and 0.34% for babies born to an HBeAg positive 
or HBeAg negative mother, respectively. In strategies 3 and 4, the rate of perinatal transmission 
of HBV from HBeAg positive mothers is reduced to 0.73%, whilst the rate of transmission 
from HBeAg negative mothers remains 0.34%. 
False HBsAg negative mothers are all considered negative for HBeAg, given the low levels of 
viremia reported among false HBsAg negative patients (Chisenga et al., 2018). These women 
are not detected as actual carriers of the virus. Babies born to these mothers are only vaccinated 
at birth, and at a 1.02% risk of acquiring HBV infection from their HBeAg negative mothers. 
False HBsAg positive women are treated at the clinic as HBsAg positive patients; both BD 
vaccination and HBIG are administered to their babies. These babies are not at risk of acquiring 
HBV infection through MTCT. 
MTCT is considered the only route of acquisition of HBV infection among infants born to the 
women included in the analysis, and complete compliance with routine HBsAg antenatal 
screening is assumed in the model. The model also presumes that all pregnant women eligible 
for antiviral prophylaxis would not refuse treatment with TDF and would adhere to the full 
course of the treatment. Full compliance with the Namibian immunization policy was also 
assumed in the model. That is all babies will be vaccinated at birth, and HBIG will be 
administered to HBV-exposed babies in strategies 2, 3, and 4. Subsequent doses of the HBV 
vaccine follow at 6, 10 and 14 weeks of the infants, this was not included in this analysis. 
 
Figure 5.2: Decision tree structure for the universal HBV vaccination strategy (Strategy 1). 
HBeAg: hepatitis B e antigen; HBsAg: hepatitis B surface antigen; TBD: timely birth dose. # refers to 
the remaining number of patients found in the next branch of the tree, branching out of a node.  
Stellenbosch University https://scholar.sun.ac.za
203 
 
 
Figure 5.3: Decision tree structure for the universal HBV vaccination and targeted HBIG strategy 
(strategy 2). HBeAg: hepatitis B e antigen; HBIG: hepatitis B immunoglobulin; HBsAg: hepatitis B 
surface antigen; TBD: timely birth dose. # refers to the remaining number of patients found in the next 
branch of the tree, branching out of a node. 
 
Figure 5.4: Decision tree structure for maternal treatment with TDF, universal HBV vaccination 
and targeted HBIG strategies (strategy 3 and strategy 4). # refers to the remaining number of 
patients found in the next branch of the tree, branching out of a node. HBeAg: hepatitis B e antigen; 
HBIG: hepatitis B immunoglobulin; HBsAg: hepatitis B surface antigen; TBD: timely birth dose. TDF: 
tenofovir disoproxil fumarate. 
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5.3.8. Cost-effectiveness analyses 
The total costs and the total number of perinatal infections averted in each strategy were 
calculated, based on the decision-tree model analysis. The strategies were arranged from least 
to the most costly. The incremental costs over the incremental outcomes, known as the ICER, 
was calculated using the formula: (CostB – CostA) / (EffectivenessB – EffectivenessA). This 
formula represents the difference in costs divided by the difference in effectiveness (expressed 
in the number of pediatric HBV infections averted) between each more costly strategy and the 
previous non-dominated less costly strategy (Drummond et al., 2015). Any interventions with 
extended or absolute dominance were removed from the analysis. Extended dominance is seen 
where a strategy is more costly and more effective, but produces an ICER higher than the next 
most expensive strategy. Absolute dominance is whereby an intervention is of high cost but 
equally effective than the previous less expensive intervention. The final ICER was interpreted 
as the incremental cost to avert an incremental perinatal HBV infection. 
5.3.9. Sensitivity analysis 
A sensitivity analysis allows for identifying the impact of uncertainties of the parameters used 
in the decision-tree model. The main parameters of the model are changed to assess their impact 
on the ICER. This analysis also helps to determine the parameters that drive the change in the 
ICER and which would require more attention during the data collection or decision-making. 
A series of one-way sensitivity analysis was performed to assess the robustness of the ICERs 
produced by the base analysis (Briggs, 1995), by altering all epidemiological parameters and 
four cost estimates used in the model. The altered cost estimates were the prices of HBIG, TDF, 
the HBeAg test and the viral load test. The range values of the epidemiological parameters, 
low and high, used in the sensitivity analysis are presented in Table 5.2. The impact of these 
changes to the incremental costs, the incremental effectiveness, and the ICERs were noted. The 
most influential variables identified in the one-way sensitivity analysis were further explored 
in two-way sensitivity analyses; in which two parameters were changed at a time. 
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5.4. Results 
5.4.1. Direct medical costs 
The direct costs involved in each strategy were estimated and are presented in Table 5.3. Based 
on the average costs and the rate of utilization of resource from patients in each strategy (Table 
5.4), four unit costs related to HBV testing were calculated: (1) cost per negative RDT test, (2) 
cost per true positive RDT result, (3) cost per HBV positive patient with a low viral 
load/HBeAg negative, and (4) the cost per HBV positive patient with a high viral load (≥ 200 
000 IU/ml)/HBeAg positive. The cost per false positive RDT test was equivalent to the cost per 
HBV positive patient with a low viral load/HBeAg negative, in the analysis. These costs are 
listed in Table 5.5. 
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Table 5.3: Costs estimates per categories and activities included in study strategies 
  IKH  WCH  Average cost 
Category Measure Cost (US$) Cost (US$) Cost (US$) 
Staff costs 
Pre-test counseling Cost per session $0.15 $0.09 $0.12 
Rapid test Cost per test $0.22 $0.22 $0.22 
Post-test counseling HBV positive Cost per session $0.74 $0.74 $0.74 
Post-test counseling HBV negative Cost per session $0.28 $0.28 $0.28 
Drawing blood – HBeAg/HBV VL 
tests 
Cost per session $1,84 $1,84 $1,84 
MO consultation for TDF patients Cost per session $4.38 $4.38 $4.38 
Patient-specific costs 
Rapid test Cost per test $2.30 $2.29 $2.30 
HBV viral load test1 Cost per test $143.11 $143.10 $143.11 
HBeAg test1 Cost per test $42.37 $42.35 $42.36 
TDF orientated lab tests2 Cost per assessment $33.93 $33.93 $33.93 
Maternal ART with TDF3 Cost per 4-month course $16.16 $16.16 $16.16 
HBIG4 Cost per HBIG $54.96 $54.96 $54.96 
HBV BD vaccination Cost per dose $1.48 $1.48 $1.48 
Overheads 
Facility overhead costs Cost per visit $2.62 $1.67 $2.14 
Capital costs - furniture and space 
Pre-test counseling room Cost per session $0.86 $0.36 $0.61 
Rapid test room – testing only Cost per session $0.07 $0.08 $0.08 
Rapid test room – testing + 
phlebotomy for HBeAg/HBV VL 
tests 
Cost per session $0.06 $0.07 $0.07 
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Post-test counseling room – IKH 
ANC5  
Cost per session $0.10 NA NA 
Post-test counseling room– no 
consultation for TDF6 
Cost per session  NA  $0.06 $0.08* 
Post-test counseling room – with 
consultation for TDF6 
Cost per session  NA  $0.06 $0.08# 
Phlebotomy for HBeAg/HBV VL 
tests 
Cost per session $0.18 $0.21 $0.19 
MO consultation room for TDF 
treatment 
Cost per session $0.04 $0.18 $0.11 
1The costs of the viral load test and the HBeAg test differ between the two ANCs due to the difference in the usage of consumables between the two 
ANCs.2Counts creatinine, FBC, ALT and AST tests. 3Cost of the drug only. 4cost of a single vial. 5includes both HBV positive and HBV negative patients. 
6Post-test counseling costs at WCH ANC include HBV positive and HBV negative. *Average of the cost of post-test counseling at IKH and WCH (without 
consultation for TDF treatment in this area - applicable to strategies 1 and 2). #Average of post-test counseling at IKH and WCH ANC (with consultation for 
TDF treatment in this area, - applicable to strategies 3 and 4). ALT: alanine transaminase; AST: aspartate transaminase; ANC: antenatal clinic; ART: 
antiretroviral therapy; BD: birth dose; FBC: full blood count; HBeAg: hepatitis B e antigen; HBsAg: hepatitis B surface antigen; HBV: hepatitis B virus; 
HBIG: hepatitis B immunoglobulin; IKH: Intermediate Katutura hospital; Lab: laboratory; MO: medical officer; NA: Not applicable; TDF: tenofovir disoproxil 
fumarate; VL: viral load; WCH: Windhoek Central hospital.  
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Table 5.4: Utilization of medical resources in each strategy 
 Universal BD 
vaccination 
Universal BD 
vaccination + 
targeted HBIG 
Universal BD vaccination + HBV 
viral load testing + maternal 
antiviral prophylaxis + targeted 
HBIG 
Universal BD vaccination + 
HBeAg testing + maternal 
antiviral prophylaxis + targeted 
HBIG 
Resources HBV 
Neg 
HBV 
Pos 
HBV 
Neg 
HBV Pos HBV 
Neg 
non-TDF 
patient 
TDF 
patient 
HBV 
Neg 
non-TDF 
patient 
TDF 
patient 
ANC 1 1 1 1 1 1 2* 1 1 2* 
HBV RDT 1 1 1 1 1 1 1 1 1 1 
HBV VL test - - - - - 1 1 - - - 
HBeAg test - - - - - - - - 1 1 
TDF orientated tests - - - - - - 1 - - 1 
Maternal ART - - - - - - 1 - - 1 
BD vaccine 1 1 1 1 1 1 1 1 1 1 
Infant HBIG - - - 1 - 1 1 - 1 1 
*These included the first ANC visit when the patient is screened for HBV, and a second visit whereby blood is drawn for the TDF-orientated tests and the TDF 
prescription is provided to the patients. ART: antiretroviral therapy; BD: birth dose; HBeAg: hepatitis B e antigen; HBsAg: hepatitis B surface antigen; HBV: 
hepatitis B virus; HBIG: hepatitis B immunoglobulin; Neg: negative; Pos: positive; RDT: rapid diagnostic test; VL: viral load; TDF: tenofovir disoproxil 
fumarate.  
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Table 5.5: Costs of each HBV status in each strategy. Costs are expressed in USD. 
 Universal BD 
vaccination 
Universal BD 
vaccination + 
targeted HBIG 
Universal BD vaccination 
+ HBV viral load testing + 
maternal antiviral 
prophylaxis + targeted 
HBIG 
Universal BD vaccination 
+ HBeAg testing + 
maternal antiviral 
prophylaxis + targeted 
HBIG 
Testing per HBV status      
HBV RDT negative1  - $5.82 $5.81 $5.81 
HBV RDT positive  - $6.28  -   -  
HBeAg negative/low viral load2  -  -  $151.42 $50.67 
HBeAg positive/high viral load  -  -  $208.14 $107.39 
Pediatric immunization per 
HBV status 
    
True HBV negative $1.48 $1.48 $1.48 $1.48 
False HBV negative $1.48 $1.48 $1.48 $1.48 
True HBV positive $1.48 $56.43 $56.43 $56.43 
False HBV positive $1.48 $56.43* $56.43# $56.43# 
1These costs applied to both false and true negative patients. 2These costs applied to both true positive patients with a low viremia/HBeAg negative status 
and false HBsAg positive patients to whom HBeAg or HBV DNA testing is performed. *The mothers of these babies aren’t ruled out as false positives given 
that HBsAg positive samples are not confirmed at the laboratory. #Mothers of these babies would test negative for HBV but are still given HBIG based on 
the positive HBsAg result. BD: birth dose; HBV: hepatitis B virus; RDT: rapid diagnostic testing.  
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5.4.2. Cost-effectiveness analysis 
Listed from the least expensive to the most expensive, strategy 1 including universal BD 
vaccination was the cheapest option, costing US$15 827.22; followed by strategy 2 (US$114 
325.96), strategy 4 (US$153 053.55), and strategy 3 (US$228 238.62). These were equivalent 
to US$1.58, US$11.43, US$ 15.31, and US$22.82 per pregnant woman presenting at the ANC, 
respectively. The considerable variation in costs between the universal BD vaccination strategy 
and the other interventions was attributed to the cost of additional HBIG, and of the HBV viral 
load and HBeAg tests. On the other hand, the lowest effectiveness was attributed to universal 
BD vaccination; which produced 31 perinatal HBV infections. These were reduced to 10 
infections with BD vaccine + HBIG, and to three infections with the use of TDF in addition to 
BD vaccine and targeted HBIG (strategies 3 and 4). 
Compared to the universal HBV BD vaccination strategy, the current Namibian strategy (BD 
vaccine + HBIG) averted an extra 22 cases of perinatal infections; thereby producing an ICER 
of US$4 550.34/pediatric HBV infection averted. Six additional cases were averted in the TDF 
strategy using HBeAg testing, in comparison to the BD vaccine + HBIG strategy; and produced 
an ICER of US$6 262.42/pediatric infection averted. The TDF strategy using HBV viral load 
testing was excluded through absolute dominance; it costed more than using HBeAg testing 
but produced the same effectiveness. A summary of these results is found in Table 5.6. 
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Table 5.6: Cost-effectiveness results by prevention strategy*. The ICER is expressed as US$ per incremental pediatric HBV infection averted. Costs are 
expressed in US$. 
Strategies Costs Incremental costs Total 
infections 
Infections 
averted  
ICER  
Universal BD vaccination $15 827.22  -  31  -   -  
Universal BD vaccination + targeted 
HBIG 
$114 325.96 $98 498.74 10 22 4 550.34 
Universal BD vaccination + HBeAg 
testing + maternal antiviral prophylaxis 
+ targeted HBIG 
$153 053.55 $38 727.59 3 6 6 262.42 
Universal BD vaccination + HBV viral 
load testing + maternal antiviral 
prophylaxis + targeted HBIG 
$228 238.62 $75 185.07 3 0 Absolute 
dominance 
*Based on a hypothetical cohort of 10000 women. Both costs and outcomes were not discounted. ART: antiretroviral therapy; BD: birth dose; HBeAg: hepatitis 
B e antigen; HBIG: hepatitis B immunoglobulin; HBV: hepatitis B virus; ICER: Incremental cost-effectiveness ratio; TBD: Timely birth dose. 
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5.4.3. Sensitivity analysis 
5.4.3.1. One-way sensitivity analysis  
Univariate sensitivity analyses were performed with all epidemiological parameters used in the 
model. Costs with a potential influence on the ICERs of the comparative strategies were also 
explored. Results from these analyses for strategies 2 and 3 are graphically presented in Figure 
5.5 and Figure 5.6, respectively. The impact of this analysis on the incremental costs and 
incremental infections averted is tabulated in Table 5.7. 
Strategy 2: Universal BD vaccination and targeted HBIG 
Two parameters, related to transmission, had the most significant impact on the ICER of this 
intervention. These were (1) the rate of MTCT with BD vaccine from HBeAg positive women, 
and (2) the rate of MTCT with BD vaccine and HBIG from HBeAg positive women. At the 
low rate of 10.17% of HBV MTCT from HBeAg positive women with BD vaccine, a sharp 
increase of the base value of the ICER from US$4 550.34 to US$13 866.73 was noted. This 
intervention was eliminated due to extended dominance; the produced ICER of US$13 866.73 
was higher than the ICER of the TDF strategy (US$6 262.42). Extended dominance of the BD 
+ HBIG strategy by the TDF strategy was also observed when the high value (10.73%) for the 
rate of HBV MTCT from HBeAg positive women with BD and HBIG was used in the model. 
The ICER of the BD + HBIG strategy decreased to US$5 531.24, and so did the ICER of the 
TDF strategy (US$3 863.91). 
A change in the epidemiology of HBV, both HBsAg and HBeAg/high VL prevalence, had a 
moderate impact on the ICER of this strategy. It rose from the base value of US$4 550.34 to 
US$ 5 550.89 at the lowest HBsAg prevalence of 5.44%, and to US$7 339.60 at the lowest 
HBeAg/high VL prevalence of 7.14%. At the highest value of 10.10% and 14.71% of these 
two parameters, the ICER decreased to US$3 740.89 and US$4 306.93, respectively. The 
sensitivity analysis also indicated that a 50% change in the cost of HBIG only led to a 21% 
change in the ICER, in both directions. The rate of transmission of HBV from HBeAg negative 
pregnant women also had a moderate influence on the ICER; as portrayed in Figure 5.5. The 
diagnostic accuracy of the HBsAg rapid test had a minimal impact on the costs and 
effectiveness of this intervention.  
 
Stellenbosch University https://scholar.sun.ac.za
213 
 
 
Figure 5.5: Tornado diagram presenting results from one-way sensitivity analyses: universal BD 
vaccination + targeted HBIG vs. universal BD vaccination only. Both strategies include antenatal 
HBsAg screening. The base ICER of this strategy is US$4 550.34/pediatric infection averted. ART: 
antiretroviral therapy; BD: birth dose; TBD: timely birth dose; HBeAg: hepatitis B e antigen; HBIG: 
hepatitis B immunoglobulin; HBsAg: hepatitis B surface antigen; HBV: hepatitis B virus; MTCT: 
mother-to-child transmission. 
 
Strategy 4: Universal BD vaccination, HBeAg testing, maternal antiviral prophylaxis, 
and targeted HBIG  
Three variables had the most significant influence on this health intervention: (1) the 
prevalence of HBeAg, (2) the rate of MTCT from these women with maternal TDF, BD vaccine 
and HBIG, and (3) the costs of the HBeAg test. As the prevalence of HBeAg positive 
women/high VL decreased from the base value of 13.73% to 7.14%, the ICER of this 
intervention increased from US$6 262.42 to US$11 193.93/pediatric HBV infection averted 
(Figure 5.6). This implies that the intervention is unlikely to be cost-effective at lower 
prevalence levels of HBeAg positive women/high VL. Based on the significant effect of this 
parameter on the ICER, and taking in consideration that this proportion may vary among HBV-
infected pregnant women across different parts of Namibia, the effect of further variations of 
5,550.89
7,339.60
13,866.73
3,988.86
6,021.47
4,251.95
3,602.96
4,534.58
4,597.81
3,740.89
4,306.93
2,461.95
5,531.24
2,994.00
5,198.94
5,497.71
4,563.50
4,479.13
0 2,000 4,000 6,000 8,000 10,000 12,000 14,000 16,000
Prevalence of HBsAg (5,44% - 10,10%)
Prevalence of HBeAg (7,14% - 14,71%)
Rate of MTCT with TBD, HBeAg positive
women (10,17% - 43,00%)
Rate of MTCT with TBD and HBIG, HBeAg
positive women (3,86% - 10,73%)
Rate of MTCT with TBD, HBeAg negative
women (0,08% - 3,02%)
Rate of MTCT with TBD and HBIG, HBeAg
negative women (0,07% - 0,82%)
Cost of HBIG ($27,48 - $82,44)
HBsAg rapid test sensitivity (88,90% - 92,40%)
HBsAg rapid test specificity (98,90% - 99,40%)
High value Low value
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the parameter was explored. A two-fold (27.46%) and a 2.5 increase (34.33%) of the prevalence 
of HBeAg positive women/high VL from the base value of 13.73% decreased the ICER to 
US$3 590.87 and US$3 056.25 for every additional pediatric HBV infection prevented by the 
intervention, respectively. By altering the variables associated with the rate of MTCT from 
HBeAg positive mothers treated with TDF during pregnancy to the lowest value of 0.10% and 
highest value of 1.93%, the ICER decreased to US$5 682.22 but increased to US$7 774.47 per 
additional pediatric infection averted, respectively.  
As mentioned above, when the lowest rate (10.17%) of HBV MTCT with BD vaccine and the 
highest rate (10.73%) of HBV MTCT with BD vaccine + HBIG from HBeAg positive women 
was used in the model, separately, the universal BD vaccination + HBIG strategy was removed 
due to extended dominance. In these two scenarios, the antiviral prophylaxis strategy was 
compared to the universal BD vaccination strategy and produced two new ICERs of 
US$10 327.57 and US$4 930.77, respectively. 
At a 50% decrease of the price of the HBeAg test (US$20.86), this intervention produced an 
ICER (US$4 371.46) lower than the universal BD vaccination + HBIG strategy’s one (ICER = 
US$4 550.34). The influence of the price of this test on the ICER of this intervention was 
further explored. It was noted that a 35% decrease of the original price of the HBeAg test to 
US$27.12 was the threshold at which the antiviral prophylaxis strategy eliminated the universal 
BD vaccination + HBIG strategy through extended dominance. At a US$27.12 cost of the 
HBsAg test, the antiviral prophylaxis strategy was compared to the universal BD vaccination 
intervention; and a new ICER of US$4 539.25 was produced.  
A reduction of the cost of TDF by half reduced the ICER to US$6 131.45/incremental infection 
averted. When the cost of TDF was increased to US$69 per 4-month course, calculated as per 
the 2016 pharmaceutical price of the TDF offered in SSA (US$207 per person per year) 
(Médecins Sans Frontières, 2016), the ICER rose to US$7 118.79/incremental infection 
averted. 
The tornado diagram representing the results of this analysis is illustrated in Figure 5.6. The 
diagram also shows that the diagnostic accuracy of the HBsAg rapid test had a minimal impact 
on this intervention; in terms of both costs and effectiveness. The change of the cost of HBIG 
and the rates of HBV MTCT with BD vaccine and BD vaccine + HBIG from HBeAg negative 
women did not influence the ICER of this strategy. 
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Figure 5.6: Tornado diagram presenting results from one-way sensitivity analyses: HBeAg testing + 
maternal antiviral prophylaxis + active-passive immunization vs. BD vaccination + targeted HBIG. 
The base ICER is US$6 262.42/pediatric infection averted. Three parameters are seen to have a high impact 
on the base ICER. These are (1) the risk of MTCT from HBeAg positive pregnant women with a high viral 
load whose babies receive both HBIG and BD vaccine, (2) the proportion of HBeAg positive pregnant 
women, and (3) the cost of the HBV viral load test. ART: antiretroviral therapy; BD: birth dose; HBIG: 
hepatitis B immunoglobulin; HBsAg: hepatitis B surface antigen; HBV: hepatitis B virus; ICER: 
incremental cost-effectiveness ratio; MTCT: mother-to-child transmission. 
Strategy 3: Universal BD vaccination, HBV viral load testing, maternal antiviral 
prophylaxis, and targeted HBIG  
Variations of the cost of the HBV viral load were completed to determine the cost at which 
viral load testing would be comparable to HBeAg testing to determine maternal antiviral 
prophylaxis eligibility. At a viral load test cost of US$41.72, which represented the price of the 
HBeAg test, HBV viral load testing was found cheaper than HBeAg testing by US$43.67. 
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Table 5.7: Results of the one-way sensitivity analysis  
Model parameters Base 
value 
Range 
values 
Incremental 
Costs  
Infections 
averted 
ICER* Base ICER* ICER* 2 
Universal BD vaccination + 
targeted HBIG 
     4 550,34  
Prevalence of HBsAg 7.30% 5.44% $89 490.61 16 5 550.89   
10.10% $112 036.74 30    
Prevalence of HBeAg/high 
VL 
13.73% 7.14% $98 498.74 13 7 339.60   
14.71% $98 498.74 23 4 306.93   
27.46% $98 498.74 39 2 539.57   
34.33% $98 498.74 47 2 079.72   
Rate of MTCT with TBD 
from HBeAg positive women 
24.68% 10.17% $98 498.74 7 13 866.73  Extended 
dominance 
43.00% $98 498.74 40 2 461.95   
Rate of MTCT with TBD + 
HBIG from HBeAg positive 
women 
6.90% 3.86% $98 498.74 25 3 988.86   
10.73% $98 498.74 18 5 531.24  Extended 
dominance 
Rate of MTCT with TBD 
from HBeAg negative women 
1.02% 0.08% $98 49874 16 6 021.47   
3.02% $98 498.74 33 2 994.00   
Rate of MTCT with TBD + 
HBIG from HBeAg negative 
women 
0.34% 0.07% $98 498.74 23 4 251.95   
0.82% $98 498.74 19 5 198.94   
Cost of HBIG $54.96 $27.48 $77 991.41 22 3 602.96   
$82.44 $119 006.07 22 5 497.71   
Rapid test sensitivity 90.80% 88.90% $97 730.03 22 4 534.58   
92.40% $99 146.08 22 4 563.50   
Rapid test specificity 99.10% 98.90% $99 526.28 22 4 597.81   
 99.40% $96 957.43 22 4 479.13   
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Universal BD vaccination + 
HBV viral load testing + 
maternal antiviral 
prophylaxis+ targeted 
HBIG 
     Absolute 
dominance 
 
Cost HBV viral load test $142.52 $71.26 $22 004,54 0 NA   
$44.85 $11 368.49 0 NA   
$42.76 $732.43 0 NA   
$41.72¥ -$43.67 0 NA   
Universal BD vaccination + 
HBeAg testing + maternal 
antiviral prophylaxis+ 
targeted HBIG 
     6 262.42  
Prevalence of HBsAg 7.30% 5.44% $29 840.61 5 6 478.90   
10.10% $52 083.54 9 6 087.28   
Prevalence of HBeAg/high 
VL 
13.73% 7.14% $35 998.86 3 11 193.93   
14.71% $39 133.38 7 5 906.45   
27.46% $44 412.79 12 3 590.87   
34.33% $47 257.46 15 3 056.25   
Rate of MTCT with TBD 
from HBeAg positive women  
24.68% 10.17% $38 727.59 6 6 262.42  4 539.25 
43.00% $38 727.59 6 6 262.42   
Rate of MTCT with TBD + 
HBIG from HBeAg positive 
women 
6.90% 3.86% $38 727.59 3 12 344.76   
10.73% $38 727.59 10 3 863.91  4 930.77 
Rate of MTCT with maternal 
TDF, TBD, and HBIG from 
HBeAg positive women 
0.073% 0.10% $38 727.59 7 5 682,22   
1.93% $38 727.59 5 7 774,47   
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Rate of MTCT with TBD 
from HBeAg negative women 
1.02% 0.08% $38 727.59 6 6 262.42   
3.02% $38 727.59 6 6 262.42   
Rate of MTCT with TBD + 
HBIG from HBeAg negative 
women 
0.34% 0.07% $38 727.59 6 6 262.42   
0.82% $38 727.59 6 6 262.42   
Cost of TDF  $16.16 $8.08 $37 917.66 6 6 131.45   
$24.24 $39 537.53 6 6 393.39   
Cost of HBeAg test $41.72 $27.12 $27 831.37 6 4 500.45  4 539,25 
$62.58 $54 293.63 6 8 779.51   
Cost of HBIG $54.96 $27.48 $38 727.59 6 6 262.42   
$82.44 $38 727.59 6 6 262.42   
Rapid test sensitivity 90.80% 88.90% $38 111.82 6 6 162.84   
92.40% $39 246.14 6 6 346.27    
Rapid test specificity 99.10% 98.90% $39 550.69  6 6 395.52   
99.40% $37 492.95 6 6 062.77   
*ICER is expressed in US$ per pediatric infection averted. ¥price of the HBeAg test; #35% decrease of the price of the HBeAg test. In red are values at which 
the universal BD vaccination + targeted HBIG strategy is dominated by the universal BD vaccination + HBeAg testing + maternal antiviral prophylaxis+ 
targeted HBIG strategy (strategy 4), and a new ICER for strategy 4 is calculated in comparison to the universal BD vaccination strategy.  ART: antiretroviral 
therapy; BD: birth dose; TBD: timely bird dose; HBIG: hepatitis B immunoglobulin; HBsAg: hepatitis B surface antigen; HBV: hepatitis B virus; ICER: 
incremental cost-effectiveness ratio; MTCT: mother-to-child transmission. 
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5.4.3.2. Multi-way sensitivity analysis  
 A series of two-way sensitivity analysis was performed, using variables with the highest influence 
on the ICERs of strategies 2 and 4 in the one-way sensitivity analyses. 
 Strategy 2: Universal BD vaccination and targeted HBIG 
A critical change of the ICER of this intervention was observed using variations of the following 
parameter combinations (1) the prevalence of HBsAg and the prevalence of HBeAg/high VL, (2) 
the cost of HBIG and the prevalence of HBeAg/high VL, (3) the prevalence of HBeAg/high VL 
and the rate of HBV MTCT with BD + HBIG from HBeAg positive/highly viremic women. The 
pairing was dependent on the impact caused on the ICER by the epidemiology of HBeAg/high VL 
pregnant women who have the highest risk of HBV MTCT, and on the effectiveness of this strategy 
in this population of high-risk women. 
In the first combination, the lowest ICER of US$1 709.77 was found at a 10.10% prevalence of 
HBsAg and 34.33% prevalence of HBeAg (Table 5.8). At the lowest values of 5.44% and 7.14% 
prevalence of HBsAg and HBeAg/high VL, respectively, the ICER rose to US$8 953.47. A 50% 
reduction of the cost of HBIG in combination with a high prevalence of HBeAg/high VL (34.33%) 
decreased the ICER by nearly 64% to US$1 646.73. But a 28% increase of the ICER to 
US$5 811.50 was observed at low prevalence of 7.14% of HBeAg/high VL, even at the low HBIG 
cost of US$27.48 (Table 5.8). A 34.44% prevalence of HBeAg/high VL combined to the lowest 
rate of HBV MTCT from highly viremic HBeAg positive women using BD + HBIG resulted in a 
lower ICER too (US$1 791.54).  
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Table 5.8: Most influential variables included in two-way sensitivity analyses of universal BD 
vaccination and targeted HBIG compared to universal BD vaccination only. 
   Prevalence of HBsAg 
 
 
5.44% 7.30% 10.10% 
Prevalence of 
HBeAg/high VL 
7.14% 8 953.47 7 339.60 6 033.98 
13.73% 5 550.89 4 550.34 3 740.89 
14.71% 5 253.96 4 306.93 3 540.78 
27.46% 3 097.98 2 539.57 2 087.81 
34.33% 2 537.02 2 079.72 1 709.77 
  Cost of HBIG 
  $27.48 $54.96 $82.44 
Prevalence of 
HBeAg/high VL 
7.14% 5 811.51 7 339.60 8 867.70 
13.73% 3 602.96 4 550.34 5 497.71 
14.71% 3 410.23 4 306.93 5 203.63 
27.46% 2 010.83 2 539.57 3 068.30 
34.33% 1 646.73 2 079.72 2 512.72 
  Rate of transmission with TBD + HBIG from HBeAg 
positive 
  3.86% 6.90% 10.73% 
Prevalence of 
HBeAg/high VL 
7.14% 6 564.53 7 339.60 8 622.16 
13.73% 3 988.86 4 550.34 5 531.24 
14.71% 3 768.95 4 306.93 5 251.30 
27.46% 2 194.74 2 539.57 3 166.34 
34.33% 1 791.54 2 079.72 2 608.33 
Values in blue represent the base ICER of the strategy. Values in red represent the lowest ICER in all 
combinations. ICERs are expressed in cost/incremental pediatric HBV infection averted. BD: birth dose; 
HBeAg: hepatitis B e antigen; HBIG: hepatitis B immunoglobulin; HBsAg: hepatitis B surface antigen; 
VL: viral load.  
Strategy 4: Universal BD vaccination, HBeAg testing, maternal antiviral prophylaxis, and 
targeted HBIG 
In section 5.4.3.1, it is shown that the ICER of this strategy was sensitive to variations of five 
parameters. These parameters were further explored as pairs in the following combinations: (1) 
cost of HBeAg test and the prevalence of HBeAg/high VL, (2) prevalence of HBsAg and 
prevalence of HBeAg/high VL, (3) the rate of transmission with TBD + HBIG and with TDF + 
TBD + HBIG from highly viremic HBeAg positive. The implementation of this strategy would be 
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dependent on the proportion of HBeAg positive/high HBV VL women in need of TDF, the cost of 
the HBeAg test used to determine antiviral prophylaxis eligibility, and of the rate of MTCT from 
these women if TDF is added to BD and HBIG. These reasons guided the combination of 
parameters used in these two-way sensitivity analyses of this strategy. 
In agreement with the one-way sensitivity analysis, the lower the cost of the HBeAg test became, 
accompanied by an increase in the proportion of HBsAg positive women requiring antiviral 
prophylaxis (HBeAg positive women/high HBV VL), the lower was the ICER. The lowest value 
of US$1 453.06 per additional pediatric infection averted was obtained when considering an 
HBeAg cost of US$8.50, the price of the HBeAg test at the NHLS in South Africa, and prevalence 
of HBeAg/high VL of 34.33%. Furthermore, at 5.44% HBsAg prevalence and 7.14% prevalence 
of HBeAg/high VL, the ICER went up to US$11 610.22; and decreased to US$2 986.20 at 10.10% 
and 34.33% prevalence of HBsAg and HBeAg/high VL, respectively. 
When the rate of HBV MTCT with antiviral prophylaxis (TDF) + BD + HBIG from HBeAg 
positive decreased to 0.10%, and the rate of HBV MTCT from HBeAg positive pregnant 
women/high HBV VL with the current Namibian strategy (BD + HBIG) decreased to 3.86%, the 
ICER of the antiviral prophylaxis strategy raised to US$10 276.36/pediatric infection averted. The 
ICER decreased to US$3 634.91 when the rate of HBV MTCT from HBeAg positive pregnant 
women/high HBV VL with BD + HBIG increased to 10.73%, while the rate of HBV MTCT using 
antiviral prophylaxis (TDF) remained at 0.10%. A summary of these results is presented in Table 
5.9 below. 
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Table 5.9: Most influential variables included in two-way sensitivity analyses of maternal antiviral 
prophylaxis using HBeAg testing, universal BD vaccination and targeted HBIG compared to 
universal BD vaccination targeted HBIG. 
    Cost of HBeAg test 
 
 
$41.72  $29.20 $27.12 $25.03 $20.86 $16.69 $8.50 
Prevalence 
of 
HBeAg/high 
VL 
7.14% 11 193.93 8 289.75 7 805.72 7 321.69 6 353.64 5 385.58 3 485.59 
13.73% 6 262.42 4 752.16 4 500.45 4 248.74 3 745.32 3 241.90 2 253.86 
14.71% 5 906.45 4 496.81 4 261.87 4 026.93 3 557.05 3 087.17 2 164.95 
27.46% 3 590.87 2 835.74 2 709.89 2 584.03 2 332.32 2 080.61 1 586.59 
34.33% 3 056.25 2 452.23 2 351.56 2 250.90 2 049.56 1 848.22 1 453.06 
  Prevalence of HBsAg  
  5.44% 7.30% 10.10%  
Prevalence 
of 
HBeAg/high 
VL 
7.14% 11 610.22 11 193.93 10 857.15  
13.73% 6 478.90 6 262.42 6 087.28  
14.71% 6 108.51 5 906.45 5 742.98  
27.46% 3 699.11 3 590.87 3 503.30  
34.33% 3 142.83 3 056.25 2 986.20  
  Rate of transmission with TBD + HBIG from HBeAg positive  
  3.86% 6.90% 10.73%  
Rate of 
MTCT with 
TDF +TBD 
+ HBIG  
0.10% 10 276.36 5 682.22 3 634.91  
0.73% 12 344.76 6 262.42 3 863.91  
1.93% 20 020.26 7 774.47 4 390.81  
Values in blue represent the base ICER of the strategy. Values in red represent the lowest ICER in all 
combinations. ICERs are expressed in cost/incremental pediatric HBV infection averted. BD: birth dose; HBeAg: 
hepatitis B e antigen; HBIG: hepatitis B immunoglobulin; HBsAg: hepatitis B surface antigen; MTCT: mother-
to-child transmission; TBD: timely birth dose; VL: viral load.  
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5.5. Summary of findings 
In the analysis presented in this study, universal HBV BD vaccination and targeted HBIG appeared 
to be more effective compared to universal HBV BD vaccination against HBV MTCT; in a cohort 
of 10 000 births, 22 extra cases of perinatal HBV infections (ICER: US$4 550.34/pediatric HBV 
infection averted) were averted in the HBV BD vaccination and targeted HBIG intervention. 
Providing maternal antiviral prophylaxis with TDF had the highest effectiveness; the intervention 
averted six extra cases of perinatal HBV infection in comparison to universal HBV BD vaccination 
and targeted HBIG. However, the costs of this intervention were high: $153 053.55 with HBeAg 
testing (ICER: US$6 262.42/pediatric HBV infection averted) and $228 238.62 with HBV viral 
load testing (ICER: Absolute dominance). Still, the sensitivity analyses demonstrated that adding 
maternal antiviral prophylaxis with sequential HBeAg testing to the current universal HBV BD 
vaccination and targeted HBIG strategy may be a cost-effective intervention against HBV MTCT 
in Namibia.  
5.6. Interpretation of findings 
5.6.1. Universal HBV BD vaccination and targeted HBIG compared to universal HBV BD 
vaccination only 
BD vaccination has been and remains an essential tool for preventing perinatal HBV infections 
globally. Consistent with the current economic literature (Griffiths, Hutton & Pascoal, 2005; 
Kim, Salomon & Goldie, 2007; Klingler, Thoumi & Mrithinjayam, 2012; Anderson et al., 
2018), this strategy was the least expensive measure for preventing HBV MTCT, with a total cost 
of US$15 827.22. Although inexpensive, 31 pediatric HBV infections were recorded still in a 
hypothetical cohort of 10 000 women, of whom 730 were HBsAg positive. Still, the need for 
implementing this intervention is not debatable. In Cameroon, where this immunoprophylaxis 
measure is not offered, a recent decision analytical model showed that 813 infections, including 
infections acquired through horizontal transmission, are still recorded per 10 000 children with 
pediatric vaccination from six weeks of age. With the delivery of the BD vaccine, an additional 
384 HBV infections were averted in the model at an incremental cost of US$130.41 per additional 
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infection averted (Anderson et al., 2018). The model by Anderson et al. (2018) also revealed a 
residual 430 infections (including both perinatally-acquired and horizontally-acquired infection), 
despite universal BD vaccination (Anderson et al., 2018). These data merely indicated that BD 
vaccination is highly effective and low cost in the SSA context, but may not be sufficient if 
provided alone to eliminate HBV MTCT in the region.  
Combining BD vaccination with passive immunity from HBIG has shown higher effectiveness in 
comparison to vaccination alone in Asia (Lee et al., 2006, 2007). In our model, providing HBIG 
to HBsAg-exposed babies in addition to the BD vaccine was at an extra cost of US$98 498.74, but 
prevented an additional 10 infections. This equated to an incremental US$4 550.34 per pediatric 
HBV infection averted (ICER). At an intermediate HBV endemicity of 5% in Taiwan, a model by 
Chen et al. (2013c) showed that combining BD vaccination with HBIG reduced the number of 
pediatric HBV infections attained with BD vaccination alone from 738 to 225 (incremental 
infections averted = 98) at an incremental costs of US$385 700, in a cohort of 100 000 people. The 
calculated ICER of the strategy was US$3 956 per infection averted (Chen et al., 2013c). In 
Thailand, the same strategy had an ICER of US$716.78 per infection averted compared to 
universal BD vaccination (Devine et al., 2017). Two main parameters differed between the model 
of this study and those two Asian models. These were the cost of HBIG and the prevalence of 
HBeAg; both parameters had a substantial impact on our ICER. At a high HBeAg prevalence of 
34.33%, which is similar to the prevalence seen in Asia, a 54% decrease of the ICER to 
US$2 079.72 was noted. Decreasing the cost of HBIG by half reduced the ICER by 21% 
(US$3 602.96). Using simultaneous variations of these two parameters, the lowest ICER of 
US$1 646.73 per pediatric infection averted was produced. These changes of the ICER of the 
strategy indicated that more efforts are needed to reduce the price of HBIG. They also showed that 
adding HBIG to BD vaccination is of value in settings where a large proportion of HBsAg positive 
pregnant women are also positive for HBeAg. Similarly, the higher is the prevalence of HBsAg, 
the lower the ICER would be; as seen in the two-way sensitivity analysis and in Taiwan too (Chen 
et al., 2013c). In the Taiwanese analytical model, a gradual increase of the ICER of the strategy 
including HBIG and BD vaccine from US$3 234 to US$3 956 was observed as the HBsAg carrier 
rate decreased from 25% to 5%, and reached US$ 8 783 at a lower HBsAg carrier rate of 1% (Chen 
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et al., 2013c). As such, a lower ICER for the HBIG + BD strategy would be observed in the 
northern part of Namibia where prevalence of HBsAg and HBeAg as high as 10.10% (Mhata et 
al., 2017) and 14.71% (Botha et al., 1984), respectively, have been reported. At these HBV 
epidemiological rates, the intervention costed US$3 540.70 per infection averted; this was 
equivalent to a 22% decrease of the ICER from its base value of US$4 550.34. 
In the presence of a high burden of pregnant women at the highest risk of transmitting HBV to 
their babies, the effectiveness of the intervention against HBV MTCT also plays a big role in the 
decision-making process. As per the two-way sensitivity analysis, the lower was the rate of HBV 
MTCT from HBeAg positive women with the use of BD and HBIG in a large population of HBeAg 
positive pregnant women, the lower the ICER was too. At a 14.71% prevalence of HBeAg among 
pregnant women in Ovamboland combined with a 3.86% rate of HBV MTCT if using this strategy, 
26 extra pediatric infections would be prevented in that region at an incremental cost of US$98 
498.74 (ICER = US$3 768.95 per infection averted); in comparison to BD vaccine alone. However, 
in Windhoek, where an HBeAg prevalence of 7.14% was found in our antenatal study, another 15 
pediatric infections would be averted; thereby costing US$6 564.53 per infection averted (ICER) 
in the region. Given that the prevalence of both HBsAg and HBeAg vary across parts of the 
country, results from the two-way sensitivity analysis has shown that the use of the strategy may 
be of high costs in some parts of the country, but low cost in other parts. Thus, the choice of an 
optimal HBV immunization strategy against HBV MTCT is dependent on the HBsAg carrier rate 
and the availability of resources in settings. Updated statistics of the epidemiology of HBV in 
Namibia would be valuable for a choice between BD vaccination alone and BD vaccination plus 
targeted HBIG for preventing HBV MTCT.  
5.6.2. Maternal antiviral prophylaxis: HBeAg testing and HBV viral load testing 
From the recent growing body of evidence, providing maternal antiviral prophylaxis may eliminate 
the residual risk of HBV MTCT where active-passive immunization fails, in babies born to highly 
viremic HBV-infected mothers (Brown et al., 2016; Pan et al., 2016; Jourdain et al., 2018). The 
recommendation of treating HBeAg positive women presenting with a viral load from 200 000 
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IU/mL has been made by international liver organizations (Sarin et al., 2016; EASL, 2017; 
Terrault et al., 2016, 2018).  
Treating HBeAg positive women with a viral load ≥ 200 000 IU/ml with TDF during pregnancy 
(from third trimester) in addition to pediatric active-passive immunization, led to the least number 
of HBV pediatric infections (three infections) at high total costs: US$153 053.55 with HBeAg 
testing, and US$228 238.62 with HBV viral load testing. The average cost per pregnant woman 
was US$15.31 and US$22.82 using HBeAg testing and HBV viral load testing, respectively, to 
prevent HBV MTCT. The difference in costs between these two interventions was primarily driven 
by the prices of the two diagnostic tests: US$41.72 for the HBeAg test and US$142.52 for the viral 
load test. In the one-way sensitivity analysis, when the price of the HBV viral load test was similar 
to the price of the HBeAg test, using HBV viral load testing to inform on maternal treatment was 
cheaper by US$43.67. The US$43.67 difference in costs was due to the prices of the consumables 
used for blood collection for these two tests (EDTA blood tubes for the viral load test and SST 
blood tubes for the HBeAg test). 
The purpose of testing for HBeAg and HBV viral load is to identify highly infectious HBsAg 
pregnant women, whose babies have the highest risk of acquiring HBV through perinatal 
transmission. Although HBeAg is often used as a surrogate marker to assess viral replication, viral 
load testing remains the most accurate tool to determine the infectivity of HBV-infected 
individuals. The majority of HBeAg positive women (Andersson et al., 2013; Ducancelle et al., 
2013; Seck et al., 2018) or all HBeAg positive women (Candotti, Danso & Allain, 2007; Chotun 
et al., 2017) would carry levels of HBV DNA ≥ 200 000 IU/ml. A small number of HBeAg 
negative patients may also present with similar viremia. For instance, in a recent Chinese study, 
24 out of 758 (3.2%) HBeAg negative pregnant women had a high viral load of ≥ 200 000 IU/mL 
(Lu et al., 2017). Similar findings were previously reported in Indonesia (Fujiko et al., 2015). In 
the context of SSA where genotypes A, D, and E are found, Seck et al. (2018) described 13 out of 
28 (46.4%) highly viremic (HBV DNA levels ≥ 200 000 IU/ml) Senegalese pregnant women with 
an HBeAg seronegative status (Seck et al., 2018). High viremia in HBeAg negative pregnant 
women may be explained by the presence of BCP and pre-C mutations, as discussed in section 
4.7.6.4. The selection of mutations in the BCP and PC region of the viral genome would abolish 
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or reduce the production of HBeAg, without affecting viral replication (Thompson et al., 2010; 
Fujiko et al., 2015). Consequently, with an antiviral prophylaxis strategy in which HBeAg testing 
is used to inform on the need for HBV treatment, a number of highly viremic HBeAg negative 
pregnant women with a high risk of transmitting HBV to their babies would be missed.  
Assuming that all HBeAg positive women would carry levels of HBV DNA ≥ 200 000 IU/ml, 
using HBeAg testing was the preferred option as opposed to viral load testing to inform on the 
need for maternal antiviral prophylaxis in this study. The maternal antiviral prophylaxis strategy 
involving HBV viral load testing was removed from the analysis due to absolute dominance: it 
costed more than using HBeAg testing but had the same effectiveness. The scenario may have 
been different with reliable SSA data regarding the proportion of HBsAg positive pregnant 
women, including both HBeAg positive and HBeAg negative, with HBV DNA levels ≥ 200 000 
IU/ml to use in the model. To further elucidate the cost-effectiveness of an antiviral prophylaxis 
strategy using sequential HBV viral load testing, additional studies reporting HBV DNA viremia 
in HBsAg positive pregnant women, both HBeAg positive and HBeAg negative, in SSA are 
warranted.  
Both HBV DNA quantification and HBeAg diagnostic assays are currently only available at the 
laboratory and are performed on sophisticated, expensive instruments operated by skilled 
laboratory technologists (Villar et al., 2015; Peeling et al., 2017). They make use of a large 
number of costly resources; hence their high costs. It is worth mentioning that despite the 
availability of the instrumentation required for these two tests at the local Namibian laboratory, 
these assays are not performed locally. Samples are shipped elsewhere for testing. The high costs 
associated with shipping blood samples may explain the high costs of the HBeAg and HBV viral 
load tests in Namibia. Implementation of these diagnostic tests locally may reduce their costs and 
render the strategy less costly in this setting. The need for inexpensive, RDTs for either of these 
two viral markers is also strongly highlighted in these results. Although a few HBeAg RDTs are 
commercially available, recent data indicated poor diagnostic sensitivity and analytical sensitivity 
of these RDTs (Seck et al., 2018). Currently, there is only one POC assay for HBV viral load 
testing: the newly developed GeneXpert HBV DNA viral load POC diagnostic technology 
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(Cepheid Inc, Sunnyvale, California, USA). There is no data regarding the performance of the 
assay as yet.  
5.6.3. Maternal antiviral prophylaxis with TDF compared to universal HBV BD vaccination 
and targeted HBIG only 
When compared to active-passive immunization, adding maternal treatment with TDF starting at 
the third trimester of pregnancy using sequential HBeAg testing, was at an incremental cost of 
US$38 727.59 for averting six more pediatric infections – equating to US$6 262.42 per pediatric 
HBV infection averted (ICER). Judgement about whether the health benefit from this intervention, 
in comparison to the BD vaccination + HBIG strategy (ICER = US$4 550.34), is worth the money 
spent should ideally be made by comparing this ICER to a WTP threshold (Drummond et al., 
2015) or CET (Leech et al., 2018; Thokala et al., 2018). The CET should be country-specific, 
reflecting local preferences and resource availabilities (Leech et al., 2018). To our knowledge, a 
CET does not exist in Namibia. In the absence of country-specific thresholds, the common practice 
has been to compare the ICER to multiples – one to three times – of the GDP per capita of the 
country in which the economic evaluation is performed (Leech et al., 2018). Given the current 
criticism attached to this practice, recent work suggests that the interpretation of ICERs in relation 
to less than half of per capita GDP are likely to be more representative of the cost-effectiveness of 
health interventions (Woods et al., 2016). In Namibia, this would be US$2 613.60 (Namibia’s 
2017 one times GDP per capita = $5 227.20) (World Bank, 2018). However, this comparison can 
only be made when the ICER is expressed using a generic measure of health such as cost/QALY 
gained or per DALY averted. For instance, in South Korea, providing maternal antiviral 
prophylaxis was deemed cost-effective (ICER = US$16 159/QALY gained) at a WTP threshold 
of US$29 000/QALY gained; the GDP per capita of the country in 2014 (Lee, Shin & Park, 
2018). Interestingly, in the USA, introducing antiviral prophylaxis with lamivudine for pregnant 
women dominated their current strategy that includes universal BD vaccination + HBIG; it led to 
more QALYs gained at lesser costs. The authors reported an ICER of US$6 376/QALY saved for 
the antiviral prophylaxis strategy, in comparison to universal HBV vaccination (Fan et al., 2016). 
ICERs expressed in disease-specific natural units, as is ours, have been compared to the country's 
one times GDP per capita in some studies. Devine et al. (2017) deemed universal BD vaccination 
Stellenbosch University https://scholar.sun.ac.za
229 
 
 
+ HBIG cost-effective at a WTP threshold of US$1 200, the GDP per capita of Myanmar; the 
ICER of the strategy (US$716.78) was lower than US$1 200 (Devine et al., 2017). However, the 
validity of this practice is unclear.  
Although our ICER may not be compared to multiples of Namibia’s GDP per capita to inform on 
the value for money of the intervention, in comparison to the universal BD vaccination + HBIG 
strategy, it is reasonable to believe that averting six more pediatric HBV infections would avert 
more than six DALYs or lead to more than six QALYs gained. For example, in a recent South 
Korea model, the provision of antiviral prophylaxis with lamivudine averted 34 cases of pediatric 
CHB per 100 000 births and led to 82 QALYs saved; in comparison to universal BD vaccination 
+ HBIG (Lee, Shin & Park, 2018). The same intervention in the USA averted 489 pediatric 
chronic infections and saved 800 QALYs; based on a hypothetical 2010 birth cohort of four million 
infants (Fan et al., 2016). 
Further exploration of the ICER of this intervention in the sensitivity analysis revealed scenarios 
in which providing antiviral prophylaxis appeared as the preferred option, in comparison to 
universal BD vaccination + HBIG. By lowering the cost of the HBeAg test alone from US$41.72 
to US$27.12, representing a 35% decrease of the base cost, the ICER of this strategy became lower 
than the ICER of the universal BD vaccination + HBIG strategy. When compared to universal 
HBV BD vaccination alone, the antiviral prophylaxis intervention prevented 28 extra pediatric 
infections at an incremental cost of US$126 330.11 – equating to an ICER of US$4 539.25 per 
infection averted. This ICER was still lower than the original ICER (US$4 550.34/infection 
averted) of the universal BD vaccination + HBIG strategy. The impact of a low-cost HBeAg test 
on the ICER of this intervention was further reiterated at a higher prevalence of HBeAg within the 
antenatal population; when used in combination in the two-way sensitivity analysis. As the 
proportion of pregnant women requiring antiviral prophylaxis increased, the ICER of the antiviral 
prophylaxis strategy decreased. Furthermore, as the prevalence of HBeAg/high HBV viral load 
among HBsAg positive pregnant women increased, a decrease of the cost of HBeAg was warranted 
to keep the intervention cheaper and more effective than the universal BD vaccination + HBIG 
strategy. What was indicated by these results was that by decreasing the cost of the HBeAg test 
alone, adding maternal antiviral prophylaxis to pediatric active-passive immunization would be 
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cheaper than pediatric active-passive immunization only, and more effective in Namibia. To 
achieve this goal, implementation of HBeAg testing locally would be required to reduce the cost 
of the HBeAg test. In doing so, extra costly activities such as shipping biological samples 
internationally would be eliminated. 
A large proportion of the costs of this intervention was driven by the cost of the HBeAg test and 
of HBIG. The treatment of highly viremic HBeAg pregnant women with TDF, on the contrary, 
had little weight on the total costs of this intervention. The generic price of TDF used in the base 
analysis was US$16.16 for a 4-month course. This is lower than the price of US$207 per person 
per year (US$69 per 4-month course) offered to SSA countries by Gilead in 2016 (Médecins Sans 
Frontières, 2016). If Namibia had to access TDF at a price of US$69 per 4-month course for the 
treatment of highly viremic mothers, the intervention would become more expensive. The 
availability of generic formulations of TDF has had a tremendous impact on access to treatment 
for HIV-infected pregnant women across SSA, for HIV PMTCT. As seen in this model, extending 
it to HBV mono-infected pregnant women would bring more benefits to prevent HBV MTCT.  
5.6.4. HBsAg rapid testing  
Unlike the universal BD vaccination strategy, provision of HBIG to HBsAg-exposed babies or 
TDF to HBeAg-exposed babies requires routine antenatal HBsAg screening. Screening may be 
performed at the laboratory or at the POC level. As opposed to laboratory testing, POC testing 
offers a number of advantages including easy manipulation, the need for fewer infrastructures, 
rapid turn-around time for results, and delivery of screening in remote areas (Kost et al., 1999; 
Hanafiah, Garcia & Anderson, 2013; Chevaliez & Pawlotsky, 2018). For these benefits, the 
use of rapid testing at the POC level was used as the methodology for HBsAg screening in the 
model described in this study. Screening costs per patient tested at the clinic came to about US$6. 
This cost is much lower than the approximate cost of US$20 of an HBsAg laboratory-based EIA 
or CLIA test. Still, HBsAg testing at the POC level would require additional resources such as 
trained counselors, constant training of these counselors, and a robust QA scheme to ensure 
validity and accuracy of the results communicated to patients. These activities may have an impact 
on the costs of this practice. Our model presumed a health system with these infrastructures already 
available. In many SSA countries, rapid test-based HIV screening is provided routinely at ANCs 
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for HIV PMTCT. The model is merely suggesting the use of infrastructures that are already in 
place for HIV rapid testing to provide HBV rapid testing to pregnant women, rather than separating 
the two. During the antenatal study described in chapter 4, the QA scheme established for HBsAg 
screening was built on the scheme that was already in place for HIV. The packaging and dispatch 
of the HBV controls were performed through the same route used for the HIV controls, and testing 
of the controls on the rapid test strips were performed at the same time for both viruses. In doing 
so, HBsAg rapid testing remains low cost. However, in settings where HIV rapid testing is not 
available yet, these specific costs need further exploration prior to implementation. 
The Determine HBsAg rapid test used to identify HBsAg positive pregnant women in the model 
carried a false positive rate of 0.9%; meaning that some children would receive HBIG when they 
do not need it in the maternal antiviral prophylaxis + universal BD vaccination + HBIG and in the 
universal BD vaccination + HBIG strategies. The higher is the false positivity rate of the rapid test; 
the more money would be spent to provide HBIG or to perform sequential HBeAg testing when it 
is not required. Although adverse effects of HBIG are rare, anaphylaxis has been previously 
documented (Bulbul et al., 2010). Eliminating the unnecessary costs of providing HBIG to babies 
who do not need it, or to perform sequential HBeAg testing when it is not warranted, and the 
possibility of adverse effects in newborns due to HBIG would require continuous training of testers 
to limit false positive events. With regards to the diagnostic sensitivity of the test, a false negative 
rate of 9.2% was attached to the DetermineTM HBsAg rapid test. Although false negative results 
have been documented in patients with low levels of HBsAg and low viremia (Njai et al., 2015; 
Chisenga et al., 2018), who would be at very low risk of transmitting HBV in the case of MTCT, 
the use of a sensitive rapid test remains vital. HBsAg rapid tests with poor diagnostic accuracy 
have been reported in the literature (Shivkumar et al., 2012; Amini et al., 2017). Care must be 
taken in the choice of the rapid test for scale-up of HBV screening, depending on the purpose of 
the screening.  
5.7. Strengths and limitations of the study 
To our knowledge, this is the first economic evaluation for the prevention of HBV MTCT 
conducted in Namibia. It is also the first describing the costs and health outcomes associated with 
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the provision of HBIG against HBV MTCT in SSA. Important insights towards driving policy 
implementations and changes in Namibia are drawn out of the analysis. These include the low 
costs associated with routine antenatal rapid test-based HBsAg screening and the health benefits 
attached to the current national strategy for preventing HBV MTCT. As per the rationale of an 
economic evaluation, the analysis also suggests ways for better use of the local resources available. 
These include implementing the HBeAg test at the local laboratory to enable provision of maternal 
antiviral prophylaxis; which would generate higher health benefits at lesser costs compared to the 
current national BD vaccination and HBIG strategy in place.  
This CEA also has a few limitations to consider. First, the long-term costs and effects associated 
with the severe sequelae of pediatric HBV infections were not evaluated in this analytical model. 
This limited our ability to appreciate the full value of preventing perinatal HBV infections. The 
ICERs were expressed in a disease-specific natural unit rather than generic units such as DALYs 
and QALYs. Thus they could not be compared to a CET/WTP threshold. The comparison of the 
ICERs to either of these two benchmarks would have enabled a more definitive assessment of the 
value for money of the interventions included in this analysis. Another limitation was the scanty 
availability of HBV epidemiological data from other provinces of Namibia. It led to uncertainties 
around the proportion of HBsAg positive pregnant women carrying levels of HBV DNA ≥ 200 
000 IU/ml and the prevalence of HBeAg among pregnant women. The data available in Windhoek, 
from our study (Chapter 4), could not be extrapolated to other provinces given that the prevalence 
of the infection varies across the country. Other data limitations include uncertainty around 
transmission rates, especially from mothers receiving antepartum antiviral prophylaxis but whose 
babies do not receive HBIG or BD vaccine or both at birth. The unavailability of this data led to 
assumptions around coverage (100%) of the BD vaccine, HBIG and clinic delivery in Namibia. 
These assumptions may have led to an overestimation the ICER. Still, by assuming a 100% 
coverage of these practices, the calculated ICER portrays the true costs of scaled-up interventions 
for maximal benefits, in an ideal setting for the elimination of HBV MTCT.  
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CHAPTER 6: Discussion and conclusion 
This chapter brings together the findings of the studied described in Chapters 3, 4 and 5 in the 
context of prevention of HBV MTCT in Namibia and possibly across the SSA region. The 
significance and originality of this study are also highlighted, and topics that deserve further 
investigation are brought forward. 
6.1 General discussion 
Horizontal transmission has been the main route of acquisition of HBV infections in children in 
SSA, leaving MTCT neglected in the region. The successful implementation and scale-up of infant 
HBV vaccination in the region, given from six weeks of age, has had a significant impact on the 
prevalence of HBV infection in the pediatric population. HBV vaccination at six weeks does not 
prevent HBV MTCT to neonates. As a result, MTCT has emerged as the current primary cause of 
pediatric CHB infections in the region (Keane et al., 2016).  
6.1.1 Chronic HBV infection in children 
Chronic carriage of HBV in children is a serious health issue, yet to be fully controlled. Where 
treatment is indicated, options are limited, especially for children below the age of 12 years. Given 
that HBV-infected children typically present in the immunotolerant phase of the infection, 
treatment is usually postponed until the late phases of the disease, during adulthood. In the context 
of co-infection with HIV and HBV, characteristics of the immunotolerant phase of CHB were 
observed in eight out of 15 HIV/HBV (8/15; 53.3%) co-infected children and adolescents 
presented in Chapter 3; these children were treated with lamivudine for their HIV infection. 
Uncontrolled HBV infection in these children was due to the presence of viral quasispecies 
resistant to lamivudine, caused by prolonged exposure to the drug. Treatment of HIV/HBV co-
infection ideally should be with TDF, given its high barrier to HBV resistance in comparison to 
lamivudine. However, with the current TDF dosage of 300 mg, bone toxicity and nephrotoxicity 
are a concern in children below the age of 10 years; and raises the issue of treatment of CHB in 
children too. Past the age of 10 years, a change of ART with TDF would be required for the control 
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of both HIV and HBV infections. Alternatively, E/C/F/TAF may be used; where it is available. 
Still, routine screening of pediatric HIV patients, before initiating HIV ART, in SSA is highly 
recommended to control both viral infections in these children.  
With regards to liver disease progression, the course of CHB in the pediatric HIV population is 
not well established. Drawing from data generated in adults (Berretta et al., 2011; Vinikoor et 
al., 2016; Boyd et al., 2017), it would be reasonable to assume that progression to liver disease 
may be hastened due to the immunosuppression brought by HIV. Severe liver diseases may 
develop at a younger age. Interestingly, despite suppressive therapy, the risk of liver disease in 
HIV/HBV co-infected children is not nullified. Seers et al. (2017) recently described a case of 
HCC in an HIV/HBV co-infected 20 years old male, whose HIV and HBV infections were both 
acquired through MTCT (Seers et al., 2017). Co-infection with both viruses was diagnosed when 
the patient was six years old, and ART with TDF was initiated on compassionate grounds (prior 
pediatric licensing in 2012) due to his active HBV infection and the profound immunosuppression 
caused by HIV. At seven years of age, advanced fibrosis was observed on biopsy and HCC 
developed thirteen years later, despite being HIV and HBV virologically suppressed (Seers et al., 
2017). Drawing from the case report by Seers et al. (2017) HBV and HIV virologically suppressed 
HIV/HBV co-infected children reported in Chapter 3 are still at risk of severe liver damage and 
should also be closely monitored. The need for longitudinal follow-up data in African HIV/HBV 
co-infected children is warranted for a better understanding of the natural history of CHB in the 
context of HIV, and to improve clinical management of this key population. While results from 
the pediatric study (Chapter 3) are in agreement with the literature, they also add emphasis to the 
critical importance of interrupting, even eliminating, HBV MTCT.  
6.1.2 Elimination of HBV MTCT 
The toolbox for the elimination of HBV MTCT includes universal BD vaccination, HBIG, and 
more recently added, the use of antiviral drugs in highly viremic pregnant women. The last two 
interventions (HBIG and maternal treatment) require routine antenatal HBsAg screening. Many 
challenges exist with each of these tools (Tamandjou et al., 2017; Dionne-Odom, Njei & Tita, 
2018).  
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Routine antenatal HBsAg screening 
Given, the expense and infrastructure required for HBsAg diagnostic testing, offering routine 
antenatal screening is a challenge in SSA. In the antenatal study (Chapter 4), implementing POC 
HBV rapid testing as an alternative of laboratory testing was found feasible, in terms of both the 
performance of the rapid test used and the perceptions of the testers. The DetermineTM HBsAg 
rapid test showed a good accuracy with regards to its ability to differentiate between HBV-infected 
and HBV-uninfected patients, in a rapid turnaround time. The cost of rapid testing ranged from 
US$5.81 to US$6.28 for an HBsAg negative RDT result and an HBsAg positive RDT result, 
respectively. With regards to implementation at health facilities, HCWs did not raise any concerns 
with the procedures of the test and recognized the advantages of this practice over laboratory HBV 
testing as an ANC service. Considering that HBV screening is taken away from the controlled 
environment that the laboratory offers and brought to the uncontrolled POC level, QA is a 
significant component to add in the implementation of HBV rapid testing. The QA structure would 
be dependent on resource availability, and the diagnostic accuracy of the rapid test of choice; thus, 
its structure would vary between settings. Constant training of the HCWs or lay counselors 
performing the tests would be necessary too.  
In addition to accessing preventive measures against HBV MTCT, HBV screening also empowers 
these women to seek care for their own health, knowing their HBV serostatus. Linkage to care of 
HBV-infected pregnant women is warranted to avert future complications of the infection and the 
risk of HBV MTCT in future pregnancies. Monitoring for post-hepatic flares every three months 
for a period of six months, following discontinuation of therapy in women treated during 
pregnancy, is recommended (Terrault et al., 2016, 2018). Extending ART, as HBV MTCT 
prevention, beyond delivery has shown no effect on the rate nor the severity of these flares 
(Nguyen et al., 2014). Continued monitoring of disease progression, for both treated and untreated 
women postpartum, is also required to determine the need for future long-term treatment (WHO, 
2015). Although follow-up rates are unknown in SSA, data from elsewhere have shown that these 
rates are low (Chang et al., 2015, 2016b). According to data by Chang et al. (2015), 47% 
(137/291) of HBV-infected women identified during pregnancy in Massachusetts, USA, had 
received HBV specialized care post-partum. Only 19% of these HBV-infected women (55/291) 
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had been appropriately tested to monitor the progression of the infection (HBeAg and HBV DNA 
levels) and liver health (ALT), within a year of their HBV diagnosis (Chang et al., 2015). Reasons 
for the low rate of follow-ups may include the absence or the lack of knowledge of a referral 
system, and the suboptimal knowledge of CHB infection diagnosis among pregnancy-specialized 
HCWs to recognize the need for referrals (Kwong et al., 2018). Shortage of liver health or 
infectious disease specialists and adherence of patients to follow-ups could also impact follow-up 
rates. Decentralization of HBV follow-up care services to the primary healthcare level may be 
required, as it is currently done for the prescription and management of ART in HIV PMTCT 
programmes (Zuber et al., 2014). Firm evidence on the challenges associated with low or poor 
linkage-to-care of HBV-infected pregnant women in SSA needs to be identified and tackled.  
HBV BD vaccination 
The critical role of BD vaccination for the prevention of HBV MTCT cannot be overstated. 
Nonetheless, the cold chain requirements and home births have impeded its implementation and 
scale-up in SSA. Drawing from the experience in Windhoek, a high proportion of births took place 
at the health facilities, including HBsAg-exposed births. All 25 HBsAg-exposed babies followed-
up were delivered at the healthcare facilities and were vaccinated against HBV at birth. These 
observations re-emphasized the role of healthcare facilities-based births for successful scale-up of 
HBV BD vaccination in SSA. In settings with a high proportion of outside-health-facilities 
deliveries, alternative delivery strategies of the HBV BD vaccine, such as the controlled 
temperature chain (CTC), may be considered. The CTC strategy has been endorsed by the WHO, 
provided the availability of monovalent vaccines licensed for use in the CTC (WHO, 2017b). This 
strategy would be cost-saving by $1 920 (95% CI: US$1 540 – US$2 140) per 1000 births and 
would avert 167 DALYs (95% CI: 136 – 198) per 1000 births, in comparison to no CTC in SSA 
(Scott et al., 2018). It should be noted that estimates calculated by Scott et al. (2018) were derived 
from SSA countries, including Namibia, where routine BD vaccination already exists. The efficacy 
attributed to vaccine timing for preventing MTCT, used in the model by Scott et al. (2018), was 
based on estimates extracted from a study (Marion et al., 1994) in which HBIG was provided to 
neonates at birth. Thus, care must be taken during the interpretation of Scott et al. (2018) findings 
(Scott et al., 2018). Education of pregnant women during ANC visits is also a critical approach to 
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consider. These antenatal care visits are opportunities to encourage pregnant women to bring their 
newborn shortly after birth for BD vaccination. These visits may also be used to bring awareness 
of HBV in the antenatal population and of prevention of HBV MTCT, and to raise the importance 
of HBV BD vaccination to prevent HBV MTCT. A growing body of evidence has described poor 
knowledge of HBV among pregnant women. Many have never heard of HBV infection (Shah et 
al., 2015), and are not aware of the risk of transmission of the virus to their newborns (Adeyemi 
et al., 2013; Abdulai et al., 2016; Dun-Dery et al., 2017; Chaquisse et al., 2018), in comparison 
to HIV (Chaquisse et al., 2018).  
As demonstrated in the health economics component of this study (chapter 5), BD vaccination is 
of low cost (US$15 827.22) and evidently effective. Therefore, scale-up of this intervention must 
be the forefront element in strategies implemented against HBV MTCT in SSA. 
Hepatitis B immunoglobulin (HBIG) 
Our model also showed that the sole use of HBV BD vaccination might not be enough for the 
elimination of HBV MTCT. Added to the constraints of cold chain requirements, similarly to BD 
vaccine, the feasibility of offering HBIG in SSA is challenging given its high cost and restrained 
supply (Spearman et al., 2017; Dionne-Odom et al., 2018). Where it is available, constant 
availability would be challenging. Fifteen out of the 25 babies followed-up in the antenatal study 
(Chapter 4) had received HBIG while the rest did not, for various reasons that include stock 
availability and oversight from the HCWs. While the cost and supply of HBIG are important issues 
to consider, the effectiveness of the combined use of these two immunoprophylaxis measures 
cannot be overlooked. In the base analysis of this study’s decision analytic model, 22 extra 
pediatric infections were averted with the addition of HBIG to BD vaccination. Although this 
intervention is the current status quo in Namibia, coverage is unknown. Therefore, the full benefits 
of this strategy, for preventing HBV MTCT in Namibia, are unknown. Still, the model indicated 
that a step closer to the elimination of HBV MTCT would be achieved in this setting with full 
coverage of this intervention.  
Stellenbosch University https://scholar.sun.ac.za
238 
 
 
Maternal antiviral prophylaxis 
The residual number of pediatric infections noted with the BD vaccine + HBIG strategy, mostly 
from highly viremic mothers, would be eliminated with maternal antiviral prophylaxis. The use of 
antiviral drugs in HBV-infected pregnant women with high viral load (HBV DNA levels ≥ 200 000 
IU/ml) requires HBV DNA testing, which is not accessible in many SSA settings (Spearman et 
al., 2017; Dionne-Odom et al., 2018). Where it is available, the high costs associated with the test 
do not permit routine testing. Thus, HBeAg remains the only measure of infectiousness in these 
women, and tool to determine treatment eligibility (Dionne-Odom et al., 2018). Certainly, the 
intervention including HBsAg rapid testing, BD vaccination, HBIG and the provision of maternal 
ART using sequential HBeAg testing was expensive (ICER = US$6 262.42 per additional 
infection averted). However, better use of the resources that are already available in Namibia, such 
as performing HBeAg testing locally with the platform that is currently used for HBsAg testing at 
the laboratory, would render this intervention cheaper than the use of BD vaccination and HBIG 
alone. For these reasons, the interpretation of the ICERs recorded in the economic evaluation 
presented in this study must not stop at the monetary value attached to the prevention of a pediatric 
infection. The parameters, such as the prevalence of HBsAg and HBeAg represented into these 
ICERs, also need consideration for decision making. Consequently, additional efforts are required 
to generate additional HBV prevalence data in this population for a better understanding of the 
epidemiology of the infection within the Namibian antenatal population. This intervention 
(HBeAg testing and maternal antiviral prophylaxis) could also form part of gateways to establish 
or improve linkage to care in the country.  
HBsAg screening, maternal antiviral prophylaxis and HBV immunization 
The high costs of the screen-treat-vaccinate intervention, using sequential HBeAg testing, 
investigated in this study was also driven by the cost of HBIG. The high cost of this 
immunoprophylactic agent questions its scale-up in SSA. The idea of a screen-treat-BD vaccine 
alone for SSA, thus, becomes attractive. This intervention was recently investigated in South 
Africa and produced an ICER of US$26 241/DALY averted. At a CET equals to half per South 
Africa’s GDP per capita (South Africa’s 2015 GDP per capita = US$7 620), the strategy was not 
cost-effective (Hecht et al., 2018). The analysis conducted by Hecht et al. (2018) made use of a 
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theoretical model developed by Nayagam et al. (2016b), who had previously investigated this 
strategy (screen-treat-BD vaccine) at a global scale (Nayagam et al., 2016b). The cost-analysis 
component of the model developed by Nayagam et al. (2016b) included HBsAg rapid test-based 
screening at the ANCs, treatment with TDF, and the human resources to deliver both BD vaccine 
and treatment at healthcare facilities. The cost of consumables and human resources associated 
with the delivery of treatment amounted to 80% of the total drug management for person per year 
and was the most expensive component of this intervention (Nayagam et al., 2016b). It is likely 
that these costs also had the biggest impact on the ICER reported by Hecht et al. (2018); especially 
if only a small proportion of HBV mono-infected, highly infectious, pregnant women would 
require treatment. In terms of effectiveness, the model assumed a 0.5% rate of HBV MTCT from 
treated-HBeAg positive women with BD vaccination provided to their babies; a rate similar to 
HBeAg negative pregnant women whose babies receive BD vaccination at birth. As pointed by 
Nayagam et al. (2016b), effectiveness data on this strategy from clinical trials are currently lacking. 
The assumption takes into consideration that a high viremia is the only cause of breakthrough 
infections in babies born to highly infectious mothers. Yet, the immune-tolerogen characteristic of 
HBeAg may also play a role in immunoprophylaxis failure in these babies and may need to be 
accounted for. 
Sequential HBV viral load or HBeAg testing are required to identify women with the need for 
treatment for the prevention of HBV MTCT. It must be acknowledged that the majority of SSA 
does not have access to both diagnostic tests. The alternative would be to provide antiviral 
prophylaxis with TDF to all HBsAg positive pregnant women. This health intervention was 
recently put forward by Spearman et al. (2017) (Spearman et al., 2017), and present with a few 
advantages. Eliminating the need to perform costly HBV viral load and HBeAg testing may 
potentially reduce the costs of preventing HBV MTCT. The delayed turnaround time associated 
with HBV viral load or HBeAg testing often leads to loss of follow-up of patients, who may end 
up not starting treatment. Treating all HBsAg positive pregnant women could serve as a safety net 
to catch all women with the highest risk to transmit HBV to their infants. The health benefits 
associated with the intervention would be maximized, provided that treatment is initiated on the 
day of HBV diagnosis as it is currently done for HIV PMTCT. A few limitations remain. Maternal 
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treatment is at present recommended for up to three months after birth for the purpose of HBV 
PMTCT (EASL, 2017). Multiple pregnancies in HBsAg positive pregnant women may lead to 
multiple on and off exposure to the drug and repeated post-treatment hepatic flares, especially for 
women who may not necessarily need treatment. The long-term consequences of these flares and 
the risks of developing antiviral drug resistance following disrupted treatment are unknown. 
Adherence rate of pregnant women to therapy during pregnancy and the effectiveness of this 
intervention with low adherence to treatment, are also not known. Consequently, the health 
benefits and risks attached to this strategy require further investigations for recommendations.  
6.2 Significance and originality of this research project 
The findings of this research project provide evidence-based data, which were previously not 
available, for policy-making against HBV MTCT in Namibia and may possibly be translated to 
the rest of SSA. To our knowledge, this is the first investigation of the health impact of BD 
vaccination in combination with HBIG and maternal antiviral prophylaxis for the prevention of 
HBV MTCT in Namibia and in SSA. The results of the study strengthen the call for implementing 
universal HBV BD vaccination in the region. They also demonstrate that routine rapid HBV testing 
as an add-on to existing HIV POCT infrastructures is feasible in Namibia and possibly in other 
SSA countries where HIV rapid testing is already in place. The challenges associated with the 
integration of this practice and to implement provision of maternal antiviral prophylaxis for HBV 
PMTCT into existing health systems are also highlighted. These stumbling blocks are important 
considerations for the roll-out of these health interventions. HBV awareness and the importance 
of HBV PMTCT were indirectly raised among HCWs through the completion of the study and 
may have improved their attitudes towards HBV PMTCT. 
This is also the first economic evaluation of a screen-treat-vaccination intervention, with HBIG, 
against HBV MTCT in SSA. This data add to the limited economic literature available in the 
region. The results of this economic evaluation confirmed the low costs associated with BD 
vaccination. Routine antenatal HBsAg screening was proven cheap and should be implemented 
for HBV PMTCT in SSA countries. The investigation of four HBV PMTCT strategies provide 
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assistance for decision-making and may be used as a guide for future economic evaluations in 
Namibia and other SSA countries.  
The originality of this research study lies in its inter-disciplinary nature. Epidemiology, virology, 
social science, and health economics were used to address a global public health issue. The 
epidemiology component of the study provided updated HBV statistics, including HBeAg 
seroprevalence and HBV viral loads, in the Namibian obstetric population. The need for robust 
and extensive HBV epidemiological data, for a better understanding of the epidemic and for policy 
planning, cannot be overly emphasized. The virology aspect of the study demonstrated the 
diversity of viral strains circulating in Namibia. The last report on the molecular characterization 
of HBV strains in the country date from an investigation conducted more than a decade ago 
(Kramvis et al., 2005). The investigation by Kramvis et al. (2005) focused on the characterization 
of genotype E viruses only, making the present study the first report on the diversity of HBV strains 
circulating in Namibia. Social science methodologies were used to determine the feasibility of 
offering rapid test-based HBsAg screening. The lack of resources has been and remains a 
stumbling block for the implementation of health intervention in SSA. As such, the principles and 
the fundamentals of economic evaluation were used to generate the first costs and health benefits 
associated to interventions including HBIG and antenatal antiviral prophylaxis to prevent HBV 
MTCT, from an SSA perspective. 
6.3 Future research focus 
Interesting opportunities for further investigations are drawn from this study. The long-term impact 
of HIV/HBV co-infection in children, with controlled and uncontrolled HBV infection, deserves 
further research. The clinical health impact and the economic impact of alternative HBV PMTCT 
strategies such as maternal antiviral prophylaxis for all HBsAg positive pregnant women or 
HBeAg positive women only, with vaccination starting at birth or from six weeks also warrant 
further investigations. Additional work is required to determine follow-up rates of HBV-infected 
women identified during pregnancy and to assess effective strategies for linkage to care in this key 
population. Large-scale studies are warranted to measure the costs and the feasibility of 
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implementing HBV public health education programmes. The impact of these programmes on 
HBV PMTCT in SSA is worth exploring too. 
6.4 Concluding remarks  
In Namibia, elimination of HBV MTCT is achievable using a screen-treat-vaccinate (BD vaccine 
+ HBIG) strategy at a relatively high cost. As was illustrated in this research project, the cost of 
this strategy can potentially be reduced by lowering the cost of the diagnostic test used to determine 
treatment eligibility for women at highest risk of HBV MTCT. Alternatively, treating HBV-
infected pregnant women with high risk of transmission in addition to universal BD vaccination 
only may also be sufficient to achieve elimination. Effectiveness data for a screen-treat-birth dose 
vaccination strategy are required in order to confirm this hypothesis and to update currently 
available cost-effectiveness models for informed policy-making.  
With regards to the rest of SSA, intervention strategies against HBV MTCT must be customized 
for each setting. The epidemiology of HBV infection, the proportion of HBeAg positive or highly 
viremic pregnant women with the highest risk of HBV MTCT, and the costs of the resource needed 
to implement these interventions must be considered. To this aim, regional efforts are required to 
generate additional robust epidemiological, clinical and economic data on HBV. Additional 
initiatives to create awareness and improve HBV knowledge among the general public, policy-
makers and HCWs are also needed. Establishing new collaboration and strengthening existing 
ones are also essential to improve intervention strategies and build innovative approaches to obtain 
maximum health benefits.  
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Appendix B – In-house validation of the COBAS AmpliPrep/COBAS TaqMan HBV test 
Version 2.0 using one DBS specimen for HBV viral load 
B.1. Aim 
The aim of this evaluation was to assess the use of DBS for quantifying HBV with the COBAS 
AmpliPrep/COBAS TaqMan HBV Version 2.0 quantitative assay for use in the diagnosis and 
treatment of HBV infected patients. 
B.2. Methodology 
B.2.1. Limit of detection (LoD) and limit of quantification (LoQ) of the one DBS assay 
Repeat testing of DBS prepared with dilutions of the third HBV WHO international standard for 
NAT assays (NIBSC 10/264) were used to infer both the LoD and LoQ of the assay. The linearity 
of the assay was also examined. Dilutions of the NIBSC were made in a known HBV negative 
whole blood sample, and 50 µl was spotted on Whatman 903 DBS cards. One DBS for each 
dilution was tested in triplicates once and thereafter in one replicate over six different days. A 
linear regression analysis was also performed to determine the levels of linearity of the assay. The 
Probit analysis was completed, with SPSS Version 25, to determine the LoQ of the assay.  
B.2.2. Correlation and linearity between DBS and serum sample measurements 
A total of 55 plasma were retrieved at the NHLS Virology laboratory for this evaluation. A volume 
of 50 µl of each whole blood sample was spotted on Whatman 903 DBS cards, and left to dry 
overnight. Plasma were collected from the residual whole blood samples. Paired DBS and plasma 
samples were tested with the COBAS AmpliPrep/COBAS TaqMan HBV Version 2.0. Prior 
testing, elution of the DBS was performed as described in Chapter 3, Section 3.4.9.1. The 
correlation between these two measurements was analyzed using a Bland-Altman plot, and linear 
regression analysis. Plasma samples with < 20 IU/ml (< 1.30 log10 IU/ml) or > 170 000 000 IU/ml 
(> 8.3log10 IU/ml) results were recorded as 10 IU/ml (1 log10 IU/ml) and as 8.3log10 IU/ml, 
respectively. Plasma samples with an undetectable viral load were removed from the analyses.  
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B.3. Results 
B.3.1. Limit of detection (LoD) and limit of quantification (LoQ) of the one DBS assay 
Table B.1 below summarizes the average values detected at the different dilutions. As observed in 
Table B.1, viral loads were undetectable below 2 log10 IU/ml. The LoD of the one DBS assay was, 
thus, concluded at 100 IU/ml (2 log10 IU/ml). The Probit analysis was completed using the data 
tabulated in Table B.2. The LoQ of the assay by the Probit analysis at the 95% quantification rate 
was at approximately 843 IU/ml (2.93 log10 IU/ml) (95% CI: 479 IU/ml – 2600 IU/ml) (Table 
B.3). The linear range of detection was concluded between 5 log10 IU/ml and 3 log10 IU/ml, as 
illustrated in Figure B.1. 
Table B.1: HBV DNA levels measurements in one DBS using dilutions of the NIBSC 10/264. 
NIBSC HBV 
DNA levels* 
NIBSC HBV 
DNA levels 
(log10) 
DBS HBV 
DNA levels 
DBS HBV 
DNA levels# 
(log10) 
X dilution 
factor 50 
X dilution 
factor 50 
(log10) 
0 - LDL - - - 
1 - LDL - - - 
10 1.00  LDL - - - 
100 2.00  < 20 < 1.30 - - 
1000 3.00  60 1.78 2983 3.47 
10 000 4.00  572 2.76 28 600 4.46 
100 000 5.00  4824 3.68 241 222 5.38 
*HBV DNA levels are expressed in IU/ml. #Calculated from nine replicates of each dilution. DBS: dried 
blood spot; HBV: hepatitis B virus; NIBSC: National Institute for Biological Standards and Control. 
Table B.2: Limit of quantification in one DBS of the COBAS AmpliPrep/COBAS TaqMan HBV Test 
version 2.0 assay.  
NIBSC HBV DNA 
levels (IU/ml) 
NIBSC HBV DNA 
levels (log10 IU/ml) 
Number of 
replicates 
Number 
quantified 
Positivity 
rate 
10 1,00 9 0 0% 
100 2,00 9 0 0% 
1000 3,00 9 9 100% 
10 000 4,00 9 9 100% 
100 000 5,00 9 9 100% 
Probit* 95% hit rate: 843 IU/ml (95% CI: 479 IU/ml – 2600 IU/ml) 
*The results of this analysis are detailed in Table B.3 below. DBS: dried blood spot; HBV: hepatitis B 
virus; NIBSC: National Institute for Biological Standards and Control. 
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Table B.3: Outputs of the Probit analysis and confidence intervals.  
Probability 
95% Confidence Limits for NIBSC HBV DNA concentrations 
Estimate Lower Bound Upper Bound 
0.010 124.829 -1416.304 489.180 
0.020 174.107 -1196.720 544.593 
0.030 205.372 -1060.809 583.158 
0.040 228.892 -960.675 614.277 
0.050 248.023 -880.750 641.115 
0.060 264.307 -813.919 665.156 
0.070 278.585 -756.310 687.225 
0.080 291.369 -705.573 707.829 
0.090 302.996 -660.167 727.305 
0.100 313.698 -619.028 745.891 
0.150 358.008 -456.106 830.243 
0.200 393.224 -336.179 906.842 
0.250 423.437 -240.813 980.078 
0.300 450.569 -161.437 1052.111 
0.350 475.710 -93.279 1124.256 
0.400 499.567 -33.360 1197.472 
0.450 522.649 20.343 1272.578 
0.500 545.365 69.300 1350.388 
0.550 568.081 114.650 1431.805 
0.600 591.163 157.330 1517.933 
0.650 615.020 198.177 1610.221 
0.700 640.162 238.010 1710.691 
0.750 667.293 277.738 1822.373 
0.800 697.506 318.533 1950.180 
0.850 732.722 362.208 2103.030 
0.900 777.032 412.310 2300.203 
0.910 787.735 423.725 2348.512 
0.920 799.361 435.859 2401.260 
0.930 812.145 448.899 2459.562 
0.940 826.423 463.113 2525.025 
0.950 842.707 478.909 2600.102 
0.960 861.838 496.946 2688.828 
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0.970 885.358 518.425 2798.601 
0.980 916.623 545.926 2945.577 
0.990 965.901 587.210 3179.290 
 
 
 
 
Figure B.1: Linearity of the one DBS assay using the NIBSC 10/264 WHO standard. The linearity of 
the assay starts from 1000 IU/ml (3 log10 IU/ml). DBS: dried blood spots; HBV: hepatitis B virus; NIBSC: 
National Institute for Biological Standards and Control.  
B.3.2. Correlation, linearity, agreement between DBS and serum sample measurements 
Thirty four out of the 55 samples (34/55; 61.8%) and 22 (22/55; 40.0%) had detectable HBV DNA 
in plasma (Range: (< 1.30 log10 IU/ml - > 8.3log10 IU/ml) and in one DBS (Range: 1 log10 IU/ml 
– 6.80 log10 IU/ml, without dilution factor adjustment), respectively (Table B.4). The mean 
difference between HBV DNA levels measurements using plasma and one DBS samples (with 
dilution factor adjustment) was -0.37 log10 IU/ml (95% CI: -0.62 log10 IU/ml – 0.12 log10 IU/ml; 
p = 0.005). These differences fell within the 95% limits of agreement (-1.03 to 1.77 log10 IU/ml) 
of the mean difference, except for one (Figure B.2). HBV DNA viral loads between the two sample 
types correlated well (R2 = 0.93) and good linearity was observed at viral loads from 3 log10 IU/ml 
(Figure B.3), as previously observed in Figure B.1.  
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Table B.4: HBD DNA levels in paired plasma and DBS clinical samples. HBV DNA levels are 
expressed in IU/ml. 
Plasma HBV 
DNA levels 
Plasma HBV 
DNA levels 
(log10) 
DBS HBV 
DNA levels 
DBS HBV 
DNA levels 
(log10) 
X dilution 
factor (50) 
X dilution 
factor (50) 
(log10) 
2810 3.45 < 20* - - - 
939 2.97 < 20 - - - 
658 2.82 < 20 - - - 
1060 3.03 < 20 - - - 
450 2.65 < 20 - - - 
2000 3.30 24,5 1.39 1225 3.09 
4180 3.62 78,8 1.90 3940 3.60 
12300 4.09 138 2.14 6900 3.84 
3160 3.50 140 2.15 7000 3.85 
9030 3.96 269 2.43 13450 4.13 
3980 3.60 309 2.49 15450 4.19 
63000 4.80 588 2.77 29400 4.47 
54500 4.74 2380 3.38 119000 5.08 
99900000 8.00 46900 4.67 2345000 6.37 
10300000 7.01 81100 4.91 4055000 6.61 
> 170000000# > 8.23 95200 4.98 4760000 6.68 
> 170000000 > 8.23 368000 5.57 18400000 7.26 
24800000 7.39 408000 5.61 20400000 7.31 
> 170000000 > 8.23 1550000 6.19 77500000 7.89 
> 170000000 > 8.23 6240000 6.80 312000000 8.49 
148 2.17 < 20 - - - 
217 2.34 < 20 - - - 
24,9 1.40 LDL$ - - - 
29 1.46 LDL - - - 
< 20* < 1.30 LDL - - - 
< 20 < 1.30 LDL - - - 
< 20 < 1.30 LDL - - - 
< 20 < 1.30 LDL - - - 
37 1.57 LDL - - - 
< 20 < 1.30 LDL - - - 
42,8 1.63 LDL - - - 
< 20 < 1.30 LDL - - - 
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< 20 < 1.30 LDL - - - 
100 2.00 LDL - - - 
*Samples with a < 20 IU/ml viral load result were assigned a viral load of 10 IU/ml for the purpose of the 
analysis. #These samples were assigned a viral load of 170 000 000 IU/ml. $These viral loads were assigned 
a 0 IU/ml value in the analyses. HBV: hepatitis B virus. LDL: lower than the detection limit.  
 
 
Figure B.2: Bland-Altman plot of agreement between HBV DNA viral loads in 34 paired plasma 
samples and DBS samples. The solid line represents the mean difference between the plasma and DBS 
viral load measurements. The dashed lines represent the upper and lower limit of agreements (±1.96 
standard deviations) of the differences between the measurements of both samples types. DBS: Dried blood 
spots; LoA: lower limit of agreement; UoA: upper limit of agreement.  
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Figure B.3: Linear regression analysis of HBV DNA levels in 34 paired DBS and plasma samples. The 
graph shows a good correlation (R2 = 0.93) between measurements attained in one DBS and plasma 
samples. DBS: dried blood spots; HBV: hepatitis B virus. 
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Appendix C – Chapter 4 Study Stellenbosch University HREC original approval letter  
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Appendix D - Chapter 4 Study Ministry of Health and Social Sciences approval letter 
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Appendix E - Chapter 4 Study Namibia Institute of Pathology approval letter 
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Appendix F – Chapter 4 Study Written inform consent form 
PARTICIPANT CONSENT FORM 
TITLE OF THE RESEARCH PROJECT: A study of the prevention of mother-to-child 
transmission of hepatitis B virus in Windhoek, Namibia 
REFERENCE NUMBER: S17/01/001  
PRINCIPAL INVESTIGATOR: Cynthia Raissa Tamandjou 
ADDRESS: Division of Medical Virology, Department of Pathology 
Faculty of Medicine and Health Sciences, Stellenbosch University  
Cape Town, South Africa  
SUB-INVESTIGATOR IN NAMIBIA: Dr. Josef Mufenda 
CONTACT NUMBER IN SOUTH AFRICA: +21 (0)21 938 9360 / +21 (0)78 227 7522  
CONTACT NUMBER IN NAMIBIA: +264 81 223 6177 
You are being invited to take part in a research project. Please take some time to read the 
information presented here, which will explain the details of this project. Please ask the nurse or 
doctor any questions about any part that you do not fully understand.  
This research project has been approved by the Health Research Ethics Committee at 
Stellenbosch University and will be conducted according to ethical guidelines and principles of 
the international Declaration of Helsinki 2008, South African Guidelines for Good Clinical 
Practice, the Medical Research Council (MRC) Ethical Guidelines for Research, the Biomedical 
Research Ethics Committee (BREC) and Research Management Committee (RMC) of Namibia 
and the Namibia Institute of Pathology (NIP) Ethical Guidelines for Research.  
1. What is this research study all about? 
We want to test 500 pregnant women to find out how many of them have hepatitis B and are at 
risk of transmitting the infection to their babies. Those at risk of transmission may be put on 
antiviral treatment for a short duration to prevent transmission of the infection to their babies. We 
also want to test the baby of those who have hepatitis B after birth to find out if the woman has 
transmitted the infection to her baby. 
2. Why have you been invited to participate? 
Because you might have hepatitis B and be at risk of transmitting the infection to your baby. Babies 
who acquire the infection from their mums at the time of birth may develop chronic hepatitis B 
and be at risk of developing severe liver problems later in life. 
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3. What will you have to do? 
If you agree to take part in this study, we will ask you a few questions so that the researcher 
can have a better understanding of the disease.  
The nurse/health counsellor will also prick your finger and use a few drops of your blood for 
a rapid test for hepatitis B. This test is quick and the nurse will inform you of your result 
after 15 minutes. 
➢ If your result is negative: The nurse/counsellor will inform you of your result and your 
participation in the study is complete. No further actions will be required from your side but 
your data will be recorded as part of the project data for analysis  
➢ If your result is positive:  
o We will collect a blood spot which is collected on a small piece of blotting paper and 
an extra 10ml of your blood to perform some tests in the laboratory. These tests will 
help the doctor (gynaecologist) decide if you need treatment or not. These results will be 
communicated to you by the nurse at the clinic. If you need treatment, we will contact 
you for an appointment with the doctor. 
o After you have given birth, your baby will be vaccinated against hepatitis B. We will 
also test your baby for hepatitis B at the age of 6 weeks and 9 months. At 6 weeks, we 
will collect 1ml of blood from your baby and test for hepatitis B markers only. 
▪ If your baby tests negative at 6 weeks, we will inform you of the result. We will test 
your baby again at 9 months to confirm that your baby truly does not have the disease. 
If the result is negative, we will inform you of the result and the participation of your 
baby to the study will be complete. If your baby tests positive for hepatitis B 
markers and viral levels at any point, we will arrange an appointment for your 
baby with a doctor (pediatrician). The doctor will use the results of the tests to 
determine how to take care of your baby. 
▪ If your baby tests positive at 6 weeks, we will test for hepatitis B viral levels using 
the same blood sample we took. The doctor will use these results to determine how to 
take care of your baby. We will not test your baby at 9 months for hepatitis B anymore. 
4. Will you benefit from taking part in this research? 
➢ The test is free and you will know if you have hepatitis B or not, and if at risk of 
transmitting this disease to your baby. 
➢ If you have the infection, we will direct you to the care of a specialist. We will also give 
you advices to prevent the spread of the infection in your home and to any future children. 
➢ We will determine if your baby is free of the disease or not. If he/she carries the disease, 
we will refer you to a specialist who will advise on how to take care of your baby. 
Stellenbosch University https://scholar.sun.ac.za
312 
 
 
5. Are there any risks involved in your taking part in this research? 
➢ You may experience some minor bruising and discomfort during rapid testing and blood 
collection, as a result of the finger prick or needle stick.  
➢ To avoid causing pain to your baby during blood collection, we will apply an anti-pain 
cream on the area where the needle stick will be administered. 
6. If you do not agree to take part, what alternatives do you have? 
You will continue to be seen in the clinic. Your care will not be harmed in any way. Your 
participation is entirely voluntary. You are also free to withdraw from the study at any point, 
even if you do agree to take part. 
7. Who will have access to your medical records? 
The only people who will have access to your information and those of your baby will be your 
doctor and the scientists working on the study.  
8. Will you be paid to take part in this study and are there any costs involved? 
➢ You will not be paid to take part in the study but all the tests associated with this study will be 
free.  
➢ Your transport costs will be covered for each follow-up visit associated with the study. 
9. Is there anything else that you should know or do? 
➢ You can contact Dr Josef Mufenda at tel +264 81 223 6177 if you have any further queries or 
encounter any problems. 
➢ You can contact the Health Research Ethics Committee at 0027 21 938 9207 if you have any 
concerns or complaints that have not been adequately addressed by your study doctor. 
➢ You will receive a copy of this information and consent form for your own records. 
10. If your blood and that of your baby is to be stored is there a chance that it will be used 
for other research? 
Your blood and that of your baby will only be used for research that is directly related to hepatitis 
B virus. Also if the researchers wish to use your stored blood for additional research in this or a 
related field they will be required to apply for permission to do so from the Health Research Ethics 
Committee at Stellenbosch University and the Biomedical Research Ethics Committee (BREC) 
and Research Management Committee (RMC) at the Namibian Ministry of Health and Social 
Services. 
If you do not wish your blood specimen and/or the blood of your baby to be stored after this 
research study is completed you will have an opportunity to request that it be discarded when you 
sign the consent form. 
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Declaration by participant 
By signing below, I …………………………………..…………. agree to take part in a 
research study entitled “A study of the prevention of mother-to-child transmission of hepatitis B 
virus in Windhoek, Namibia”.  
I declare that: 
• I have read or someone had read to me this information and consent form and it is 
written in a language with which I am fluent and comfortable. 
• I have had a chance to ask questions and all my questions have been adequately 
answered. 
• I understand that taking part in this study is voluntary and I have not been pressurised 
to take part. I may choose to leave the study at any time and will not be penalised or 
prejudiced in any way. 
• I may be asked to leave the study before it has finished, if the study doctor or researcher 
feels it is in my best interests, or if I do not follow the study plan, as agreed to. 
Tick the option you choose: 
 I agree that my blood or tissue sample and that of my baby can be stored for 5 years 
from the end of this project, but I can choose to request at any time that these stored 
samples be destroyed. My sample and that of my baby will be identified with a special 
study code that will remain linked to our names and my contact details. I have the right 
to receive confirmation that my request has been carried out. 
I agree that my blood or tissue sample and that of my baby can be stored for 5 years 
after the project is completed but that it is anonymized with all possible links to our 
identity removed, and that the researchers may then use it for additional research in 
this or a related field. Once our samples are anonymised, our rights to those samples 
are waivered. Our samples may be shipped to another laboratory in SA or abroad to 
be used in other research projects in this or a related field 
Please destroy my blood sample and that of my baby as soon as the current research project 
has been completed. 
Signed at (place)......................…........…………….. on (date) …………....……….. 2017. 
 
 
......................................................................   ...................................................................  
Signature of Participant Signature of witness 
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6.4.1 Declaration by investigator 
I (name) Cynthia Raissa Tamandjou declare that: 
• I explained the information in this document to ………………………………….. 
• I encouraged him/her to ask questions and took adequate time to answer them. 
• I am satisfied that he/she adequately understands all aspects of the research, as 
discussed above 
• I did/did not use an interpreter. (If an interpreter is used then the interpreter must sign 
the declaration below. 
Signed at (place)......................…........…………….. on (date) …………....……….. 2017. 
......................................................................   ...................................................................  
Signature of investigator Signature of witness 
6.5 Declaration by interpreter 
I (name) ……………………………………………..……… declare that: 
• I assisted the investigator (name) …Cynthia Raissa Tamandjou……………. to 
explain the information in this document to (name of participant) 
……………..…………………………….. using the native language of the patient. 
• We encouraged him/her to ask questions and took adequate time to answer them. 
• I conveyed a factually correct version of what was related to me. 
• I am satisfied that the participant fully understands the content of this informed consent 
document and has had all his/her question satisfactorily answered. 
Signed at (place)......................…........…………….. on (date) …………....………………..2017. 
......................................................................   ...................................................................  
Signature of interpreter Signature of witness 
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Appendix G – HBV rapid test-based screening questionnaire 
HBV RAPID TEST-BASED SCREENING ASSESSMENT FOR NURSE 
PMTCT NURSE NAME: ----------------------------------------------------------------------------------- 
CLINIC NAME: ---------------------------------------------------------------------------------------------- 
DEMOGRAPHIC DATA 
 Registered Nurse      Enrolled Nurse 
Years after qualifications: ----------------------------------------------------------- 
 
Please marks with a cross (☒). Only one choice, unless specified. 
1. Have you previously perform rapid 
test? 
 Yes  No 
2. Did you find the instructions of use of 
the kit easy to understand? 
 Very easy 
 A little difficult 
 Easy 
 Very difficult 
3. How convenient was it to perform the 
rapid test? 
 Very convenient 
 A little inconvenient  
 Convenient  
 Inconvenient 
4. Which steps of the kit did you find 
difficult? 
 Preparing the kit 
 Adding the buffer 
 Taking the sample 
 Reading the results 
 None  
5. Please, justify your answer to Question 4 
6. How confident are you that you have 
done the HBV rapid test correctly? 
 Very confident 
 A little unconfident 
 Confident 
 Very unconfident 
7. Do you trust the result of the HBV 
rapid test? 
 Yes  No 
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8. Please justify your answer to Question 7 
 
9. How did the patient react to the HBV 
rapid test? 
 A little anxious 
 Not anxious 
 Very anxious 
10. Do you think that knowing the 
results in 15 minutes is useful for the 
patient? 
 Yes  No 
11. Please justify your answer to Question 10 
12. Would you recommend the use of 
this test at the clinic for antenatal care? 
 Yes  No 
13. Please justify your answer to Question 12 
 
14. Was the test acceptable by the 
patient? 
 Yes  No 
15. Please justify your answer to Question 14 
16. Any additional comments: 
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Appendix H – HBV rapid test quality control record sheet: Intermediate Katutura hospital ANC 
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Appendix I – HBV rapid test quality control record sheet: Windhoek Central hospital ANC 
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Appendix J – Outputs of the Probit analysis  
Parameters estimates 
 Parameter 
Estimat
e 
Std. 
Error 
Z 
Signific
ance 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
PROBITa 
HBV DNA Conc 
(IU/ml) 
0.001 0.001 1.317 0.188 0.000 0.002 
Intercept -4.006 2.923 -1.371 .171 -6.929 -1.083 
aPROBIT model: PROBIT(p) = Intercept + BX  
Chi-Square tests 
 Chi-Square dfb Significance 
PROBIT Pearson Goodness-of-Fit Test 0.052 6 1.000a 
aSince the significance level is greater than 0.150, no heterogeneity factor is used in the calculation of 
confidence limits. bStatistics based on individual cases differ from statistics based on aggregated cases. 
Cell counts and residuals 
 Number 
HBV DNA 
Conc (IU/ml) 
Number of 
Subjects 
Observed 
Responses 
Expected 
Responses 
Residual Probability 
PROBIT 
1 2000.000 6 0 .047 -0.047 0.008 
2 5000.000 6 3 2.924 0.076 0.487 
3 10 000.000 6 6 6.000 0.000 1.000 
4 15 000.000 6 6 6.000 0.000 1.000 
5 20 000.000 6 6 6.000 0.000 1.000 
6 30 000.000 6 6 6.000 0.000 1.000 
7 35 000.000 6 6 6.000 0.000 1.000 
8 200 000.000 6 6 6.000 0.000 1.000 
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Confidence limits 
Probability 
95% Confidence Limits for HBV DNA Conc (IU/ml) 
Estimate Lower Bound Upper Bound 
0.010 2113.363 . . 
0.020 2456.328 . . 
0.030 2673.929 . . 
0.040 2837.621 . . 
0.050 2970.772 . . 
0.060 3084.105 . . 
0.070 3183.475 . . 
0.080 3272.450 . . 
0.090 3353.368 . . 
0.100 3427.854 . . 
0.150 3736.245 . . 
0.200 3981.344 . . 
0.250 4191.617 . . 
0.300 4380.449 . . 
0.350 4555.430 . . 
0.400 4721.470 . . 
0.450 4882.116 . . 
0.500 5040.214 . . 
0.550 5198.312 . . 
0.600 5358.958 . . 
0.650 5524.998 . . 
0.700 5699.979 . . 
0.750 5888.811 . . 
0.800 6099.084 . . 
0.850 6344.183 . . 
0.900 6652.574 . . 
0.910 6727.060 . . 
0.920 6807.978 . . 
0.930 6896.953 . . 
0.940 6996.323 . . 
0.950 7109.656 . . 
0.960 7242.807 . . 
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0.970 7406.499 . . 
0.980 7624.100 . . 
0.990 7967.065 . . 
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